"assess the relative contribution of ENTITY2 uptake in human hepatocyte for ENTITY1 ( 42%-62% ) , CHEMICAL"
"assess the relative contribution of ENTITY2 uptake in human hepatocyte for CHEMICAL ( 42%-62% ) , CHEMICAL ( 28%-81% ) , ENTITY1 ( 64%-72% ) , CHEMICAL"
"assess the relative contribution of ENTITY2 uptake in human hepatocyte for CHEMICAL ( 42%-62% ) , CHEMICAL ( 28%-81% ) , CHEMICAL ( 64%-72% ) , CHEMICAL ( 84%-98% ) and ENTITY1 ( 64%-89% ) ."
"after ENTITY1 administration ENTITY2 level fall to a nadir"
"ENTITY1 , a second - generation ENTITY2 receptor antagonist with a different"
"ENTITY1 , a second - generation GENE receptor antagonist with a different half - life , a different binding capacity and a different mechanism of action than the first - generation ENTITY2 receptor antagonist appear to be"
"strengthen the idea of alpha ENTITY1 beta - endorphin-(1 - 31 ) act as a non - competitive regulator of GENE GENE and ENTITY2 - mediate supraspinal antinociception ."
"CHEMICAL and ENTITY1 be other ENTITY2 antagonist that be currently in"
"ENTITY1 and CHEMICAL be other ENTITY2 antagonist that be currently in"
"33 mm ) and the ENTITY2 ( GENE ) inhibitor ( ENTITY1 , 33 μm ) further"
"GENE GENE GENE GENE ( ENTITY2 ) inhibitor ( ENTITY1 , 33 μm ) further"
"CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 , 33 mm ) and the ENTITY2 ( GENE ) inhibitor ("
"CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 , 33 mm ) and the GENE GENE GENE GENE GENE GENE GENE ( ENTITY2 ) inhibitor ( CHEMICAL ,"
"ENTITY1 ( CHEMICAL , 33 mm ) and the ENTITY2 ( GENE ) inhibitor ("
"ENTITY1 ( CHEMICAL , 33 mm ) and the GENE GENE GENE GENE GENE GENE GENE ( ENTITY2 ) inhibitor ( CHEMICAL ,"
"however , mutate putative ENTITY2 do not substantially reduce induction of GENE GENE GENE GENE activity by ENTITY1 , suggest additional GENE GENE"
"GENE GENE GENE activity by ENTITY1 , suggest additional ENTITY2 within the 5'-flanking region be"
"not substantially reduce induction of ENTITY2 activity by ENTITY1 , suggest additional GENE GENE"
", GENE , GENE and ENTITY2 correlate with chronic sensitization to ENTITY1 nephrotoxicity in rat . 	"
"of GENE , GENE , ENTITY2 and GENE correlate with chronic sensitization to ENTITY1 nephrotoxicity in rat . 	"
"increase urinary excretion of ENTITY2 , GENE , GENE and GENE correlate with chronic sensitization to ENTITY1 nephrotoxicity in rat . 	"
"urinary excretion of GENE , ENTITY2 , GENE and GENE correlate with chronic sensitization to ENTITY1 nephrotoxicity in rat . 	"
"the sensitivity of GENE to ENTITY1 and to ENTITY2 and appear to be involve"
"in mediate the sensitivity of ENTITY2 to ENTITY1 and to GENE and appear"
"GENE to CHEMICAL and to ENTITY2 and appear to be involve in transduce and enhance the signal give by ENTITY1 for the closure of the"
"in mediate the sensitivity of ENTITY2 to CHEMICAL and to GENE and appear to be involve in transduce and enhance the signal give by ENTITY1 for the closure of the"
"the four ENTITY1 residue locate in the smg loop , CHEMICAL , CHEMICAL , CHEMICAL , and CHEMICAL , also play an important role in mediate the sensitivity of GENE to CHEMICAL and to ENTITY2 and appear to be involve"
"the four ENTITY1 residue locate in the smg loop , CHEMICAL , CHEMICAL , CHEMICAL , and CHEMICAL , also play an important role in mediate the sensitivity of ENTITY2 to CHEMICAL and to GENE"
"inactive and active form of ENTITY2 , with the CHEMICAL group not in close contact with the ENTITY1 group of the essential CHEMICAL"
"2.0a crystal structure of the ENTITY2 / CHEMICAL binary complex show that the CHEMICAL substrate adopt a conformation see previously with both inactive and active form of GENE GENE , with the CHEMICAL group not in close contact with the ENTITY1 group of the essential CHEMICAL"
"inactive and active form of ENTITY2 , with the CHEMICAL group not in close contact with the CHEMICAL group of the essential CHEMICAL CHEMICAL ( ENTITY1 ) cofactor ."
"2.0a crystal structure of the ENTITY2 / CHEMICAL binary complex show that the CHEMICAL substrate adopt a conformation see previously with both inactive and active form of GENE GENE , with the CHEMICAL group not in close contact with the CHEMICAL group of the essential CHEMICAL CHEMICAL ( ENTITY1 ) cofactor ."
"inactive and active form of ENTITY2 , with the CHEMICAL group not in close contact with the CHEMICAL group of the essential ENTITY1 ( CHEMICAL ) cofactor ."
"2.0a crystal structure of the ENTITY2 / CHEMICAL binary complex show that the CHEMICAL substrate adopt a conformation see previously with both inactive and active form of GENE GENE , with the CHEMICAL group not in close contact with the CHEMICAL group of the essential ENTITY1 ( CHEMICAL ) cofactor ."
"inactive and active form of ENTITY2 , with the ENTITY1 group not in close contact"
"2.0a crystal structure of the ENTITY2 / CHEMICAL binary complex show that the CHEMICAL substrate adopt a conformation see previously with both inactive and active form of GENE GENE , with the ENTITY1 group not in close contact"
"structure of the GENE / ENTITY1 binary complex show that the CHEMICAL substrate adopt a conformation see previously with both inactive and active form of ENTITY2 , with the CHEMICAL group"
"2.0a crystal structure of the ENTITY2 / ENTITY1 binary complex show that the"
"binary complex show that the ENTITY1 substrate adopt a conformation see previously with both inactive and active form of ENTITY2 , with the CHEMICAL group"
"2.0a crystal structure of the ENTITY2 / CHEMICAL binary complex show that the ENTITY1 substrate adopt a conformation see"
"two - chain rec - ENTITY2 , with a ka of approximately 3.7 microm in activation system contain physiological level of ENTITY1 ."
"ENTITY2 appear to exert -PRON- stimulatory property mainly through effect on the enzyme , two - chain rec - GENE GENE GENE , with a ka of approximately 3.7 microm in activation system contain physiological level of ENTITY1 ."
"the presence of ENTITY1 inhibit the stimulation of GENE GENE activation that would normally occur in the presence of GENE , a result of possible importance to the observation that some degree of systemic fibrinogenolysis accompany therapeutic use of ENTITY2 . 
"
"the presence of ENTITY1 inhibit the stimulation of GENE GENE activation that would normally occur in the presence of ENTITY2 , a result of possible"
"the presence of ENTITY1 inhibit the stimulation of ENTITY2 activation that would normally occur"
"stabilize the negative - charge ENTITY1 , whereas in the inactive form of ENTITY2 this key residue be hold"
"in the active ENTITY2 enzyme , the residue arg569 stabilize the negative - charge ENTITY1 , whereas in the inactive"
"ENTITY1 deregulate the autophagic pathway through blockage of autophagic flux , result in accumulation of autophagosome and sequestration of GENE , GENE , and ENTITY2 ."
"ENTITY1 deregulate the autophagic pathway through blockage of autophagic flux , result in accumulation of autophagosome and sequestration of GENE , ENTITY2 , and GENE ."
"ENTITY1 deregulate the autophagic pathway through blockage of autophagic flux , result in accumulation of autophagosome and sequestration of ENTITY2 , GENE , and GENE"
"the comparison between ENTITY2 structure show that his377 , through a hydrogen bond with the ENTITY1 group of CHEMICAL substrate ,"
"the comparison between ENTITY2 structure show that his377 , through a hydrogen bond with the CHEMICAL group of ENTITY1 substrate , trigger a conformational"
"the inverse functional response to ENTITY1 in ENTITY2 and GENE channel be related"
"the inverse functional response to ENTITY1 in GENE and ENTITY2 channel be related to difference"
"functional response to CHEMICAL in ENTITY2 and GENE channel be related to difference in ENTITY1 bind site or to intrinsic"
"to CHEMICAL in GENE and ENTITY2 channel be related to difference in ENTITY1 bind site or to intrinsic"
"small - molecule GENE antagonist ENTITY1 be link to ENTITY2 pharmacology . 	"
"profile of small - molecule ENTITY2 antagonist ENTITY1 be link to GENE pharmacology"
"different aspect of the vitamin ENTITY1 , start with a patient with multiple ENTITY2 deficiency ( mcd ) ."
"ENTITY1 treatment of the cell largely prevent the activation of ENTITY2 , a regulator of translation"
"ENTITY1 treatment of the cell largely prevent the activation of GENE GENE GENE GENE GENE GENE GENE GENE GENE , a regulator of translation initiation and substrate of the GENE GENE GENE GENE ( ENTITY2 ) ."
"ENTITY1 treatment of the cell largely prevent the activation of GENE GENE GENE GENE GENE GENE GENE GENE GENE , a regulator of translation initiation and substrate of the ENTITY2 ( GENE ) ."
"this group of drug contain ENTITY1 , and these result suggest that ENTITY2 preferably conjugate CHEMICAL CHEMICAL ."
"and these result suggest that ENTITY2 preferably conjugate ENTITY1 ."
"effect of ENTITY1 on ENTITY2 production in hepg2 cell ."
"carotid artery - infusion of ENTITY1 ( 45 μm ) dilate the pial cerebral arteriole via selective ENTITY2 targeting ."
"can diffuse quickly into the ENTITY2 / ENTITY1 crystal and the enzymatic reaction"
"enantiomer be equipotent in downregulat ENTITY2 expression . ENTITY1 may be a promising drug"
"enantiomer be equipotent in downregulat ENTITY2 expression . CHEMICAL CHEMICAL CHEMICAL CHEMICAL may be a promising drug , either alone or in combination with ENTITY1 , to attenuate the progression"
"probability that the action of ENTITY1 to cause cardiac fibrosis in this experimental model be an effect via non - epithelial ENTITY2 , the locus of CHEMICAL"
"probability that the action of ENTITY1 to cause cardiac fibrosis in this experimental model be an effect via non - epithelial GENE , the locus of CHEMICAL action remain to be establish , as do the molecular mechanism link ENTITY2 occupancy by CHEMICAL and collagen"
"effect via non - epithelial ENTITY2 , the locus of ENTITY1 action remain to be establish"
"GENE , the locus of ENTITY1 action remain to be establish , as do the molecular mechanism link ENTITY2 occupancy by CHEMICAL and collagen"
"effect via non - epithelial ENTITY2 , the locus of CHEMICAL action remain to be establish , as do the molecular mechanism link GENE occupancy by ENTITY1 and collagen deposition ."
"do the molecular mechanism link ENTITY2 occupancy by ENTITY1 and collagen deposition ."
"each statin induce ENTITY2 expression ( mrna and protein ) dose - dependently : the rank order of the GENE GENE GENE induction ENTITY1 ( 3 CHEMICAL ( 10"
"the rank order of the ENTITY2 induction ENTITY1 ( 3 CHEMICAL ( 10"
"on the other hand , ENTITY2 ( GENE ) mrna level be markedly low in the deficient animal , and increase upon ENTITY1 injection ."
"hand , GENE GENE ( ENTITY2 ) mrna level be markedly low in the deficient animal , and increase upon ENTITY1 injection ."
"study show that GENE and ENTITY2 metabolize ENTITY1 to inactive metabolite and suggest"
"these study show that ENTITY2 and GENE metabolize ENTITY1 to inactive metabolite and suggest"
"study show that GENE and ENTITY2 metabolize CHEMICAL to inactive metabolite and suggest that difference in the expression or function of these enzyme in the lung and/or liver could influence ENTITY1 disposition in human . 
"
"these study show that ENTITY2 and GENE metabolize CHEMICAL to inactive metabolite and suggest that difference in the expression or function of these enzyme in the lung and/or liver could influence ENTITY1 disposition in human . 
"
"not significantly inhibit by the ENTITY1 analogue CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ) , indicate that ENTITY2 bind be not just through"
"not significantly inhibit by the ENTITY1 analogue CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ) , indicate that GENE bind be not just through CHEMICAL bind site as suggest for other ENTITY2 bind site ."
"CHEMICAL ) , indicate that ENTITY2 bind be not just through ENTITY1 bind site as suggest for"
"bind be not just through ENTITY1 bind site as suggest for other ENTITY2 bind site ."
"CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) , indicate that ENTITY2 bind be not just through"
"CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) , indicate that GENE bind be not just through CHEMICAL bind site as suggest for other ENTITY2 bind site ."
"inhibit by the CHEMICAL analogue ENTITY1 ( CHEMICAL ) , indicate that ENTITY2 bind be not just through"
"inhibit by the CHEMICAL analogue ENTITY1 ( CHEMICAL ) , indicate that GENE bind be not just through CHEMICAL bind site as suggest for other ENTITY2 bind site ."
"the induction of ENTITY2 by statin disappear with addition of ENTITY1 , which indicate that the"
"statin disappear with addition of ENTITY1 , which indicate that the effect be ENTITY2 inhibition - dependent ."
"nonsteroidal agent that selectively activate ENTITY2 by target the ENTITY1 - sense site in GENE"
"GENE GENE by target the ENTITY1 - sense site in ENTITY2 , render vasodilation . 
"
"ENTITY1 be a mixed agonist of mutant ENTITY2 and GENE / GENE chimera"
"ENTITY1 be a mixed agonist of mutant GENE and ENTITY2 / GENE chimera channel that"
"ENTITY1 be a mixed agonist of mutant GENE and GENE / ENTITY2 chimera channel that inactivate by"
"opioid possess activity at the ENTITY2 be determine use [ 3h]nociceptin and nociceptin - stimulate ENTITY1 binding ."
"-PRON- be now look for ENTITY1 effect on specific gene and protein , such as CHEMICAL and ENTITY2 , and on -PRON- proteome"
"and protein , such as ENTITY1 and ENTITY2 , and on -PRON- proteome"
"= 0.30 microm ) to ENTITY2 receptor label by ENTITY1 in cortical membrane ."
"interestingly , ENTITY1 bind with a good affinity ( ic50 = 0.30 microm ) to ENTITY2 receptor label by CHEMICAL CHEMICAL"
"further study reveal that ENTITY1 increase GENE mrna in CHEMICAL CHEMICAL CHEMICAL GENE - dependent manner and that GENE and GENE GENE inhibitor ( c3 t and CHEMICAL ) increase ENTITY2 production in the hepg2 cell"
"further study reveal that ENTITY1 increase ENTITY2 mrna in CHEMICAL CHEMICAL CHEMICAL"
"further study reveal that ENTITY1 increase GENE mrna in CHEMICAL CHEMICAL CHEMICAL GENE - dependent manner and that GENE and ENTITY2 inhibitor ( c3 t and"
"further study reveal that ENTITY1 increase GENE mrna in CHEMICAL CHEMICAL CHEMICAL GENE - dependent manner and that ENTITY2 and GENE GENE inhibitor ("
"inhibitor ( c3 t and ENTITY1 ) increase ENTITY2 production in the hepg2 cell"
"study reveal that CHEMICAL increase ENTITY2 mrna in CHEMICAL CHEMICAL CHEMICAL GENE - dependent manner and that GENE and GENE GENE inhibitor ( c3 t and ENTITY1 ) increase GENE GENE GENE"
"manner and that GENE and ENTITY2 inhibitor ( c3 t and ENTITY1 ) increase GENE GENE GENE"
"- dependent manner and that ENTITY2 and GENE GENE inhibitor ( c3 t and ENTITY1 ) increase GENE GENE GENE"
"CHEMICAL increase GENE mrna in ENTITY1 GENE - dependent manner and that GENE and GENE GENE inhibitor ( c3 t and CHEMICAL ) increase ENTITY2 production in the hepg2 cell"
"study reveal that CHEMICAL increase ENTITY2 mrna in ENTITY1 GENE - dependent manner and"
"CHEMICAL increase GENE mrna in ENTITY1 GENE - dependent manner and that GENE and ENTITY2 inhibitor ( c3 t and"
"CHEMICAL increase GENE mrna in ENTITY1 GENE - dependent manner and that ENTITY2 and GENE GENE inhibitor ("
"CHEMICAL , ENTITY1 , and ENTITY2 each decrease GENE GENE GENE"
"CHEMICAL , ENTITY1 , and GENE each decrease ENTITY2 mrna level by 70 -"
"ENTITY1 , CHEMICAL CHEMICAL , and ENTITY2 each decrease GENE GENE GENE"
"ENTITY1 , CHEMICAL CHEMICAL , and GENE each decrease ENTITY2 mrna level by 70 -"
"these result suggest that ENTITY1 efficiently increase ENTITY2 in the culture medium of"
"these result suggest that ENTITY1 efficiently increase GENE GENE GENE in the culture medium of hepg2 cell by promote ENTITY2 production through inhibition of GENE"
"these result suggest that ENTITY1 efficiently increase GENE GENE GENE in the culture medium of hepg2 cell by promote GENE GENE GENE production through inhibition of GENE GENE GENE GENE and suppression of GENE activity and by protect ENTITY2 from catabolism through GENE induction"
"these result suggest that ENTITY1 efficiently increase GENE GENE GENE in the culture medium of hepg2 cell by promote GENE GENE GENE production through inhibition of ENTITY2 and suppression of GENE activity"
"these result suggest that ENTITY1 efficiently increase GENE GENE GENE in the culture medium of hepg2 cell by promote GENE GENE GENE production through inhibition of GENE GENE GENE GENE and suppression of GENE activity and by protect GENE GENE GENE from catabolism through ENTITY2 induction and lipidation of GENE"
"these result suggest that ENTITY1 efficiently increase GENE GENE GENE in the culture medium of hepg2 cell by promote GENE GENE GENE production through inhibition of GENE GENE GENE GENE and suppression of ENTITY2 activity and by protect GENE"
"the related CHEMICAL CHEMICAL and ENTITY1 and the nonselective GENE GENE agonist CHEMICAL be less potent ENTITY2 agonist ."
"the related CHEMICAL CHEMICAL and ENTITY1 and the nonselective ENTITY2 agonist CHEMICAL be less potent"
"the nonselective GENE GENE agonist ENTITY1 be less potent ENTITY2 agonist ."
"and CHEMICAL and the nonselective ENTITY2 agonist ENTITY1 be less potent GENE GENE"
"the related ENTITY1 CHEMICAL and CHEMICAL and the nonselective GENE GENE agonist CHEMICAL be less potent ENTITY2 agonist ."
"the related ENTITY1 CHEMICAL and CHEMICAL and the nonselective ENTITY2 agonist CHEMICAL be less potent"
"the related CHEMICAL ENTITY1 and CHEMICAL and the nonselective GENE GENE agonist CHEMICAL be less potent ENTITY2 agonist ."
"the related CHEMICAL ENTITY1 and CHEMICAL and the nonselective ENTITY2 agonist CHEMICAL be less potent"
"be derive from deamination of ENTITY1 by ENTITY2 in peripheral neuron ; that"
"from deamination of CHEMICAL by ENTITY2 in peripheral neuron ; that CHEMICAL in plasma be derive from cell outside the central nervous system ; that CHEMICAL in plasma be derive virtually exclusively from the metabolism of ENTITY1 in sympathetic nerve ending and"
"suggest that most of the ENTITY1 in plasma be derive from deamination of CHEMICAL by ENTITY2 in peripheral neuron ; that"
"from deamination of CHEMICAL by ENTITY2 in peripheral neuron ; that CHEMICAL in plasma be derive from cell outside the central nervous system ; that CHEMICAL in plasma be derive virtually exclusively from the metabolism of CHEMICAL in sympathetic nerve ending and that residual level of ENTITY1 after treatment with CHEMICAL provide"
"from deamination of CHEMICAL by ENTITY2 in peripheral neuron ; that CHEMICAL in plasma be derive from cell outside the central nervous system ; that CHEMICAL in plasma be derive virtually exclusively from the metabolism of CHEMICAL in sympathetic nerve ending and that residual level of CHEMICAL after treatment with ENTITY1 provide an improved but limited"
"from deamination of CHEMICAL by ENTITY2 in peripheral neuron ; that ENTITY1 in plasma be derive from"
"from deamination of CHEMICAL by ENTITY2 in peripheral neuron ; that CHEMICAL in plasma be derive from cell outside the central nervous system ; that ENTITY1 in plasma be derive virtually"
"synthesis and biological evaluation of ENTITY1 analogue as novel ENTITY2 and GENE inhibitor . 	"
"synthesis and biological evaluation of ENTITY1 analogue as novel GENE and ENTITY2 inhibitor . 	"
"chemotherapy consisting of treatment with ENTITY2 inhibitor , CHEMICAL and ENTITY1 , and an alkylat agent"
"chemotherapy consisting of treatment with ENTITY2 inhibitor , CHEMICAL and CHEMICAL , and an alkylat agent , ENTITY1 ."
"chemotherapy consisting of treatment with ENTITY2 inhibitor , ENTITY1 and CHEMICAL , and an"
"- jarisch reflex confirm that ENTITY1 really act in vivo as a ENTITY2 antagonist ( ic50 = 50"
"- jarisch reflex confirm that ENTITY1 really act in vivo as a GENE antagonist ( ic50 = 50 micrograms / kg i.v . ) , whereas CHEMICAL be essentially inactive on ENTITY2 receptor ."
"act in vivo as a ENTITY2 antagonist ( ic50 = 50 micrograms / kg i.v . ) , whereas ENTITY1 be essentially inactive on GENE"
"i.v . ) , whereas ENTITY1 be essentially inactive on ENTITY2 receptor ."
"mutation introduce into ENTITY2 to replicate the ENTITY1 bind site in GENE do"
"into GENE to replicate the ENTITY1 bind site in ENTITY2 do not alter the functional"
"mutation introduce into ENTITY2 to replicate the CHEMICAL bind site in GENE do not alter the functional response to ENTITY1 ."
"the CHEMICAL bind site in ENTITY2 do not alter the functional response to ENTITY1 ."
"ENTITY1 , a selective ENTITY2 inhibitor , improve glycemic control"
"CHEMICAL CHEMICAL , a selective ENTITY2 inhibitor , improve glycemic control in ENTITY1 - induce diabetic rat and"
"the low - affinity ENTITY1 CHEMICAL GENE ( ENTITY2 ) be responsible for most"
"the low - affinity CHEMICAL ENTITY1 GENE ( ENTITY2 ) be responsible for most"
"affinity CHEMICAL CHEMICAL GENE ( ENTITY2 ) be responsible for most of the ENTITY1 reabsorption in the kidney and"
"ENTITY2 be activate by ENTITY1 as assess use a glucocorticoid"
"show cross - resistance to ENTITY1 and CHEMICAL probably due to enhance expression of ENTITY2 ."
"- resistance to CHEMICAL and ENTITY1 probably due to enhance expression of ENTITY2 ."
"the mechanism by which ENTITY1 ( CHEMICAL ) down - regulate ENTITY2 ( GENE GENE GENE )"
"the mechanism by which ENTITY1 ( CHEMICAL ) down - regulate GENE GENE GENE GENE GENE ( ENTITY2 ) mrna be study in"
"mechanism by which CHEMICAL ( ENTITY1 ) down - regulate ENTITY2 ( GENE GENE GENE )"
"mechanism by which CHEMICAL ( ENTITY1 ) down - regulate GENE GENE GENE GENE GENE ( ENTITY2 ) mrna be study in"
"the mechanism of ENTITY1 poisoning involve inhibition of ENTITY2 ( GENE ) lead to"
"the mechanism of ENTITY1 poisoning involve inhibition of GENE ( ENTITY2 ) lead to inactivation of"
"-PRON- discover ENTITY1 , a novel selective ENTITY2 inhibitor , and find that"
"-PRON- discover ENTITY1 , a novel selective GENE inhibitor , and find that selective inhibition of ENTITY2 increase urinary CHEMICAL excretion and"
"CHEMICAL , a novel selective ENTITY2 inhibitor , and find that selective inhibition of GENE increase urinary ENTITY1 excretion and consequently decrease plasma"
"find that selective inhibition of ENTITY2 increase urinary ENTITY1 excretion and consequently decrease plasma"
"CHEMICAL , a novel selective ENTITY2 inhibitor , and find that selective inhibition of GENE increase urinary CHEMICAL excretion and consequently decrease plasma ENTITY1 level ."
"find that selective inhibition of ENTITY2 increase urinary CHEMICAL excretion and consequently decrease plasma ENTITY1 level ."
"ENTITY1 cause significant increase in both ENTITY2 mrna and protein in 3t3"
"show that oral administration of ENTITY1 , which lead to activation of an GENE GENE GENE GENE , suppress cardiac hypertrophy and fibrosis and restore cardiac diastolic function in ENTITY2 - deficient mdx mouse ."
"show that oral administration of ENTITY1 , which lead to activation of an ENTITY2 , suppress cardiac hypertrophy and"
"examine the antihyperglycemic effect of ENTITY1 in normal and diabetic rat in comparison with those of a CHEMICAL ( CHEMICAL ) and an ENTITY2 inhibitor ( CHEMICAL ) ."
"comparison with those of a ENTITY1 ( CHEMICAL ) and an ENTITY2 inhibitor ( CHEMICAL ) ."
"those of a CHEMICAL ( ENTITY1 ) and an ENTITY2 inhibitor ( CHEMICAL ) ."
"( CHEMICAL ) and an ENTITY2 inhibitor ( ENTITY1 ) ."
"effect of ENTITY1 on ENTITY2 mrna be antagonize by CHEMICAL"
"effect of CHEMICAL on ENTITY2 mrna be antagonize by ENTITY1 ."
"ENTITY1 induce apoptotic change in neural stem cell : amelioration by ENTITY2 support . 	"
"together these finding suggest that ENTITY1 bind to the same site in ENTITY2 and GENE channel to elicit"
"together these finding suggest that ENTITY1 bind to the same site in GENE and ENTITY2 channel to elicit opposite functional"
"conclusion : ENTITY1 do dose - dependently inhibit the ENTITY2 activity of platelet GENE of"
"conclusion : ENTITY1 do dose - dependently inhibit the GENE activity of platelet ENTITY2 of healthy subject both in"
"GENE GENE GENE , and ENTITY2 expression whereas the GENE ) presence decrease with ENTITY1 time exposure ."
"evidence by an increase of ENTITY2 , GENE GENE GENE GENE , and GENE expression whereas the GENE ) presence decrease with ENTITY1 time exposure ."
"an increase of GENE , ENTITY2 , and GENE expression whereas the GENE ) presence decrease with ENTITY1 time exposure ."
"bind affinity of CHEMICAL to ENTITY2 , -PRON- design and synthesize the prodrug ENTITY1 ."
"reduce the bind affinity of ENTITY1 to ENTITY2 , -PRON- design and synthesize"
"of action of CHEMICAL and ENTITY1 have be identify , both drug be ENTITY2 antagonist at drug concentration that"
"numerous mechanism of action of ENTITY1 and CHEMICAL have be identify , both drug be ENTITY2 antagonist at drug concentration that"
"the presence of ENTITY2 confer -PRON- responsiveness to glucocorticoid and indicate that the airway epithelium may be a target for the anti - inflammatory effect of inhale ENTITY1 . 
"
"these datum indicate that ENTITY1 could improve glycemic control without -PRON- use result in ENTITY2 secretion , hypoglycemia , and"
"study demonstrate that CHEMICAL and ENTITY1 stimulate ENTITY2 level in vitro and that"
"study demonstrate that CHEMICAL and ENTITY1 stimulate GENE level in vitro and that GENE bind could be a commonality between the mechanism of ENTITY2 induction of these two compound"
"study demonstrate that CHEMICAL and ENTITY1 stimulate GENE level in vitro and that ENTITY2 bind could be a commonality"
"this study demonstrate that ENTITY1 and CHEMICAL stimulate ENTITY2 level in vitro and that"
"this study demonstrate that ENTITY1 and CHEMICAL stimulate GENE level in vitro and that GENE bind could be a commonality between the mechanism of ENTITY2 induction of these two compound"
"this study demonstrate that ENTITY1 and CHEMICAL stimulate GENE level in vitro and that ENTITY2 bind could be a commonality"
"the crystal structure of ENTITY2 complexed with CHEMICAL CHEMICAL and ENTITY1 reveal that CHEMICAL bind to"
"complexed with CHEMICAL CHEMICAL and ENTITY1 reveal that CHEMICAL bind to the ENTITY2 and that upon bind ,"
"the crystal structure of ENTITY2 complexed with CHEMICAL CHEMICAL and CHEMICAL reveal that ENTITY1 bind to the GENE GENE"
"CHEMICAL and CHEMICAL reveal that ENTITY1 bind to the ENTITY2 and that upon bind ,"
"the crystal structure of ENTITY2 complexed with CHEMICAL CHEMICAL and CHEMICAL reveal that CHEMICAL bind to the GENE GENE and that upon bind , -PRON- acetylate ENTITY1 199 ."
"that CHEMICAL bind to the ENTITY2 and that upon bind , -PRON- acetylate ENTITY1 199 ."
"the crystal structure of ENTITY2 complexed with ENTITY1 and CHEMICAL reveal that CHEMICAL"
"structure of GENE complexed with ENTITY1 and CHEMICAL reveal that CHEMICAL bind to the ENTITY2 and that upon bind ,"
"mechanism by which CHEMICAL inhibit ENTITY1 and CHEMICAL ) by examine the level of GENE GENE ( GENE ) activation within the ENTITY2 ( GENE ) pathway ,"
"mechanism by which CHEMICAL inhibit ENTITY1 and CHEMICAL ) by examine the level of GENE GENE ( GENE ) activation within the GENE GENE GENE GENE GENE ( ENTITY2 ) pathway , which be"
"mechanism by which CHEMICAL inhibit ENTITY1 and CHEMICAL ) by examine the level of GENE GENE ( ENTITY2 ) activation within the GENE"
"mechanism by which CHEMICAL inhibit ENTITY1 and CHEMICAL ) by examine the level of ENTITY2 ( GENE ) activation within"
"investigate the mechanism by which ENTITY1 inhibit CHEMICAL and CHEMICAL ) by examine the level of GENE GENE ( GENE ) activation within the ENTITY2 ( GENE ) pathway ,"
"investigate the mechanism by which ENTITY1 inhibit CHEMICAL and CHEMICAL ) by examine the level of GENE GENE ( GENE ) activation within the GENE GENE GENE GENE GENE ( ENTITY2 ) pathway , which be"
"investigate the mechanism by which ENTITY1 inhibit CHEMICAL and CHEMICAL ) by examine the level of GENE GENE ( ENTITY2 ) activation within the GENE"
"investigate the mechanism by which ENTITY1 inhibit CHEMICAL and CHEMICAL ) by examine the level of ENTITY2 ( GENE ) activation within"
"ENTITY2 be characterize by a late s(n)1 transition state with significant participation of the ENTITY1 nucleophile . 
"
"ENTITY1 inhibit lps - induce phosphorylation of GENE , ENTITY2 , and GENE ."
"ENTITY1 inhibit lps - induce phosphorylation of GENE , GENE , and ENTITY2 ."
"ENTITY1 inhibit lps - induce phosphorylation of ENTITY2 , GENE , and GENE"
"the ENTITY2 have twofold weak bind affinity for ENTITY1 as demonstrate by fluorescence quenching"
"of female mouse deplete of ENTITY1 with CHEMICAL CHEMICAL CHEMICAL do not induce inhibition of ENTITY2 indicate that CHEMICAL level be"
"of female mouse deplete of ENTITY1 with CHEMICAL CHEMICAL CHEMICAL do not induce inhibition of GENE GENE indicate that CHEMICAL level be not critical for maintain ENTITY2 activity in female mouse unlike"
"do not induce inhibition of ENTITY2 indicate that ENTITY1 level be not critical for"
"of GENE GENE indicate that ENTITY1 level be not critical for maintain ENTITY2 activity in female mouse unlike"
"mouse deplete of CHEMICAL with ENTITY1 do not induce inhibition of ENTITY2 indicate that CHEMICAL level be"
"mouse deplete of CHEMICAL with ENTITY1 do not induce inhibition of GENE GENE indicate that CHEMICAL level be not critical for maintain ENTITY2 activity in female mouse unlike"
"reduce bind affinity mean that ENTITY1 be more easily release from ENTITY2 into the circulation ."
"furthermore , ENTITY1 inhibit the lps - induce phosphorylation of GENE GENE GENE GENE and GENE ENTITY2 ."
"furthermore , ENTITY1 inhibit the lps - induce phosphorylation of ENTITY2 and GENE GENE ."
"furthermore , ENTITY1 inhibit the lps - induce phosphorylation of GENE GENE GENE GENE and ENTITY2 GENE ."
"a selective inhibitor of platelet ENTITY2 , cause a cumulative inhibition of urinary ENTITY1 and whole blood CHEMICAL production"
"administration of low - dose ENTITY1 ( 40 mg ) , a selective inhibitor of platelet ENTITY2 , cause a cumulative inhibition"
"a selective inhibitor of platelet ENTITY2 , cause a cumulative inhibition of urinary CHEMICAL CHEMICAL CHEMICAL and whole blood ENTITY1 production that recover with a"
"a template for design of ENTITY2 - base prodrug , but also pave the way toward more effective use of ENTITY1 in the clinic . 
"
"share structural , but not ENTITY1 , homology with gap junction protein , the ENTITY2 ."
"ENTITY2 be a widely express protein that share structural , but not ENTITY1 , homology with gap junction"
"finally , ENTITY1 53 in the GENE GENE GENE be require for functional expression of ENTITY2 but be not critical for"
"finally , ENTITY1 53 in the ENTITY2 be require for functional expression"
"of this study demonstrate that ENTITY1 inhibit lps - stimulate inflammation by block the GENE and ENTITY2 pathway in macrophage . 
"
"of this study demonstrate that ENTITY1 inhibit lps - stimulate inflammation by block the ENTITY2 and GENE pathway in macrophage"
"agent that control ENTITY2 activity be beneficial for treat ENTITY1 - mediate symptom , such"
"thus , ENTITY1 activate ENTITY2 through a non - canonical"
"thus , ENTITY1 activate GENE through a non - canonical mechanism ( GENE ) , lead to a chronic , sustained activation of ENTITY2 ."
"the past decade , include ENTITY1 and the ENTITY2 inhibitor , have contribute significantly"
", include CHEMICAL and the ENTITY2 inhibitor , have contribute significantly to the reduced mortality of ENTITY1 - sensitive breast cancer ."
"-PRON- find compound that inhibit ENTITY2 current with a rank order of potency : CHEMICAL > CHEMICAL CHEMICAL ( CHEMICAL ) approximately CHEMICAL CHEMICAL CHEMICAL CHEMICAL approximately CHEMICAL CHEMICAL > CHEMICAL CHEMICAL CHEMICAL > > CHEMICAL > > ENTITY1 = CHEMICAL CHEMICAL ."
"-PRON- find compound that inhibit ENTITY2 current with a rank order of potency : ENTITY1 > CHEMICAL CHEMICAL ( CHEMICAL"
"-PRON- find compound that inhibit ENTITY2 current with a rank order of potency : CHEMICAL > ENTITY1 ( CHEMICAL ) approximately CHEMICAL"
"-PRON- find compound that inhibit ENTITY2 current with a rank order of potency : CHEMICAL > CHEMICAL CHEMICAL ( CHEMICAL ) approximately CHEMICAL CHEMICAL CHEMICAL CHEMICAL approximately CHEMICAL CHEMICAL > CHEMICAL CHEMICAL CHEMICAL > > ENTITY1 > > CHEMICAL CHEMICAL ="
"-PRON- find compound that inhibit ENTITY2 current with a rank order of potency : CHEMICAL > CHEMICAL CHEMICAL ( CHEMICAL ) approximately ENTITY1 approximately CHEMICAL CHEMICAL > CHEMICAL"
"-PRON- find compound that inhibit ENTITY2 current with a rank order of potency : CHEMICAL > CHEMICAL CHEMICAL ( ENTITY1 ) approximately CHEMICAL CHEMICAL CHEMICAL"
"-PRON- find compound that inhibit ENTITY2 current with a rank order of potency : CHEMICAL > CHEMICAL CHEMICAL ( CHEMICAL ) approximately CHEMICAL CHEMICAL CHEMICAL CHEMICAL approximately CHEMICAL CHEMICAL > CHEMICAL CHEMICAL CHEMICAL > > CHEMICAL > > CHEMICAL CHEMICAL = ENTITY1 ."
"-PRON- find compound that inhibit ENTITY2 current with a rank order of potency : CHEMICAL > CHEMICAL CHEMICAL ( CHEMICAL ) approximately CHEMICAL CHEMICAL CHEMICAL CHEMICAL approximately CHEMICAL CHEMICAL > ENTITY1 > > CHEMICAL > >"
"-PRON- find compound that inhibit ENTITY2 current with a rank order of potency : CHEMICAL > CHEMICAL CHEMICAL ( CHEMICAL ) approximately CHEMICAL CHEMICAL CHEMICAL CHEMICAL approximately ENTITY1 > CHEMICAL CHEMICAL CHEMICAL >"
"CHEMICAL CHEMICAL ( CHEMICAL , ENTITY1 , and CHEMICAL ) rapidly and reversibly inhibit ENTITY2 current via mechanism(s ) independent"
"CHEMICAL CHEMICAL ( CHEMICAL , ENTITY1 , and CHEMICAL ) rapidly and reversibly inhibit GENE current via mechanism(s ) independent of ENTITY2 ."
"CHEMICAL , CHEMICAL , and ENTITY1 ) rapidly and reversibly inhibit ENTITY2 current via mechanism(s ) independent"
"CHEMICAL , CHEMICAL , and ENTITY1 ) rapidly and reversibly inhibit GENE current via mechanism(s ) independent of ENTITY2 ."
"CHEMICAL CHEMICAL ( ENTITY1 , CHEMICAL , and CHEMICAL ) rapidly and reversibly inhibit ENTITY2 current via mechanism(s ) independent"
"CHEMICAL CHEMICAL ( ENTITY1 , CHEMICAL , and CHEMICAL ) rapidly and reversibly inhibit GENE current via mechanism(s ) independent of ENTITY2 ."
"ENTITY1 ( CHEMICAL , CHEMICAL , and CHEMICAL ) rapidly and reversibly inhibit ENTITY2 current via mechanism(s ) independent"
"ENTITY1 ( CHEMICAL , CHEMICAL , and CHEMICAL ) rapidly and reversibly inhibit GENE current via mechanism(s ) independent of ENTITY2 ."
"uptake of ENTITY1 ( 5   nm ) by ENTITY2 be reduce by 82%-95% ."
"additionally , ENTITY1 suppress the production of inflammatory GENE , include GENE GENE GENE ( GENE ) , ENTITY2 , and GENE ."
"additionally , ENTITY1 suppress the production of inflammatory GENE , include GENE GENE GENE ( ENTITY2 ) , GENE GENE GENE"
"additionally , ENTITY1 suppress the production of inflammatory GENE , include ENTITY2 ( GENE ) , GENE"
"additionally , ENTITY1 suppress the production of inflammatory GENE , include GENE GENE GENE ( GENE ) , GENE GENE GENE , and ENTITY2 ."
"additionally , ENTITY1 suppress the production of inflammatory ENTITY2 , include GENE GENE GENE"
"ENTITY2 , an inactivating GENE GENE ENTITY1 GENE . 	"
"reversal of inhibition by ENTITY2 agonist ENTITY1 be produce by CHEMICAL ("
"of inhibition by GENE agonist ENTITY1 be produce by CHEMICAL ( 50 µm ) and by ENTITY2 ( 5 - 10 nm"
"reversal of inhibition by ENTITY2 agonist CHEMICAL be produce by ENTITY1 ( 50 µm ) and"
"agonist CHEMICAL be produce by ENTITY1 ( 50 µm ) and by ENTITY2 ( 5 - 10 nm"
"inhibit the GENE cascade and ENTITY1 radical formation , follow by suppress the activation of ENTITY2 and GENE ."
"inhibit the GENE cascade and ENTITY1 radical formation , follow by suppress the activation of GENE and ENTITY2 ."
"in conclusion , ENTITY1 may inhibit platelet activation by inhibit the GENE cascade and CHEMICAL radical formation , follow by suppress the activation of ENTITY2 and GENE ."
"in conclusion , ENTITY1 may inhibit platelet activation by inhibit the GENE cascade and CHEMICAL radical formation , follow by suppress the activation of GENE and ENTITY2 ."
"ENTITY1 improve cardiomyopathy in GENE - deficient mouse through ENTITY2 protein - mediate modulation of"
"ENTITY1 improve cardiomyopathy in ENTITY2 - deficient mouse through GENE"
"ENTITY1 improve cardiomyopathy in GENE - deficient mouse through GENE protein - mediate modulation of ENTITY2 protein . 	"
"of h9c2 cell to high ENTITY1 reduce GENE activity , inhibit GENE CHEMICAL GENE GENE ( GENE GENE GENE GENE GENE ( GENE ) signal , and promote ENTITY2 bind to GENE ."
"of h9c2 cell to high ENTITY1 reduce GENE activity , inhibit GENE CHEMICAL GENE GENE ( GENE GENE GENE GENE GENE ( ENTITY2 ) signal , and promote"
"of h9c2 cell to high ENTITY1 reduce GENE activity , inhibit GENE CHEMICAL GENE GENE ( GENE GENE GENE GENE GENE ( GENE ) signal , and promote GENE bind to ENTITY2 ."
"of h9c2 cell to high ENTITY1 reduce ENTITY2 activity , inhibit GENE CHEMICAL"
"target GENE , thereby decrease ENTITY1 production without interfere with the GENE ENTITY2 function ."
"/ GENE complex by target ENTITY2 , thereby decrease ENTITY1 production without interfere with the"
"alternative approach to modulate the ENTITY2 - relate activity be to perturb the GENE / GENE complex by target GENE , thereby decrease ENTITY1 production without interfere with the"
"activity be to perturb the ENTITY2 / GENE complex by target GENE , thereby decrease ENTITY1 production without interfere with the"
"target GENE , thereby decrease ENTITY1 production without interfere with the ENTITY2 GENE GENE function ."
"three residue , the specific ENTITY1 that form the putative binding pocket for CHEMICAL in GENE be conserve in ENTITY2 ."
"three residue , the specific ENTITY1 that form the putative binding pocket for CHEMICAL in ENTITY2 be conserve in GENE ."
"the putative binding pocket for ENTITY1 in GENE be conserve in ENTITY2 ."
"the putative binding pocket for ENTITY1 in ENTITY2 be conserve in GENE ."
"of rp-1 enhanced level of ENTITY1 induce increase in ENTITY2 ( upto 16 h )"
"of rp-1 enhanced level of ENTITY1 induce increase in GENE GENE ( upto 16 h ) , ENTITY2 ( 4 h ) GENE"
"of rp-1 enhanced level of ENTITY1 induce increase in GENE GENE ( upto 16 h ) , GENE GENE GENE GENE ( 4 h ) ENTITY2 activity ( upto 24 h"
"neither ENTITY1 nor CHEMICAL inhibit down - regulation of ENTITY2 mrna by CHEMICAL ."
"inhibit down - regulation of ENTITY2 mrna by ENTITY1 ."
"neither CHEMICAL nor ENTITY1 inhibit down - regulation of ENTITY2 mrna by CHEMICAL ."
"ENTITY2 act as a ENTITY1 GENE ( GENE ) on"
"GENE act as a ENTITY1 GENE ( ENTITY2 ) on small molecule substrate"
"ENTITY2 act as a CHEMICAL GENE ( GENE ) on small molecule substrate , include CHEMICAL , the anticancer drug ENTITY1 , and the neuropeptide CHEMICAL"
"as a CHEMICAL GENE ( ENTITY2 ) on small molecule substrate , include CHEMICAL , the anticancer drug ENTITY1 , and the neuropeptide CHEMICAL"
"ENTITY2 act as a CHEMICAL GENE ( GENE ) on small molecule substrate , include CHEMICAL , the anticancer drug CHEMICAL , and the neuropeptide ENTITY1 ."
"as a CHEMICAL GENE ( ENTITY2 ) on small molecule substrate , include CHEMICAL , the anticancer drug CHEMICAL , and the neuropeptide ENTITY1 ."
"ENTITY2 act as a CHEMICAL GENE ( GENE ) on small molecule substrate , include ENTITY1 , the anticancer drug CHEMICAL"
"as a CHEMICAL GENE ( ENTITY2 ) on small molecule substrate , include ENTITY1 , the anticancer drug CHEMICAL"
"- hypertrophic co - activator ENTITY2 protein but not GENE mrna be up - regulate in the mdx heart , and ENTITY1 administration down - regulate the"
"activator GENE protein but not ENTITY2 mrna be up - regulate in the mdx heart , and ENTITY1 administration down - regulate the"
"the mdx heart , and ENTITY1 administration down - regulate the ENTITY2 protein level ."
"be measure by CHEMICAL and ENTITY1 ( he ) stain , balf level of treg / th17 ENTITY2 be measure by enzyme -"
"/ kg ) , and ENTITY1 ( 50mg / kg , 100mg / kg , 200mg / kg ) . airway resistance ( raw ) be measure by the force oscillation technique , differential cell count in bal fluid ( balf ) be measure by wright - giemsa staining , histological assessment be measure by CHEMICAL and CHEMICAL ( he ) stain , balf level of treg / th17 ENTITY2 be measure by enzyme -"
": control , model , ENTITY1 ( 2mg / kg ) , and CHEMICAL ( 50mg / kg , 100mg / kg , 200mg / kg ) . airway resistance ( raw ) be measure by the force oscillation technique , differential cell count in bal fluid ( balf ) be measure by wright - giemsa staining , histological assessment be measure by CHEMICAL and CHEMICAL ( he ) stain , balf level of treg / th17 ENTITY2 be measure by enzyme -"
"histological assessment be measure by ENTITY1 and CHEMICAL ( he ) stain , balf level of treg / th17 ENTITY2 be measure by enzyme -"
"physiological CHEMICAL ) gradient , ENTITY2 be half inhibit by 0.1 mm ENTITY1 , CHEMICAL , and CHEMICAL"
"physiological CHEMICAL ) gradient , ENTITY2 be half inhibit by 0.1 mm CHEMICAL CHEMICAL CHEMICAL , ENTITY1 , and CHEMICAL ."
"physiological CHEMICAL ) gradient , ENTITY2 be half inhibit by 0.1 mm CHEMICAL CHEMICAL CHEMICAL , CHEMICAL , and ENTITY1 ."
"3.5-a crystal structure of the ENTITY2 , which reveal a homodimer with structural similarity to GENE GENE , a receptor for ENTITY1 - load GENE that lack"
"GENE , a receptor for ENTITY1 - load ENTITY2 that lack GENE activity ."
"GENE , a receptor for ENTITY1 - load GENE that lack ENTITY2 activity ."
"homodimer with structural similarity to ENTITY2 , a receptor for ENTITY1 - load GENE that lack"
"the antiherpetic action of ENTITY1 be measure by plaque reduction assay , and the immunomodulatory effect be determine by measure the ENTITY2 production use a bioassay and"
"inhibit by the overexpression of ENTITY2 as well as ENTITY1 , both of which down"
"of GENE as well as ENTITY1 , both of which down - regulate ENTITY2 protein level but not GENE"
"of GENE as well as ENTITY1 , both of which down - regulate GENE protein level but not ENTITY2 mrna level ."
"hypertrophy induce by the α(1)-agonist ENTITY1 be inhibit by the overexpression of ENTITY2 as well as CHEMICAL ,"
"hypertrophy induce by the α(1)-agonist ENTITY1 be inhibit by the overexpression of GENE as well as CHEMICAL , both of which down - regulate ENTITY2 protein level but not GENE"
"hypertrophy induce by the α(1)-agonist ENTITY1 be inhibit by the overexpression of GENE as well as CHEMICAL , both of which down - regulate GENE protein level but not ENTITY2 mrna level ."
", no , GENE and ENTITY2 be increase by ENTITY1 use alone or in combination"
", GENE , no , ENTITY2 and GENE be increase by ENTITY1 use alone or in combination"
"in macrophage , level of ENTITY2 , GENE , no , GENE and GENE be increase by ENTITY1 use alone or in combination"
", level of GENE , ENTITY2 , no , GENE and GENE be increase by ENTITY1 use alone or in combination"
"contrast , activation of both ENTITY2 and GENE in the pfc be find follow memory retrieval but not other process in ENTITY1 - treat mouse group ."
"activation of both GENE and ENTITY2 in the pfc be find follow memory retrieval but not other process in ENTITY1 - treat mouse group ."
"ENTITY1 cause ENTITY2 mrna level to decrease with"
", the GENE GENE of ENTITY2 contain a binuclear CHEMICAL site , catalytic residue , and a propose substrate - bind ENTITY1 patch ."
"unlike GENE GENE , the ENTITY2 of GENE contain a binuclear CHEMICAL site , catalytic residue , and a propose substrate - bind ENTITY1 patch ."
"unlike ENTITY2 , the GENE GENE of GENE contain a binuclear CHEMICAL site , catalytic residue , and a propose substrate - bind ENTITY1 patch ."
", the GENE GENE of ENTITY2 contain a binuclear ENTITY1 site , catalytic residue ,"
"unlike GENE GENE , the ENTITY2 of GENE contain a binuclear ENTITY1 site , catalytic residue ,"
"unlike ENTITY2 , the GENE GENE of GENE contain a binuclear ENTITY1 site , catalytic residue ,"
"elucidation of the ENTITY2 structure combine with docking study and a propose catalytic mechanism provide insight into the recognition of inhibitor and the natural substrate ENTITY1 ."
"mouse expres high level of ENTITY2 in certain cns region and downregulation of GENE use antisense oligonucleotide sensitize -PRON- to ENTITY1 toxicity see as GENE GENE"
"cns region and downregulation of ENTITY2 use antisense oligonucleotide sensitize -PRON- to ENTITY1 toxicity see as GENE GENE"
"antisense oligonucleotide sensitize -PRON- to ENTITY1 toxicity see as ENTITY2 los ."
"result indicate that ENTITY1 inhibit hsv-2 multiplication in epithelial cell and also increase ENTITY2 production in macrophage , both"
"and inhibition study of the ENTITY2 , a new target for ENTITY1 and CHEMICAL inhibitor . 	"
"ENTITY2 inhibitor . dna cloning , characterization , and inhibition study of the GENE GENE GENE GENE , a new target for ENTITY1 and CHEMICAL inhibitor . 	"
"and inhibition study of the ENTITY2 , a new target for CHEMICAL and ENTITY1 inhibitor . 	"
"ENTITY2 inhibitor . dna cloning , characterization , and inhibition study of the GENE GENE GENE GENE , a new target for CHEMICAL and ENTITY1 inhibitor . 	"
"ENTITY2 inhibitor such as CHEMICAL , ENTITY1 , and CHEMICAL CHEMICAL inhibit"
"ENTITY2 inhibitor such as ENTITY1 , CHEMICAL CHEMICAL , and"
"ENTITY2 inhibitor such as CHEMICAL , CHEMICAL CHEMICAL , and ENTITY1 inhibit the reaction drastically ,"
"ENTITY2 inhibitor such as CHEMICAL , CHEMICAL CHEMICAL , and CHEMICAL CHEMICAL inhibit the reaction drastically , suggest the participation of the active site ENTITY1 of the enzyme in the"
"the ENTITY2 inhibitor be currently use as second - line therapy after ENTITY1 failure ."
"ENTITY1 be the first synthetic ENTITY2 inhibitor to be evaluate for"
"identify the molecular determinant for ENTITY1 block , -PRON- first engineer chimera between ENTITY2 and GENE and then use"
"identify the molecular determinant for ENTITY1 block , -PRON- first engineer chimera between GENE and ENTITY2 and then use site -"
"-PRON- first engineer chimera between ENTITY2 and GENE and then use site - direct mutagenesis to localize single ENTITY1 residue responsible for block ."
"engineer chimera between GENE and ENTITY2 and then use site - direct mutagenesis to localize single ENTITY1 residue responsible for block ."
"-PRON- find that ENTITY2 induce GENE down - regulation via the GENE - GENE pathway by deacetylation of ENTITY1 residue for ubiquitination ."
"regulation via the GENE - ENTITY2 pathway by deacetylation of ENTITY1 residue for ubiquitination ."
"-PRON- find that GENE induce ENTITY2 down - regulation via the GENE - GENE pathway by deacetylation of ENTITY1 residue for ubiquitination ."
"down - regulation via the ENTITY2 - GENE pathway by deacetylation of ENTITY1 residue for ubiquitination ."
"ENTITY1 do not prevent or reverse that modulatory activity ; moreover , pretreatment with the acetylate peptide do not change the pa2 value display by the antagonist at the ENTITY2 ."
"protective effect of ENTITY1 anesthesia on retinal light damage : inhibition of metabolic ENTITY2 regeneration . 	"
"for GENE GENE GENE ( ENTITY2 ) , induce these gene via upregulation of ENTITY1 GENE GENE GENE GENE ("
"these gene via upregulation of ENTITY1 GENE GENE GENE GENE ( ENTITY2 ) that bind to the"
", the natural ligand for ENTITY2 ( GENE ) , induce these gene via upregulation of ENTITY1 GENE GENE GENE GENE ("
"further , ENTITY1 metabolite , predominantly the CHEMICAL , the natural ligand for GENE GENE GENE ( ENTITY2 ) , induce these gene"
"further , ENTITY1 metabolite , predominantly the CHEMICAL , the natural ligand for GENE GENE GENE ( GENE ) , induce these gene via upregulation of CHEMICAL GENE GENE GENE GENE ( ENTITY2 ) that bind to the"
"further , ENTITY1 metabolite , predominantly the CHEMICAL , the natural ligand for ENTITY2 ( GENE ) , induce"
"CHEMICAL metabolite , predominantly the ENTITY1 , the natural ligand for GENE GENE GENE ( ENTITY2 ) , induce these gene"
"CHEMICAL metabolite , predominantly the ENTITY1 , the natural ligand for GENE GENE GENE ( GENE ) , induce these gene via upregulation of CHEMICAL GENE GENE GENE GENE ( ENTITY2 ) that bind to the"
"CHEMICAL metabolite , predominantly the ENTITY1 , the natural ligand for ENTITY2 ( GENE ) , induce"
"CHEMICAL ( ENTITY1 ) and GENE ( ENTITY2 ) mediate -PRON- biological action"
"CHEMICAL ( ENTITY1 ) and GENE ( GENE ) mediate -PRON- biological action by act on four known receptor : the GENE ( uterine ) and the ENTITY2 GENE ) ( vasopressor )"
"CHEMICAL ( ENTITY1 ) and GENE ( GENE ) mediate -PRON- biological action by act on four known receptor : the GENE ( uterine ) and the GENE GENE ) ( vasopressor ) , GENE ) ( pituitary ) , GENE ) ( renal ) receptor and a fifth putative ENTITY2 GENE GENE ? ( vasodilat"
"CHEMICAL ( ENTITY1 ) and GENE ( GENE ) mediate -PRON- biological action by act on four known receptor : the ENTITY2 ( uterine ) and the"
"CHEMICAL ( ENTITY1 ) and GENE ( GENE ) mediate -PRON- biological action by act on four known receptor : the GENE ( uterine ) and the GENE GENE ) ( vasopressor ) , GENE ) ( pituitary ) , GENE ) ( renal ) receptor and a fifth putative GENE ENTITY2 ? ( vasodilat ) receptor"
"CHEMICAL ( ENTITY1 ) and ENTITY2 ( GENE ) mediate -PRON-"
"ENTITY1 ( CHEMICAL ) and GENE ( ENTITY2 ) mediate -PRON- biological action"
"ENTITY1 ( CHEMICAL ) and GENE ( GENE ) mediate -PRON- biological action by act on four known receptor : the GENE ( uterine ) and the ENTITY2 GENE ) ( vasopressor )"
"ENTITY1 ( CHEMICAL ) and GENE ( GENE ) mediate -PRON- biological action by act on four known receptor : the GENE ( uterine ) and the GENE GENE ) ( vasopressor ) , GENE ) ( pituitary ) , GENE ) ( renal ) receptor and a fifth putative ENTITY2 GENE GENE ? ( vasodilat"
"ENTITY1 ( CHEMICAL ) and GENE ( GENE ) mediate -PRON- biological action by act on four known receptor : the ENTITY2 ( uterine ) and the"
"ENTITY1 ( CHEMICAL ) and GENE ( GENE ) mediate -PRON- biological action by act on four known receptor : the GENE ( uterine ) and the GENE GENE ) ( vasopressor ) , GENE ) ( pituitary ) , GENE ) ( renal ) receptor and a fifth putative GENE ENTITY2 ? ( vasodilat ) receptor"
"ENTITY1 ( CHEMICAL ) and ENTITY2 ( GENE ) mediate -PRON-"
"determine whether the volatile anesthetic ENTITY1 protect against light - induce ENTITY2 degeneration in the rodent retina"
"treatment with pertussis toxin or ENTITY1 , agent know to impair the function of GENE / ENTITY2 transducer protein ."
"treatment with pertussis toxin or ENTITY1 , agent know to impair the function of ENTITY2 / GENE transducer protein ."
"the reduce activity of alpha ENTITY1 beta - endorphin-(1 - 31 ) upon CHEMICAL and beta - endorphin - induce analgesia be not exhibit in mouse undergo treatment with pertussis toxin or CHEMICAL CHEMICAL CHEMICAL , agent know to impair the function of GENE / ENTITY2 transducer protein ."
"the reduce activity of alpha ENTITY1 beta - endorphin-(1 - 31 ) upon CHEMICAL and beta - endorphin - induce analgesia be not exhibit in mouse undergo treatment with pertussis toxin or CHEMICAL CHEMICAL CHEMICAL , agent know to impair the function of ENTITY2 / GENE transducer protein ."
"and also increase activity of ENTITY1 GENE ( GENE ) , CHEMICAL GENE ( GENE ) and ENTITY2 ( GENE ) ."
"and also increase activity of ENTITY1 GENE ( GENE ) , CHEMICAL GENE ( GENE ) and GENE GENE ( ENTITY2 ) ."
"and also increase activity of ENTITY1 GENE ( GENE ) , CHEMICAL GENE ( ENTITY2 ) and GENE GENE ("
"and also increase activity of ENTITY1 GENE ( ENTITY2 ) , CHEMICAL GENE ("
"GENE , GENE GENE , ENTITY2 and glycogen content significantly ( p<0.05 ) decrease in the liver of diabetic rat and also increase activity of ENTITY1 GENE ( GENE ) ,"
") increase whereas GENE , ENTITY2 , GENE GENE and glycogen content significantly ( p<0.05 ) decrease in the liver of diabetic rat and also increase activity of ENTITY1 GENE ( GENE ) ,"
"( p<0.05 ) increase whereas ENTITY2 , GENE GENE , GENE GENE and glycogen content significantly ( p<0.05 ) decrease in the liver of diabetic rat and also increase activity of ENTITY1 GENE ( GENE ) ,"
"GENE ( GENE ) , ENTITY1 GENE ( GENE ) and ENTITY2 ( GENE ) ."
"GENE ( GENE ) , ENTITY1 GENE ( GENE ) and GENE GENE ( ENTITY2 ) ."
"GENE ( GENE ) , ENTITY1 GENE ( ENTITY2 ) and GENE GENE ("
"activity of CHEMICAL GENE ( ENTITY2 ) , ENTITY1 GENE ( GENE ) and"
"GENE , GENE GENE , ENTITY2 and glycogen content significantly ( p<0.05 ) decrease in the liver of diabetic rat and also increase activity of CHEMICAL GENE ( GENE ) , ENTITY1 GENE ( GENE ) and"
") increase whereas GENE , ENTITY2 , GENE GENE and glycogen content significantly ( p<0.05 ) decrease in the liver of diabetic rat and also increase activity of CHEMICAL GENE ( GENE ) , ENTITY1 GENE ( GENE ) and"
"( p<0.05 ) increase whereas ENTITY2 , GENE GENE , GENE GENE and glycogen content significantly ( p<0.05 ) decrease in the liver of diabetic rat and also increase activity of CHEMICAL GENE ( GENE ) , ENTITY1 GENE ( GENE ) and"
"as CHEMICAL and CHEMICAL of ENTITY1 metabolism significantly ( p<0.05 ) increase whereas GENE , GENE GENE , GENE GENE and glycogen content significantly ( p<0.05 ) decrease in the liver of diabetic rat and also increase activity of CHEMICAL GENE ( GENE ) , CHEMICAL GENE ( GENE ) and ENTITY2 ( GENE ) ."
"as CHEMICAL and CHEMICAL of ENTITY1 metabolism significantly ( p<0.05 ) increase whereas GENE , GENE GENE , GENE GENE and glycogen content significantly ( p<0.05 ) decrease in the liver of diabetic rat and also increase activity of CHEMICAL GENE ( GENE ) , CHEMICAL GENE ( GENE ) and GENE GENE ( ENTITY2 ) ."
"as CHEMICAL and CHEMICAL of ENTITY1 metabolism significantly ( p<0.05 ) increase whereas GENE , GENE GENE , GENE GENE and glycogen content significantly ( p<0.05 ) decrease in the liver of diabetic rat and also increase activity of CHEMICAL GENE ( GENE ) , CHEMICAL GENE ( ENTITY2 ) and GENE GENE ("
"as CHEMICAL and CHEMICAL of ENTITY1 metabolism significantly ( p<0.05 ) increase whereas GENE , GENE GENE , GENE GENE and glycogen content significantly ( p<0.05 ) decrease in the liver of diabetic rat and also increase activity of CHEMICAL GENE ( ENTITY2 ) , CHEMICAL GENE ("
"as CHEMICAL and CHEMICAL of ENTITY1 metabolism significantly ( p<0.05 ) increase whereas GENE , GENE GENE , ENTITY2 and glycogen content significantly ("
"as CHEMICAL and CHEMICAL of ENTITY1 metabolism significantly ( p<0.05 ) increase whereas GENE , ENTITY2 , GENE GENE and glycogen"
"as CHEMICAL and CHEMICAL of ENTITY1 metabolism significantly ( p<0.05 ) increase whereas ENTITY2 , GENE GENE , GENE"
"ENTITY1 ( CHEMICAL ) have primarily fungicidal action against many fungi as a result of -PRON- specific mechanism of ENTITY2 inhibition ."
"CHEMICAL ( ENTITY1 ) have primarily fungicidal action against many fungi as a result of -PRON- specific mechanism of ENTITY2 inhibition ."
"the kinetic parameter for the ENTITY1 hydration reaction prove ENTITY2 to possess a kcat of"
"result : ENTITY1 anesthesia reversibly inhibit metabolic ENTITY2 regeneration and thus prevent GENE"
"result : ENTITY1 anesthesia reversibly inhibit metabolic GENE regeneration and thus prevent ENTITY2 from absorb high number of"
"ENTITY2 play a role in cardiac pacemaking , ENTITY1 secretion , and renal hemodynamic"
"effect of ENTITY2 inhibitor on level of ENTITY1 and CHEMICAL CHEMICAL in striatum"
"effect of ENTITY2 inhibitor on level of CHEMICAL and ENTITY1 in striatum and plasma ."
"identify compound that block the ENTITY2 GENE GENE GENE GENE with high affinity , focus on two class of compound : CHEMICAL ( e.g. , CHEMICAL ) and CHEMICAL ( e.g. , ENTITY1 ) ."
"compound that block the GENE ENTITY2 with high affinity , focus on two class of compound : CHEMICAL ( e.g. , CHEMICAL ) and CHEMICAL ( e.g. , ENTITY1 ) ."
"identify compound that block the ENTITY2 GENE GENE GENE GENE with high affinity , focus on two class of compound : CHEMICAL ( e.g. , CHEMICAL ) and ENTITY1 ( e.g. , CHEMICAL )"
"compound that block the GENE ENTITY2 with high affinity , focus on two class of compound : CHEMICAL ( e.g. , CHEMICAL ) and ENTITY1 ( e.g. , CHEMICAL )"
"identify compound that block the ENTITY2 GENE GENE GENE GENE with high affinity , focus on two class of compound : CHEMICAL ( e.g. , ENTITY1 ) and CHEMICAL ( e.g."
"compound that block the GENE ENTITY2 with high affinity , focus on two class of compound : CHEMICAL ( e.g. , ENTITY1 ) and CHEMICAL ( e.g."
"identify compound that block the ENTITY2 GENE GENE GENE GENE with high affinity , focus on two class of compound : ENTITY1 ( e.g. , CHEMICAL )"
"compound that block the GENE ENTITY2 with high affinity , focus on two class of compound : ENTITY1 ( e.g. , CHEMICAL )"
"GENE - induce GENE and ENTITY2 activation by interfere with ENTITY1 phosphorylation of GENE GENE GENE"
"GENE GENE GENE - induce ENTITY2 and GENE activation by interfere with ENTITY1 phosphorylation of GENE GENE GENE"
"that CHEMICAL inhibit endogenous and ENTITY2 - induce GENE and GENE activation by interfere with ENTITY1 phosphorylation of GENE GENE GENE"
""" work upwards "" from ENTITY2 , -PRON- observe that CHEMICAL inhibit endogenous and GENE GENE GENE - induce GENE and GENE activation by interfere with ENTITY1 phosphorylation of GENE GENE GENE"
"GENE activation by interfere with ENTITY1 phosphorylation of ENTITY2 ."
"GENE , -PRON- observe that ENTITY1 inhibit endogenous and GENE GENE GENE - induce GENE and ENTITY2 activation by interfere with CHEMICAL"
"GENE , -PRON- observe that ENTITY1 inhibit endogenous and GENE GENE GENE - induce ENTITY2 and GENE activation by interfere"
"GENE , -PRON- observe that ENTITY1 inhibit endogenous and ENTITY2 - induce GENE and GENE"
""" work upwards "" from ENTITY2 , -PRON- observe that ENTITY1 inhibit endogenous and GENE GENE"
"GENE , -PRON- observe that ENTITY1 inhibit endogenous and GENE GENE GENE - induce GENE and GENE activation by interfere with CHEMICAL phosphorylation of ENTITY2 ."
"after the initial bleach , ENTITY1 impede photon absorption by ENTITY2 by inhibit metabolic GENE regeneration"
"after the initial bleach , ENTITY1 impede photon absorption by GENE by inhibit metabolic ENTITY2 regeneration ."
"improve overall profile of the ENTITY1 series of gsms , in particular the ENTITY2 activity , conformational modification of"
"improve overall profile of the ENTITY1 series of gsms , in particular the GENE activity , conformational modification of the core structure result in the identification of fuse CHEMICAL such as 7i which have an improved ENTITY2 inhibition profile and be a"
"gsms , in particular the ENTITY2 activity , conformational modification of the core structure result in the identification of fuse ENTITY1 such as 7i which have"
"in the identification of fuse ENTITY1 such as 7i which have an improved ENTITY2 inhibition profile and be a"
"ENTITY1 - induce or GENE - induce reversal be block by β-ark1 inhibitor , dynasore , or ENTITY2 antagonist CHEMICAL CHEMICAL CHEMICAL ("
"ENTITY1 - induce or ENTITY2 - induce reversal be block"
"inhibitor , dynasore , or ENTITY2 antagonist ENTITY1 ( CHEMICAL ) ."
"CHEMICAL - induce or ENTITY2 - induce reversal be block by β-ark1 inhibitor , dynasore , or GENE antagonist ENTITY1 ( CHEMICAL ) ."
"inhibitor , dynasore , or ENTITY2 antagonist CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) ."
"CHEMICAL - induce or ENTITY2 - induce reversal be block by β-ark1 inhibitor , dynasore , or GENE antagonist CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) ."
"at the level of the ENTITY2 receptor that mediate most , if not all , of the important action of CHEMICAL CHEMICAL , and avoid the nonspecificity of the ENTITY1 GENE GENE inhibitor ."
"selectively block the GENE - ENTITY2 - CHEMICAL system at the level of the GENE receptor that mediate most , if not all , of the important action of CHEMICAL CHEMICAL , and avoid the nonspecificity of the ENTITY1 GENE GENE inhibitor ."
"benefit of selectively block the ENTITY2 - GENE - CHEMICAL system at the level of the GENE receptor that mediate most , if not all , of the important action of CHEMICAL CHEMICAL , and avoid the nonspecificity of the ENTITY1 GENE GENE inhibitor ."
"the GENE - GENE - ENTITY1 system at the level of the ENTITY2 receptor that mediate most ,"
"selectively block the GENE - ENTITY2 - ENTITY1 system at the level of"
"benefit of selectively block the ENTITY2 - GENE - ENTITY1 system at the level of"
"active and long act nonpeptide ENTITY1 GENE GENE GENE GENE GENE GENE antagonist have provide the opportunity to obtain the benefit of selectively block the GENE - GENE - CHEMICAL system at the level of the ENTITY2 receptor that mediate most ,"
"active and long act nonpeptide ENTITY1 GENE GENE GENE GENE GENE GENE antagonist have provide the opportunity to obtain the benefit of selectively block the GENE - ENTITY2 - CHEMICAL system at the"
"active and long act nonpeptide ENTITY1 GENE GENE GENE GENE GENE GENE antagonist have provide the opportunity to obtain the benefit of selectively block the ENTITY2 - GENE - CHEMICAL system"
"at the level of the ENTITY2 receptor that mediate most , if not all , of the important action of ENTITY1 , and avoid the nonspecificity"
"selectively block the GENE - ENTITY2 - CHEMICAL system at the level of the GENE receptor that mediate most , if not all , of the important action of ENTITY1 , and avoid the nonspecificity"
"benefit of selectively block the ENTITY2 - GENE - CHEMICAL system at the level of the GENE receptor that mediate most , if not all , of the important action of ENTITY1 , and avoid the nonspecificity"
"the density of ENTITY2 in testis and ovary tissue show no significant difference between ENTITY1 group and control group at"
"ENTITY1 be the first , but by no mean remain the only , ENTITY2 receptor antagonist ."
"long - term treatment with ENTITY1 further enhance the expression of ENTITY2 ."
"the earliest know ENTITY2 inhibitor , namely , CHEMICAL and ENTITY1 , perform poorly in clinical"
"the earliest know ENTITY2 inhibitor , namely , ENTITY1 and CHEMICAL , perform poorly"
"hepatic mrna expression of ENTITY2 and GENE GENE GENE GENE be significantly low in ENTITY1 group than in other group"
"expression of GENE GENE and ENTITY2 be significantly low in ENTITY1 group than in other group"
"of the non - selective ENTITY2 antagonist CHEMICAL ( id50 = 1.45 microg ) , the GENE GENE GENE antagonist CHEMICAL ( id50 = 4.33 microg ) , the GENE GENE GENE antagonist CHEMICAL ( id50 = 1.39 microg ) and the GENE GENE GENE antagonist ENTITY1 ( id50 = 31.19 microg"
"4.33 microg ) , the ENTITY2 antagonist CHEMICAL ( id50 = 1.39 microg ) and the GENE GENE GENE antagonist ENTITY1 ( id50 = 31.19 microg"
"1.39 microg ) and the ENTITY2 antagonist ENTITY1 ( id50 = 31.19 microg"
"1.45 microg ) , the ENTITY2 antagonist CHEMICAL ( id50 = 4.33 microg ) , the GENE GENE GENE antagonist CHEMICAL ( id50 = 1.39 microg ) and the GENE GENE GENE antagonist ENTITY1 ( id50 = 31.19 microg"
"of the non - selective ENTITY2 antagonist CHEMICAL ( id50 = 1.45 microg ) , the GENE GENE GENE antagonist CHEMICAL ( id50 = 4.33 microg ) , the GENE GENE GENE antagonist ENTITY1 ( id50 = 1.39 microg"
"4.33 microg ) , the ENTITY2 antagonist ENTITY1 ( id50 = 1.39 microg"
"the GENE GENE GENE antagonist ENTITY1 ( id50 = 1.39 microg ) and the ENTITY2 antagonist CHEMICAL CHEMICAL CHEMICAL CHEMICAL"
"1.45 microg ) , the ENTITY2 antagonist CHEMICAL ( id50 = 4.33 microg ) , the GENE GENE GENE antagonist ENTITY1 ( id50 = 1.39 microg"
"of the non - selective ENTITY2 antagonist ENTITY1 ( id50 = 1.45 microg"
"- selective GENE GENE antagonist ENTITY1 ( id50 = 1.45 microg ) , the GENE GENE GENE antagonist CHEMICAL ( id50 = 4.33 microg ) , the ENTITY2 antagonist CHEMICAL ( id50 ="
"- selective GENE GENE antagonist ENTITY1 ( id50 = 1.45 microg ) , the GENE GENE GENE antagonist CHEMICAL ( id50 = 4.33 microg ) , the GENE GENE GENE antagonist CHEMICAL ( id50 = 1.39 microg ) and the ENTITY2 antagonist CHEMICAL CHEMICAL CHEMICAL CHEMICAL"
"- selective GENE GENE antagonist ENTITY1 ( id50 = 1.45 microg ) , the ENTITY2 antagonist CHEMICAL ( id50 ="
"of the non - selective ENTITY2 antagonist CHEMICAL ( id50 = 1.45 microg ) , the GENE GENE GENE antagonist ENTITY1 ( id50 = 4.33 microg"
"the GENE GENE GENE antagonist ENTITY1 ( id50 = 4.33 microg ) , the ENTITY2 antagonist CHEMICAL ( id50 ="
"the GENE GENE GENE antagonist ENTITY1 ( id50 = 4.33 microg ) , the GENE GENE GENE antagonist CHEMICAL ( id50 = 1.39 microg ) and the ENTITY2 antagonist CHEMICAL CHEMICAL CHEMICAL CHEMICAL"
"1.45 microg ) , the ENTITY2 antagonist ENTITY1 ( id50 = 4.33 microg"
"find to alter the plasma ENTITY2 - c - relate factor ; meanwhile , ENTITY1 supplementation be very effective in"
"relate factor ; meanwhile , ENTITY1 supplementation be very effective in enhance CHEMICAL metabolism , except for a negative effect that reduce plasma ENTITY2 - c concentration . 
"
"ENTITY1 supplementation be find to alter the plasma ENTITY2 - c - relate factor"
"ENTITY1 supplementation be find to alter the plasma GENE - c - relate factor ; meanwhile , CHEMICAL supplementation be very effective in enhance CHEMICAL metabolism , except for a negative effect that reduce plasma ENTITY2 - c concentration . 
"
"find to alter the plasma ENTITY2 - c - relate factor ; meanwhile , CHEMICAL supplementation be very effective in enhance ENTITY1 metabolism , except for a"
"be very effective in enhance ENTITY1 metabolism , except for a negative effect that reduce plasma ENTITY2 - c concentration . 
"
"simple CHEMICAL be rather ineffective ENTITY2 inhibitor , with inhibition constant in the range of 1090 - 6680 nm. better inhibitor be detect among such derivative bear CHEMICAL CHEMICAL CHEMICAL , CHEMICAL , or CHEMICAL moiety or among halogenat ENTITY1 ( ki value of 608"
"simple ENTITY1 be rather ineffective ENTITY2 inhibitor , with inhibition constant"
"simple CHEMICAL be rather ineffective ENTITY2 inhibitor , with inhibition constant in the range of 1090 - 6680 nm. better inhibitor be detect among such derivative bear CHEMICAL CHEMICAL CHEMICAL , CHEMICAL , or ENTITY1 moiety or among halogenat CHEMICAL"
"conclusion : ENTITY1 up - regulate the density of ENTITY2 in liver tissue , whereas"
"conclusion : ENTITY1 up - regulate the density of GENE in liver tissue , whereas -PRON- have no significant effect on the density of ENTITY2 in testis and ovary tissue"
"ENTITY1 inaugurate a new class of ENTITY2 inhibitor with long and more"
"of GENE by CHEMICAL and ENTITY1 depend upon GENE and not ENTITY2 ( the canonical mechanism )"
"in contrast , activation of ENTITY2 by CHEMICAL and ENTITY1 depend upon GENE and not"
", activation of GENE by ENTITY1 and CHEMICAL CHEMICAL CHEMICAL depend upon GENE and not ENTITY2 ( the canonical mechanism )"
"in contrast , activation of ENTITY2 by ENTITY1 and CHEMICAL CHEMICAL CHEMICAL depend"
"among the current ENTITY2 receptor antagonist , the rank order of the relative binding affinity ( high affinity = 1 ) be : CHEMICAL 1 , CHEMICAL 10 , CHEMICAL ( the active metabolite of CHEMICAL ) 10 , ENTITY1 20 , CHEMICAL 50 ,"
"among the current ENTITY2 receptor antagonist , the rank order of the relative binding affinity ( high affinity = 1 ) be : ENTITY1 1 , CHEMICAL 10 ,"
"among the current ENTITY2 receptor antagonist , the rank order of the relative binding affinity ( high affinity = 1 ) be : CHEMICAL 1 , CHEMICAL 10 , ENTITY1 ( the active metabolite of"
"among the current ENTITY2 receptor antagonist , the rank order of the relative binding affinity ( high affinity = 1 ) be : CHEMICAL 1 , ENTITY1 10 , CHEMICAL ( the"
"among the current ENTITY2 receptor antagonist , the rank order of the relative binding affinity ( high affinity = 1 ) be : CHEMICAL 1 , CHEMICAL 10 , CHEMICAL ( the active metabolite of ENTITY1 ) 10 , CHEMICAL 20"
"among the current ENTITY2 receptor antagonist , the rank order of the relative binding affinity ( high affinity = 1 ) be : CHEMICAL 1 , CHEMICAL 10 , CHEMICAL ( the active metabolite of CHEMICAL ) 10 , CHEMICAL 20 , ENTITY1 50 , CHEMICAL 100 and"
"among the current ENTITY2 receptor antagonist , the rank order of the relative binding affinity ( high affinity = 1 ) be : CHEMICAL 1 , CHEMICAL 10 , CHEMICAL ( the active metabolite of CHEMICAL ) 10 , CHEMICAL 20 , CHEMICAL 50 , ENTITY1 100 and the prodrug CHEMICAL"
"among the current ENTITY2 receptor antagonist , the rank order of the relative binding affinity ( high affinity = 1 ) be : CHEMICAL 1 , CHEMICAL 10 , CHEMICAL ( the active metabolite of CHEMICAL ) 10 , CHEMICAL 20 , CHEMICAL 50 , CHEMICAL 100 and the prodrug ENTITY1 280 ."
", CHEMICAL , CHEMICAL , ENTITY1 , CHEMICAL , and CHEMICAL , or the orphan drug CHEMICAL , show effective ENTITY2 inhibitory activity , with inhibition"
", CHEMICAL , CHEMICAL , ENTITY1 , CHEMICAL , and CHEMICAL , or the orphan drug CHEMICAL , show effective GENE GENE inhibitory activity , with inhibition constant of 0.8 - 79 nm. the good inhibitor be CHEMICAL and CHEMICAL ( ki value of 0.8 - 0.9 nm ) , the latter compound be also a ENTITY2 - selective inhibitor ."
", CHEMICAL , CHEMICAL , ENTITY1 , and CHEMICAL , or the orphan drug CHEMICAL , show effective ENTITY2 inhibitory activity , with inhibition"
", CHEMICAL , CHEMICAL , ENTITY1 , and CHEMICAL , or the orphan drug CHEMICAL , show effective GENE GENE inhibitory activity , with inhibition constant of 0.8 - 79 nm. the good inhibitor be CHEMICAL and CHEMICAL ( ki value of 0.8 - 0.9 nm ) , the latter compound be also a ENTITY2 - selective inhibitor ."
"drug CHEMICAL , show effective ENTITY2 inhibitory activity , with inhibition constant of 0.8 - 79 nm. the good inhibitor be CHEMICAL and ENTITY1 ( ki value of 0.8"
"good inhibitor be CHEMICAL and ENTITY1 ( ki value of 0.8 - 0.9 nm ) , the latter compound be also a ENTITY2 - selective inhibitor ."
", such as CHEMICAL , ENTITY1 , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , and CHEMICAL , or the orphan drug CHEMICAL , show effective ENTITY2 inhibitory activity , with inhibition"
", such as CHEMICAL , ENTITY1 , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , and CHEMICAL , or the orphan drug CHEMICAL , show effective GENE GENE inhibitory activity , with inhibition constant of 0.8 - 79 nm. the good inhibitor be CHEMICAL and CHEMICAL ( ki value of 0.8 - 0.9 nm ) , the latter compound be also a ENTITY2 - selective inhibitor ."
", CHEMICAL , CHEMICAL , ENTITY1 , CHEMICAL , CHEMICAL , CHEMICAL , and CHEMICAL , or the orphan drug CHEMICAL , show effective ENTITY2 inhibitory activity , with inhibition"
", CHEMICAL , CHEMICAL , ENTITY1 , CHEMICAL , CHEMICAL , CHEMICAL , and CHEMICAL , or the orphan drug CHEMICAL , show effective GENE GENE inhibitory activity , with inhibition constant of 0.8 - 79 nm. the good inhibitor be CHEMICAL and CHEMICAL ( ki value of 0.8 - 0.9 nm ) , the latter compound be also a ENTITY2 - selective inhibitor ."
"as CHEMICAL , CHEMICAL , ENTITY1 , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , and CHEMICAL , or the orphan drug CHEMICAL , show effective ENTITY2 inhibitory activity , with inhibition"
"as CHEMICAL , CHEMICAL , ENTITY1 , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , and CHEMICAL , or the orphan drug CHEMICAL , show effective GENE GENE inhibitory activity , with inhibition constant of 0.8 - 79 nm. the good inhibitor be CHEMICAL and CHEMICAL ( ki value of 0.8 - 0.9 nm ) , the latter compound be also a ENTITY2 - selective inhibitor ."
", or the orphan drug ENTITY1 , show effective ENTITY2 inhibitory activity , with inhibition"
", or the orphan drug ENTITY1 , show effective GENE GENE inhibitory activity , with inhibition constant of 0.8 - 79 nm. the good inhibitor be CHEMICAL and CHEMICAL ( ki value of 0.8 - 0.9 nm ) , the latter compound be also a ENTITY2 - selective inhibitor ."
"used compound , such as ENTITY1 , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , and CHEMICAL , or the orphan drug CHEMICAL , show effective ENTITY2 inhibitory activity , with inhibition"
"used compound , such as ENTITY1 , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , and CHEMICAL , or the orphan drug CHEMICAL , show effective GENE GENE inhibitory activity , with inhibition constant of 0.8 - 79 nm. the good inhibitor be CHEMICAL and CHEMICAL ( ki value of 0.8 - 0.9 nm ) , the latter compound be also a ENTITY2 - selective inhibitor ."
"CHEMICAL , CHEMICAL , and ENTITY1 , or the orphan drug CHEMICAL , show effective ENTITY2 inhibitory activity , with inhibition"
"CHEMICAL , CHEMICAL , and ENTITY1 , or the orphan drug CHEMICAL , show effective GENE GENE inhibitory activity , with inhibition constant of 0.8 - 79 nm. the good inhibitor be CHEMICAL and CHEMICAL ( ki value of 0.8 - 0.9 nm ) , the latter compound be also a ENTITY2 - selective inhibitor ."
", CHEMICAL , CHEMICAL , ENTITY1 , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , and CHEMICAL , or the orphan drug CHEMICAL , show effective ENTITY2 inhibitory activity , with inhibition"
", CHEMICAL , CHEMICAL , ENTITY1 , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , and CHEMICAL , or the orphan drug CHEMICAL , show effective GENE GENE inhibitory activity , with inhibition constant of 0.8 - 79 nm. the good inhibitor be CHEMICAL and CHEMICAL ( ki value of 0.8 - 0.9 nm ) , the latter compound be also a ENTITY2 - selective inhibitor ."
", CHEMICAL , CHEMICAL , ENTITY1 , CHEMICAL , CHEMICAL , and CHEMICAL , or the orphan drug CHEMICAL , show effective ENTITY2 inhibitory activity , with inhibition"
", CHEMICAL , CHEMICAL , ENTITY1 , CHEMICAL , CHEMICAL , and CHEMICAL , or the orphan drug CHEMICAL , show effective GENE GENE inhibitory activity , with inhibition constant of 0.8 - 79 nm. the good inhibitor be CHEMICAL and CHEMICAL ( ki value of 0.8 - 0.9 nm ) , the latter compound be also a ENTITY2 - selective inhibitor ."
"drug CHEMICAL , show effective ENTITY2 inhibitory activity , with inhibition constant of 0.8 - 79 nm. the good inhibitor be ENTITY1 and CHEMICAL ( ki value"
"nm. the good inhibitor be ENTITY1 and CHEMICAL ( ki value of 0.8 - 0.9 nm ) , the latter compound be also a ENTITY2 - selective inhibitor ."
"mode of ( functional ) ENTITY2 receptor antagonism have be characterize as surmountable / noncompetitive ( CHEMICAL , ENTITY1 , CHEMICAL ) or insurmountable"
"mode of ( functional ) ENTITY2 receptor antagonism have be characterize as surmountable / noncompetitive ( CHEMICAL , CHEMICAL , CHEMICAL ) or insurmountable / noncompetitive ( ENTITY1 , CHEMICAL , CHEMICAL ,"
"mode of ( functional ) ENTITY2 receptor antagonism have be characterize as surmountable / noncompetitive ( CHEMICAL , CHEMICAL , CHEMICAL ) or insurmountable / noncompetitive ( CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , ENTITY1 ) ."
"mode of ( functional ) ENTITY2 receptor antagonism have be characterize as surmountable / noncompetitive ( CHEMICAL , CHEMICAL , CHEMICAL ) or insurmountable / noncompetitive ( CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , ENTITY1 , CHEMICAL ) ."
"mode of ( functional ) ENTITY2 receptor antagonism have be characterize as surmountable / noncompetitive ( ENTITY1 , CHEMICAL , CHEMICAL )"
"mode of ( functional ) ENTITY2 receptor antagonism have be characterize as surmountable / noncompetitive ( CHEMICAL , CHEMICAL , ENTITY1 ) or insurmountable / noncompetitive"
"mode of ( functional ) ENTITY2 receptor antagonism have be characterize as surmountable / noncompetitive ( CHEMICAL , CHEMICAL , CHEMICAL ) or insurmountable / noncompetitive ( CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , ENTITY1 , CHEMICAL , CHEMICAL )"
"mode of ( functional ) ENTITY2 receptor antagonism have be characterize as surmountable / noncompetitive ( CHEMICAL , CHEMICAL , CHEMICAL ) or insurmountable / noncompetitive ( CHEMICAL , CHEMICAL , CHEMICAL , ENTITY1 , CHEMICAL , CHEMICAL ,"
"mode of ( functional ) ENTITY2 receptor antagonism have be characterize as surmountable / noncompetitive ( CHEMICAL , CHEMICAL , CHEMICAL ) or insurmountable / noncompetitive ( CHEMICAL , ENTITY1 , CHEMICAL , CHEMICAL ,"
"mode of ( functional ) ENTITY2 receptor antagonism have be characterize as surmountable / noncompetitive ( CHEMICAL , CHEMICAL , CHEMICAL ) or insurmountable / noncompetitive ( CHEMICAL , CHEMICAL , ENTITY1 , CHEMICAL , CHEMICAL ,"
"this preference be partial because ENTITY2 do not conjugate the CHEMICAL CHEMICAL CHEMICAL in ENTITY1 ."
"this preference be partial because ENTITY2 do not conjugate the ENTITY1 in CHEMICAL ."
"effect of ENTITY1 on weight be dose - dependent , and -PRON- could be give orally . 1 , 2 , 4 , 5 down - regulate ENTITY2 mrna expression . 
"
"lv remodeling be benefit by ENTITY1 GENE GENE GENE ( ENTITY2 ) blocker ."
"have dual function as a ENTITY1 GENE GENE agonist and ENTITY2 antagonist ."
"ENTITY1 ( CHEMICAL ) , an active ingredient of the chinese herb stephania , be the first compound find to have dual function as a CHEMICAL GENE GENE agonist and ENTITY2 antagonist ."
"CHEMICAL CHEMICAL ( ENTITY1 ) , an active ingredient of the chinese herb stephania , be the first compound find to have dual function as a CHEMICAL GENE GENE agonist and ENTITY2 antagonist ."
"ENTITY1 , a derivative of CHEMICAL , be first describe as an inhibitor of ENTITY2 ( GENE ) and be"
"ENTITY1 , a derivative of CHEMICAL , be first describe as an inhibitor of GENE ( ENTITY2 ) and be show to"
"CHEMICAL , a derivative of ENTITY1 , be first describe as an inhibitor of ENTITY2 ( GENE ) and be"
"CHEMICAL , a derivative of ENTITY1 , be first describe as an inhibitor of GENE ( ENTITY2 ) and be show to"
"inhibition be mediate by a ENTITY1 - induce secrete factor which be identify as ENTITY2 ( GENE ) ."
"inhibition be mediate by a ENTITY1 - induce secrete factor which be identify as GENE GENE GENE GENE GENE GENE GENE GENE ( ENTITY2 ) ."
"antagonize CHEMICAL activation of the ENTITY2 in prostate cell through focal adhesion complex involve GENE . 	 ENTITY1 ( GENE ) analog constitute"
"through focal adhesion complex involve ENTITY2 . 	 ENTITY1 ( GENE ) analog constitute"
"ENTITY2 functionally antagonize CHEMICAL activation of the GENE GENE GENE in prostate cell through focal adhesion complex involve GENE . 	 ENTITY1 ( GENE ) analog constitute"
"complex involve GENE . 	 ENTITY1 ( ENTITY2 ) analog constitute the most"
"GENE GENE GENE functionally antagonize ENTITY1 activation of the ENTITY2 in prostate cell through focal"
"GENE GENE GENE functionally antagonize ENTITY1 activation of the GENE GENE GENE in prostate cell through focal adhesion complex involve ENTITY2 . 	 CHEMICAL CHEMICAL CHEMICAL"
"ENTITY2 functionally antagonize ENTITY1 activation of the GENE GENE"
"GENE GENE GENE functionally antagonize ENTITY1 activation of the GENE GENE GENE in prostate cell through focal adhesion complex involve GENE . 	 CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY2 ) analog constitute the most"
"of CHEMICAL , a preferential ENTITY2 inhibitor , against ENTITY1 ( CHEMICAL chemical kindle and"
"neuroprotective effect of ENTITY1 , a preferential ENTITY2 inhibitor , against CHEMICAL ("
"recent observation reveal that ENTITY2 catalyze n - glucuronidation of ENTITY1 - contain compound ."
"ENTITY1 deserve attention for an additional quality of action : in addition to inhibit GENE , -PRON- modulate the amount of ENTITY2 ( GENE ) in neuronal"
"ENTITY1 deserve attention for an additional quality of action : in addition to inhibit GENE , -PRON- modulate the amount of GENE GENE GENE GENE GENE ( ENTITY2 ) in neuronal cell culture"
"ENTITY1 deserve attention for an additional quality of action : in addition to inhibit GENE , -PRON- modulate the amount of GENE GENE GENE GENE GENE ( GENE ) in neuronal cell culture by reduce ENTITY2 translation ."
"ENTITY1 deserve attention for an additional quality of action : in addition to inhibit ENTITY2 , -PRON- modulate the amount"
"brain ENTITY2 ( GENE ) , the rate - limit enzyme in ENTITY1 synthesis , be rapidly and"
"brain GENE ( ENTITY2 ) , the rate - limit enzyme in ENTITY1 synthesis , be rapidly and"
"effect probably involve interaction of ENTITY1 with a regulatory element in the 5'-untranslated region of the ENTITY2 gene that control GENE expression"
"effect probably involve interaction of ENTITY1 with a regulatory element in the 5'-untranslated region of the GENE gene that control ENTITY2 expression ."
"ENTITY1 apparently reduce translational efficiency of ENTITY2 mrna into protein , a"
"apparently reduce translational efficiency of ENTITY2 mrna into protein , a process that may involve an interaction with ENTITY1 and/or an CHEMICAL - responsive"
"apparently reduce translational efficiency of ENTITY2 mrna into protein , a process that may involve an interaction with CHEMICAL and/or an ENTITY1 - responsive element ."
"since the ENTITY1 GENE have be show to affect GENE GENE GENE GENE function , -PRON- consider that part of GENE analog action on prostate cell may be mediate through modulation of the ENTITY2 ."
"since the ENTITY1 GENE have be show to affect ENTITY2 function , -PRON- consider that"
"since the ENTITY1 GENE have be show to affect GENE GENE GENE GENE function , -PRON- consider that part of ENTITY2 analog action on prostate cell"
"the ki for ENTITY1 in serum - free medium alone , 0.46 microm , be similar to that determine in the presence of GENE ( 0.42 microm ) , ENTITY2 ( 0.54 microm ) ,"
"the ki for ENTITY1 in serum - free medium alone , 0.46 microm , be similar to that determine in the presence of ENTITY2 ( 0.42 microm ) ,"
"the ki for ENTITY1 in serum - free medium alone , 0.46 microm , be similar to that determine in the presence of GENE ( 0.42 microm ) , GENE GENE GENE GENE GENE GENE ( 0.54 microm ) , and ENTITY2 ( 0.43 microm ) ."
"CHEMICAL enhance the expression of ENTITY2 gene and the cellular ENTITY1 content in vital organ such"
"show that dietary supplement of ENTITY1 enhance the expression of ENTITY2 gene and the cellular CHEMICAL"
"of CHEMICAL ( a preferential ENTITY2 inhibitor ) against ENTITY1 ( CHEMICAL kindle epilepsy in"
"explore the possible effect of ENTITY1 ( a preferential ENTITY2 inhibitor ) against CHEMICAL ("
"day of a mixture of ENTITY2 ( GENE ) agonist ( CHEMICAL CHEMICAL CHEMICAL CHEMICAL , ENTITY1 and CHEMICAL CHEMICAL CHEMICAL )"
"of GENE GENE GENE ( ENTITY2 ) agonist ( CHEMICAL CHEMICAL CHEMICAL CHEMICAL , ENTITY1 and CHEMICAL CHEMICAL CHEMICAL )"
"day of a mixture of ENTITY2 ( GENE ) agonist ( CHEMICAL CHEMICAL CHEMICAL CHEMICAL , CHEMICAL CHEMICAL CHEMICAL and ENTITY1 ) without or with 0.5"
"of GENE GENE GENE ( ENTITY2 ) agonist ( CHEMICAL CHEMICAL CHEMICAL CHEMICAL , CHEMICAL CHEMICAL CHEMICAL and ENTITY1 ) without or with 0.5"
"this mechanism involve the ENTITY1 - dependent GENE GENE GENE , the GENE GENE GENE GENE GENE GENE GENE GENE and the GENE GENE GENE / GENE GENE GENE GENE GENE , ENTITY2 ."
"this mechanism involve the ENTITY1 - dependent GENE GENE GENE , the GENE GENE GENE GENE GENE GENE GENE GENE and the ENTITY2 / GENE GENE GENE GENE"
"this mechanism involve the ENTITY1 - dependent ENTITY2 GENE , the GENE GENE"
"this mechanism involve the ENTITY1 - dependent GENE GENE ENTITY2 , the GENE GENE GENE"
"this mechanism involve the ENTITY1 - dependent GENE GENE GENE , the GENE GENE GENE GENE GENE GENE GENE GENE and the GENE GENE GENE / ENTITY2 , GENE ."
"this mechanism involve the ENTITY1 - dependent GENE GENE GENE , the GENE GENE GENE GENE GENE ENTITY2 and the GENE GENE GENE"
"this mechanism involve the ENTITY1 - dependent GENE GENE GENE , the ENTITY2 GENE GENE GENE and the"
"ovariectomy downregulat ENTITY2 and render female mouse vulnerable to CHEMICAL CHEMICAL CHEMICAL toxicity as evidence by activation of GENE , loss of ENTITY1 and GENE GENE activity indicate"
"of GENE , loss of ENTITY1 and GENE GENE activity indicate the important role of ENTITY2 in neuroprotection ."
"of GENE , loss of ENTITY1 and ENTITY2 activity indicate the important role"
"as evidence by activation of ENTITY2 , loss of ENTITY1 and GENE GENE activity indicate"
"ovariectomy downregulat ENTITY2 and render female mouse vulnerable to ENTITY1 toxicity as evidence by activation"
"render female mouse vulnerable to ENTITY1 toxicity as evidence by activation of GENE , loss of CHEMICAL and GENE GENE activity indicate the important role of ENTITY2 in neuroprotection ."
"render female mouse vulnerable to ENTITY1 toxicity as evidence by activation of GENE , loss of CHEMICAL and ENTITY2 activity indicate the important role"
"render female mouse vulnerable to ENTITY1 toxicity as evidence by activation of ENTITY2 , loss of CHEMICAL and"
"this setting there be a ENTITY1 - induce association and nuclear translocation of the GENE GENE with ENTITY2 ."
"this setting there be a ENTITY1 - induce association and nuclear translocation of the ENTITY2 with GENE ."
"dominant negative GENE enhance the ENTITY1 - induce nuclear translocation of a green fluorescent protein - tag ENTITY2 ."
"GENE - induce ENTITY2 activation oppose the association of GENE with GENE GENE as overexpression of a dominant negative GENE enhance the ENTITY1 - induce nuclear translocation of"
"overexpression of a dominant negative ENTITY2 enhance the ENTITY1 - induce nuclear translocation of"
"activation oppose the association of ENTITY2 with GENE GENE as overexpression of a dominant negative GENE enhance the ENTITY1 - induce nuclear translocation of"
"ENTITY2 - induce GENE activation oppose the association of GENE with GENE GENE as overexpression of a dominant negative GENE enhance the ENTITY1 - induce nuclear translocation of"
"the association of GENE with ENTITY2 as overexpression of a dominant negative GENE enhance the ENTITY1 - induce nuclear translocation of"
", GENE GENE GENE by ENTITY1 ( 1 mg / kg i.p . ) , both GENE GENE GENE and GENE GENE GENE by CHEMICAL ( 75 mg / kg i.p . ) or peripheral neuronal ENTITY2 by CHEMICAL ( 40 mg"
"kg i.p . ) , ENTITY2 by ENTITY1 ( 1 mg / kg"
", GENE GENE GENE by ENTITY1 ( 1 mg / kg i.p . ) , both GENE GENE GENE and ENTITY2 by CHEMICAL ( 75 mg"
"be measure after inhibition of ENTITY2 ( GENE GENE GENE ) by CHEMICAL ( 4 mg / kg i.p . ) , GENE GENE GENE by ENTITY1 ( 1 mg / kg"
"GENE GENE GENE GENE ( ENTITY2 ) by CHEMICAL ( 4 mg / kg i.p . ) , GENE GENE GENE by ENTITY1 ( 1 mg / kg"
", GENE GENE GENE by ENTITY1 ( 1 mg / kg i.p . ) , both ENTITY2 and GENE GENE GENE by"
"level of CHEMICAL CHEMICAL ( ENTITY1 ) , CHEMICAL CHEMICAL ( CHEMICAL ) and CHEMICAL ( CHEMICAL ) in plasma and the striatium be measure after inhibition of GENE GENE GENE GENE ( GENE GENE GENE ) by CHEMICAL ( 4 mg / kg i.p . ) , GENE GENE GENE by CHEMICAL CHEMICAL ( 1 mg / kg i.p . ) , both GENE GENE GENE and GENE GENE GENE by CHEMICAL ( 75 mg / kg i.p . ) or peripheral neuronal ENTITY2 by CHEMICAL ( 40 mg"
"level of CHEMICAL CHEMICAL ( ENTITY1 ) , CHEMICAL CHEMICAL ( CHEMICAL ) and CHEMICAL ( CHEMICAL ) in plasma and the striatium be measure after inhibition of GENE GENE GENE GENE ( GENE GENE GENE ) by CHEMICAL ( 4 mg / kg i.p . ) , ENTITY2 by CHEMICAL CHEMICAL ( 1"
"level of CHEMICAL CHEMICAL ( ENTITY1 ) , CHEMICAL CHEMICAL ( CHEMICAL ) and CHEMICAL ( CHEMICAL ) in plasma and the striatium be measure after inhibition of GENE GENE GENE GENE ( GENE GENE GENE ) by CHEMICAL ( 4 mg / kg i.p . ) , GENE GENE GENE by CHEMICAL CHEMICAL ( 1 mg / kg i.p . ) , both GENE GENE GENE and ENTITY2 by CHEMICAL ( 75 mg"
"level of CHEMICAL CHEMICAL ( ENTITY1 ) , CHEMICAL CHEMICAL ( CHEMICAL ) and CHEMICAL ( CHEMICAL ) in plasma and the striatium be measure after inhibition of ENTITY2 ( GENE GENE GENE )"
"level of CHEMICAL CHEMICAL ( ENTITY1 ) , CHEMICAL CHEMICAL ( CHEMICAL ) and CHEMICAL ( CHEMICAL ) in plasma and the striatium be measure after inhibition of GENE GENE GENE GENE ( ENTITY2 ) by CHEMICAL ( 4"
"level of CHEMICAL CHEMICAL ( ENTITY1 ) , CHEMICAL CHEMICAL ( CHEMICAL ) and CHEMICAL ( CHEMICAL ) in plasma and the striatium be measure after inhibition of GENE GENE GENE GENE ( GENE GENE GENE ) by CHEMICAL ( 4 mg / kg i.p . ) , GENE GENE GENE by CHEMICAL CHEMICAL ( 1 mg / kg i.p . ) , both ENTITY2 and GENE GENE GENE by"
". ) or peripheral neuronal ENTITY2 by ENTITY1 ( 40 mg / kg"
"kg i.p . ) , ENTITY2 by CHEMICAL CHEMICAL ( 1 mg / kg i.p . ) , both GENE GENE GENE and GENE GENE GENE by CHEMICAL ( 75 mg / kg i.p . ) or peripheral neuronal GENE by ENTITY1 ( 40 mg / kg"
"both GENE GENE GENE and ENTITY2 by CHEMICAL ( 75 mg / kg i.p . ) or peripheral neuronal GENE by ENTITY1 ( 40 mg / kg"
"be measure after inhibition of ENTITY2 ( GENE GENE GENE ) by CHEMICAL ( 4 mg / kg i.p . ) , GENE GENE GENE by CHEMICAL CHEMICAL ( 1 mg / kg i.p . ) , both GENE GENE GENE and GENE GENE GENE by CHEMICAL ( 75 mg / kg i.p . ) or peripheral neuronal GENE by ENTITY1 ( 40 mg / kg"
"GENE GENE GENE GENE ( ENTITY2 ) by CHEMICAL ( 4 mg / kg i.p . ) , GENE GENE GENE by CHEMICAL CHEMICAL ( 1 mg / kg i.p . ) , both GENE GENE GENE and GENE GENE GENE by CHEMICAL ( 75 mg / kg i.p . ) or peripheral neuronal GENE by ENTITY1 ( 40 mg / kg"
"i.p . ) , both ENTITY2 and GENE GENE GENE by CHEMICAL ( 75 mg / kg i.p . ) or peripheral neuronal GENE by ENTITY1 ( 40 mg / kg"
"level of ENTITY1 ( CHEMICAL ) , CHEMICAL CHEMICAL ( CHEMICAL ) and CHEMICAL ( CHEMICAL ) in plasma and the striatium be measure after inhibition of GENE GENE GENE GENE ( GENE GENE GENE ) by CHEMICAL ( 4 mg / kg i.p . ) , GENE GENE GENE by CHEMICAL CHEMICAL ( 1 mg / kg i.p . ) , both GENE GENE GENE and GENE GENE GENE by CHEMICAL ( 75 mg / kg i.p . ) or peripheral neuronal ENTITY2 by CHEMICAL ( 40 mg"
"level of ENTITY1 ( CHEMICAL ) , CHEMICAL CHEMICAL ( CHEMICAL ) and CHEMICAL ( CHEMICAL ) in plasma and the striatium be measure after inhibition of GENE GENE GENE GENE ( GENE GENE GENE ) by CHEMICAL ( 4 mg / kg i.p . ) , ENTITY2 by CHEMICAL CHEMICAL ( 1"
"level of ENTITY1 ( CHEMICAL ) , CHEMICAL CHEMICAL ( CHEMICAL ) and CHEMICAL ( CHEMICAL ) in plasma and the striatium be measure after inhibition of GENE GENE GENE GENE ( GENE GENE GENE ) by CHEMICAL ( 4 mg / kg i.p . ) , GENE GENE GENE by CHEMICAL CHEMICAL ( 1 mg / kg i.p . ) , both GENE GENE GENE and ENTITY2 by CHEMICAL ( 75 mg"
"level of ENTITY1 ( CHEMICAL ) , CHEMICAL CHEMICAL ( CHEMICAL ) and CHEMICAL ( CHEMICAL ) in plasma and the striatium be measure after inhibition of ENTITY2 ( GENE GENE GENE )"
"level of ENTITY1 ( CHEMICAL ) , CHEMICAL CHEMICAL ( CHEMICAL ) and CHEMICAL ( CHEMICAL ) in plasma and the striatium be measure after inhibition of GENE GENE GENE GENE ( ENTITY2 ) by CHEMICAL ( 4"
"level of ENTITY1 ( CHEMICAL ) , CHEMICAL CHEMICAL ( CHEMICAL ) and CHEMICAL ( CHEMICAL ) in plasma and the striatium be measure after inhibition of GENE GENE GENE GENE ( GENE GENE GENE ) by CHEMICAL ( 4 mg / kg i.p . ) , GENE GENE GENE by CHEMICAL CHEMICAL ( 1 mg / kg i.p . ) , both ENTITY2 and GENE GENE GENE by"
"GENE GENE GENE ) by ENTITY1 ( 4 mg / kg i.p . ) , GENE GENE GENE by CHEMICAL CHEMICAL ( 1 mg / kg i.p . ) , both GENE GENE GENE and GENE GENE GENE by CHEMICAL ( 75 mg / kg i.p . ) or peripheral neuronal ENTITY2 by CHEMICAL ( 40 mg"
"GENE GENE GENE ) by ENTITY1 ( 4 mg / kg i.p . ) , ENTITY2 by CHEMICAL CHEMICAL ( 1"
"GENE GENE GENE ) by ENTITY1 ( 4 mg / kg i.p . ) , GENE GENE GENE by CHEMICAL CHEMICAL ( 1 mg / kg i.p . ) , both GENE GENE GENE and ENTITY2 by CHEMICAL ( 75 mg"
"be measure after inhibition of ENTITY2 ( GENE GENE GENE ) by ENTITY1 ( 4 mg / kg"
"GENE GENE GENE GENE ( ENTITY2 ) by ENTITY1 ( 4 mg / kg"
"GENE GENE GENE ) by ENTITY1 ( 4 mg / kg i.p . ) , GENE GENE GENE by CHEMICAL CHEMICAL ( 1 mg / kg i.p . ) , both ENTITY2 and GENE GENE GENE by"
") , CHEMICAL CHEMICAL ( ENTITY1 ) and CHEMICAL ( CHEMICAL ) in plasma and the striatium be measure after inhibition of GENE GENE GENE GENE ( GENE GENE GENE ) by CHEMICAL ( 4 mg / kg i.p . ) , GENE GENE GENE by CHEMICAL CHEMICAL ( 1 mg / kg i.p . ) , both GENE GENE GENE and GENE GENE GENE by CHEMICAL ( 75 mg / kg i.p . ) or peripheral neuronal ENTITY2 by CHEMICAL ( 40 mg"
") , CHEMICAL CHEMICAL ( ENTITY1 ) and CHEMICAL ( CHEMICAL ) in plasma and the striatium be measure after inhibition of GENE GENE GENE GENE ( GENE GENE GENE ) by CHEMICAL ( 4 mg / kg i.p . ) , ENTITY2 by CHEMICAL CHEMICAL ( 1"
") , CHEMICAL CHEMICAL ( ENTITY1 ) and CHEMICAL ( CHEMICAL ) in plasma and the striatium be measure after inhibition of GENE GENE GENE GENE ( GENE GENE GENE ) by CHEMICAL ( 4 mg / kg i.p . ) , GENE GENE GENE by CHEMICAL CHEMICAL ( 1 mg / kg i.p . ) , both GENE GENE GENE and ENTITY2 by CHEMICAL ( 75 mg"
") , CHEMICAL CHEMICAL ( ENTITY1 ) and CHEMICAL ( CHEMICAL ) in plasma and the striatium be measure after inhibition of ENTITY2 ( GENE GENE GENE )"
") , CHEMICAL CHEMICAL ( ENTITY1 ) and CHEMICAL ( CHEMICAL ) in plasma and the striatium be measure after inhibition of GENE GENE GENE GENE ( ENTITY2 ) by CHEMICAL ( 4"
") , CHEMICAL CHEMICAL ( ENTITY1 ) and CHEMICAL ( CHEMICAL ) in plasma and the striatium be measure after inhibition of GENE GENE GENE GENE ( GENE GENE GENE ) by CHEMICAL ( 4 mg / kg i.p . ) , GENE GENE GENE by CHEMICAL CHEMICAL ( 1 mg / kg i.p . ) , both ENTITY2 and GENE GENE GENE by"
"CHEMICAL ( CHEMICAL ) and ENTITY1 ( CHEMICAL ) in plasma and the striatium be measure after inhibition of GENE GENE GENE GENE ( GENE GENE GENE ) by CHEMICAL ( 4 mg / kg i.p . ) , GENE GENE GENE by CHEMICAL CHEMICAL ( 1 mg / kg i.p . ) , both GENE GENE GENE and GENE GENE GENE by CHEMICAL ( 75 mg / kg i.p . ) or peripheral neuronal ENTITY2 by CHEMICAL ( 40 mg"
"CHEMICAL ( CHEMICAL ) and ENTITY1 ( CHEMICAL ) in plasma and the striatium be measure after inhibition of GENE GENE GENE GENE ( GENE GENE GENE ) by CHEMICAL ( 4 mg / kg i.p . ) , ENTITY2 by CHEMICAL CHEMICAL ( 1"
"CHEMICAL ( CHEMICAL ) and ENTITY1 ( CHEMICAL ) in plasma and the striatium be measure after inhibition of GENE GENE GENE GENE ( GENE GENE GENE ) by CHEMICAL ( 4 mg / kg i.p . ) , GENE GENE GENE by CHEMICAL CHEMICAL ( 1 mg / kg i.p . ) , both GENE GENE GENE and ENTITY2 by CHEMICAL ( 75 mg"
"CHEMICAL ( CHEMICAL ) and ENTITY1 ( CHEMICAL ) in plasma and the striatium be measure after inhibition of ENTITY2 ( GENE GENE GENE )"
"CHEMICAL ( CHEMICAL ) and ENTITY1 ( CHEMICAL ) in plasma and the striatium be measure after inhibition of GENE GENE GENE GENE ( ENTITY2 ) by CHEMICAL ( 4"
"CHEMICAL ( CHEMICAL ) and ENTITY1 ( CHEMICAL ) in plasma and the striatium be measure after inhibition of GENE GENE GENE GENE ( GENE GENE GENE ) by CHEMICAL ( 4 mg / kg i.p . ) , GENE GENE GENE by CHEMICAL CHEMICAL ( 1 mg / kg i.p . ) , both ENTITY2 and GENE GENE GENE by"
"CHEMICAL ) and CHEMICAL ( ENTITY1 ) in plasma and the striatium be measure after inhibition of GENE GENE GENE GENE ( GENE GENE GENE ) by CHEMICAL ( 4 mg / kg i.p . ) , GENE GENE GENE by CHEMICAL CHEMICAL ( 1 mg / kg i.p . ) , both GENE GENE GENE and GENE GENE GENE by CHEMICAL ( 75 mg / kg i.p . ) or peripheral neuronal ENTITY2 by CHEMICAL ( 40 mg"
"CHEMICAL ) and CHEMICAL ( ENTITY1 ) in plasma and the striatium be measure after inhibition of GENE GENE GENE GENE ( GENE GENE GENE ) by CHEMICAL ( 4 mg / kg i.p . ) , ENTITY2 by CHEMICAL CHEMICAL ( 1"
"CHEMICAL ) and CHEMICAL ( ENTITY1 ) in plasma and the striatium be measure after inhibition of GENE GENE GENE GENE ( GENE GENE GENE ) by CHEMICAL ( 4 mg / kg i.p . ) , GENE GENE GENE by CHEMICAL CHEMICAL ( 1 mg / kg i.p . ) , both GENE GENE GENE and ENTITY2 by CHEMICAL ( 75 mg"
"CHEMICAL ) and CHEMICAL ( ENTITY1 ) in plasma and the striatium be measure after inhibition of ENTITY2 ( GENE GENE GENE )"
"CHEMICAL ) and CHEMICAL ( ENTITY1 ) in plasma and the striatium be measure after inhibition of GENE GENE GENE GENE ( ENTITY2 ) by CHEMICAL ( 4"
"CHEMICAL ) and CHEMICAL ( ENTITY1 ) in plasma and the striatium be measure after inhibition of GENE GENE GENE GENE ( GENE GENE GENE ) by CHEMICAL ( 4 mg / kg i.p . ) , GENE GENE GENE by CHEMICAL CHEMICAL ( 1 mg / kg i.p . ) , both ENTITY2 and GENE GENE GENE by"
"and GENE GENE GENE by ENTITY1 ( 75 mg / kg i.p . ) or peripheral neuronal ENTITY2 by CHEMICAL ( 40 mg"
"kg i.p . ) , ENTITY2 by CHEMICAL CHEMICAL ( 1 mg / kg i.p . ) , both GENE GENE GENE and GENE GENE GENE by ENTITY1 ( 75 mg / kg"
"both GENE GENE GENE and ENTITY2 by ENTITY1 ( 75 mg / kg"
"be measure after inhibition of ENTITY2 ( GENE GENE GENE ) by CHEMICAL ( 4 mg / kg i.p . ) , GENE GENE GENE by CHEMICAL CHEMICAL ( 1 mg / kg i.p . ) , both GENE GENE GENE and GENE GENE GENE by ENTITY1 ( 75 mg / kg"
"GENE GENE GENE GENE ( ENTITY2 ) by CHEMICAL ( 4 mg / kg i.p . ) , GENE GENE GENE by CHEMICAL CHEMICAL ( 1 mg / kg i.p . ) , both GENE GENE GENE and GENE GENE GENE by ENTITY1 ( 75 mg / kg"
"i.p . ) , both ENTITY2 and GENE GENE GENE by ENTITY1 ( 75 mg / kg"
"CHEMICAL ( CHEMICAL ) , ENTITY1 ( CHEMICAL ) and CHEMICAL ( CHEMICAL ) in plasma and the striatium be measure after inhibition of GENE GENE GENE GENE ( GENE GENE GENE ) by CHEMICAL ( 4 mg / kg i.p . ) , GENE GENE GENE by CHEMICAL CHEMICAL ( 1 mg / kg i.p . ) , both GENE GENE GENE and GENE GENE GENE by CHEMICAL ( 75 mg / kg i.p . ) or peripheral neuronal ENTITY2 by CHEMICAL ( 40 mg"
"CHEMICAL ( CHEMICAL ) , ENTITY1 ( CHEMICAL ) and CHEMICAL ( CHEMICAL ) in plasma and the striatium be measure after inhibition of GENE GENE GENE GENE ( GENE GENE GENE ) by CHEMICAL ( 4 mg / kg i.p . ) , ENTITY2 by CHEMICAL CHEMICAL ( 1"
"CHEMICAL ( CHEMICAL ) , ENTITY1 ( CHEMICAL ) and CHEMICAL ( CHEMICAL ) in plasma and the striatium be measure after inhibition of GENE GENE GENE GENE ( GENE GENE GENE ) by CHEMICAL ( 4 mg / kg i.p . ) , GENE GENE GENE by CHEMICAL CHEMICAL ( 1 mg / kg i.p . ) , both GENE GENE GENE and ENTITY2 by CHEMICAL ( 75 mg"
"CHEMICAL ( CHEMICAL ) , ENTITY1 ( CHEMICAL ) and CHEMICAL ( CHEMICAL ) in plasma and the striatium be measure after inhibition of ENTITY2 ( GENE GENE GENE )"
"CHEMICAL ( CHEMICAL ) , ENTITY1 ( CHEMICAL ) and CHEMICAL ( CHEMICAL ) in plasma and the striatium be measure after inhibition of GENE GENE GENE GENE ( ENTITY2 ) by CHEMICAL ( 4"
"CHEMICAL ( CHEMICAL ) , ENTITY1 ( CHEMICAL ) and CHEMICAL ( CHEMICAL ) in plasma and the striatium be measure after inhibition of GENE GENE GENE GENE ( GENE GENE GENE ) by CHEMICAL ( 4 mg / kg i.p . ) , GENE GENE GENE by CHEMICAL CHEMICAL ( 1 mg / kg i.p . ) , both ENTITY2 and GENE GENE GENE by"
"accumulation of the post - ENTITY2 product of 22:5n-3 , 24:6n-3 and CHEMICAL , in cell phospholipid be saturate at concentration of > 18 microm ENTITY1 ."
"accumulation of the post - ENTITY2 product of 22:5n-3 , 24:6n-3 and ENTITY1 , in cell phospholipid be"
"ENTITY1 - induce GENE GENE GENE activation result in the phosphorylation of express GENE and promote -PRON- association with the ENTITY2 ."
"ENTITY1 - induce ENTITY2 activation result in the phosphorylation"
"ENTITY1 - induce GENE GENE GENE activation result in the phosphorylation of express ENTITY2 and promote -PRON- association with"
"the surface receptor for extracellular ENTITY1 be call ENTITY2 ."
"high level of CHEMICAL , ENTITY1 , ENTITY2 but have low level of"
"with normal control group , ENTITY1 - kindle mouse have significantly high level of CHEMICAL , CHEMICAL , ENTITY2 but have low level of"
"have significantly high level of ENTITY1 , CHEMICAL , ENTITY2 but have low level of"
"of CHEMICAL , CHEMICAL , ENTITY2 but have low level of reduce ENTITY1 in the whole brain homogenate"
"activation be influence by GENE ENTITY1 GENE ( ENTITY2 ) signal , but the"
"ENTITY2 activation be influence by GENE ENTITY1 GENE ( GENE ) signal"
"of yeast mutant deficient in ENTITY2 or GENE activity , and by measure in vitro CHEMICAL incorporation into CHEMICAL or ENTITY1 ."
"mutant deficient in GENE or ENTITY2 activity , and by measure in vitro CHEMICAL incorporation into CHEMICAL or ENTITY1 ."
"of yeast mutant deficient in ENTITY2 or GENE activity , and by measure in vitro ENTITY1 incorporation into CHEMICAL or CHEMICAL"
"mutant deficient in GENE or ENTITY2 activity , and by measure in vitro ENTITY1 incorporation into CHEMICAL or CHEMICAL"
"of yeast mutant deficient in ENTITY2 or GENE activity , and by measure in vitro CHEMICAL incorporation into ENTITY1 or CHEMICAL ."
"mutant deficient in GENE or ENTITY2 activity , and by measure in vitro CHEMICAL incorporation into ENTITY1 or CHEMICAL ."
"response to increase concentration of ENTITY1 suggest that the competition between 24:5n-3 and CHEMICAL for ENTITY2 may contribute to the limited"
"the competition between 24:5n-3 and ENTITY1 for ENTITY2 may contribute to the limited"
"of accumulation of 24:6n-3 and ENTITY1 in response to increase concentration of CHEMICAL suggest that the competition between 24:5n-3 and CHEMICAL for ENTITY2 may contribute to the limited"
"between 24:5n-3 and CHEMICAL for ENTITY2 may contribute to the limited accumulation of ENTITY1 in cell membrane . 
"
"in contrast to ENTITY1 , ENTITY2 - induce nuclear translocation do"
"in contrast to ENTITY1 , GENE - induce nuclear translocation do not transcriptionally activate the ENTITY2 ."
"ENTITY2 be present exclusively in the mitochondria , make this compartment the sole site of synthesis of ENTITY1 in the plant cell ."
"oviduct ENTITY2 , GENE and uterine GENE be down - regulate by either ENTITY1 or CHEMICAL ."
"oviduct GENE , ENTITY2 and uterine GENE be down - regulate by either ENTITY1 or CHEMICAL ."
"GENE , GENE and uterine ENTITY2 be down - regulate by either ENTITY1 or CHEMICAL ."
"oviduct ENTITY2 , GENE and uterine GENE be down - regulate by either CHEMICAL or ENTITY1 ."
"oviduct GENE , ENTITY2 and uterine GENE be down - regulate by either CHEMICAL or ENTITY1 ."
"GENE , GENE and uterine ENTITY2 be down - regulate by either CHEMICAL or ENTITY1 ."
"-PRON- then demonstrate that ENTITY1 can also stimulate ENTITY2 mobilization in human prostate pc3"
"that CHEMICAL , a preferential ENTITY2 inhibitor offer neuroprotection against ENTITY1 - induce kindle in mouse"
"these result suggest that ENTITY1 , a preferential ENTITY2 inhibitor offer neuroprotection against CHEMICAL"
"the activation of ENTITY2 [ GENE GENE ) by human recombinant ( rec ) two - chain GENE GENE GENE ( GENE GENE GENE ) be inhibit by CHEMICAL , at physiological concentration , and stimulate by ENTITY1 ( CHEMICAL ) , as"
"rec ) two - chain ENTITY2 ( GENE GENE GENE ) be inhibit by CHEMICAL , at physiological concentration , and stimulate by ENTITY1 ( CHEMICAL ) , as"
"of GENE GENE GENE [ ENTITY2 ) by human recombinant ( rec ) two - chain GENE GENE GENE ( GENE GENE GENE ) be inhibit by CHEMICAL , at physiological concentration , and stimulate by ENTITY1 ( CHEMICAL ) , as"
"chain GENE GENE GENE ( ENTITY2 ) be inhibit by CHEMICAL , at physiological concentration , and stimulate by ENTITY1 ( CHEMICAL ) , as"
"the activation of ENTITY2 [ GENE GENE ) by human recombinant ( rec ) two - chain GENE GENE GENE ( GENE GENE GENE ) be inhibit by CHEMICAL , at physiological concentration , and stimulate by CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) , as well as"
"rec ) two - chain ENTITY2 ( GENE GENE GENE ) be inhibit by CHEMICAL , at physiological concentration , and stimulate by CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) , as well as"
"of GENE GENE GENE [ ENTITY2 ) by human recombinant ( rec ) two - chain GENE GENE GENE ( GENE GENE GENE ) be inhibit by CHEMICAL , at physiological concentration , and stimulate by CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) , as well as"
"chain GENE GENE GENE ( ENTITY2 ) be inhibit by CHEMICAL , at physiological concentration , and stimulate by CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) , as well as"
"the activation of ENTITY2 [ GENE GENE ) by human recombinant ( rec ) two - chain GENE GENE GENE ( GENE GENE GENE ) be inhibit by ENTITY1 , at physiological concentration ,"
"rec ) two - chain ENTITY2 ( GENE GENE GENE ) be inhibit by ENTITY1 , at physiological concentration ,"
"of GENE GENE GENE [ ENTITY2 ) by human recombinant ( rec ) two - chain GENE GENE GENE ( GENE GENE GENE ) be inhibit by ENTITY1 , at physiological concentration ,"
"chain GENE GENE GENE ( ENTITY2 ) be inhibit by ENTITY1 , at physiological concentration ,"
"CHEMICAL - lower agent ( ENTITY1 ) downregulat the expression of ENTITY2 gene in several organ especially"
"consistently , the ENTITY1 - lower agent ( CHEMICAL CHEMICAL ) downregulat the expression of ENTITY2 gene in several organ especially"
"ENTITY1 and CHEMICAL exert opposite effect on e2 and p4 , and -PRON- differentially regulate the expression of ENTITY2 in female reproductive tissue ."
"CHEMICAL and ENTITY1 exert opposite effect on e2 and p4 , and -PRON- differentially regulate the expression of ENTITY2 in female reproductive tissue ."
"this antagonism of ENTITY1 action by GENE may underlie in part the capacity of ENTITY2 activation to inhibit prostate tumor"
"this antagonism of ENTITY1 action by ENTITY2 may underlie in part the"
"after the treatment with systemic ENTITY1 may be due to the inhibition of the ENTITY2 ."
"reaction of the hydrolysis of ENTITY1 at ph 8 in the presence of ENTITY2 and the inhibitor study be"
"8 in the presence of ENTITY2 and the inhibitor study be determine by measure at 230 nm the peak area of the reaction product ENTITY1 ( tch ) ."
"thus , the combination of ENTITY2 with these CHEMICAL - mediate reaction can supply each compartment with the polyglutamylat CHEMICAL coenzyme require for the reaction of ENTITY1 metabolism ."
"thus , the combination of ENTITY2 with these ENTITY1 - mediate reaction can supply"
"thus , the combination of ENTITY2 with these CHEMICAL - mediate reaction can supply each compartment with the polyglutamylat ENTITY1 coenzyme require for the reaction"
"use recombinant ENTITY2 , -PRON- find that -PRON- catalyze the n - glucuronidation of CHEMICAL , ENTITY1 , CHEMICAL , CHEMICAL ,"
"use recombinant ENTITY2 , -PRON- find that -PRON- catalyze the n - glucuronidation of CHEMICAL , CHEMICAL , ENTITY1 , CHEMICAL , CHEMICAL ,"
"use recombinant ENTITY2 , -PRON- find that -PRON- catalyze the n - glucuronidation of CHEMICAL , CHEMICAL , CHEMICAL , ENTITY1 , CHEMICAL , CHEMICAL ,"
"use recombinant ENTITY2 , -PRON- find that -PRON- catalyze the n - glucuronidation of CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , ENTITY1 , CHEMICAL and CHEMICAL ."
"use recombinant ENTITY2 , -PRON- find that -PRON- catalyze the n - glucuronidation of CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , ENTITY1 , CHEMICAL , CHEMICAL and"
"use recombinant ENTITY2 , -PRON- find that -PRON- catalyze the n - glucuronidation of ENTITY1 , CHEMICAL , CHEMICAL ,"
"use recombinant ENTITY2 , -PRON- find that -PRON- catalyze the n - glucuronidation of CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , ENTITY1 , CHEMICAL , CHEMICAL ,"
"use recombinant ENTITY2 , -PRON- find that -PRON- catalyze the n - glucuronidation of CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , ENTITY1 and CHEMICAL ."
"use recombinant ENTITY2 , -PRON- find that -PRON- catalyze the n - glucuronidation of CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL and ENTITY1 ."
"first fill with 30 mm ENTITY1 - CHEMICAL buffer ( ph 8.0 ) and subsequently , plug of : ( i ) water , ( ii ) ENTITY2 solution , ( iii )"
"first fill with 30 mm ENTITY1 - CHEMICAL buffer ( ph 8.0 ) and subsequently , plug of : ( i ) water , ( ii ) GENE solution , ( iii ) substrate solution with or without inhibitor , ( iv ) ENTITY2 solution , and ( v"
"with 30 mm CHEMICAL - ENTITY1 buffer ( ph 8.0 ) and subsequently , plug of : ( i ) water , ( ii ) ENTITY2 solution , ( iii )"
"with 30 mm CHEMICAL - ENTITY1 buffer ( ph 8.0 ) and subsequently , plug of : ( i ) water , ( ii ) GENE solution , ( iii ) substrate solution with or without inhibitor , ( iv ) ENTITY2 solution , and ( v"
"furthermore , ENTITY1 cause mechanism - base inactivation of ENTITY2 - dependent CHEMICAL 1'-hydroxylation in"
"mechanism - base inactivation of ENTITY2 - dependent ENTITY1 1'-hydroxylation in mouse , rat"
"ENTITY1 20 micromol / l reverse only 50% of the effect of ENTITY2 and fail to completely suppress"
"more potent and selective than ENTITY1 in inhibit CHEMICAL re - uptake in the cns , and less potent than various other selective CHEMICAL re - uptake inhibitor in relation to other transporter protein and receptor : in particular , -PRON- be six time less potent than CHEMICAL in bind to the CHEMICAL GENE and ENTITY2 ."
"six time less potent than ENTITY1 in bind to the CHEMICAL GENE and ENTITY2 ."
"selective than CHEMICAL in inhibit ENTITY1 re - uptake in the cns , and less potent than various other selective CHEMICAL re - uptake inhibitor in relation to other transporter protein and receptor : in particular , -PRON- be six time less potent than CHEMICAL in bind to the CHEMICAL GENE and ENTITY2 ."
"potent than various other selective ENTITY1 re - uptake inhibitor in relation to other transporter protein and receptor : in particular , -PRON- be six time less potent than CHEMICAL in bind to the CHEMICAL GENE and ENTITY2 ."
"CHEMICAL in bind to the ENTITY1 GENE and ENTITY2 ."
"ENTITY1 ( CHEMICAL ) , a chemotherapeutic agent with autofluorescence , be use to evaluate the pump activity , and ENTITY2 increase the drug pumping -"
"CHEMICAL ( ENTITY1 ) , a chemotherapeutic agent with autofluorescence , be use to evaluate the pump activity , and ENTITY2 increase the drug pumping -"
"ENTITY1 initiate platelet aggregation by ' simultaneous activation of two ENTITY2 , GENE and GENE ."
"ENTITY1 initiate platelet aggregation by ' simultaneous activation of two GENE GENE GENE GENE GENE , ENTITY2 and GENE ."
"ENTITY1 initiate platelet aggregation by ' simultaneous activation of two GENE GENE GENE GENE GENE , GENE and ENTITY2 ."
"indicate that important determinant of ENTITY1 binding be localize to the pore region of ENTITY2 ."
"coadminister with drug metabolise by ENTITY2 , such as ENTITY1 , or administer to the"
"GENE GENE GENE GENE ( ENTITY2 ) gene expression be negatively regulate by ENTITY1 without direct binding of CHEMICAL"
"ENTITY2 ( GENE ) gene expression be negatively regulate by ENTITY1 without direct binding of CHEMICAL"
"GENE GENE GENE GENE ( ENTITY2 ) gene expression be negatively regulate by CHEMICAL CHEMICAL without direct binding of ENTITY1 GENE to the gene promoter"
"ENTITY2 ( GENE ) gene expression be negatively regulate by CHEMICAL CHEMICAL without direct binding of ENTITY1 GENE to the gene promoter"
"ENTITY1 protect against mitochondrial dysfunction cause by excitotoxicity by maintain cellular redox status through high constitutive expression of ENTITY2 in the cns ."
"recent study suggest that selective ENTITY1 reuptake inhibitor be inactive in 40-week - old male mouse in the mouse force swimming test , possibly because of alteration of ENTITY2 receptor ."
"GENE GENE GENE GENE ( ENTITY2 ) play a pivotal role in an increase of ENTITY1 by an excess of dietary"
"ENTITY2 ( GENE ) play a pivotal role in an increase of ENTITY1 by an excess of dietary"
"GENE GENE GENE GENE ( ENTITY2 ) play a pivotal role in an increase of CHEMICAL by an excess of dietary ENTITY1 intake ."
"ENTITY2 ( GENE ) play a pivotal role in an increase of CHEMICAL by an excess of dietary ENTITY1 intake ."
"activation of ENTITY2 , which normalize cardiac autophagy , attenuated high ENTITY1 - induce apoptosis in cultured"
"dietary ENTITY1 increase ENTITY2 gene expression in liver by"
"dietary ENTITY1 increase GENE gene expression in liver by ENTITY2 - dependent and GENE -independent"
"dietary ENTITY1 increase GENE gene expression in liver by GENE GENE GENE GENE GENE GENE GENE - dependent and ENTITY2 -independent pathway ."
"previous report demonstrate that ENTITY1 ( th ) negatively regulate GENE GENE GENE GENE before ENTITY2 be reveal ."
"previous report demonstrate that ENTITY1 ( th ) negatively regulate ENTITY2 before GENE be reveal ."
"the antinociceptive activity of the ENTITY2 agonist CHEMICAL be also increase in mouse treat with alpha ENTITY1 beta - endorphin-(1 - 31"
"the antinociceptive activity of the ENTITY2 agonist ENTITY1 be also increase in mouse"
"with the exception of ENTITY2 , where CHEMICAL be a constituent of the ENTITY1 - cofactor , CHEMICAL be"
"with the exception of ENTITY2 , where ENTITY1 be a constituent of the"
"with the exception of ENTITY2 , where CHEMICAL be a constituent of the CHEMICAL - cofactor , ENTITY1 be bind to a CHEMICAL"
"with the exception of ENTITY2 , where CHEMICAL be a constituent of the CHEMICAL - cofactor , CHEMICAL be bind to a CHEMICAL , thus form the CHEMICAL cofactor ( moco ) which be the active compound at the catalytic site of all other ENTITY1 - enzyme ."
"with the exception of ENTITY2 , where CHEMICAL be a constituent of the CHEMICAL - cofactor , CHEMICAL be bind to a ENTITY1 , thus form the CHEMICAL"
"with the exception of ENTITY2 , where CHEMICAL be a constituent of the CHEMICAL - cofactor , CHEMICAL be bind to a CHEMICAL , thus form the ENTITY1 cofactor ( moco ) which"
"effector of the isr be ENTITY2 ( GENE ) , a transcription factor that regulate gene involve in redox homeostasis and ENTITY1 metabolism and transport ."
"GENE GENE GENE GENE ( ENTITY2 ) , a transcription factor that regulate gene involve in redox homeostasis and ENTITY1 metabolism and transport ."
"production , ( 3 ) ENTITY1 GENE , which oxidize a variety of CHEMICAL and be essential for the biosynthesis of the phytohormone CHEMICAL CHEMICAL , and in autotrophic organism also ( 4 ) ENTITY2 , which catalyze the key"
"CHEMICAL , ( 2 ) ENTITY2 , which be involve in CHEMICAL catabolism and reactive CHEMICAL production , ( 3 ) ENTITY1 GENE , which oxidize a"
"enzyme be ( 1 ) ENTITY2 , which catalyze the final step in the degradation of CHEMICAL - contain CHEMICAL CHEMICAL and be involve in detoxify excess CHEMICAL , ( 2 ) GENE GENE , which be involve in CHEMICAL catabolism and reactive CHEMICAL production , ( 3 ) ENTITY1 GENE , which oxidize a"
"which oxidize a variety of ENTITY1 and be essential for the biosynthesis of the phytohormone CHEMICAL CHEMICAL , and in autotrophic organism also ( 4 ) ENTITY2 , which catalyze the key"
"CHEMICAL , ( 2 ) ENTITY2 , which be involve in CHEMICAL catabolism and reactive CHEMICAL production , ( 3 ) CHEMICAL GENE , which oxidize a variety of ENTITY1 and be essential for the"
"enzyme be ( 1 ) ENTITY2 , which catalyze the final step in the degradation of CHEMICAL - contain CHEMICAL CHEMICAL and be involve in detoxify excess CHEMICAL , ( 2 ) GENE GENE , which be involve in CHEMICAL catabolism and reactive CHEMICAL production , ( 3 ) CHEMICAL GENE , which oxidize a variety of ENTITY1 and be essential for the"
"organism also ( 4 ) ENTITY2 , which catalyze the key step in inorganic ENTITY1 assimilation ."
"CHEMICAL , ( 2 ) ENTITY2 , which be involve in CHEMICAL catabolism and reactive CHEMICAL production , ( 3 ) CHEMICAL GENE , which oxidize a variety of CHEMICAL and be essential for the biosynthesis of the phytohormone CHEMICAL CHEMICAL , and in autotrophic organism also ( 4 ) GENE GENE , which catalyze the key step in inorganic ENTITY1 assimilation ."
"enzyme be ( 1 ) ENTITY2 , which catalyze the final step in the degradation of CHEMICAL - contain CHEMICAL CHEMICAL and be involve in detoxify excess CHEMICAL , ( 2 ) GENE GENE , which be involve in CHEMICAL catabolism and reactive CHEMICAL production , ( 3 ) CHEMICAL GENE , which oxidize a variety of CHEMICAL and be essential for the biosynthesis of the phytohormone CHEMICAL CHEMICAL , and in autotrophic organism also ( 4 ) GENE GENE , which catalyze the key step in inorganic ENTITY1 assimilation ."
"in CHEMICAL catabolism and reactive ENTITY1 production , ( 3 ) CHEMICAL GENE , which oxidize a variety of CHEMICAL and be essential for the biosynthesis of the phytohormone CHEMICAL CHEMICAL , and in autotrophic organism also ( 4 ) ENTITY2 , which catalyze the key"
"CHEMICAL , ( 2 ) ENTITY2 , which be involve in CHEMICAL catabolism and reactive ENTITY1 production , ( 3 )"
"enzyme be ( 1 ) ENTITY2 , which catalyze the final step in the degradation of CHEMICAL - contain CHEMICAL CHEMICAL and be involve in detoxify excess CHEMICAL , ( 2 ) GENE GENE , which be involve in CHEMICAL catabolism and reactive ENTITY1 production , ( 3 )"
"be involve in detoxify excess ENTITY1 , ( 2 ) GENE GENE , which be involve in CHEMICAL catabolism and reactive CHEMICAL production , ( 3 ) CHEMICAL GENE , which oxidize a variety of CHEMICAL and be essential for the biosynthesis of the phytohormone CHEMICAL CHEMICAL , and in autotrophic organism also ( 4 ) ENTITY2 , which catalyze the key"
"be involve in detoxify excess ENTITY1 , ( 2 ) ENTITY2 , which be involve in"
"enzyme be ( 1 ) ENTITY2 , which catalyze the final step in the degradation of CHEMICAL - contain CHEMICAL CHEMICAL and be involve in detoxify excess ENTITY1 , ( 2 ) GENE"
"eukaryote , the most prominent ENTITY1 - enzyme be ( 1 ) GENE GENE , which catalyze the final step in the degradation of CHEMICAL - contain CHEMICAL CHEMICAL and be involve in detoxify excess CHEMICAL , ( 2 ) GENE GENE , which be involve in CHEMICAL catabolism and reactive CHEMICAL production , ( 3 ) CHEMICAL GENE , which oxidize a variety of CHEMICAL and be essential for the biosynthesis of the phytohormone CHEMICAL CHEMICAL , and in autotrophic organism also ( 4 ) ENTITY2 , which catalyze the key"
"eukaryote , the most prominent ENTITY1 - enzyme be ( 1 ) GENE GENE , which catalyze the final step in the degradation of CHEMICAL - contain CHEMICAL CHEMICAL and be involve in detoxify excess CHEMICAL , ( 2 ) ENTITY2 , which be involve in"
"eukaryote , the most prominent ENTITY1 - enzyme be ( 1 ) ENTITY2 , which catalyze the final"
"degradation of CHEMICAL - contain ENTITY1 and be involve in detoxify excess CHEMICAL , ( 2 ) GENE GENE , which be involve in CHEMICAL catabolism and reactive CHEMICAL production , ( 3 ) CHEMICAL GENE , which oxidize a variety of CHEMICAL and be essential for the biosynthesis of the phytohormone CHEMICAL CHEMICAL , and in autotrophic organism also ( 4 ) ENTITY2 , which catalyze the key"
"degradation of CHEMICAL - contain ENTITY1 and be involve in detoxify excess CHEMICAL , ( 2 ) ENTITY2 , which be involve in"
"enzyme be ( 1 ) ENTITY2 , which catalyze the final step in the degradation of CHEMICAL - contain ENTITY1 and be involve in detoxify"
"step in the degradation of ENTITY1 - contain CHEMICAL CHEMICAL and be involve in detoxify excess CHEMICAL , ( 2 ) GENE GENE , which be involve in CHEMICAL catabolism and reactive CHEMICAL production , ( 3 ) CHEMICAL GENE , which oxidize a variety of CHEMICAL and be essential for the biosynthesis of the phytohormone CHEMICAL CHEMICAL , and in autotrophic organism also ( 4 ) ENTITY2 , which catalyze the key"
"step in the degradation of ENTITY1 - contain CHEMICAL CHEMICAL and be involve in detoxify excess CHEMICAL , ( 2 ) ENTITY2 , which be involve in"
"enzyme be ( 1 ) ENTITY2 , which catalyze the final step in the degradation of ENTITY1 - contain CHEMICAL CHEMICAL and"
"the biosynthesis of the phytohormone ENTITY1 , and in autotrophic organism also ( 4 ) ENTITY2 , which catalyze the key"
"CHEMICAL , ( 2 ) ENTITY2 , which be involve in CHEMICAL catabolism and reactive CHEMICAL production , ( 3 ) CHEMICAL GENE , which oxidize a variety of CHEMICAL and be essential for the biosynthesis of the phytohormone ENTITY1 , and in autotrophic organism"
"enzyme be ( 1 ) ENTITY2 , which catalyze the final step in the degradation of CHEMICAL - contain CHEMICAL CHEMICAL and be involve in detoxify excess CHEMICAL , ( 2 ) GENE GENE , which be involve in CHEMICAL catabolism and reactive CHEMICAL production , ( 3 ) CHEMICAL GENE , which oxidize a variety of CHEMICAL and be essential for the biosynthesis of the phytohormone ENTITY1 , and in autotrophic organism"
", which be involve in ENTITY1 catabolism and reactive CHEMICAL production , ( 3 ) CHEMICAL GENE , which oxidize a variety of CHEMICAL and be essential for the biosynthesis of the phytohormone CHEMICAL CHEMICAL , and in autotrophic organism also ( 4 ) ENTITY2 , which catalyze the key"
"CHEMICAL , ( 2 ) ENTITY2 , which be involve in ENTITY1 catabolism and reactive CHEMICAL production"
"enzyme be ( 1 ) ENTITY2 , which catalyze the final step in the degradation of CHEMICAL - contain CHEMICAL CHEMICAL and be involve in detoxify excess CHEMICAL , ( 2 ) GENE GENE , which be involve in ENTITY1 catabolism and reactive CHEMICAL production"
"all ENTITY1 - enzyme , except ENTITY2 , ne at least one"
"CHEMICAL - enzyme , except ENTITY2 , ne at least one more redox active center , many of -PRON- involve ENTITY1 in electron transfer ."
"the bacterial enzyme ENTITY2 ( GENE ) catalyse the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrin , remove the non - reduce CHEMICAL residue of linear oligosaccharide as ENTITY1 ( CHEMICAL ) ."
"bacterial enzyme GENE GENE ( ENTITY2 ) catalyse the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrin , remove the non - reduce CHEMICAL residue of linear oligosaccharide as ENTITY1 ( CHEMICAL ) ."
"the bacterial enzyme ENTITY2 ( GENE ) catalyse the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrin , remove the non - reduce ENTITY1 residue of linear oligosaccharide as"
"bacterial enzyme GENE GENE ( ENTITY2 ) catalyse the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrin , remove the non - reduce ENTITY1 residue of linear oligosaccharide as"
"the bacterial enzyme ENTITY2 ( GENE ) catalyse the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrin , remove the non - reduce CHEMICAL residue of linear oligosaccharide as CHEMICAL ( ENTITY1 ) ."
"bacterial enzyme GENE GENE ( ENTITY2 ) catalyse the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrin , remove the non - reduce CHEMICAL residue of linear oligosaccharide as CHEMICAL ( ENTITY1 ) ."
"molecular pharmacology of GENE GENE ENTITY2 : block by antihypertensive , antiarrhythmic , and -PRON- analog . 	 antihypertensive drug of the "" ENTITY1 GENE blocker "" or """
"molecular pharmacology of ENTITY2 GENE GENE GENE GENE GENE GENE : block by antihypertensive , antiarrhythmic , and -PRON- analog . 	 antihypertensive drug of the "" ENTITY1 GENE blocker "" or """
"molecular pharmacology of GENE GENE ENTITY2 : block by antihypertensive , antiarrhythmic , and -PRON- analog . 	 antihypertensive drug of the "" CHEMICAL GENE blocker "" or "" ENTITY1 antagonist "" class have be"
"molecular pharmacology of ENTITY2 GENE GENE GENE GENE GENE GENE : block by antihypertensive , antiarrhythmic , and -PRON- analog . 	 antihypertensive drug of the "" CHEMICAL GENE blocker "" or "" ENTITY1 antagonist "" class have be"
"CHEMICAL GENE and ENTITY2 , but not CHEMICAL GENE and CHEMICAL GENE , require the post - translational sulfuration of -PRON- ENTITY1 - site for become active"
"CHEMICAL GENE and ENTITY2 , but not CHEMICAL GENE and ENTITY1 GENE , require the post"
"ENTITY1 GENE and ENTITY2 , but not CHEMICAL GENE"
"CHEMICAL GENE and ENTITY2 , but not ENTITY1 GENE and CHEMICAL GENE ,"
"step be catalyze by a ENTITY2 enzyme , which mobilize CHEMICAL from ENTITY1 in a CHEMICAL CHEMICAL -"
", which mobilize CHEMICAL from ENTITY1 in a CHEMICAL CHEMICAL - dependent manner as typical for ENTITY2 . 
"
"step be catalyze by a ENTITY2 enzyme , which mobilize CHEMICAL from CHEMICAL CHEMICAL CHEMICAL in a ENTITY1 - dependent manner as typical"
"CHEMICAL CHEMICAL CHEMICAL in a ENTITY1 - dependent manner as typical for ENTITY2 . 
"
"step be catalyze by a ENTITY2 enzyme , which mobilize ENTITY1 from CHEMICAL CHEMICAL CHEMICAL in"
"GENE enzyme , which mobilize ENTITY1 from CHEMICAL CHEMICAL CHEMICAL in a CHEMICAL CHEMICAL - dependent manner as typical for ENTITY2 . 
"
"a selective inhibitor of neuronal ENTITY1 GENE ( ENTITY2 ) , because -PRON- be"
"a selective inhibitor of neuronal ENTITY1 GENE ( GENE ) , because -PRON- be a much more potent ENTITY2 inhibitor in intact tissue ,"
"result in the classification of ENTITY1 as a selective inhibitor of neuronal CHEMICAL GENE ( ENTITY2 ) , because -PRON- be"
"result in the classification of ENTITY1 as a selective inhibitor of neuronal CHEMICAL GENE ( GENE ) , because -PRON- be a much more potent ENTITY2 inhibitor in intact tissue ,"
"blockade of the GENE - ENTITY2 system be assess before and 4 , 24 , and 30 hour after drug intake by 3 independent method : inhibition of the blood pressure response to exogenous ENTITY1 , in vitro GENE GENE"
"blood pressure response to exogenous ENTITY1 , in vitro GENE GENE GENE assay , and reactive change in plasma ENTITY2 level ."
"blockade of the ENTITY2 - GENE system be assess before and 4 , 24 , and 30 hour after drug intake by 3 independent method : inhibition of the blood pressure response to exogenous ENTITY1 , in vitro GENE GENE"
"blood pressure response to exogenous ENTITY1 , in vitro ENTITY2 assay , and reactive change"
"attach to both CHEMICAL and ENTITY1 framework demonstrate that the cis-(3s,4r)- stereochemistry be optimal for all of the ENTITY2 test ."
"CHEMICAL functionality attach to both ENTITY1 and CHEMICAL framework demonstrate that the cis-(3s,4r)- stereochemistry be optimal for all of the ENTITY2 test ."
"-PRON- previous work with the ENTITY1 functionality attach to both CHEMICAL and CHEMICAL framework demonstrate that the cis-(3s,4r)- stereochemistry be optimal for all of the ENTITY2 test ."
"ENTITY1 fail to activate the channel make of cbv1 + β2 , β3 , β4 , or β1t169a , indicate that this drug selectively target ENTITY2 via the GENE GENE CHEMICAL"
"ENTITY1 fail to activate the channel make of cbv1 + β2 , β3 , β4 , or β1t169a , indicate that this drug selectively target GENE GENE GENE via the ENTITY2 CHEMICAL - sense site ."
"that this drug selectively target ENTITY2 via the GENE GENE ENTITY1 - sense site ."
"GENE GENE GENE via the ENTITY2 ENTITY1 - sense site ."
"CHEMICAL and related enzyme , ENTITY2 in maintain mitochondrial function during excitotoxicity cause by ENTITY1 ( CHEMICAL CHEMICAL CHEMICAL )"
"CHEMICAL and related enzyme , ENTITY2 in maintain mitochondrial function during excitotoxicity cause by CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) , the causative factor"
"non - protein CHEMICAL , ENTITY1 and related enzyme , ENTITY2 in maintain mitochondrial function during"
"antioxidant , non - protein ENTITY1 , CHEMICAL and related enzyme , ENTITY2 in maintain mitochondrial function during"
"CHEMICAL CHEMICAL cause loss of ENTITY1 and inhibition of ENTITY2 in lumbosacral cord of male"
"ENTITY1 cause loss of CHEMICAL and inhibition of ENTITY2 in lumbosacral cord of male"
"of CHEMICAL and inhibition of ENTITY2 in lumbosacral cord of male mouse through oxidation of ENTITY1 group , while female mouse"
"the transcription factors GENE and ENTITY2 mediate the enhancement of CHEMICAL levels by the ENTITY1 CHEMICAL . 	"
"regulation of the transcription factors ENTITY2 and GENE mediate the enhancement of CHEMICAL levels by the ENTITY1 CHEMICAL . 	"
"the transcription factors GENE and ENTITY2 mediate the enhancement of CHEMICAL levels by the CHEMICAL ENTITY1 . 	"
"regulation of the transcription factors ENTITY2 and GENE mediate the enhancement of CHEMICAL levels by the CHEMICAL ENTITY1 . 	"
"the transcription factors GENE and ENTITY2 mediate the enhancement of ENTITY1 levels by the CHEMICAL CHEMICAL"
"regulation of the transcription factors ENTITY2 and GENE mediate the enhancement of ENTITY1 levels by the CHEMICAL CHEMICAL"
"the CHEMICAL CHEMICAL bind ENTITY1 in ENTITY2 be identify as CHEMICAL 69"
"the CHEMICAL CHEMICAL bind ENTITY1 in GENE GENE be identify as CHEMICAL 69 of the mouse sequence by reduction of the purified holoenzyme form with CHEMICAL follow by digestion of the carboxymethylat protein with ENTITY2 , radioactive peptide mapping use"
"CHEMICAL CHEMICAL bind CHEMICAL in ENTITY2 be identify as ENTITY1 69 of the mouse sequence"
"GENE GENE be identify as ENTITY1 69 of the mouse sequence by reduction of the purified holoenzyme form with CHEMICAL follow by digestion of the carboxymethylat protein with ENTITY2 , radioactive peptide mapping use"
"the ENTITY1 bind CHEMICAL in ENTITY2 be identify as CHEMICAL 69"
"the ENTITY1 bind CHEMICAL in GENE GENE be identify as CHEMICAL 69 of the mouse sequence by reduction of the purified holoenzyme form with CHEMICAL follow by digestion of the carboxymethylat protein with ENTITY2 , radioactive peptide mapping use"
"CHEMICAL CHEMICAL bind CHEMICAL in ENTITY2 be identify as CHEMICAL 69 of the mouse sequence by reduction of the purified holoenzyme form with ENTITY1 follow by digestion of the"
"the purified holoenzyme form with ENTITY1 follow by digestion of the carboxymethylat protein with ENTITY2 , radioactive peptide mapping use"
"ENTITY1 GENE blockade in normotensive subject : a direct comparison of three ENTITY2 antagonist . 	"
"paper a series of new ENTITY1 derivative have be design , synthesize and evaluate as the ENTITY2 inhibitor ."
"mouse cns by pretreatment with ENTITY1 or CHEMICAL CHEMICAL CHEMICAL CHEMICAL do not result in inhibition of ENTITY2 activity , unlike male mouse"
"reduce ENTITY1 level in female mouse cns by pretreatment with CHEMICAL CHEMICAL or CHEMICAL CHEMICAL CHEMICAL CHEMICAL do not result in inhibition of ENTITY2 activity , unlike male mouse"
"pretreatment with CHEMICAL CHEMICAL or ENTITY1 do not result in inhibition of ENTITY2 activity , unlike male mouse"
"the ENTITY2 inhibitor CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ) abolish the effect of ENTITY1 and CHEMICAL and decrease basal"
"the ENTITY2 inhibitor CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) abolish the effect of"
"the ENTITY2 inhibitor CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ) abolish the effect of CHEMICAL CHEMICAL and ENTITY1 and decrease basal mrna level"
"the ENTITY2 inhibitor ENTITY1 ( CHEMICAL ) abolish the"
"GENE , a GENE ENTITY1 GENE help maintain redox status of protein and downregulation of ENTITY2 result in loss of GENE"
"GENE , a GENE ENTITY1 GENE help maintain redox status of protein and downregulation of GENE result in loss of ENTITY2 activity ."
"ENTITY2 , a GENE ENTITY1 GENE help maintain redox status"
"ENTITY1 be a small - molecule inhibitor    of GENE and ENTITY2 and recently become the first"
"ENTITY1 be a small - molecule inhibitor    of ENTITY2 and GENE and recently become"
"cell growth by the selective ENTITY2 antagonist CHEMICAL and CHEMICAL be consistent with a role for GENE antagonism in the broad growth - inhibitory property of ENTITY1 ."
"consistent with a role for ENTITY2 antagonism in the broad growth - inhibitory property of ENTITY1 ."
"cell growth by the selective ENTITY2 antagonist ENTITY1 and CHEMICAL be consistent with"
"by the selective GENE antagonist ENTITY1 and CHEMICAL be consistent with a role for ENTITY2 antagonism in the broad growth"
"cell growth by the selective ENTITY2 antagonist CHEMICAL and ENTITY1 be consistent with a role"
"selective GENE antagonist CHEMICAL and ENTITY1 be consistent with a role for ENTITY2 antagonism in the broad growth"
"and discovery of highly functionaliz ENTITY1 as ENTITY2 inhibitor . 	"
"moderate inhibitory effect of ENTITY2 - c oxidation by ENTITY1 be observe ."
"CHEMICAL also inhibit incorporation of ENTITY1 into mcf-7 cell stimulate by ENTITY2 in serum - free medium"
"furthermore , ENTITY1 also inhibit incorporation of CHEMICAL CHEMICAL into mcf-7 cell stimulate by ENTITY2 in serum - free medium"
"among -PRON- , CHEMICAL ( ENTITY1 ) be an GENE and ENTITY2 - specific ( but GENE"
"among -PRON- , CHEMICAL ( ENTITY1 ) be an GENE and GENE - specific ( but GENE and ENTITY2 - nonbinding ) synthetic CHEMICAL"
") be an GENE and ENTITY2 - specific ( but GENE and GENE - nonbinding ) synthetic ENTITY1 that be effective in the"
"specific ( but GENE and ENTITY2 - nonbinding ) synthetic ENTITY1 that be effective in the"
"among -PRON- , ENTITY1 ( CHEMICAL ) be an GENE and ENTITY2 - specific ( but GENE"
"among -PRON- , ENTITY1 ( CHEMICAL ) be an GENE and GENE - specific ( but GENE and ENTITY2 - nonbinding ) synthetic CHEMICAL"
"and dual biological effect of ENTITY1 / CHEMICAL CHEMICAL CHEMICAL derivative as ENTITY2 inhibitor and antioxidant . 	"
"effect of CHEMICAL CHEMICAL / ENTITY1 derivative as ENTITY2 inhibitor and antioxidant . 	"
"role of ENTITY2 and mast cell in gaseous ENTITY1 - induce airway microvascular leakage"
"discovery of a synthetic ENTITY2 inhibitor ENTITY1 as a potential anticancer agent"
"besides , ENTITY1 not only synergiz ENTITY2 production combine with GENE ,"
"besides , ENTITY1 not only synergiz GENE production combine with ENTITY2 , but also prolong -PRON-"
"ENTITY2 be a class of cell surface receptor for CHEMICAL that prefer CHEMICAL or CHEMICAL over ENTITY1 ."
"ENTITY2 be a class of cell surface receptor for CHEMICAL that prefer ENTITY1 or CHEMICAL over CHEMICAL ."
"ENTITY2 be a class of cell surface receptor for ENTITY1 that prefer CHEMICAL or CHEMICAL"
"ENTITY2 be a class of cell surface receptor for CHEMICAL that prefer CHEMICAL or ENTITY1 over CHEMICAL ."
"CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) act as both a good antioxidant and ENTITY2 inhibitor , in particular when"
"-PRON- previously report that ENTITY1 ( CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ) act as both a good antioxidant and ENTITY2 inhibitor , in particular when"
"both a good antioxidant and ENTITY2 inhibitor , in particular when CHEMICAL CHEMICAL be conjugate with ENTITY1 or CHEMICAL CHEMICAL have aromatic"
"both a good antioxidant and ENTITY2 inhibitor , in particular when CHEMICAL CHEMICAL be conjugate with CHEMICAL or ENTITY1 have aromatic ring like CHEMICAL"
"both a good antioxidant and ENTITY2 inhibitor , in particular when ENTITY1 be conjugate with CHEMICAL or"
"both a good antioxidant and ENTITY2 inhibitor , in particular when CHEMICAL CHEMICAL be conjugate with CHEMICAL or CHEMICAL CHEMICAL have aromatic ring like ENTITY1 ."
"status of non - peptide ENTITY1 and ENTITY2 antagonist and agonist be also"
"consequently , ENTITY2 of mouse and rat anesthetize with ENTITY1 be completely protect against degeneration"
"and CHEMICAL , preferentially increase ENTITY1 and CHEMICAL release in rat medial prefrontal cortex : role of ENTITY2 receptor agonism . 	"
"CHEMICAL , CHEMICAL , and ENTITY1 , preferentially increase CHEMICAL and CHEMICAL release in rat medial prefrontal cortex : role of ENTITY2 receptor agonism . 	"
", preferentially increase CHEMICAL and ENTITY1 release in rat medial prefrontal cortex : role of ENTITY2 receptor agonism . 	"
"antipsychotic drug , CHEMICAL , ENTITY1 , and CHEMICAL , preferentially increase CHEMICAL and CHEMICAL release in rat medial prefrontal cortex : role of ENTITY2 receptor agonism . 	"
"atypical antipsychotic drug , ENTITY1 , CHEMICAL , and CHEMICAL , preferentially increase CHEMICAL and CHEMICAL release in rat medial prefrontal cortex : role of ENTITY2 receptor agonism . 	"
"in addition to ENTITY2 and to a less extent ENTITY1 ( pitressin ) , a"
"and to a less extent ENTITY1 ( pitressin ) , a number of ENTITY2 and CHEMICAL analogue ; such"
"in addition to ENTITY2 and to a less extent CHEMICAL ( pitressin ) , a number of GENE and ENTITY1 analogue ; such as CHEMICAL"
") , a number of ENTITY2 and ENTITY1 analogue ; such as CHEMICAL"
"in addition to ENTITY2 and to a less extent CHEMICAL ( pitressin ) , a number of GENE and CHEMICAL analogue ; such as CHEMICAL ( CHEMICAL agonist ) GENE ( CHEMICAL , GENE ) agonist ) , CHEMICAL ( GENE ) agonist ) , CHEMICAL ( GENE ) agonist ) and ENTITY1 ( CHEMICAL CHEMICAL antagonist )"
") , a number of ENTITY2 and CHEMICAL analogue ; such as CHEMICAL ( CHEMICAL agonist ) GENE ( CHEMICAL , GENE ) agonist ) , CHEMICAL ( GENE ) agonist ) , CHEMICAL ( GENE ) agonist ) and ENTITY1 ( CHEMICAL CHEMICAL antagonist )"
"in addition to ENTITY2 and to a less extent CHEMICAL ( pitressin ) , a number of GENE and CHEMICAL analogue ; such as CHEMICAL ( ENTITY1 agonist ) GENE ( CHEMICAL"
") , a number of ENTITY2 and CHEMICAL analogue ; such as CHEMICAL ( ENTITY1 agonist ) GENE ( CHEMICAL"
"in addition to ENTITY2 and to a less extent CHEMICAL ( pitressin ) , a number of GENE and CHEMICAL analogue ; such as CHEMICAL ( CHEMICAL agonist ) GENE ( CHEMICAL , GENE ) agonist ) , CHEMICAL ( GENE ) agonist ) , CHEMICAL ( GENE ) agonist ) and CHEMICAL ( CHEMICAL ENTITY1 antagonist ) be also in"
") , a number of ENTITY2 and CHEMICAL analogue ; such as CHEMICAL ( CHEMICAL agonist ) GENE ( CHEMICAL , GENE ) agonist ) , CHEMICAL ( GENE ) agonist ) , CHEMICAL ( GENE ) agonist ) and CHEMICAL ( CHEMICAL ENTITY1 antagonist ) be also in"
"in addition to ENTITY2 and to a less extent CHEMICAL ( pitressin ) , a number of GENE and CHEMICAL analogue ; such as ENTITY1 ( CHEMICAL agonist ) GENE"
") , a number of ENTITY2 and CHEMICAL analogue ; such as ENTITY1 ( CHEMICAL agonist ) GENE"
"in addition to ENTITY2 and to a less extent CHEMICAL ( pitressin ) , a number of GENE and CHEMICAL analogue ; such as CHEMICAL ( CHEMICAL agonist ) GENE ( CHEMICAL , GENE ) agonist ) , CHEMICAL ( GENE ) agonist ) , ENTITY1 ( GENE ) agonist )"
") , a number of ENTITY2 and CHEMICAL analogue ; such as CHEMICAL ( CHEMICAL agonist ) GENE ( CHEMICAL , GENE ) agonist ) , CHEMICAL ( GENE ) agonist ) , ENTITY1 ( GENE ) agonist )"
"in addition to ENTITY2 and to a less extent CHEMICAL ( pitressin ) , a number of GENE and CHEMICAL analogue ; such as CHEMICAL ( CHEMICAL agonist ) GENE ( ENTITY1 , GENE ) agonist )"
") , a number of ENTITY2 and CHEMICAL analogue ; such as CHEMICAL ( CHEMICAL agonist ) GENE ( ENTITY1 , GENE ) agonist )"
"in addition to ENTITY2 and to a less extent CHEMICAL ( pitressin ) , a number of GENE and CHEMICAL analogue ; such as CHEMICAL ( CHEMICAL agonist ) GENE ( CHEMICAL , GENE ) agonist ) , ENTITY1 ( GENE ) agonist )"
") , a number of ENTITY2 and CHEMICAL analogue ; such as CHEMICAL ( CHEMICAL agonist ) GENE ( CHEMICAL , GENE ) agonist ) , ENTITY1 ( GENE ) agonist )"
"in addition to ENTITY2 and to a less extent CHEMICAL ( pitressin ) , a number of GENE and CHEMICAL analogue ; such as CHEMICAL ( CHEMICAL agonist ) GENE ( CHEMICAL , GENE ) agonist ) , CHEMICAL ( GENE ) agonist ) , CHEMICAL ( GENE ) agonist ) and CHEMICAL ( ENTITY1 CHEMICAL antagonist ) be also"
") , a number of ENTITY2 and CHEMICAL analogue ; such as CHEMICAL ( CHEMICAL agonist ) GENE ( CHEMICAL , GENE ) agonist ) , CHEMICAL ( GENE ) agonist ) , CHEMICAL ( GENE ) agonist ) and CHEMICAL ( ENTITY1 CHEMICAL antagonist ) be also"
"ENTITY2 have be show to be the target of the ENTITY1 drug , CHEMICAL and CHEMICAL"
"ENTITY2 have be show to be the target of the CHEMICAL drug , ENTITY1 and CHEMICAL ."
"ENTITY2 have be show to be the target of the CHEMICAL drug , CHEMICAL and ENTITY1 ."
", the active site of ENTITY2 for ENTITY1 as well as CHEMICAL be"
", the active site of ENTITY2 for CHEMICAL as well as ENTITY1 be predict by bioinformatic and"
"ENTITY2 be not induce by ENTITY1 in the parental cell line"
"most probable active site of ENTITY2 be predict use the scoring matrix , which include three distant area : "" head area "" ( CHEMICAL , 87 - 96 ) , "" middle area "" ( ENTITY1 , 38 - 47 ,"
""" middle area "" ( ENTITY1 , 38 - 47 , and ENTITY2 , 139 - 148 )"
"most probable active site of ENTITY2 be predict use the scoring matrix , which include three distant area : "" head area "" ( CHEMICAL , 87 - 96 ) , "" middle area "" ( CHEMICAL , 38 - 47 , and GENE , 139 - 148 ) , and "" bottom area "" ( ENTITY1 , 222 - 231 )"
"38 - 47 , and ENTITY2 , 139 - 148 ) , and "" bottom area "" ( ENTITY1 , 222 - 231 )"
"most probable active site of ENTITY2 be predict use the scoring matrix , which include three distant area : "" head area "" ( ENTITY1 , 87 - 96 )"
""" head area "" ( ENTITY1 , 87 - 96 ) , "" middle area "" ( CHEMICAL , 38 - 47 , and ENTITY2 , 139 - 148 )"
"of GENE be dock with ENTITY1 / CHEMICAL in comparison with ENTITY2 ( GENE GENE GENE )"
"subsequently the structural model of ENTITY2 be dock with ENTITY1 / CHEMICAL in comparison with"
"of GENE be dock with ENTITY1 / CHEMICAL in comparison with GENE ( ENTITY2 ) ."
"be dock with CHEMICAL / ENTITY1 in comparison with ENTITY2 ( GENE GENE GENE )"
"subsequently the structural model of ENTITY2 be dock with CHEMICAL / ENTITY1 in comparison with GENE ("
"be dock with CHEMICAL / ENTITY1 in comparison with GENE ( ENTITY2 ) ."
"also examine the effect of ENTITY1 , a ENTITY2 antagonist , in parallel ."
"proinflammatory pathway mediate by three ENTITY1 ligand whose stability and potency be different and by multiple ENTITY2 whose function may be non"
"basis for the development of ENTITY2 inhibitor for a proinflammatory pathway mediate by three ENTITY1 ligand whose stability and potency"
"the antioxidant defence system ( ENTITY1 GENE ( GENE ) , GENE ( GENE ) , GENE GENE ( GENE GENE GENE ) , CHEMICAL GENE ( GENE ) , CHEMICAL ( CHEMICAL ) , and GENE GENE CHEMICAL GENE GENE ( ENTITY2 ) ) ."
"the antioxidant defence system ( ENTITY1 GENE ( GENE ) , GENE ( ENTITY2 ) , GENE GENE ("
"the antioxidant defence system ( ENTITY1 GENE ( GENE ) , GENE ( GENE ) , GENE GENE ( ENTITY2 ) , CHEMICAL GENE ("
"the antioxidant defence system ( ENTITY1 GENE ( GENE ) , ENTITY2 ( GENE ) , GENE"
"the antioxidant defence system ( ENTITY1 GENE ( ENTITY2 ) , GENE ( GENE"
"the antioxidant defence system ( ENTITY1 GENE ( GENE ) , GENE ( GENE ) , GENE GENE ( GENE GENE GENE ) , CHEMICAL GENE ( ENTITY2 ) , CHEMICAL ( CHEMICAL"
"the antioxidant defence system ( ENTITY1 GENE ( GENE ) , GENE ( GENE ) , ENTITY2 ( GENE GENE GENE )"
"GENE ) , CHEMICAL ( ENTITY1 ) , and GENE GENE CHEMICAL GENE GENE ( ENTITY2 ) ) ."
"GENE ) , GENE ( ENTITY2 ) , GENE GENE ( GENE GENE GENE ) , CHEMICAL GENE ( GENE ) , CHEMICAL ( ENTITY1 ) , and GENE GENE"
") , GENE GENE ( ENTITY2 ) , CHEMICAL GENE ( GENE ) , CHEMICAL ( ENTITY1 ) , and GENE GENE"
"GENE ( GENE ) , ENTITY2 ( GENE ) , GENE GENE ( GENE GENE GENE ) , CHEMICAL GENE ( GENE ) , CHEMICAL ( ENTITY1 ) , and GENE GENE"
"system ( CHEMICAL GENE ( ENTITY2 ) , GENE ( GENE ) , GENE GENE ( GENE GENE GENE ) , CHEMICAL GENE ( GENE ) , CHEMICAL ( ENTITY1 ) , and GENE GENE"
") , CHEMICAL GENE ( ENTITY2 ) , CHEMICAL ( ENTITY1 ) , and GENE GENE"
"GENE ( GENE ) , ENTITY2 ( GENE GENE GENE ) , CHEMICAL GENE ( GENE ) , CHEMICAL ( ENTITY1 ) , and GENE GENE"
"acute intoxication with ENTITY1 be also follow by significantly decrease activity of the antioxidant defence system ( CHEMICAL GENE ( GENE ) , GENE ( GENE ) , GENE GENE ( GENE GENE GENE ) , CHEMICAL GENE ( GENE ) , CHEMICAL ( CHEMICAL ) , and GENE GENE CHEMICAL GENE GENE ( ENTITY2 ) ) ."
"acute intoxication with ENTITY1 be also follow by significantly decrease activity of the antioxidant defence system ( CHEMICAL GENE ( GENE ) , GENE ( ENTITY2 ) , GENE GENE ("
"acute intoxication with ENTITY1 be also follow by significantly decrease activity of the antioxidant defence system ( CHEMICAL GENE ( GENE ) , GENE ( GENE ) , GENE GENE ( ENTITY2 ) , CHEMICAL GENE ("
"acute intoxication with ENTITY1 be also follow by significantly decrease activity of the antioxidant defence system ( CHEMICAL GENE ( GENE ) , ENTITY2 ( GENE ) , GENE"
"acute intoxication with ENTITY1 be also follow by significantly decrease activity of the antioxidant defence system ( CHEMICAL GENE ( ENTITY2 ) , GENE ( GENE"
"acute intoxication with ENTITY1 be also follow by significantly decrease activity of the antioxidant defence system ( CHEMICAL GENE ( GENE ) , GENE ( GENE ) , GENE GENE ( GENE GENE GENE ) , CHEMICAL GENE ( ENTITY2 ) , CHEMICAL ( CHEMICAL"
"acute intoxication with ENTITY1 be also follow by significantly decrease activity of the antioxidant defence system ( CHEMICAL GENE ( GENE ) , GENE ( GENE ) , ENTITY2 ( GENE GENE GENE )"
") , and GENE GENE ENTITY1 GENE GENE ( ENTITY2 ) ) ."
"GENE ) , GENE ( ENTITY2 ) , GENE GENE ( GENE GENE GENE ) , CHEMICAL GENE ( GENE ) , CHEMICAL ( CHEMICAL ) , and GENE GENE ENTITY1 GENE GENE ( GENE )"
") , GENE GENE ( ENTITY2 ) , CHEMICAL GENE ( GENE ) , CHEMICAL ( CHEMICAL ) , and GENE GENE ENTITY1 GENE GENE ( GENE )"
"GENE ( GENE ) , ENTITY2 ( GENE ) , GENE GENE ( GENE GENE GENE ) , CHEMICAL GENE ( GENE ) , CHEMICAL ( CHEMICAL ) , and GENE GENE ENTITY1 GENE GENE ( GENE )"
"system ( CHEMICAL GENE ( ENTITY2 ) , GENE ( GENE ) , GENE GENE ( GENE GENE GENE ) , CHEMICAL GENE ( GENE ) , CHEMICAL ( CHEMICAL ) , and GENE GENE ENTITY1 GENE GENE ( GENE )"
") , CHEMICAL GENE ( ENTITY2 ) , CHEMICAL ( CHEMICAL ) , and GENE GENE ENTITY1 GENE GENE ( GENE )"
"GENE ( GENE ) , ENTITY2 ( GENE GENE GENE ) , CHEMICAL GENE ( GENE ) , CHEMICAL ( CHEMICAL ) , and GENE GENE ENTITY1 GENE GENE ( GENE )"
"GENE GENE GENE ) , ENTITY1 GENE ( GENE ) , CHEMICAL ( CHEMICAL ) , and GENE GENE CHEMICAL GENE GENE ( ENTITY2 ) ) ."
"GENE ) , GENE ( ENTITY2 ) , GENE GENE ( GENE GENE GENE ) , ENTITY1 GENE ( GENE ) ,"
") , GENE GENE ( ENTITY2 ) , ENTITY1 GENE ( GENE ) ,"
"GENE ( GENE ) , ENTITY2 ( GENE ) , GENE GENE ( GENE GENE GENE ) , ENTITY1 GENE ( GENE ) ,"
"system ( CHEMICAL GENE ( ENTITY2 ) , GENE ( GENE ) , GENE GENE ( GENE GENE GENE ) , ENTITY1 GENE ( GENE ) ,"
"GENE GENE GENE ) , ENTITY1 GENE ( ENTITY2 ) , CHEMICAL ( CHEMICAL"
"GENE ( GENE ) , ENTITY2 ( GENE GENE GENE ) , ENTITY1 GENE ( GENE ) ,"
"GENE ( GENE ) , ENTITY1 ( CHEMICAL ) , and GENE GENE CHEMICAL GENE GENE ( ENTITY2 ) ) ."
"GENE ) , GENE ( ENTITY2 ) , GENE GENE ( GENE GENE GENE ) , CHEMICAL GENE ( GENE ) , ENTITY1 ( CHEMICAL ) , and"
") , GENE GENE ( ENTITY2 ) , CHEMICAL GENE ( GENE ) , ENTITY1 ( CHEMICAL ) , and"
"GENE ( GENE ) , ENTITY2 ( GENE ) , GENE GENE ( GENE GENE GENE ) , CHEMICAL GENE ( GENE ) , ENTITY1 ( CHEMICAL ) , and"
"system ( CHEMICAL GENE ( ENTITY2 ) , GENE ( GENE ) , GENE GENE ( GENE GENE GENE ) , CHEMICAL GENE ( GENE ) , ENTITY1 ( CHEMICAL ) , and"
") , CHEMICAL GENE ( ENTITY2 ) , ENTITY1 ( CHEMICAL ) , and"
"GENE ( GENE ) , ENTITY2 ( GENE GENE GENE ) , CHEMICAL GENE ( GENE ) , ENTITY1 ( CHEMICAL ) , and"
"objective : ENTITY1 be the first in a new class of synthetic ENTITY2 inhibitor that bind reversibly with"
"objective : ENTITY1 be the first in a new class of synthetic GENE GENE inhibitor that bind reversibly with high affinity to ENTITY2 ."
"ENTITY2 mediate excitotoxicity in cerebral cortex of ENTITY1 induce diabetic rat : ameliorating"
"ENTITY2 mediate excitotoxicity in cerebral cortex of CHEMICAL induce diabetic rat : ameliorating effect of ENTITY1 . 	"
"hand , the GENE ( ENTITY2 ) gene disrupt mutant produce significantly high level of CHEMICAL but do not form ENTITY1 at all ."
"the other hand , the ENTITY2 ( GENE ) gene disrupt mutant produce significantly high level of CHEMICAL but do not form ENTITY1 at all ."
"hand , the GENE ( ENTITY2 ) gene disrupt mutant produce significantly high level of ENTITY1 but do not form CHEMICAL"
"the other hand , the ENTITY2 ( GENE ) gene disrupt mutant produce significantly high level of ENTITY1 but do not form CHEMICAL"
"be a site where the ENTITY1 transporter be non - neuronal ENTITY2 ."
"CHEMICAL on the deamination of ENTITY1 be investigate in intact lung of rat , since the pulmonary endothelial cell be a site where the CHEMICAL transporter be non - neuronal ENTITY2 ."
"study , the effect of ENTITY1 on the deamination of CHEMICAL be investigate in intact lung of rat , since the pulmonary endothelial cell be a site where the CHEMICAL transporter be non - neuronal ENTITY2 ."
"present study demonstrate that ENTITY2 will also catalyze ENTITY1 production with the same active"
"present study demonstrate that ENTITY2 will also catalyze CHEMICAL CHEMICAL production with the same active site copper if a suitable substrate such as ENTITY1 be provide . 
"
"clinically approve antihypertensive drug ( ENTITY1 , CHEMICAL , CHEMICAL , and CHEMICAL ) as potent ENTITY2 blocker ( ic(50 ) <"
"CHEMICAL , CHEMICAL , and ENTITY1 ) as potent ENTITY2 blocker ( ic(50 ) <"
"antihypertensive drug ( CHEMICAL , ENTITY1 , CHEMICAL , and CHEMICAL ) as potent ENTITY2 blocker ( ic(50 ) <"
"( CHEMICAL , CHEMICAL , ENTITY1 , and CHEMICAL ) as potent ENTITY2 blocker ( ic(50 ) <"
"interestingly , ENTITY1 , a selective inhibitor of ENTITY2 GENE , block GENE phosphorylation"
"interestingly , ENTITY1 , a selective inhibitor of GENE ENTITY2 , block GENE phosphorylation and"
"interestingly , ENTITY1 , a selective inhibitor of GENE GENE , block ENTITY2 phosphorylation and lead to sustain"
"CHEMICAL CHEMICAL CHEMICAL , a ENTITY2 antagonist , and ENTITY1 CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL"
"CHEMICAL CHEMICAL CHEMICAL , a ENTITY2 antagonist , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL , a GENE GENE GENE antagonist , and ENTITY1 CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL"
"CHEMICAL CHEMICAL CHEMICAL , a ENTITY2 antagonist , and CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL , a ENTITY1 GENE GENE antagonist with mast"
"CHEMICAL CHEMICAL CHEMICAL , a ENTITY2 antagonist , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL , a GENE GENE GENE antagonist , and CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL , a ENTITY1 GENE GENE antagonist with mast"
"CHEMICAL CHEMICAL CHEMICAL , a ENTITY2 antagonist , and CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL , a CHEMICAL GENE GENE antagonist with mast cell - stabilize property , on microvascular leakage induce by gaseous ENTITY1 ."
"CHEMICAL CHEMICAL CHEMICAL , a ENTITY2 antagonist , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL , a GENE GENE GENE antagonist , and CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL , a CHEMICAL GENE GENE antagonist with mast cell - stabilize property , on microvascular leakage induce by gaseous ENTITY1 ."
"CHEMICAL CHEMICAL CHEMICAL , a ENTITY2 antagonist , and CHEMICAL ENTITY1 , a CHEMICAL GENE GENE"
"CHEMICAL CHEMICAL CHEMICAL , a ENTITY2 antagonist , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL , a GENE GENE GENE antagonist , and CHEMICAL ENTITY1 , a CHEMICAL GENE GENE"
"GENE antagonist , CHEMICAL CHEMICAL ENTITY1 , a ENTITY2 antagonist , and CHEMICAL CHEMICAL"
"CHEMICAL CHEMICAL CHEMICAL , a ENTITY2 antagonist , CHEMICAL CHEMICAL ENTITY1 , a GENE GENE GENE"
"GENE GENE GENE antagonist , ENTITY1 CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL , a ENTITY2 antagonist , and CHEMICAL CHEMICAL"
"CHEMICAL CHEMICAL CHEMICAL , a ENTITY2 antagonist , ENTITY1 CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL"
"have investigate the effect of ENTITY1 CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL , a GENE GENE GENE antagonist , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL , a ENTITY2 antagonist , and CHEMICAL CHEMICAL"
"have investigate the effect of ENTITY1 CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL , a ENTITY2 antagonist , CHEMICAL CHEMICAL CHEMICAL"
"investigate the effect of CHEMICAL ENTITY1 , a GENE GENE GENE antagonist , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL , a ENTITY2 antagonist , and CHEMICAL CHEMICAL"
"investigate the effect of CHEMICAL ENTITY1 , a ENTITY2 antagonist , CHEMICAL CHEMICAL CHEMICAL"
"the arsenolysis of CHEMICAL ( ENTITY1 ) catalyze by ENTITY2 and be correct for the"
"measure on the arsenolysis of ENTITY1 ( CHEMICAL ) catalyze by ENTITY2 and be correct for the"
"composition of CHEMICAL CHEMICAL ( ENTITY1 ) in diet , and the expression of GENE GENE ( ENTITY2 ) and GENE GENE ("
"composition of CHEMICAL CHEMICAL ( ENTITY1 ) in diet , and the expression of GENE GENE ( GENE ) and ENTITY2 ( GENE ) gene in"
"composition of CHEMICAL CHEMICAL ( ENTITY1 ) in diet , and the expression of ENTITY2 ( GENE ) and GENE"
"composition of CHEMICAL CHEMICAL ( ENTITY1 ) in diet , and the expression of GENE GENE ( GENE ) and GENE GENE ( ENTITY2 ) gene in peripheral blood"
"to compare the composition of ENTITY1 ( CHEMICAL ) in diet , and the expression of GENE GENE ( ENTITY2 ) and GENE GENE ("
"to compare the composition of ENTITY1 ( CHEMICAL ) in diet , and the expression of GENE GENE ( GENE ) and ENTITY2 ( GENE ) gene in"
"to compare the composition of ENTITY1 ( CHEMICAL ) in diet , and the expression of ENTITY2 ( GENE ) and GENE"
"to compare the composition of ENTITY1 ( CHEMICAL ) in diet , and the expression of GENE GENE ( GENE ) and GENE GENE ( ENTITY2 ) gene in peripheral blood"
"ENTITY1 - mediate downregulation of ENTITY2 GENE GENE GENE GENE GENE"
"ENTITY1 - mediate downregulation of GENE ENTITY2 - dependent excision repair cross"
"CHEMICAL - mediate downregulation of ENTITY2 GENE GENE GENE GENE GENE - dependent excision repair cross - complement 1 decrease dna repair capacity and sensitize human lung cancer cell to ENTITY1 . 	"
"- mediate downregulation of GENE ENTITY2 - dependent excision repair cross - complement 1 decrease dna repair capacity and sensitize human lung cancer cell to ENTITY1 . 	"
"the discovery of fuse ENTITY1 as ENTITY2 modulator for treatment of alzheimer"
"ENTITY1 inhibit the checkpoint GENE ENTITY2 . 	"
"ENTITY1 inhibit the checkpoint ENTITY2 GENE . 	"
"interaction with the ENTITY2 channel and cytotoxicity of ENTITY1 and CHEMICAL analogue . 	"
"interaction with the ENTITY2 channel and cytotoxicity of CHEMICAL and ENTITY1 analogue . 	"
"CHEMICAL , CHEMICAL GENE , ENTITY2 , GENE GENE and GENE GENE GENE : CHEMICAL GENE ( GENE ) , GENE activity as well as epididymal sperm count and motility , while ENTITY1 and CHEMICAL treatment reverse this"
"GENE , GENE GENE , ENTITY2 and GENE GENE GENE : CHEMICAL GENE ( GENE ) , GENE activity as well as epididymal sperm count and motility , while ENTITY1 and CHEMICAL treatment reverse this"
"GENE ( GENE ) , ENTITY2 activity as well as epididymal sperm count and motility , while ENTITY1 and CHEMICAL treatment reverse this"
"GENE , GENE GENE and ENTITY2 : CHEMICAL GENE ( GENE ) , GENE activity as well as epididymal sperm count and motility , while ENTITY1 and CHEMICAL treatment reverse this"
"GENE : CHEMICAL GENE ( ENTITY2 ) , GENE activity as well as epididymal sperm count and motility , while ENTITY1 and CHEMICAL treatment reverse this"
"the obtain result show that ENTITY1 increase lipid peroxidation and abnormal sperm count and decrease plasma CHEMICAL , CHEMICAL GENE , ENTITY2 , GENE GENE and GENE"
"the obtain result show that ENTITY1 increase lipid peroxidation and abnormal sperm count and decrease plasma CHEMICAL , CHEMICAL GENE , GENE GENE , ENTITY2 and GENE GENE GENE :"
"the obtain result show that ENTITY1 increase lipid peroxidation and abnormal sperm count and decrease plasma CHEMICAL , CHEMICAL GENE , GENE GENE , GENE GENE and GENE GENE GENE : CHEMICAL GENE ( GENE ) , ENTITY2 activity as well as epididymal"
"the obtain result show that ENTITY1 increase lipid peroxidation and abnormal sperm count and decrease plasma CHEMICAL , CHEMICAL GENE , GENE GENE , GENE GENE and ENTITY2 : CHEMICAL GENE ( GENE"
"the obtain result show that ENTITY1 increase lipid peroxidation and abnormal sperm count and decrease plasma CHEMICAL , CHEMICAL GENE , GENE GENE , GENE GENE and GENE GENE GENE : CHEMICAL GENE ( ENTITY2 ) , GENE activity as"
"CHEMICAL , CHEMICAL GENE , ENTITY2 , GENE GENE and GENE GENE GENE : ENTITY1 GENE ( GENE ) ,"
"GENE , GENE GENE , ENTITY2 and GENE GENE GENE : ENTITY1 GENE ( GENE ) ,"
"and GENE GENE GENE : ENTITY1 GENE ( GENE ) , ENTITY2 activity as well as epididymal"
"GENE , GENE GENE and ENTITY2 : ENTITY1 GENE ( GENE ) ,"
"and GENE GENE GENE : ENTITY1 GENE ( ENTITY2 ) , GENE activity as"
"CHEMICAL , CHEMICAL GENE , ENTITY2 , GENE GENE and GENE GENE GENE : CHEMICAL GENE ( GENE ) , GENE activity as well as epididymal sperm count and motility , while CHEMICAL and ENTITY1 treatment reverse this change to"
"GENE , GENE GENE , ENTITY2 and GENE GENE GENE : CHEMICAL GENE ( GENE ) , GENE activity as well as epididymal sperm count and motility , while CHEMICAL and ENTITY1 treatment reverse this change to"
"GENE ( GENE ) , ENTITY2 activity as well as epididymal sperm count and motility , while CHEMICAL and ENTITY1 treatment reverse this change to"
"GENE , GENE GENE and ENTITY2 : CHEMICAL GENE ( GENE ) , GENE activity as well as epididymal sperm count and motility , while CHEMICAL and ENTITY1 treatment reverse this change to"
"GENE : CHEMICAL GENE ( ENTITY2 ) , GENE activity as well as epididymal sperm count and motility , while CHEMICAL and ENTITY1 treatment reverse this change to"
"and decrease plasma CHEMICAL , ENTITY1 GENE , ENTITY2 , GENE GENE and GENE"
"and decrease plasma CHEMICAL , ENTITY1 GENE , GENE GENE , ENTITY2 and GENE GENE GENE :"
"and decrease plasma CHEMICAL , ENTITY1 GENE , GENE GENE , GENE GENE and GENE GENE GENE : CHEMICAL GENE ( GENE ) , ENTITY2 activity as well as epididymal"
"and decrease plasma CHEMICAL , ENTITY1 GENE , GENE GENE , GENE GENE and ENTITY2 : CHEMICAL GENE ( GENE"
"and decrease plasma CHEMICAL , ENTITY1 GENE , GENE GENE , GENE GENE and GENE GENE GENE : CHEMICAL GENE ( ENTITY2 ) , GENE activity as"
"sperm count and decrease plasma ENTITY1 , CHEMICAL GENE , ENTITY2 , GENE GENE and GENE"
"sperm count and decrease plasma ENTITY1 , CHEMICAL GENE , GENE GENE , ENTITY2 and GENE GENE GENE :"
"sperm count and decrease plasma ENTITY1 , CHEMICAL GENE , GENE GENE , GENE GENE and GENE GENE GENE : CHEMICAL GENE ( GENE ) , ENTITY2 activity as well as epididymal"
"sperm count and decrease plasma ENTITY1 , CHEMICAL GENE , GENE GENE , GENE GENE and ENTITY2 : CHEMICAL GENE ( GENE"
"sperm count and decrease plasma ENTITY1 , CHEMICAL GENE , GENE GENE , GENE GENE and GENE GENE GENE : CHEMICAL GENE ( ENTITY2 ) , GENE activity as"
"furthermore , no impact on ENTITY2 release ( i.e. , on GENE , GENE , GENE and GENE level ) be see in lps - stimulate human pbmc , except with ENTITY1 and CHEMICAL which cause a"
", GENE , GENE and ENTITY2 level ) be see in lps - stimulate human pbmc , except with ENTITY1 and CHEMICAL which cause a"
"human pbmc , except with ENTITY1 and CHEMICAL which cause a decrease of ENTITY2 and GENE ."
"release ( i.e. , on ENTITY2 , GENE , GENE and GENE level ) be see in lps - stimulate human pbmc , except with ENTITY1 and CHEMICAL which cause a"
"i.e. , on GENE , ENTITY2 , GENE and GENE level ) be see in lps - stimulate human pbmc , except with ENTITY1 and CHEMICAL which cause a"
"furthermore , no impact on ENTITY2 release ( i.e. , on GENE , GENE , GENE and GENE level ) be see in lps - stimulate human pbmc , except with CHEMICAL and ENTITY1 which cause a decrease of"
", GENE , GENE and ENTITY2 level ) be see in lps - stimulate human pbmc , except with CHEMICAL and ENTITY1 which cause a decrease of"
", except with CHEMICAL and ENTITY1 which cause a decrease of ENTITY2 and GENE ."
"release ( i.e. , on ENTITY2 , GENE , GENE and GENE level ) be see in lps - stimulate human pbmc , except with CHEMICAL and ENTITY1 which cause a decrease of"
"i.e. , on GENE , ENTITY2 , GENE and GENE level ) be see in lps - stimulate human pbmc , except with CHEMICAL and ENTITY1 which cause a decrease of"
"quantification of endogenous ENTITY1 in scrh may reveal important adaptive response associate with exposure to know ENTITY2 inhibitor . 
"
"GENE inhibitor , CHEMICAL and ENTITY1 , be use to disrupt ENTITY2 - mediate pericyte support of"
"GENE inhibitor , CHEMICAL and ENTITY1 , be use to disrupt GENE - mediate pericyte support of tumor endothelial cell in concert with maximum - tolerate dose ( mtd ) or metronomic chemotherapy and/or ENTITY2 inhibition ."
"GENE CHEMICAL GENE inhibitor , ENTITY1 and CHEMICAL , be use to disrupt ENTITY2 - mediate pericyte support of"
"GENE CHEMICAL GENE inhibitor , ENTITY1 and CHEMICAL , be use to disrupt GENE - mediate pericyte support of tumor endothelial cell in concert with maximum - tolerate dose ( mtd ) or metronomic chemotherapy and/or ENTITY2 inhibition ."
"islet tumor , two GENE ENTITY1 GENE inhibitor , CHEMICAL and CHEMICAL , be use to disrupt ENTITY2 - mediate pericyte support of"
"islet tumor , two GENE ENTITY1 GENE inhibitor , CHEMICAL and CHEMICAL , be use to disrupt GENE - mediate pericyte support of tumor endothelial cell in concert with maximum - tolerate dose ( mtd ) or metronomic chemotherapy and/or ENTITY2 inhibition ."
"gcs , CHEMICAL CHEMICAL , ENTITY1 , CHEMICAL , and CHEMICAL CHEMICAL , by the ENTITY2 family of enzyme be study"
"CHEMICAL , CHEMICAL , and ENTITY1 , by the ENTITY2 family of enzyme be study"
"CHEMICAL CHEMICAL , CHEMICAL , ENTITY1 , and CHEMICAL CHEMICAL , by the ENTITY2 family of enzyme be study"
"frequently prescribe inhale gcs , ENTITY1 , CHEMICAL , CHEMICAL , and CHEMICAL CHEMICAL , by the ENTITY2 family of enzyme be study"
"result : ENTITY1 , despite equivocal efficacy as monotherapy , reduce pericyte coverage of tumor vessel and enhance efficacy in combination with metronomic chemotherapy or ENTITY2 inhibition ."
") potentially protect nsc against ENTITY1 through activate ENTITY2 / GENE pathway ."
") potentially protect nsc against ENTITY1 through activate GENE / ENTITY2 pathway ."
"report to be substrate for ENTITY2 or GENE and that contain in -PRON- structure either ENTITY1 , CHEMICAL CHEMICAL , or"
"be substrate for GENE or ENTITY2 and that contain in -PRON- structure either ENTITY1 , CHEMICAL CHEMICAL , or"
"report to be substrate for ENTITY2 or GENE and that contain in -PRON- structure either CHEMICAL CHEMICAL CHEMICAL , CHEMICAL CHEMICAL , or an ENTITY1 group ."
"be substrate for GENE or ENTITY2 and that contain in -PRON- structure either CHEMICAL CHEMICAL CHEMICAL , CHEMICAL CHEMICAL , or an ENTITY1 group ."
"report to be substrate for ENTITY2 or GENE and that contain in -PRON- structure either CHEMICAL CHEMICAL CHEMICAL , ENTITY1 , or an CHEMICAL group"
"be substrate for GENE or ENTITY2 and that contain in -PRON- structure either CHEMICAL CHEMICAL CHEMICAL , ENTITY1 , or an CHEMICAL group"
"1 mum. for the isolated ENTITY2 in the presence of physiological CHEMICAL + level , the target lipid ENTITY1 ( CHEMICAL ) and CHEMICAL"
"1 mum. for the isolated ENTITY2 in the presence of physiological CHEMICAL + level , the target lipid CHEMICAL ( ENTITY1 ) and CHEMICAL ( CHEMICAL"
"1 mum. for the isolated ENTITY2 in the presence of physiological CHEMICAL + level , the target lipid CHEMICAL ( CHEMICAL ) and CHEMICAL ( ENTITY1 ) be together sufficient to"
"1 mum. for the isolated ENTITY2 in the presence of physiological CHEMICAL + level , the target lipid CHEMICAL ( CHEMICAL ) and ENTITY1 ( CHEMICAL ) be together"
"for the ENTITY2 , the target lipid CHEMICAL ( ENTITY1 ) appear to be sufficient"
"for the ENTITY2 , the target lipid ENTITY1 ( CHEMICAL ) appear to"
"the anti - inflammatory drug ENTITY1 have be characterize as a selective inhibitor of the inducible GENE GENE GENE ( ENTITY2 ) ."
"the anti - inflammatory drug ENTITY1 have be characterize as a selective inhibitor of the inducible ENTITY2 ( GENE ) ."
"differential activation of ENTITY2 in discrete nucleus accumbens subregion during early and late ENTITY1 sensitization . 	"
"- induce activation of the ENTITY1 GENE GENE GENE GENE GENE GENE GENE ( ENTITY2 ) throughout discrete zone of"
"present study examine the differential ENTITY1 - induce activation of the CHEMICAL CHEMICAL CHEMICAL GENE GENE GENE GENE GENE GENE GENE ( ENTITY2 ) throughout discrete zone of"
"metabolism of ENTITY1 by ENTITY2 enzymes . 	"
"GENE GENE , GENE , ENTITY2 , GENE GENE , ENTITY1 GENE GENE GENE , and"
"GENE , GENE GENE , ENTITY2 , ENTITY1 GENE GENE GENE , and"
"reaction : GENE GENE , ENTITY2 , GENE GENE , GENE GENE , ENTITY1 GENE GENE GENE , and"
"GENE , GENE GENE , ENTITY1 GENE GENE GENE , and ENTITY2 ."
"catalyze the new reaction : ENTITY2 , GENE , GENE GENE , GENE GENE , ENTITY1 GENE GENE GENE , and"
"-PRON- show that soce activate ENTITY1 GENE GENE GENE GENE ( GENE ) ; -PRON- effector ENTITY2 GENE GENE GENE GENE GENE"
"-PRON- show that soce activate ENTITY1 GENE GENE GENE GENE ( GENE ) ; -PRON- effector GENE GENE GENE GENE GENE GENE ( ENTITY2 GENE ) phosphorylat GENE ,"
"-PRON- show that soce activate ENTITY1 GENE GENE GENE GENE ( GENE ) ; -PRON- effector GENE GENE GENE GENE GENE GENE ( GENE GENE ) phosphorylat ENTITY2 , thus inhibit soce in"
"-PRON- show that soce activate ENTITY1 GENE GENE GENE GENE ( GENE ) ; -PRON- effector GENE ENTITY2 ( GENE GENE ) phosphorylat"
"-PRON- show that soce activate ENTITY1 GENE GENE GENE GENE ( GENE ) ; -PRON- effector GENE GENE GENE GENE GENE GENE ( GENE ENTITY2 ) phosphorylat GENE , thus"
"-PRON- show that soce activate ENTITY1 GENE GENE GENE GENE ( ENTITY2 ) ; -PRON- effector GENE"
"ENTITY2 - dependent gene transcription , which may underlie long - last drug - induce change in behavior and the subjective effect of ENTITY1 , vary depend on the"
"ENTITY1 downregulat GENE GENE GENE GENE GENE through activation of ENTITY2 . 	"
"ENTITY1 downregulat ENTITY2 through activation of GENE GENE"
"finally , chronic administration of ENTITY1 in diabetic mouse restore cardiac autophagy by activate GENE pathway and dissociate ENTITY2 and GENE ."
"finally , chronic administration of ENTITY1 in diabetic mouse restore cardiac autophagy by activate GENE pathway and dissociate GENE and ENTITY2 ."
", ligand for the renal ENTITY2 ( CHEMICAL and CHEMICAL ) and for CHEMICAL recognition site ( CHEMICAL , CHEMICAL and ENTITY1 ) displace the binding of"
"( CHEMICAL , CHEMICAL and ENTITY1 ) displace the binding of CHEMICAL CHEMICAL CHEMICAL to CHEMICAL - insensitive site at micromolar concentration . photoaffinity labeling with CHEMICAL CHEMICAL CHEMICAL show CHEMICAL - insensitive labeling at around 100 kda , a molecular size large than that of ENTITY2 express in 293 cell ("
", ligand for the renal ENTITY2 ( CHEMICAL and CHEMICAL ) and for CHEMICAL recognition site ( ENTITY1 , CHEMICAL and CHEMICAL )"
"for CHEMICAL recognition site ( ENTITY1 , CHEMICAL and CHEMICAL ) displace the binding of CHEMICAL CHEMICAL CHEMICAL to CHEMICAL - insensitive site at micromolar concentration . photoaffinity labeling with CHEMICAL CHEMICAL CHEMICAL show CHEMICAL - insensitive labeling at around 100 kda , a molecular size large than that of ENTITY2 express in 293 cell ("
", ligand for the renal ENTITY2 ( CHEMICAL and CHEMICAL ) and for CHEMICAL recognition site ( CHEMICAL , CHEMICAL and CHEMICAL ) displace the binding of CHEMICAL CHEMICAL CHEMICAL to ENTITY1 - insensitive site at micromolar"
"of CHEMICAL CHEMICAL CHEMICAL to ENTITY1 - insensitive site at micromolar concentration . photoaffinity labeling with CHEMICAL CHEMICAL CHEMICAL show CHEMICAL - insensitive labeling at around 100 kda , a molecular size large than that of ENTITY2 express in 293 cell ("
", ligand for the renal ENTITY2 ( CHEMICAL and CHEMICAL ) and for CHEMICAL recognition site ( CHEMICAL , CHEMICAL and CHEMICAL ) displace the binding of CHEMICAL CHEMICAL CHEMICAL to CHEMICAL - insensitive site at micromolar concentration . photoaffinity labeling with CHEMICAL CHEMICAL CHEMICAL show ENTITY1 - insensitive labeling at around"
"with CHEMICAL CHEMICAL CHEMICAL show ENTITY1 - insensitive labeling at around 100 kda , a molecular size large than that of ENTITY2 express in 293 cell ("
", ligand for the renal ENTITY2 ( ENTITY1 and CHEMICAL ) and for"
"for the renal GENE ( ENTITY1 and CHEMICAL ) and for CHEMICAL recognition site ( CHEMICAL , CHEMICAL and CHEMICAL ) displace the binding of CHEMICAL CHEMICAL CHEMICAL to CHEMICAL - insensitive site at micromolar concentration . photoaffinity labeling with CHEMICAL CHEMICAL CHEMICAL show CHEMICAL - insensitive labeling at around 100 kda , a molecular size large than that of ENTITY2 express in 293 cell ("
", ligand for the renal ENTITY2 ( CHEMICAL and CHEMICAL ) and for CHEMICAL recognition site ( CHEMICAL , CHEMICAL and CHEMICAL ) displace the binding of CHEMICAL CHEMICAL CHEMICAL to CHEMICAL - insensitive site at micromolar concentration . photoaffinity labeling with ENTITY1 show CHEMICAL - insensitive labeling"
"concentration . photoaffinity labeling with ENTITY1 show CHEMICAL - insensitive labeling at around 100 kda , a molecular size large than that of ENTITY2 express in 293 cell ("
", ligand for the renal ENTITY2 ( CHEMICAL and CHEMICAL ) and for CHEMICAL recognition site ( CHEMICAL , CHEMICAL and CHEMICAL ) displace the binding of ENTITY1 to CHEMICAL - insensitive site"
") displace the binding of ENTITY1 to CHEMICAL - insensitive site at micromolar concentration . photoaffinity labeling with CHEMICAL CHEMICAL CHEMICAL show CHEMICAL - insensitive labeling at around 100 kda , a molecular size large than that of ENTITY2 express in 293 cell ("
", ligand for the renal ENTITY2 ( CHEMICAL and ENTITY1 ) and for CHEMICAL recognition"
"renal GENE ( CHEMICAL and ENTITY1 ) and for CHEMICAL recognition site ( CHEMICAL , CHEMICAL and CHEMICAL ) displace the binding of CHEMICAL CHEMICAL CHEMICAL to CHEMICAL - insensitive site at micromolar concentration . photoaffinity labeling with CHEMICAL CHEMICAL CHEMICAL show CHEMICAL - insensitive labeling at around 100 kda , a molecular size large than that of ENTITY2 express in 293 cell ("
", ligand for the renal ENTITY2 ( CHEMICAL and CHEMICAL ) and for CHEMICAL recognition site ( CHEMICAL , ENTITY1 and CHEMICAL ) displace the"
"recognition site ( CHEMICAL , ENTITY1 and CHEMICAL ) displace the binding of CHEMICAL CHEMICAL CHEMICAL to CHEMICAL - insensitive site at micromolar concentration . photoaffinity labeling with CHEMICAL CHEMICAL CHEMICAL show CHEMICAL - insensitive labeling at around 100 kda , a molecular size large than that of ENTITY2 express in 293 cell ("
", ligand for the renal ENTITY2 ( CHEMICAL and CHEMICAL ) and for ENTITY1 recognition site ( CHEMICAL ,"
"and CHEMICAL ) and for ENTITY1 recognition site ( CHEMICAL , CHEMICAL and CHEMICAL ) displace the binding of CHEMICAL CHEMICAL CHEMICAL to CHEMICAL - insensitive site at micromolar concentration . photoaffinity labeling with CHEMICAL CHEMICAL CHEMICAL show CHEMICAL - insensitive labeling at around 100 kda , a molecular size large than that of ENTITY2 express in 293 cell ("
"objective : ENTITY1 , an GENE GENE GENE GENE GENE ( GENE ) antagonist , be find to have a unique property : -PRON- be a partial agonist of ENTITY2 ( GENE ) ."
"objective : ENTITY1 , an ENTITY2 ( GENE ) antagonist ,"
"objective : ENTITY1 , an GENE GENE GENE GENE GENE ( ENTITY2 ) antagonist , be find"
"objective : ENTITY1 , an GENE GENE GENE GENE GENE ( GENE ) antagonist , be find to have a unique property : -PRON- be a partial agonist of GENE GENE GENE GENE GENE GENE ( ENTITY2 ) ."
", there be no detectable ENTITY1 - insensitive bind site but be CHEMICAL - sensitive ENTITY2 in human liver ( pk(d)=10.0+/-0.06"
"insensitive bind site but be ENTITY1 - sensitive ENTITY2 in human liver ( pk(d)=10.0+/-0.06"
"of the abuse liability of ENTITY1 , a novel ENTITY2 antagonist . 	"
"CHEMICAL GENE receptor antagonist , ENTITY1 and a ENTITY2 antagonist have significantly improve the"
"a combination of a CHEMICAL ENTITY2 receptor antagonist , ENTITY1 and a GENE GENE GENE"
"of a combination of a ENTITY1 GENE receptor antagonist , CHEMICAL and a ENTITY2 antagonist have significantly improve the"
"of a combination of a ENTITY1 ENTITY2 receptor antagonist , CHEMICAL and"
"the anticonvulsant efficacy of the ENTITY2 ( GENE CHEMICAL GENE GENE GENE GENE antagonist ENTITY1 ( CHEMICAL ) in rat"
"the anticonvulsant efficacy of the ENTITY2 ( GENE CHEMICAL GENE GENE GENE GENE antagonist CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) in rat that do"
"decrease ENTITY2 activity with unchanged mrna stability suggest that ENTITY1 suppress GENE gene expression at"
"unchanged mrna stability suggest that ENTITY1 suppress ENTITY2 gene expression at the transcriptional"
"however , the expression of ENTITY2 be not suppress by other GENE antagonist such as CHEMICAL or ENTITY1 ."
"be not suppress by other ENTITY2 antagonist such as CHEMICAL or ENTITY1 ."
"however , the expression of ENTITY2 be not suppress by other GENE antagonist such as ENTITY1 or CHEMICAL ."
"be not suppress by other ENTITY2 antagonist such as ENTITY1 or CHEMICAL ."
"ENTITY1 ( 0.1% ) fail to significantly attenuate either serotonin or platelet - activate - factor induce vascular permeability change indicate high selectivity for the ENTITY2 ."
"of -PRON- kind apply to ENTITY2 antagonist , indicate that ENTITY1 be unlikely to possess a"
"GENE antagonist , indicate that ENTITY1 be unlikely to possess a high potential for abuse in the human population and suggest that ENTITY2 antagonist , as a class"
"since the suppression of ENTITY2 expression be prevent by pretreatment with ENTITY1 , a GENE antagonist ,"
"be prevent by pretreatment with ENTITY1 , a ENTITY2 antagonist , GENE should have"
"be prevent by pretreatment with ENTITY1 , a GENE antagonist , ENTITY2 should have participate in the"
"gene promoter indicate that a ENTITY2 locate in the proximal promoter region be responsible for the ENTITY1 - induce downregulation ."
"and mutation analysis of the ENTITY2 gene promoter indicate that a GENE GENE locate in the proximal promoter region be responsible for the ENTITY1 - induce downregulation ."
"the ENTITY2 antagonist ENTITY1 ( CHEMICAL ) significantly counteract"
"the GENE GENE antagonist ENTITY1 ( CHEMICAL ) significantly counteract the effect of CHEMICAL on ENTITY2 activation , indicate that the"
"the GENE GENE antagonist ENTITY1 ( CHEMICAL ) significantly counteract the effect of CHEMICAL on GENE GENE activation , indicate that the CHEMICAL effect be specific and be mediate through the ENTITY2 ."
"the ENTITY2 antagonist CHEMICAL ( ENTITY1 ) significantly counteract the effect"
"GENE GENE antagonist CHEMICAL ( ENTITY1 ) significantly counteract the effect of CHEMICAL on ENTITY2 activation , indicate that the"
"GENE GENE antagonist CHEMICAL ( ENTITY1 ) significantly counteract the effect of CHEMICAL on GENE GENE activation , indicate that the CHEMICAL effect be specific and be mediate through the ENTITY2 ."
"the ENTITY2 antagonist CHEMICAL ( CHEMICAL ) significantly counteract the effect of ENTITY1 on GENE GENE activation ,"
"significantly counteract the effect of ENTITY1 on ENTITY2 activation , indicate that the"
"significantly counteract the effect of ENTITY1 on GENE GENE activation , indicate that the CHEMICAL effect be specific and be mediate through the ENTITY2 ."
"the ENTITY2 antagonist CHEMICAL ( CHEMICAL ) significantly counteract the effect of CHEMICAL on GENE GENE activation , indicate that the ENTITY1 effect be specific and be"
"the effect of CHEMICAL on ENTITY2 activation , indicate that the ENTITY1 effect be specific and be"
"activation , indicate that the ENTITY1 effect be specific and be mediate through the ENTITY2 ."
"in most pediatric case of ENTITY2 inhibitor - associate leukemia , there be disruption of the breakpoint cluster region of the GENE gene at chromosomal band 11q23 . ( 2 ) exposure history vary in secondary 11q23 leukemia , as the only GENE GENE inhibitor be ENTITY1 in one case , and"
"leukemia , as the only ENTITY2 inhibitor be ENTITY1 in one case , and"
"only GENE GENE inhibitor be ENTITY1 in one case , and , in another case , no ENTITY2 inhibitor be administer ."
"breakpoint cluster region of the ENTITY2 gene at chromosomal band 11q23 . ( 2 ) exposure history vary in secondary 11q23 leukemia , as the only GENE GENE inhibitor be ENTITY1 in one case , and"
"insight into an effect of ENTITY1 : CHEMICAL inhibit ENTITY2 gene expression through GENE activation"
"insight into an effect of ENTITY1 : CHEMICAL inhibit GENE gene expression through ENTITY2 activation ."
"an effect of CHEMICAL : ENTITY1 inhibit ENTITY2 gene expression through GENE activation"
"an effect of CHEMICAL : ENTITY1 inhibit GENE gene expression through ENTITY2 activation ."
"that normal plasma component , ENTITY1 and GENE , exert major regulatory role on the ability of GENE GENE to be activate by two - chain rec - ENTITY2 , in in vitro system"
"that normal plasma component , ENTITY1 and ENTITY2 , exert major regulatory role"
"that normal plasma component , ENTITY1 and GENE , exert major regulatory role on the ability of ENTITY2 to be activate by two"
"inhibition of the ENTITY1 GENE GENE ( ENTITY2 ) can cause intracellular accumulation"
"CHEMICAL CHEMICAL GENE GENE ( ENTITY2 ) can cause intracellular accumulation of ENTITY1 and be a risk factor"
"agent clinically available in the ENTITY2 antagonist drug class have be use effectively as an additive agent to the GENE receptor antagonist and ENTITY1 to control cinv ."
"an additive agent to the ENTITY2 receptor antagonist and ENTITY1 to control cinv ."
"ENTITY1 , the first and only agent clinically available in the ENTITY2 antagonist drug class have be"
"ENTITY1 , the first and only agent clinically available in the GENE GENE antagonist drug class have be use effectively as an additive agent to the ENTITY2 receptor antagonist and CHEMICAL to"
"antiretroviral GENE inhibitor ENTITY1 ( CHEMICAL ) and CHEMICAL ( CHEMICAL ) be report ENTITY2 inhibitor ."
"antiretroviral ENTITY2 inhibitor ENTITY1 ( CHEMICAL ) and CHEMICAL"
"antiretroviral GENE inhibitor CHEMICAL ( ENTITY1 ) and CHEMICAL ( CHEMICAL ) be report ENTITY2 inhibitor ."
"antiretroviral ENTITY2 inhibitor CHEMICAL ( ENTITY1 ) and CHEMICAL ( CHEMICAL"
"CHEMICAL ( CHEMICAL ) and ENTITY1 ( CHEMICAL ) be report ENTITY2 inhibitor ."
"antiretroviral ENTITY2 inhibitor CHEMICAL ( CHEMICAL ) and ENTITY1 ( CHEMICAL ) be report"
"CHEMICAL ) and CHEMICAL ( ENTITY1 ) be report ENTITY2 inhibitor ."
"antiretroviral ENTITY2 inhibitor CHEMICAL ( CHEMICAL ) and CHEMICAL ( ENTITY1 ) be report GENE inhibitor"
"decrease via the downregulation of ENTITY2 activity by either a GENE GENE inhibitor ENTITY1 or GENE knockdown with specific"
"GENE activity by either a ENTITY2 GENE inhibitor ENTITY1 or GENE knockdown with specific"
"either a GENE GENE inhibitor ENTITY1 or ENTITY2 knockdown with specific small interfere"
"activity by either a GENE ENTITY2 inhibitor ENTITY1 or GENE knockdown with specific"
"moreover , CHEMICAL - induce ENTITY2 protein and mrna level significantly decrease via the downregulation of GENE activity by either a GENE GENE inhibitor ENTITY1 or GENE knockdown with specific"
"moreover , ENTITY1 - induce GENE protein and mrna level significantly decrease via the downregulation of ENTITY2 activity by either a GENE"
"moreover , ENTITY1 - induce GENE protein and mrna level significantly decrease via the downregulation of GENE activity by either a ENTITY2 GENE inhibitor CHEMICAL or GENE"
"moreover , ENTITY1 - induce GENE protein and mrna level significantly decrease via the downregulation of GENE activity by either a GENE GENE inhibitor CHEMICAL or ENTITY2 knockdown with specific small interfere"
"moreover , ENTITY1 - induce GENE protein and mrna level significantly decrease via the downregulation of GENE activity by either a GENE ENTITY2 inhibitor CHEMICAL or GENE knockdown"
"moreover , ENTITY1 - induce ENTITY2 protein and mrna level significantly"
"also , the multicompartmentation of ENTITY2 in the plant cell suggest that the transport form of ENTITY1 be unconjugated . 
"
"fluorescent triflavin probe to the ENTITY2 on platelet membrane , and neither CHEMICAL nor ENTITY1 significantly reverse the CHEMICAL -"
"fluorescent triflavin probe to the ENTITY2 on platelet membrane , and neither ENTITY1 nor CHEMICAL significantly reverse the"
"fluorescent triflavin probe to the ENTITY2 on platelet membrane , and neither CHEMICAL nor CHEMICAL significantly reverse the ENTITY1 - mediate inhibition of platelet"
"ENTITY1 do not influence the binding of a fluorescent triflavin probe to the ENTITY2 on platelet membrane , and"
"effect of these drug on ENTITY2 activation , CHEMICAL CHEMICAL concentration , transepithelial CHEMICAL - sensitive ( CHEMICAL ) ) and ENTITY1 - sensitive basolateral ( CHEMICAL"
"effect of these drug on ENTITY2 activation , ENTITY1 concentration , transepithelial CHEMICAL -"
"effect of these drug on ENTITY2 activation , CHEMICAL CHEMICAL concentration , transepithelial ENTITY1 - sensitive ( CHEMICAL )"
"ENTITY1 inhibit ENTITY2 and have show therapeutic effect"
"the affinity and clearance of ENTITY2 for CHEMICAL , ENTITY1 , and CHEMICAL be significantly"
"of GENE for CHEMICAL , ENTITY1 , and CHEMICAL be significantly high than the correspond value of ENTITY2 and GENE , although the"
"of GENE for CHEMICAL , ENTITY1 , and CHEMICAL be significantly high than the correspond value of GENE and GENE , although the vmax value of ENTITY2 toward these drug be considerably"
"of GENE for CHEMICAL , ENTITY1 , and CHEMICAL be significantly high than the correspond value of GENE and ENTITY2 , although the vmax value"
"the affinity and clearance of ENTITY2 for CHEMICAL , CHEMICAL , and ENTITY1 be significantly high than the"
"CHEMICAL , CHEMICAL , and ENTITY1 be significantly high than the correspond value of ENTITY2 and GENE , although the"
"CHEMICAL , CHEMICAL , and ENTITY1 be significantly high than the correspond value of GENE and GENE , although the vmax value of ENTITY2 toward these drug be considerably"
"CHEMICAL , CHEMICAL , and ENTITY1 be significantly high than the correspond value of GENE and ENTITY2 , although the vmax value"
"the affinity and clearance of ENTITY2 for ENTITY1 , CHEMICAL , and CHEMICAL"
"and clearance of GENE for ENTITY1 , CHEMICAL , and CHEMICAL be significantly high than the correspond value of ENTITY2 and GENE , although the"
"and clearance of GENE for ENTITY1 , CHEMICAL , and CHEMICAL be significantly high than the correspond value of GENE and GENE , although the vmax value of ENTITY2 toward these drug be considerably"
"and clearance of GENE for ENTITY1 , CHEMICAL , and CHEMICAL be significantly high than the correspond value of GENE and ENTITY2 , although the vmax value"
"want to test whether sensory ENTITY2 be a molecular target for ENTITY1 ."
"ENTITY2 activity be measure as the amount of radiolabell ENTITY1 transfer to the sams peptide"
"ENTITY1 inhibit ENTITY2 expression in malignant glioma cell"
"in the nanomolar range with ENTITY2 receptor label by ENTITY1 in cortical membrane ."
"binding study show that both ENTITY1 and CHEMICAL interact in the nanomolar range with ENTITY2 receptor label by CHEMICAL CHEMICAL"
"show that both CHEMICAL and ENTITY1 interact in the nanomolar range with ENTITY2 receptor label by CHEMICAL CHEMICAL"
"by contrast , neither ENTITY1 nor CHEMICAL can be consider as possible ligand of GENE and ENTITY2 receptor because -PRON- affinity for"
"by contrast , neither ENTITY1 nor CHEMICAL can be consider as possible ligand of ENTITY2 and GENE receptor because -PRON-"
"contrast , neither CHEMICAL nor ENTITY1 can be consider as possible ligand of GENE and ENTITY2 receptor because -PRON- affinity for"
"contrast , neither CHEMICAL nor ENTITY1 can be consider as possible ligand of ENTITY2 and GENE receptor because -PRON-"
"GENE use CHEMICAL result in ENTITY2 phosphorylation on ENTITY1 residue and prevent GENE CHEMICAL"
"activation of ENTITY2 use CHEMICAL result in GENE phosphorylation on ENTITY1 residue and prevent GENE CHEMICAL"
"activation of GENE use ENTITY1 result in ENTITY2 phosphorylation on CHEMICAL residue and"
"activation of ENTITY2 use ENTITY1 result in GENE phosphorylation on"
"the ENTITY2 inhibitor compound c prevent the action of CHEMICAL and ENTITY1 but not CHEMICAL ."
"the ENTITY2 inhibitor compound c prevent the action of ENTITY1 and CHEMICAL but not CHEMICAL"
"the ENTITY2 inhibitor compound c prevent the action of CHEMICAL and CHEMICAL but not ENTITY1 ."
"-PRON- show that GENE , ENTITY2 , GENE , and GENE , as well as GENE , and GENE , which be express in dorsal root ganglion neuron , be insensitive toward ENTITY1 treatment ."
"here , -PRON- show that ENTITY2 , GENE , GENE , and GENE , as well as GENE , and GENE , which be express in dorsal root ganglion neuron , be insensitive toward ENTITY1 treatment ."
"GENE , as well as ENTITY2 , and GENE , which be express in dorsal root ganglion neuron , be insensitive toward ENTITY1 treatment ."
"well as GENE , and ENTITY2 , which be express in dorsal root ganglion neuron , be insensitive toward ENTITY1 treatment ."
"that GENE , GENE , ENTITY2 , and GENE , as well as GENE , and GENE , which be express in dorsal root ganglion neuron , be insensitive toward ENTITY1 treatment ."
"GENE , GENE , and ENTITY2 , as well as GENE , and GENE , which be express in dorsal root ganglion neuron , be insensitive toward ENTITY1 treatment ."
"the antifibrotic drug CHEMICAL ( ENTITY1 , CHEMICAL ) elicit growth - inhibitory effect and reduce ENTITY2 protein level in human glioma"
"report that the antifibrotic drug ENTITY1 ( CHEMICAL , CHEMICAL ) elicit growth - inhibitory effect and reduce ENTITY2 protein level in human glioma"
"drug CHEMICAL ( CHEMICAL , ENTITY1 ) elicit growth - inhibitory effect and reduce ENTITY2 protein level in human glioma"
"GENE be biologically relevant since ENTITY1 treatment reduce the growth inhibition of ENTITY2 - sensitive ccl-64 cell mediate"
"this reduction in ENTITY2 be biologically relevant since ENTITY1 treatment reduce the growth inhibition"
"for possible change in central ENTITY2 24 h after either a single or a repeat ( for 14 day ) treatment with ENTITY1 ( 10 mg / kg"
"damage induce by CHEMICAL or ENTITY1 include down - regulation of endogenous GENE coincident with increase in ENTITY2 ."
"damage induce by CHEMICAL or ENTITY1 include down - regulation of endogenous ENTITY2 coincident with increase in GENE"
"to dna damage induce by ENTITY1 or CHEMICAL include down - regulation of endogenous GENE coincident with increase in ENTITY2 ."
"to dna damage induce by ENTITY1 or CHEMICAL include down - regulation of endogenous ENTITY2 coincident with increase in GENE"
"ENTITY1 induce GENE transcriptional activity lead to expression of several ENTITY2 and GENE , of which"
"ENTITY1 induce ENTITY2 transcriptional activity lead to expression"
"ENTITY1 induce GENE transcriptional activity lead to expression of several GENE and ENTITY2 , of which GENE GENE"
"ENTITY1 induce GENE transcriptional activity lead to expression of several GENE and GENE , of which GENE GENE GENE GENE ( ENTITY2 ) be the most important"
"ENTITY1 induce GENE transcriptional activity lead to expression of several GENE and GENE , of which ENTITY2 ( GENE ) be the"
"GENE GENE GENE GENE ( ENTITY2 ) , which have important implication for the clinical use of ENTITY1 ."
"associate with inhibition of apical ENTITY2 ( GENE ) , which have important implication for the clinical use of ENTITY1 ."
"and implication : activation of ENTITY2 be associate with inhibition of apical GENE GENE GENE GENE GENE GENE ( GENE ) , which have important implication for the clinical use of ENTITY1 ."
"reaction where GENE GENE ( ENTITY2 ) catalyze the terminal reaction of CHEMICAL biosynthesis from ENTITY1 , a rate - limit"
"cascade of metabolic reaction where ENTITY2 ( GENE ) catalyze the terminal reaction of CHEMICAL biosynthesis from ENTITY1 , a rate - limit"
"the tissue ENTITY1 level be maintain through a cascade of metabolic reaction where GENE GENE ( ENTITY2 ) catalyze the terminal reaction"
"the tissue ENTITY1 level be maintain through a cascade of metabolic reaction where ENTITY2 ( GENE ) catalyze the"
"reaction where GENE GENE ( ENTITY2 ) catalyze the terminal reaction of ENTITY1 biosynthesis from CHEMICAL , a"
"cascade of metabolic reaction where ENTITY2 ( GENE ) catalyze the terminal reaction of ENTITY1 biosynthesis from CHEMICAL , a"
"novel ENTITY1 derivative as potent ENTITY2 inhibitor . 	"
"be effectively block by the ENTITY2 receptor antagonist , isamoltane , the GENE GENE antagonist , CHEMICAL , and the GENE selective antagonist ( 0.01 - 10 microm ) : ENTITY1 ( CHEMICAL CHEMICAL CHEMICAL )"
", CHEMICAL , and the ENTITY2 selective antagonist ( 0.01 - 10 microm ) : ENTITY1 ( CHEMICAL CHEMICAL CHEMICAL )"
"be effectively block by the ENTITY2 receptor antagonist , isamoltane , the GENE GENE antagonist , CHEMICAL , and the GENE selective antagonist ( 0.01 - 10 microm ) : CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL CHEMICAL CHEMICAL ) and ENTITY1 ( CHEMICAL CHEMICAL CHEMICAL )"
", CHEMICAL , and the ENTITY2 selective antagonist ( 0.01 - 10 microm ) : CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL CHEMICAL CHEMICAL ) and ENTITY1 ( CHEMICAL CHEMICAL CHEMICAL )"
"be effectively block by the ENTITY2 receptor antagonist , isamoltane , the GENE GENE antagonist , CHEMICAL , and the GENE selective antagonist ( 0.01 - 10 microm ) : CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) and CHEMICAL CHEMICAL CHEMICAL"
", CHEMICAL , and the ENTITY2 selective antagonist ( 0.01 - 10 microm ) : CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) and CHEMICAL CHEMICAL CHEMICAL"
"be effectively block by the ENTITY2 receptor antagonist , isamoltane , the GENE GENE antagonist , ENTITY1 , and the GENE selective"
"the GENE GENE antagonist , ENTITY1 , and the ENTITY2 selective antagonist ( 0.01 -"
"be effectively block by the ENTITY2 receptor antagonist , isamoltane , the GENE GENE antagonist , CHEMICAL , and the GENE selective antagonist ( 0.01 - 10 microm ) : CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL CHEMICAL CHEMICAL ) and CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) ."
", CHEMICAL , and the ENTITY2 selective antagonist ( 0.01 - 10 microm ) : CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL CHEMICAL CHEMICAL ) and CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) ."
"ENTITY1 lead to a reduction of GENE GENE GENE mrna level and of the mature GENE GENE GENE protein due to decrease expression and direct inhibition of the GENE GENE GENE ENTITY2 GENE ."
"ENTITY1 lead to a reduction of GENE GENE GENE mrna level and of the mature GENE GENE GENE protein due to decrease expression and direct inhibition of the ENTITY2 GENE GENE GENE GENE GENE"
"ENTITY1 lead to a reduction of GENE GENE GENE mrna level and of the mature GENE GENE GENE protein due to decrease expression and direct inhibition of the GENE GENE GENE GENE GENE GENE GENE ENTITY2 ."
"ENTITY1 lead to a reduction of ENTITY2 mrna level and of the"
"ENTITY1 lead to a reduction of GENE GENE GENE mrna level and of the mature ENTITY2 protein due to decrease expression"
"and pharmacological characterization of novel ENTITY1 analogues as extremely potent ENTITY2 agonist . 	"
"be both a substrate of ENTITY2 and a GENE inhibitor , ENTITY1 , be investigate in the"
"substrate of GENE and a ENTITY2 inhibitor , ENTITY1 , be investigate in the"
"knockdown of endogenous ENTITY2 potentiate the ENTITY1 - induce apoptosis of pc-3"
"by the stimulation of central ENTITY2 induce a secondary increase in sympathetic outflow and ENTITY1 release ."
"-PRON- result show that ENTITY2 inhibitor induce significant cardiovascular effect with a pressor response mediate mainly by the stimulation of central GENE GENE GENE induce a secondary increase in sympathetic outflow and ENTITY1 release ."
"activation of both ENTITY2 and GENE in the hippocampus be find follow memory consolidation but not after retrieval or reconsolidation in ENTITY1 - treat mouse group ."
"activation of both GENE and ENTITY2 in the hippocampus be find follow memory consolidation but not after retrieval or reconsolidation in ENTITY1 - treat mouse group ."
"in addition , ENTITY1 reduce the protein level of the ENTITY2 , a GENE GENE GENE"
"in addition , ENTITY1 reduce the protein level of the GENE GENE GENE GENE , a ENTITY2 target gene and GENE substrate"
"in addition , ENTITY1 reduce the protein level of the GENE GENE GENE GENE , a GENE GENE GENE target gene and ENTITY2 substrate involve in carcinogenesis ."
"the author analyze change in ENTITY2 phosphorylation in the nac after 5 day of ENTITY1 , a short or long"
"the primary intrinsic ky ( ENTITY1 and CHEMICAL ) suggest that ENTITY2 have a dissociative s(n)1 transition"
"intrinsic ky ( CHEMICAL and ENTITY1 ) suggest that ENTITY2 have a dissociative s(n)1 transition"
"and CHEMICAL ) suggest that ENTITY2 have a dissociative s(n)1 transition state with -PRON- cationic center at the anomeric ENTITY1 and insignificant bond order to"
"greatly attenuate outward current in ENTITY1 GENE GENE GENE GENE GENE GENE GENE GENE GENE ( GENE ) ENTITY2 ."
"greatly attenuate outward current in ENTITY1 GENE GENE GENE GENE GENE GENE GENE GENE GENE ( ENTITY2 ) GENE GENE GENE ."
"these datum define ENTITY1 or CHEMICAL - relate agent as promising agent for human cancer associate with enhanced ENTITY2 activity . 
"
"these datum define CHEMICAL or ENTITY1 - relate agent as promising agent for human cancer associate with enhanced ENTITY2 activity . 
"
"be a second - generation ENTITY1 GENE GENE antagonist , with a distinct pharmacological profile that differ from first - generation ENTITY2 antagonist ."
"ENTITY1 be a second - generation CHEMICAL GENE GENE antagonist , with a distinct pharmacological profile that differ from first - generation ENTITY2 antagonist ."
"on the contrary , ENTITY2 could be concentration - dependently modulate by ENTITY1 ."
"moreover , activation of the ENTITY2 and GENE signal pathway in the hippocampus may be involve in ENTITY1 - induce spatial memory change"
"activation of the GENE and ENTITY2 signal pathway in the hippocampus may be involve in ENTITY1 - induce spatial memory change"
"as a potent synthetic ENTITY2 inhibitor ( ic50=850nm , versus CHEMICAL of 8.1μm ) , ENTITY1 be determined to have more"
"as a potent synthetic ENTITY2 inhibitor ( ic50=850nm , versus ENTITY1 of 8.1μm ) , CHEMICAL"
"as a potent synthetic ENTITY2 inhibitor ( ic50=850nm , versus CHEMICAL of 8.1μm ) , CHEMICAL be determined to have more significant block effect to cancer cell invasion and angiogenesis than ENTITY1 ."
"( mkis ) CHEMICAL , ENTITY1 , and CHEMICAL , which target multiple ENTITY2 as well as GENE GENE"
", include the multiple - ENTITY2 inhibitor ( mkis ) CHEMICAL , ENTITY1 , and CHEMICAL , which"
"( mkis ) CHEMICAL , ENTITY1 , and CHEMICAL , which target multiple GENE as well as ENTITY2 ."
"CHEMICAL , CHEMICAL , and ENTITY1 , which target multiple ENTITY2 as well as GENE GENE"
", include the multiple - ENTITY2 inhibitor ( mkis ) CHEMICAL , CHEMICAL , and ENTITY1 , which target multiple GENE"
"CHEMICAL , CHEMICAL , and ENTITY1 , which target multiple GENE as well as ENTITY2 ."
"GENE inhibitor ( mkis ) ENTITY1 , CHEMICAL , and CHEMICAL , which target multiple ENTITY2 as well as GENE GENE"
", include the multiple - ENTITY2 inhibitor ( mkis ) ENTITY1 , CHEMICAL , and CHEMICAL"
"GENE inhibitor ( mkis ) ENTITY1 , CHEMICAL , and CHEMICAL , which target multiple GENE as well as ENTITY2 ."
"ENTITY1 ( 50 to 100 nmol / l ) be use to mimic an increase in beta - adrenergic tone , CHEMICAL CHEMICAL CHEMICAL ( 100 micromol / l ) to block GENE ) ( lqt2 model ) , and ENTITY2 ( 20 nmol / l"
"beta - adrenergic tone , ENTITY1 ( 100 micromol / l ) to block GENE ) ( lqt2 model ) , and ENTITY2 ( 20 nmol / l"
"whereas the addition of ENTITY1 in the low micromolar range produce an irreversible activation of the channel , application of high concentration cause a reversible voltage - dependent inhibition of heterologously express ENTITY2 channel , result from a"
", the reverse mutation GENE ENTITY2 increase the affinity of GENE GENE GENE for ENTITY1 , whereas c - type"
"increase the affinity of GENE ENTITY2 for ENTITY1 , whereas c - type"
"moreover , the reverse mutation ENTITY2 GENE increase the affinity of GENE GENE GENE for ENTITY1 , whereas c - type"
"GENE increase the affinity of ENTITY2 GENE GENE for ENTITY1 , whereas c - type"
"thus , the ENTITY1 in position ENTITY2 620 may participate directly in"
", the CHEMICAL in position ENTITY2 620 may participate directly in ENTITY1 binding ; however , an"
"the mechanism of interaction between ENTITY1 and CHEMICAL ) could be explain at least in part by inhibitory effect of CHEMICAL ) on expression of ENTITY2 in rat kidney . 
"
"ENTITY1 have the add advantage of inhibit multiple different GENE isoform , which enable -PRON- to target GENE GENE GENE / GENE signal and may also enhance -PRON- inhibition of ENTITY2 and GENE GENE GENE ."
"ENTITY1 have the add advantage of inhibit multiple different GENE isoform , which enable -PRON- to target GENE GENE GENE / ENTITY2 signal and may also enhance"
"ENTITY1 have the add advantage of inhibit multiple different GENE isoform , which enable -PRON- to target GENE GENE GENE / GENE signal and may also enhance -PRON- inhibition of GENE and ENTITY2 ."
"ENTITY1 have the add advantage of inhibit multiple different ENTITY2 isoform , which enable -PRON-"
"ENTITY1 have the add advantage of inhibit multiple different GENE isoform , which enable -PRON- to target ENTITY2 / GENE signal and may"
"western blot assay demonstrate that ENTITY1 decrease ENTITY2 level and induce GENE translocation"
"western blot assay demonstrate that ENTITY1 decrease GENE level and induce ENTITY2 translocation to cause GENE GENE"
"western blot assay demonstrate that ENTITY1 decrease GENE level and induce GENE translocation to cause ENTITY2 release ."
"t(16;21)(q24;q22 ) after chemotherapy with ENTITY2 inhibitor , CHEMICAL and ENTITY1 , and the alkylat agent"
"t(16;21)(q24;q22 ) after chemotherapy with ENTITY2 inhibitor , CHEMICAL and CHEMICAL , and the alkylat agent , ENTITY1 . 	"
"t(16;21)(q24;q22 ) after chemotherapy with ENTITY2 inhibitor , ENTITY1 and CHEMICAL , and the"
"repeat ENTITY1 result in ENTITY2 phosphorylation in all analyze subregion"
"repeat ENTITY1 result in GENE phosphorylation in all analyze subregion of the nac exclude the most ventrolateral region of the shell 2 week after cessation of repeat CHEMICAL , but rat challenge after 2 drug - free day yield a more localized activation of ENTITY2 in the 3 most dorsomedial"
"repeat CHEMICAL result in ENTITY2 phosphorylation in all analyze subregion of the nac exclude the most ventrolateral region of the shell 2 week after cessation of repeat ENTITY1 , but rat challenge after"
"week after cessation of repeat ENTITY1 , but rat challenge after 2 drug - free day yield a more localized activation of ENTITY2 in the 3 most dorsomedial"
"the involvement of GENE and ENTITY2 receptor mediate the effect . method : different class of antidepressant [ CHEMICAL ( CHEMICAL ) , CHEMICAL ( CHEMICAL reuptake inhibitor ) , CHEMICAL ( mixed CHEMICAL and CHEMICAL reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and GENE receptor agonist [ CHEMICAL ( partial GENE agonist ) , ENTITY1 ( GENE agonist ) ]"
"in combination with GENE and ENTITY2 receptor agonist [ CHEMICAL ( partial GENE agonist ) , ENTITY1 ( GENE agonist ) ]"
"partial GENE agonist ) , ENTITY1 ( ENTITY2 agonist ) ] in the"
"and determine the involvement of ENTITY2 and GENE receptor mediate the effect . method : different class of antidepressant [ CHEMICAL ( CHEMICAL ) , CHEMICAL ( CHEMICAL reuptake inhibitor ) , CHEMICAL ( mixed CHEMICAL and CHEMICAL reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and GENE receptor agonist [ CHEMICAL ( partial GENE agonist ) , ENTITY1 ( GENE agonist ) ]"
"alone and in combination with ENTITY2 and GENE receptor agonist [ CHEMICAL ( partial GENE agonist ) , ENTITY1 ( GENE agonist ) ]"
"agonist [ CHEMICAL ( partial ENTITY2 agonist ) , ENTITY1 ( GENE agonist ) ]"
"the involvement of GENE and ENTITY2 receptor mediate the effect . method : different class of antidepressant [ ENTITY1 ( CHEMICAL ) , CHEMICAL"
"different class of antidepressant [ ENTITY1 ( CHEMICAL ) , CHEMICAL ( CHEMICAL reuptake inhibitor ) , CHEMICAL ( mixed CHEMICAL and CHEMICAL reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and ENTITY2 receptor agonist [ CHEMICAL ("
"different class of antidepressant [ ENTITY1 ( CHEMICAL ) , CHEMICAL ( CHEMICAL reuptake inhibitor ) , CHEMICAL ( mixed CHEMICAL and CHEMICAL reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and GENE receptor agonist [ CHEMICAL ( partial GENE agonist ) , CHEMICAL ( ENTITY2 agonist ) ] in the"
"and determine the involvement of ENTITY2 and GENE receptor mediate the effect . method : different class of antidepressant [ ENTITY1 ( CHEMICAL ) , CHEMICAL"
"different class of antidepressant [ ENTITY1 ( CHEMICAL ) , CHEMICAL ( CHEMICAL reuptake inhibitor ) , CHEMICAL ( mixed CHEMICAL and CHEMICAL reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with ENTITY2 and GENE receptor agonist ["
"different class of antidepressant [ ENTITY1 ( CHEMICAL ) , CHEMICAL ( CHEMICAL reuptake inhibitor ) , CHEMICAL ( mixed CHEMICAL and CHEMICAL reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and GENE receptor agonist [ CHEMICAL ( partial ENTITY2 agonist ) , CHEMICAL ("
"the involvement of GENE and ENTITY2 receptor mediate the effect . method : different class of antidepressant [ CHEMICAL ( CHEMICAL ) , CHEMICAL ( CHEMICAL reuptake inhibitor ) , CHEMICAL ( mixed ENTITY1 and CHEMICAL reuptake inhibitor )"
") , CHEMICAL ( mixed ENTITY1 and CHEMICAL reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and ENTITY2 receptor agonist [ CHEMICAL ("
") , CHEMICAL ( mixed ENTITY1 and CHEMICAL reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and GENE receptor agonist [ CHEMICAL ( partial GENE agonist ) , CHEMICAL ( ENTITY2 agonist ) ] in the"
"and determine the involvement of ENTITY2 and GENE receptor mediate the effect . method : different class of antidepressant [ CHEMICAL ( CHEMICAL ) , CHEMICAL ( CHEMICAL reuptake inhibitor ) , CHEMICAL ( mixed ENTITY1 and CHEMICAL reuptake inhibitor )"
") , CHEMICAL ( mixed ENTITY1 and CHEMICAL reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with ENTITY2 and GENE receptor agonist ["
") , CHEMICAL ( mixed ENTITY1 and CHEMICAL reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and GENE receptor agonist [ CHEMICAL ( partial ENTITY2 agonist ) , CHEMICAL ("
"the involvement of GENE and ENTITY2 receptor mediate the effect . method : different class of antidepressant [ CHEMICAL ( CHEMICAL ) , CHEMICAL ( CHEMICAL reuptake inhibitor ) , CHEMICAL ( mixed CHEMICAL and CHEMICAL reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective ENTITY1 reuptake inhibitor ) ] be"
"CHEMICAL and CHEMICAL ( selective ENTITY1 reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and ENTITY2 receptor agonist [ CHEMICAL ("
"CHEMICAL and CHEMICAL ( selective ENTITY1 reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and GENE receptor agonist [ CHEMICAL ( partial GENE agonist ) , CHEMICAL ( ENTITY2 agonist ) ] in the"
"and determine the involvement of ENTITY2 and GENE receptor mediate the effect . method : different class of antidepressant [ CHEMICAL ( CHEMICAL ) , CHEMICAL ( CHEMICAL reuptake inhibitor ) , CHEMICAL ( mixed CHEMICAL and CHEMICAL reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective ENTITY1 reuptake inhibitor ) ] be"
"CHEMICAL and CHEMICAL ( selective ENTITY1 reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with ENTITY2 and GENE receptor agonist ["
"CHEMICAL and CHEMICAL ( selective ENTITY1 reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and GENE receptor agonist [ CHEMICAL ( partial ENTITY2 agonist ) , CHEMICAL ("
"the involvement of GENE and ENTITY2 receptor mediate the effect . method : different class of antidepressant [ CHEMICAL ( CHEMICAL ) , CHEMICAL ( CHEMICAL reuptake inhibitor ) , CHEMICAL ( mixed CHEMICAL and ENTITY1 reuptake inhibitor ) , CHEMICAL"
"CHEMICAL ( mixed CHEMICAL and ENTITY1 reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and ENTITY2 receptor agonist [ CHEMICAL ("
"CHEMICAL ( mixed CHEMICAL and ENTITY1 reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and GENE receptor agonist [ CHEMICAL ( partial GENE agonist ) , CHEMICAL ( ENTITY2 agonist ) ] in the"
"and determine the involvement of ENTITY2 and GENE receptor mediate the effect . method : different class of antidepressant [ CHEMICAL ( CHEMICAL ) , CHEMICAL ( CHEMICAL reuptake inhibitor ) , CHEMICAL ( mixed CHEMICAL and ENTITY1 reuptake inhibitor ) , CHEMICAL"
"CHEMICAL ( mixed CHEMICAL and ENTITY1 reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with ENTITY2 and GENE receptor agonist ["
"CHEMICAL ( mixed CHEMICAL and ENTITY1 reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and GENE receptor agonist [ CHEMICAL ( partial ENTITY2 agonist ) , CHEMICAL ("
"the involvement of GENE and ENTITY2 receptor mediate the effect . method : different class of antidepressant [ CHEMICAL ( CHEMICAL ) , CHEMICAL ( ENTITY1 reuptake inhibitor ) , CHEMICAL"
"CHEMICAL ) , CHEMICAL ( ENTITY1 reuptake inhibitor ) , CHEMICAL ( mixed CHEMICAL and CHEMICAL reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and ENTITY2 receptor agonist [ CHEMICAL ("
"CHEMICAL ) , CHEMICAL ( ENTITY1 reuptake inhibitor ) , CHEMICAL ( mixed CHEMICAL and CHEMICAL reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and GENE receptor agonist [ CHEMICAL ( partial GENE agonist ) , CHEMICAL ( ENTITY2 agonist ) ] in the"
"and determine the involvement of ENTITY2 and GENE receptor mediate the effect . method : different class of antidepressant [ CHEMICAL ( CHEMICAL ) , CHEMICAL ( ENTITY1 reuptake inhibitor ) , CHEMICAL"
"CHEMICAL ) , CHEMICAL ( ENTITY1 reuptake inhibitor ) , CHEMICAL ( mixed CHEMICAL and CHEMICAL reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with ENTITY2 and GENE receptor agonist ["
"CHEMICAL ) , CHEMICAL ( ENTITY1 reuptake inhibitor ) , CHEMICAL ( mixed CHEMICAL and CHEMICAL reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and GENE receptor agonist [ CHEMICAL ( partial ENTITY2 agonist ) , CHEMICAL ("
"the involvement of GENE and ENTITY2 receptor mediate the effect . method : different class of antidepressant [ CHEMICAL ( CHEMICAL ) , CHEMICAL ( CHEMICAL reuptake inhibitor ) , ENTITY1 ( mixed CHEMICAL and CHEMICAL"
"CHEMICAL reuptake inhibitor ) , ENTITY1 ( mixed CHEMICAL and CHEMICAL reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and ENTITY2 receptor agonist [ CHEMICAL ("
"CHEMICAL reuptake inhibitor ) , ENTITY1 ( mixed CHEMICAL and CHEMICAL reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and GENE receptor agonist [ CHEMICAL ( partial GENE agonist ) , CHEMICAL ( ENTITY2 agonist ) ] in the"
"and determine the involvement of ENTITY2 and GENE receptor mediate the effect . method : different class of antidepressant [ CHEMICAL ( CHEMICAL ) , CHEMICAL ( CHEMICAL reuptake inhibitor ) , ENTITY1 ( mixed CHEMICAL and CHEMICAL"
"CHEMICAL reuptake inhibitor ) , ENTITY1 ( mixed CHEMICAL and CHEMICAL reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with ENTITY2 and GENE receptor agonist ["
"CHEMICAL reuptake inhibitor ) , ENTITY1 ( mixed CHEMICAL and CHEMICAL reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and GENE receptor agonist [ CHEMICAL ( partial ENTITY2 agonist ) , CHEMICAL ("
"the involvement of GENE and ENTITY2 receptor mediate the effect . method : different class of antidepressant [ CHEMICAL ( ENTITY1 ) , CHEMICAL ( CHEMICAL"
"of antidepressant [ CHEMICAL ( ENTITY1 ) , CHEMICAL ( CHEMICAL reuptake inhibitor ) , CHEMICAL ( mixed CHEMICAL and CHEMICAL reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and ENTITY2 receptor agonist [ CHEMICAL ("
"of antidepressant [ CHEMICAL ( ENTITY1 ) , CHEMICAL ( CHEMICAL reuptake inhibitor ) , CHEMICAL ( mixed CHEMICAL and CHEMICAL reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and GENE receptor agonist [ CHEMICAL ( partial GENE agonist ) , CHEMICAL ( ENTITY2 agonist ) ] in the"
"and determine the involvement of ENTITY2 and GENE receptor mediate the effect . method : different class of antidepressant [ CHEMICAL ( ENTITY1 ) , CHEMICAL ( CHEMICAL"
"of antidepressant [ CHEMICAL ( ENTITY1 ) , CHEMICAL ( CHEMICAL reuptake inhibitor ) , CHEMICAL ( mixed CHEMICAL and CHEMICAL reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with ENTITY2 and GENE receptor agonist ["
"of antidepressant [ CHEMICAL ( ENTITY1 ) , CHEMICAL ( CHEMICAL reuptake inhibitor ) , CHEMICAL ( mixed CHEMICAL and CHEMICAL reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and GENE receptor agonist [ CHEMICAL ( partial ENTITY2 agonist ) , CHEMICAL ("
"the involvement of GENE and ENTITY2 receptor mediate the effect . method : different class of antidepressant [ CHEMICAL ( CHEMICAL ) , CHEMICAL ( CHEMICAL reuptake inhibitor ) , CHEMICAL ( mixed CHEMICAL and CHEMICAL reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and GENE receptor agonist [ ENTITY1 ( partial GENE agonist )"
"in combination with GENE and ENTITY2 receptor agonist [ ENTITY1 ( partial GENE agonist )"
"and GENE receptor agonist [ ENTITY1 ( partial GENE agonist ) , CHEMICAL ( ENTITY2 agonist ) ] in the"
"and determine the involvement of ENTITY2 and GENE receptor mediate the effect . method : different class of antidepressant [ CHEMICAL ( CHEMICAL ) , CHEMICAL ( CHEMICAL reuptake inhibitor ) , CHEMICAL ( mixed CHEMICAL and CHEMICAL reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and GENE receptor agonist [ ENTITY1 ( partial GENE agonist )"
"alone and in combination with ENTITY2 and GENE receptor agonist [ ENTITY1 ( partial GENE agonist )"
"and GENE receptor agonist [ ENTITY1 ( partial ENTITY2 agonist ) , CHEMICAL ("
"the involvement of GENE and ENTITY2 receptor mediate the effect . method : different class of antidepressant [ CHEMICAL ( CHEMICAL ) , ENTITY1 ( CHEMICAL reuptake inhibitor )"
"CHEMICAL ( CHEMICAL ) , ENTITY1 ( CHEMICAL reuptake inhibitor ) , CHEMICAL ( mixed CHEMICAL and CHEMICAL reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and ENTITY2 receptor agonist [ CHEMICAL ("
"CHEMICAL ( CHEMICAL ) , ENTITY1 ( CHEMICAL reuptake inhibitor ) , CHEMICAL ( mixed CHEMICAL and CHEMICAL reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and GENE receptor agonist [ CHEMICAL ( partial GENE agonist ) , CHEMICAL ( ENTITY2 agonist ) ] in the"
"and determine the involvement of ENTITY2 and GENE receptor mediate the effect . method : different class of antidepressant [ CHEMICAL ( CHEMICAL ) , ENTITY1 ( CHEMICAL reuptake inhibitor )"
"CHEMICAL ( CHEMICAL ) , ENTITY1 ( CHEMICAL reuptake inhibitor ) , CHEMICAL ( mixed CHEMICAL and CHEMICAL reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with ENTITY2 and GENE receptor agonist ["
"CHEMICAL ( CHEMICAL ) , ENTITY1 ( CHEMICAL reuptake inhibitor ) , CHEMICAL ( mixed CHEMICAL and CHEMICAL reuptake inhibitor ) , CHEMICAL and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and GENE receptor agonist [ CHEMICAL ( partial ENTITY2 agonist ) , CHEMICAL ("
"the involvement of GENE and ENTITY2 receptor mediate the effect . method : different class of antidepressant [ CHEMICAL ( CHEMICAL ) , CHEMICAL ( CHEMICAL reuptake inhibitor ) , CHEMICAL ( mixed CHEMICAL and CHEMICAL reuptake inhibitor ) , ENTITY1 and CHEMICAL ( selective CHEMICAL"
"CHEMICAL reuptake inhibitor ) , ENTITY1 and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and ENTITY2 receptor agonist [ CHEMICAL ("
"CHEMICAL reuptake inhibitor ) , ENTITY1 and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and GENE receptor agonist [ CHEMICAL ( partial GENE agonist ) , CHEMICAL ( ENTITY2 agonist ) ] in the"
"and determine the involvement of ENTITY2 and GENE receptor mediate the effect . method : different class of antidepressant [ CHEMICAL ( CHEMICAL ) , CHEMICAL ( CHEMICAL reuptake inhibitor ) , CHEMICAL ( mixed CHEMICAL and CHEMICAL reuptake inhibitor ) , ENTITY1 and CHEMICAL ( selective CHEMICAL"
"CHEMICAL reuptake inhibitor ) , ENTITY1 and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with ENTITY2 and GENE receptor agonist ["
"CHEMICAL reuptake inhibitor ) , ENTITY1 and CHEMICAL ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and GENE receptor agonist [ CHEMICAL ( partial ENTITY2 agonist ) , CHEMICAL ("
"the involvement of GENE and ENTITY2 receptor mediate the effect . method : different class of antidepressant [ CHEMICAL ( CHEMICAL ) , CHEMICAL ( CHEMICAL reuptake inhibitor ) , CHEMICAL ( mixed CHEMICAL and CHEMICAL reuptake inhibitor ) , CHEMICAL and ENTITY1 ( selective CHEMICAL reuptake inhibitor"
"inhibitor ) , CHEMICAL and ENTITY1 ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and ENTITY2 receptor agonist [ CHEMICAL ("
"inhibitor ) , CHEMICAL and ENTITY1 ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and GENE receptor agonist [ CHEMICAL ( partial GENE agonist ) , CHEMICAL ( ENTITY2 agonist ) ] in the"
"and determine the involvement of ENTITY2 and GENE receptor mediate the effect . method : different class of antidepressant [ CHEMICAL ( CHEMICAL ) , CHEMICAL ( CHEMICAL reuptake inhibitor ) , CHEMICAL ( mixed CHEMICAL and CHEMICAL reuptake inhibitor ) , CHEMICAL and ENTITY1 ( selective CHEMICAL reuptake inhibitor"
"inhibitor ) , CHEMICAL and ENTITY1 ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with ENTITY2 and GENE receptor agonist ["
"inhibitor ) , CHEMICAL and ENTITY1 ( selective CHEMICAL reuptake inhibitor ) ] be test in the same randomise experimental session , alone and in combination with GENE and GENE receptor agonist [ CHEMICAL ( partial ENTITY2 agonist ) , CHEMICAL ("
"ENTITY1 be a small - molecule drug that trigger tumor cell apoptosis by selectively antagonize ENTITY2 ."
"the role of other vascular ENTITY1 GENE in the stimulation of ENTITY2 activity . 
"
"conclusion and implication : ENTITY1 analogu with good ENTITY2 channel inhibition and cytotoxicity profile"
"conclusion and implication : ENTITY1 analogu with good GENE channel inhibition and cytotoxicity profile than the parent compound have be identify , demonstrate that cytotoxicity and ENTITY2 channel interaction be mechanistically distinct"
"in the present study , ENTITY1 ( 1 and 2μm ) inhibit the ENTITY2 - induce aggregation of human"
"in the present study , ENTITY1 ( 1 and 2μm ) inhibit the GENE - induce aggregation of human platelet , but do not inhibit the activation of platelet by other agonist , include ENTITY2 , CHEMICAL CHEMICAL , and"
"and 2μm ) inhibit the ENTITY2 - induce aggregation of human platelet , but do not inhibit the activation of platelet by other agonist , include GENE , ENTITY1 , and CHEMICAL ."
"by other agonist , include ENTITY2 , ENTITY1 , and CHEMICAL ."
"and 2μm ) inhibit the ENTITY2 - induce aggregation of human platelet , but do not inhibit the activation of platelet by other agonist , include GENE , CHEMICAL CHEMICAL , and ENTITY1 ."
"by other agonist , include ENTITY2 , CHEMICAL CHEMICAL , and ENTITY1 ."
"ENTITY2 catalyze an unusual oxidative decarboxylation of ENTITY1 . 	"
"of 18 mutation where ENTITY2 CHEMICAL CHEMICAL residue be exchange with those of the GENE GENE GENE , mria have increase potency for inhibition of ENTITY1 uptake for three mutation ("
"exchange with those of the ENTITY2 , mria have increase potency for inhibition of ENTITY1 uptake for three mutation ("
"of 18 mutation where ENTITY2 ENTITY1 residue be exchange with those"
"of 18 mutation where GENE ENTITY1 residue be exchange with those of the ENTITY2 , mria have increase potency"
"preclinical efficacy of ENTITY1 , a potent , selective ENTITY2 antagonist for topical ocular use"
"-PRON- study show that ENTITY2 be a target for ENTITY1 , suggest that an activation"
"GENE be a target for ENTITY1 , suggest that an activation of ENTITY2 may contribute to adverse side"
"-PRON- study show that ENTITY2 be a target for CHEMICAL , suggest that an activation of GENE may contribute to adverse side effect such as nausea and painful injection , which can occur during treatment with ENTITY1 . 
"
"suggest that an activation of ENTITY2 may contribute to adverse side effect such as nausea and painful injection , which can occur during treatment with ENTITY1 . 
"
"trigger a production of several ENTITY2 in mouse and replacement of plasmid by ENTITY1 reduce the elevation of all"
"and replacement of plasmid by ENTITY1 reduce the elevation of all assay ENTITY2 ."
"[ the effect of ENTITY1 on ENTITY2 of liver and sexual gland"
") , and GENE in ENTITY2 - activate human platelet , and significantly reduce intracellular CHEMICAL mobilization and CHEMICAL radical ( ENTITY1 ) formation ."
"CHEMICAL inhibit the phosphorylation of ENTITY2 , GENE GENE GENE ( GENE ) , GENE GENE GENE GENE GENE ( GENE ) , and GENE in GENE - activate human platelet , and significantly reduce intracellular CHEMICAL mobilization and CHEMICAL radical ( ENTITY1 ) formation ."
", GENE GENE GENE ( ENTITY2 ) , GENE GENE GENE GENE GENE ( GENE ) , and GENE in GENE - activate human platelet , and significantly reduce intracellular CHEMICAL mobilization and CHEMICAL radical ( ENTITY1 ) formation ."
"GENE ( GENE ) , ENTITY2 ( GENE ) , and GENE in GENE - activate human platelet , and significantly reduce intracellular CHEMICAL mobilization and CHEMICAL radical ( ENTITY1 ) formation ."
"GENE GENE GENE GENE ( ENTITY2 ) , and GENE in GENE - activate human platelet , and significantly reduce intracellular CHEMICAL mobilization and CHEMICAL radical ( ENTITY1 ) formation ."
"GENE GENE GENE GENE , ENTITY2 ( GENE ) , GENE GENE GENE GENE GENE ( GENE ) , and GENE in GENE - activate human platelet , and significantly reduce intracellular CHEMICAL mobilization and CHEMICAL radical ( ENTITY1 ) formation ."
"( GENE ) , and ENTITY2 in GENE - activate human platelet , and significantly reduce intracellular CHEMICAL mobilization and CHEMICAL radical ( ENTITY1 ) formation ."
") , and GENE in ENTITY2 - activate human platelet , and significantly reduce intracellular ENTITY1 mobilization and CHEMICAL radical ("
"CHEMICAL inhibit the phosphorylation of ENTITY2 , GENE GENE GENE ( GENE ) , GENE GENE GENE GENE GENE ( GENE ) , and GENE in GENE - activate human platelet , and significantly reduce intracellular ENTITY1 mobilization and CHEMICAL radical ("
", GENE GENE GENE ( ENTITY2 ) , GENE GENE GENE GENE GENE ( GENE ) , and GENE in GENE - activate human platelet , and significantly reduce intracellular ENTITY1 mobilization and CHEMICAL radical ("
"GENE ( GENE ) , ENTITY2 ( GENE ) , and GENE in GENE - activate human platelet , and significantly reduce intracellular ENTITY1 mobilization and CHEMICAL radical ("
"GENE GENE GENE GENE ( ENTITY2 ) , and GENE in GENE - activate human platelet , and significantly reduce intracellular ENTITY1 mobilization and CHEMICAL radical ("
"GENE GENE GENE GENE , ENTITY2 ( GENE ) , GENE GENE GENE GENE GENE ( GENE ) , and GENE in GENE - activate human platelet , and significantly reduce intracellular ENTITY1 mobilization and CHEMICAL radical ("
"( GENE ) , and ENTITY2 in GENE - activate human platelet , and significantly reduce intracellular ENTITY1 mobilization and CHEMICAL radical ("
") , and GENE in ENTITY2 - activate human platelet , and significantly reduce intracellular CHEMICAL mobilization and ENTITY1 radical ( CHEMICAL ) formation"
"CHEMICAL inhibit the phosphorylation of ENTITY2 , GENE GENE GENE ( GENE ) , GENE GENE GENE GENE GENE ( GENE ) , and GENE in GENE - activate human platelet , and significantly reduce intracellular CHEMICAL mobilization and ENTITY1 radical ( CHEMICAL ) formation"
", GENE GENE GENE ( ENTITY2 ) , GENE GENE GENE GENE GENE ( GENE ) , and GENE in GENE - activate human platelet , and significantly reduce intracellular CHEMICAL mobilization and ENTITY1 radical ( CHEMICAL ) formation"
"GENE ( GENE ) , ENTITY2 ( GENE ) , and GENE in GENE - activate human platelet , and significantly reduce intracellular CHEMICAL mobilization and ENTITY1 radical ( CHEMICAL ) formation"
"GENE GENE GENE GENE ( ENTITY2 ) , and GENE in GENE - activate human platelet , and significantly reduce intracellular CHEMICAL mobilization and ENTITY1 radical ( CHEMICAL ) formation"
"GENE GENE GENE GENE , ENTITY2 ( GENE ) , GENE GENE GENE GENE GENE ( GENE ) , and GENE in GENE - activate human platelet , and significantly reduce intracellular CHEMICAL mobilization and ENTITY1 radical ( CHEMICAL ) formation"
"( GENE ) , and ENTITY2 in GENE - activate human platelet , and significantly reduce intracellular CHEMICAL mobilization and ENTITY1 radical ( CHEMICAL ) formation"
"ENTITY1 inhibit the phosphorylation of GENE GENE GENE GENE , GENE GENE GENE ( GENE ) , GENE GENE GENE GENE GENE ( GENE ) , and GENE in ENTITY2 - activate human platelet ,"
"ENTITY1 inhibit the phosphorylation of ENTITY2 , GENE GENE GENE ("
"ENTITY1 inhibit the phosphorylation of GENE GENE GENE GENE , GENE GENE GENE ( ENTITY2 ) , GENE GENE GENE"
"ENTITY1 inhibit the phosphorylation of GENE GENE GENE GENE , GENE GENE GENE ( GENE ) , ENTITY2 ( GENE ) , and"
"ENTITY1 inhibit the phosphorylation of GENE GENE GENE GENE , GENE GENE GENE ( GENE ) , GENE GENE GENE GENE GENE ( ENTITY2 ) , and GENE in"
"ENTITY1 inhibit the phosphorylation of GENE GENE GENE GENE , ENTITY2 ( GENE ) , GENE"
"ENTITY1 inhibit the phosphorylation of GENE GENE GENE GENE , GENE GENE GENE ( GENE ) , GENE GENE GENE GENE GENE ( GENE ) , and ENTITY2 in GENE - activate human"
"mufa and expression of pbmc ENTITY2 and GENE gene , but a significant negative correlation between dietary intake of CHEMICAL CHEMICAL ( CHEMICAL ) and ENTITY1 ( CHEMICAL ) and the"
"CHEMICAL ( CHEMICAL ) and ENTITY1 ( CHEMICAL ) and the expression of pbmc ENTITY2 and GENE gene ."
"expression of pbmc GENE and ENTITY2 gene , but a significant negative correlation between dietary intake of CHEMICAL CHEMICAL ( CHEMICAL ) and ENTITY1 ( CHEMICAL ) and the"
"CHEMICAL ( CHEMICAL ) and ENTITY1 ( CHEMICAL ) and the expression of pbmc GENE and ENTITY2 gene ."
"mufa and expression of pbmc ENTITY2 and GENE gene , but a significant negative correlation between dietary intake of CHEMICAL CHEMICAL ( CHEMICAL ) and CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) and the expression of"
"CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) and the expression of pbmc ENTITY2 and GENE gene ."
"expression of pbmc GENE and ENTITY2 gene , but a significant negative correlation between dietary intake of CHEMICAL CHEMICAL ( CHEMICAL ) and CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) and the expression of"
"CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) and the expression of pbmc GENE and ENTITY2 gene ."
"mufa and expression of pbmc ENTITY2 and GENE gene , but a significant negative correlation between dietary intake of CHEMICAL CHEMICAL ( ENTITY1 ) and CHEMICAL CHEMICAL CHEMICAL"
"intake of CHEMICAL CHEMICAL ( ENTITY1 ) and CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ) and the expression of pbmc ENTITY2 and GENE gene ."
"expression of pbmc GENE and ENTITY2 gene , but a significant negative correlation between dietary intake of CHEMICAL CHEMICAL ( ENTITY1 ) and CHEMICAL CHEMICAL CHEMICAL"
"intake of CHEMICAL CHEMICAL ( ENTITY1 ) and CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ) and the expression of pbmc GENE and ENTITY2 gene ."
"mufa and expression of pbmc ENTITY2 and GENE gene , but a significant negative correlation between dietary intake of ENTITY1 ( CHEMICAL ) and CHEMICAL"
"correlation between dietary intake of ENTITY1 ( CHEMICAL ) and CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ) and the expression of pbmc ENTITY2 and GENE gene ."
"expression of pbmc GENE and ENTITY2 gene , but a significant negative correlation between dietary intake of ENTITY1 ( CHEMICAL ) and CHEMICAL"
"correlation between dietary intake of ENTITY1 ( CHEMICAL ) and CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ) and the expression of pbmc GENE and ENTITY2 gene ."
"in this current study , ENTITY1 be find to increase phosphorylation of ENTITY2 ( mapk ) kinase 3/6"
"in this current study , ENTITY1 be find to increase phosphorylation of GENE GENE GENE GENE GENE ( mapk ) kinase 3/6 ( GENE ENTITY2 as well as protein and"
"in this current study , ENTITY1 be find to increase phosphorylation of GENE GENE GENE GENE GENE ( mapk ) kinase 3/6 ( GENE GENE as well as protein and mrna level of ENTITY2 in h1650 and h1703 cell"
"ENTITY1 , a well - know competitive inhibitor of ENTITY2 , competitively inhibit the new"
"ENTITY2 usually catalyze the conversion of CHEMICAL to o - diphenol and oxidation of ENTITY1 to the corresponding quinone ."
"ENTITY2 usually catalyze the conversion of ENTITY1 to o - diphenol and"
"effect of CHEMICAL CHEMICAL ( ENTITY1 ) on ENTITY2 ( GENE ) of liver"
"effect of CHEMICAL CHEMICAL ( ENTITY1 ) on GENE GENE ( ENTITY2 ) of liver and sexual"
"to assess the effect of ENTITY1 ( CHEMICAL ) on ENTITY2 ( GENE ) of liver"
"to assess the effect of ENTITY1 ( CHEMICAL ) on GENE GENE ( ENTITY2 ) of liver and sexual"
"the ENTITY2 inhibitor , ENTITY1 , be use in the"
"CHEMICAL and ENTITY1 be substrate of ENTITY2 and potent inhibitor of GENE"
"CHEMICAL and ENTITY1 be substrate of GENE and potent inhibitor of ENTITY2 in perfused lung of rat"
"ENTITY1 and CHEMICAL be substrate of ENTITY2 and potent inhibitor of GENE"
"ENTITY1 and CHEMICAL be substrate of GENE and potent inhibitor of ENTITY2 in perfused lung of rat"
"mrna expression be induce by ENTITY1 , but be not affect by the GENE ENTITY2 length ."
"mrna expression be induce by ENTITY1 , but be not affect by the ENTITY2 GENE length ."
"the GENE target gene ENTITY2 mrna expression be induce by ENTITY1 , but be not affect"
"the ENTITY2 target gene GENE mrna expression be induce by ENTITY1 , but be not affect"
"ENTITY1 also reduce the ENTITY2 activation and platelet aggregation stimulate"
"the first study show that ENTITY1 pharmacokinetic be linear in a 30,000-fold concentration range , and therefore that nano- and microgram dos of CHEMICAL can reliably predict the pharmacokinetic of CHEMICAL in therapeutic dos and can be use to assess ENTITY2 activity even in the presence"
"the first study show that ENTITY1 pharmacokinetic be linear in a 30,000-fold concentration range , and therefore that nano- and microgram dos of CHEMICAL can reliably predict the pharmacokinetic of CHEMICAL in therapeutic dos and can be use to assess GENE activity even in the presence of strong ENTITY2 inhibitor ."
"nano- and microgram dos of ENTITY1 can reliably predict the pharmacokinetic of CHEMICAL in therapeutic dos and can be use to assess ENTITY2 activity even in the presence"
"nano- and microgram dos of ENTITY1 can reliably predict the pharmacokinetic of CHEMICAL in therapeutic dos and can be use to assess GENE activity even in the presence of strong ENTITY2 inhibitor ."
"reliably predict the pharmacokinetic of ENTITY1 in therapeutic dos and can be use to assess ENTITY2 activity even in the presence"
"reliably predict the pharmacokinetic of ENTITY1 in therapeutic dos and can be use to assess GENE activity even in the presence of strong ENTITY2 inhibitor ."
"soce in endothelial cells through ENTITY1 GENE GENE GENE GENE and GENE ENTITY2 . 	"
"( soce ) induce by ENTITY2 mediate GENE phosphorylation to inhibit soce in endothelial cells through ENTITY1 GENE GENE GENE GENE and"
"GENE GENE GENE GENE mediate ENTITY2 phosphorylation to inhibit soce in endothelial cells through ENTITY1 GENE GENE GENE GENE and"
"soce in endothelial cells through ENTITY1 GENE GENE GENE GENE and ENTITY2 GENE GENE GENE GENE GENE"
"diffusion of oligosaccharide ( either ENTITY1 , g4 or CHEMICAL , g5 ) into ENTITY2 / CHEMICAL crystal show the"
"either CHEMICAL , g4 or ENTITY1 , g5 ) into ENTITY2 / CHEMICAL crystal show the"
"CHEMICAL , g5 ) into ENTITY2 / CHEMICAL crystal show the formation of ENTITY1 and elongation of the oligosaccharide"
"CHEMICAL , g5 ) into ENTITY2 / ENTITY1 crystal show the formation of"
"specific inhibition of ENTITY2 with sirna be find to enhance the ENTITY1 - induce cytotoxic effect and"
"CHEMICAL CHEMICAL , ENTITY1 , and ENTITY2 produce preferential prolongation of the"
"contain the CHEMICAL CHEMICAL bind ENTITY1 in a number of other ENTITY2 include GENE from e. coli"
"contain the CHEMICAL CHEMICAL bind ENTITY1 in a number of other GENE include ENTITY2 from e. coli ."
"to the consensus sequence of ENTITY2 , which contain the CHEMICAL CHEMICAL bind ENTITY1 in a number of other"
"GENE , which contain the ENTITY1 bind CHEMICAL in a number of other ENTITY2 include GENE from e. coli"
"GENE , which contain the ENTITY1 bind CHEMICAL in a number of other GENE include ENTITY2 from e. coli ."
"to the consensus sequence of ENTITY2 , which contain the ENTITY1 bind CHEMICAL in a number"
"the precede ENTITY1 do not conform to the consensus sequence of GENE , which contain the CHEMICAL CHEMICAL bind CHEMICAL in a number of other ENTITY2 include GENE from e. coli"
"the precede ENTITY1 do not conform to the consensus sequence of GENE , which contain the CHEMICAL CHEMICAL bind CHEMICAL in a number of other GENE include ENTITY2 from e. coli ."
"the precede ENTITY1 do not conform to the consensus sequence of ENTITY2 , which contain the CHEMICAL"
"functional and bioenergetic consequence of ENTITY2 antagonist ENTITY1 in heart with postinfarction lv"
"the proof that any putative ENTITY2 inhibitor be block ENTITY1 production be an important stage"
"by systemic administration of nonselective ENTITY2 antagonist , ENTITY1 ( 0.3 - 3 mg"
"GENE GENE GENE antagonist , ENTITY1 ( 0.3 - 3 mg / kg ) and CHEMICAL ( 0.03 - 0.3 mg / kg ) , as well as by the selective ENTITY2 antagonist , CHEMICAL ( 0.3"
"involvement of ENTITY2 be establish as mydriatic response be inhibit by systemic administration of nonselective GENE GENE GENE antagonist , ENTITY1 ( 0.3 - 3 mg"
"by systemic administration of nonselective ENTITY2 antagonist , CHEMICAL ( 0.3 - 3 mg / kg ) and CHEMICAL ( 0.03 - 0.3 mg / kg ) , as well as by the selective GENE antagonist , ENTITY1 ( 0.3 mg / kg"
"well as by the selective ENTITY2 antagonist , ENTITY1 ( 0.3 mg / kg"
"involvement of ENTITY2 be establish as mydriatic response be inhibit by systemic administration of nonselective GENE GENE GENE antagonist , CHEMICAL ( 0.3 - 3 mg / kg ) and CHEMICAL ( 0.03 - 0.3 mg / kg ) , as well as by the selective GENE antagonist , ENTITY1 ( 0.3 mg / kg"
"by systemic administration of nonselective ENTITY2 antagonist , CHEMICAL ( 0.3 - 3 mg / kg ) and ENTITY1 ( 0.03 - 0.3 mg"
"mg / kg ) and ENTITY1 ( 0.03 - 0.3 mg / kg ) , as well as by the selective ENTITY2 antagonist , CHEMICAL ( 0.3"
"involvement of ENTITY2 be establish as mydriatic response be inhibit by systemic administration of nonselective GENE GENE GENE antagonist , CHEMICAL ( 0.3 - 3 mg / kg ) and ENTITY1 ( 0.03 - 0.3 mg"
"these finding provide evidence that ENTITY1 cause prolong activation of ENTITY2 through autophagy dysfunction , possibly"
"these finding provide evidence that ENTITY1 cause prolong activation of GENE through autophagy dysfunction , possibly provide a similar scenario to constitutive activation of ENTITY2 find in certain human cancer"
"finding lend evidence of a ENTITY2 receptor / GENE pathway , account in part for the activation of GENE by ENTITY1 ."
"of a GENE receptor / ENTITY2 pathway , account in part for the activation of GENE by ENTITY1 ."
"part for the activation of ENTITY2 by ENTITY1 ."
"the GENE selective antagonist , ENTITY1 ( CHEMICAL ; 0.3 - 1 mg / kg ) , as well as the ENTITY2 selective antagonist , CHEMICAL ("
"/ kg ) , the ENTITY2 selective antagonist , ENTITY1 ( CHEMICAL ; 0.3 -"
"the GENE selective antagonist , ENTITY1 ( CHEMICAL ; 0.3 - 1 mg / kg ) , as well as the GENE selective antagonist , CHEMICAL ( CHEMICAL ; 1 mg / kg ) , be use to delineate the ENTITY2 subtype involve ."
", as well as the ENTITY2 selective antagonist , CHEMICAL ( ENTITY1 ; 1 mg / kg"
"/ kg ) , the ENTITY2 selective antagonist , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ; 0.3 - 1 mg / kg ) , as well as the GENE selective antagonist , CHEMICAL ( ENTITY1 ; 1 mg / kg"
"selective antagonist , CHEMICAL ( ENTITY1 ; 1 mg / kg ) , be use to delineate the ENTITY2 subtype involve ."
"CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ; 0.3 - 1 mg / kg ) , as well as the ENTITY2 selective antagonist , CHEMICAL ("
"/ kg ) , the ENTITY2 selective antagonist , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ; 0.3 - 1 mg"
"CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ; 0.3 - 1 mg / kg ) , as well as the GENE selective antagonist , CHEMICAL ( CHEMICAL ; 1 mg / kg ) , be use to delineate the ENTITY2 subtype involve ."
"mg / kg ) and ENTITY1 ( 0.1 - 1 mg / kg ) , the GENE selective antagonist , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ; 0.3 - 1 mg / kg ) , as well as the ENTITY2 selective antagonist , CHEMICAL ("
"mg / kg ) and ENTITY1 ( 0.1 - 1 mg / kg ) , the ENTITY2 selective antagonist , CHEMICAL CHEMICAL"
"mg / kg ) and ENTITY1 ( 0.1 - 1 mg / kg ) , the GENE selective antagonist , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ; 0.3 - 1 mg / kg ) , as well as the GENE selective antagonist , CHEMICAL ( CHEMICAL ; 1 mg / kg ) , be use to delineate the ENTITY2 subtype involve ."
"selective antagonist , CHEMICAL ( ENTITY1 ; 0.1 - 1 mg / kg ) and CHEMICAL ( 0.1 - 1 mg / kg ) , the GENE selective antagonist , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ; 0.3 - 1 mg / kg ) , as well as the ENTITY2 selective antagonist , CHEMICAL ("
"selective antagonist , CHEMICAL ( ENTITY1 ; 0.1 - 1 mg / kg ) and CHEMICAL ( 0.1 - 1 mg / kg ) , the ENTITY2 selective antagonist , CHEMICAL CHEMICAL"
"selective antagonist , CHEMICAL ( ENTITY1 ; 0.1 - 1 mg / kg ) and CHEMICAL ( 0.1 - 1 mg / kg ) , the GENE selective antagonist , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ; 0.3 - 1 mg / kg ) , as well as the GENE selective antagonist , CHEMICAL ( CHEMICAL ; 1 mg / kg ) , be use to delineate the ENTITY2 subtype involve ."
"selective antagonist , ENTITY1 ( CHEMICAL ; 0.1 - 1 mg / kg ) and CHEMICAL ( 0.1 - 1 mg / kg ) , the GENE selective antagonist , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ; 0.3 - 1 mg / kg ) , as well as the ENTITY2 selective antagonist , CHEMICAL ("
"selective antagonist , ENTITY1 ( CHEMICAL ; 0.1 - 1 mg / kg ) and CHEMICAL ( 0.1 - 1 mg / kg ) , the ENTITY2 selective antagonist , CHEMICAL CHEMICAL"
"selective antagonist , ENTITY1 ( CHEMICAL ; 0.1 - 1 mg / kg ) and CHEMICAL ( 0.1 - 1 mg / kg ) , the GENE selective antagonist , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ; 0.3 - 1 mg / kg ) , as well as the GENE selective antagonist , CHEMICAL ( CHEMICAL ; 1 mg / kg ) , be use to delineate the ENTITY2 subtype involve ."
", as well as the ENTITY2 selective antagonist , ENTITY1 ( CHEMICAL ; 1 mg"
"/ kg ) , the ENTITY2 selective antagonist , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ; 0.3 - 1 mg / kg ) , as well as the GENE selective antagonist , ENTITY1 ( CHEMICAL ; 1 mg"
"the GENE selective antagonist , ENTITY1 ( CHEMICAL ; 1 mg / kg ) , be use to delineate the ENTITY2 subtype involve ."
"unique role of the enzyme ENTITY2 ( GENE ) in the production of ENTITY1 ( CHEMICAL ) make -PRON-"
"of the enzyme GENE ( ENTITY2 ) in the production of ENTITY1 ( CHEMICAL ) make -PRON-"
"unique role of the enzyme ENTITY2 ( GENE ) in the production of CHEMICAL ( ENTITY1 ) make -PRON- a likely"
"of the enzyme GENE ( ENTITY2 ) in the production of CHEMICAL ( ENTITY1 ) make -PRON- a likely"
"inhibitory effect of ENTITY1 on excretion of CHEMICAL via ENTITY2 in rat . 	"
"CHEMICAL CHEMICAL on excretion of ENTITY1 via ENTITY2 in rat . 	"
"the rationale for use ENTITY2 inhibitor for the treatment of inflammatory bowel disease ( ibd ) be base on the increased generation of CHEMICAL in the inflamed mucosa , ENTITY1 be the most potent chemotactic"
"the rationale for use ENTITY2 inhibitor for the treatment of inflammatory bowel disease ( ibd ) be base on the increased generation of ENTITY1 in the inflamed mucosa ,"
"the rationale for use ENTITY2 inhibitor for the treatment of inflammatory bowel disease ( ibd ) be base on the increased generation of CHEMICAL in the inflamed mucosa , CHEMICAL be the most potent chemotactic and chemokinetic metabolite of ENTITY1 ."
"demonstrate reduction in both mitochondrial ENTITY2 expression and myocardial high - energy ENTITY1 level ."
"phenotype be prevent by the ENTITY2 antagonist ENTITY1 . 
"
"and CHEMICAL CHEMICAL , inhibit ENTITY1 production and specific ENTITY2 inhibition accelerate heal in animal"
"corticosteroid , CHEMICAL , and ENTITY1 , inhibit CHEMICAL production and specific ENTITY2 inhibition accelerate heal in animal"
", such as corticosteroid , ENTITY1 , and CHEMICAL CHEMICAL , inhibit CHEMICAL production and specific ENTITY2 inhibition accelerate heal in animal"
"that , before apoptosis , ENTITY1 induce GENE GENE GENE and ENTITY2 expression in the oocyte ."
"that , before apoptosis , ENTITY1 induce ENTITY2 and GENE expression in the"
"of the substrate specificity of ENTITY2 , highlight -PRON- preference for ENTITY1 with high affinity and clearance"
", highlight -PRON- preference for ENTITY1 with high affinity and clearance value than those of ENTITY2 and GENE . 
"
", highlight -PRON- preference for ENTITY1 with high affinity and clearance value than those of GENE and ENTITY2 . 
"
"activate GENE or ha - ENTITY2 GENE vector in lung cancer cell be able to abrogate GENE downregulation by ENTITY1 and CHEMICAL as well as"
", expression of constitutive activate ENTITY2 or ha - GENE GENE vector in lung cancer cell be able to abrogate GENE downregulation by ENTITY1 and CHEMICAL as well as"
"GENE or ha - GENE ENTITY2 vector in lung cancer cell be able to abrogate GENE downregulation by ENTITY1 and CHEMICAL as well as"
"cell be able to abrogate ENTITY2 downregulation by ENTITY1 and CHEMICAL as well as"
"activate GENE or ha - ENTITY2 GENE vector in lung cancer cell be able to abrogate GENE downregulation by CHEMICAL and ENTITY1 as well as cell viability"
", expression of constitutive activate ENTITY2 or ha - GENE GENE vector in lung cancer cell be able to abrogate GENE downregulation by CHEMICAL and ENTITY1 as well as cell viability"
"GENE or ha - GENE ENTITY2 vector in lung cancer cell be able to abrogate GENE downregulation by CHEMICAL and ENTITY1 as well as cell viability"
"cell be able to abrogate ENTITY2 downregulation by CHEMICAL and ENTITY1 as well as cell viability"
"ENTITY1 GENE ENTITY2 length modify the effect of"
"CHEMICAL GENE ENTITY2 length modify the effect of ENTITY1 on receptor activity in human"
"also block cell growth and ENTITY1 incorporation into the ENTITY2 - positive t47d and zr75"
"also block cell growth and ENTITY1 incorporation into the GENE - positive t47d and zr75 - 1b human breast cancer cell line and the ENTITY2 - negative human breast cancer"
"ENTITY1 also block cell growth and CHEMICAL CHEMICAL incorporation into the ENTITY2 - positive t47d and zr75"
"ENTITY1 also block cell growth and CHEMICAL CHEMICAL incorporation into the GENE - positive t47d and zr75 - 1b human breast cancer cell line and the ENTITY2 - negative human breast cancer"
"the ENTITY2 antagonist , ENTITY1 ( 0.5 mg / kg"
"inhibitory transmitter , CHEMICAL and ENTITY1 , share the same GENE GENE CHEMICAL CHEMICAL GENE ( ENTITY2 ) and be both present"
"two main inhibitory transmitter , ENTITY1 and CHEMICAL , share the same GENE GENE CHEMICAL CHEMICAL GENE ( ENTITY2 ) and be both present"
"share the same GENE GENE ENTITY1 GENE ( ENTITY2 ) and be both present"
"-PRON- conclude that CHEMICAL and ENTITY1 may be useful in the control of CHEMICAL and ENTITY2 - induce growth of GENE"
"-PRON- conclude that CHEMICAL and ENTITY1 may be useful in the control of CHEMICAL and GENE GENE - induce growth of ENTITY2 - positive and GENE -"
"-PRON- conclude that CHEMICAL and ENTITY1 may be useful in the control of CHEMICAL and GENE GENE - induce growth of GENE - positive and ENTITY2 - negative human breast tumor"
"-PRON- conclude that ENTITY1 and CHEMICAL may be useful in the control of CHEMICAL and ENTITY2 - induce growth of GENE"
"-PRON- conclude that ENTITY1 and CHEMICAL may be useful in the control of CHEMICAL and GENE GENE - induce growth of ENTITY2 - positive and GENE -"
"-PRON- conclude that ENTITY1 and CHEMICAL may be useful in the control of CHEMICAL and GENE GENE - induce growth of GENE - positive and ENTITY2 - negative human breast tumor"
"have express GENE and the ENTITY2 for CHEMICAL and ENTITY1 in a neuroendocrine cell line"
"-PRON- have express ENTITY2 and the GENE GENE for CHEMICAL and ENTITY1 in a neuroendocrine cell line"
"have express GENE and the ENTITY2 for CHEMICAL and CHEMICAL in a neuroendocrine cell line and measure the quantal release of CHEMICAL and ENTITY1 use a novel double -"
"-PRON- have express ENTITY2 and the GENE GENE for CHEMICAL and CHEMICAL in a neuroendocrine cell line and measure the quantal release of CHEMICAL and ENTITY1 use a novel double -"
"have express GENE and the ENTITY2 for ENTITY1 and CHEMICAL in a neuroendocrine"
"-PRON- have express ENTITY2 and the GENE GENE for ENTITY1 and CHEMICAL in a neuroendocrine"
"have express GENE and the ENTITY2 for CHEMICAL and CHEMICAL in a neuroendocrine cell line and measure the quantal release of ENTITY1 and CHEMICAL use a novel"
"-PRON- have express ENTITY2 and the GENE GENE for CHEMICAL and CHEMICAL in a neuroendocrine cell line and measure the quantal release of ENTITY1 and CHEMICAL use a novel"
"suggest that inhibition of the ENTITY2 GENE signal by ENTITY1 couple with CHEMICAL therapy in"
"that inhibition of the GENE ENTITY2 signal by ENTITY1 couple with CHEMICAL therapy in"
"suggest that inhibition of the ENTITY2 GENE signal by CHEMICAL couple with ENTITY1 therapy in human nsclc cell"
"that inhibition of the GENE ENTITY2 signal by CHEMICAL couple with ENTITY1 therapy in human nsclc cell"
"-PRON- find that ENTITY1 be release from vesicle when GENE be coexpress with either the GENE GENE GENE or the ENTITY2 GENE ."
"-PRON- find that ENTITY1 be release from vesicle when GENE be coexpress with either the GENE GENE GENE or the GENE GENE ENTITY2 ."
"-PRON- find that ENTITY1 be release from vesicle when GENE be coexpress with either the GENE GENE ENTITY2 or the GENE GENE GENE"
"-PRON- find that ENTITY1 be release from vesicle when GENE be coexpress with either the ENTITY2 GENE or the GENE GENE"
"-PRON- find that ENTITY1 be release from vesicle when ENTITY2 be coexpress with either the"
"the preparation and ENTITY2 profiling of CHEMICAL and ENTITY1 enantiomer . 	"
"the preparation and ENTITY2 profiling of ENTITY1 and CHEMICAL CHEMICAL CHEMICAL enantiomer"
"ENTITY1 360 , which be the major adduct accounting for about 90% of the total labeling , be contain within the sequence GENE , which be present in all know ENTITY2 ."
"ENTITY1 ( CHEMICAL ) , a nonselective irreversible inhibitor of GENE GENE ( GENE ) , also inhibit ENTITY2 ( GENE GENE GENE )"
"ENTITY1 ( CHEMICAL ) , a nonselective irreversible inhibitor of ENTITY2 ( GENE ) , also"
"ENTITY1 ( CHEMICAL ) , a nonselective irreversible inhibitor of GENE GENE ( ENTITY2 ) , also inhibit GENE"
"ENTITY1 ( CHEMICAL ) , a nonselective irreversible inhibitor of GENE GENE ( GENE ) , also inhibit GENE GENE GENE ( ENTITY2 ) , markedly increase brain"
"CHEMICAL ( ENTITY1 ) , a nonselective irreversible inhibitor of GENE GENE ( GENE ) , also inhibit ENTITY2 ( GENE GENE GENE )"
"CHEMICAL ( ENTITY1 ) , a nonselective irreversible inhibitor of ENTITY2 ( GENE ) , also"
"CHEMICAL ( ENTITY1 ) , a nonselective irreversible inhibitor of GENE GENE ( ENTITY2 ) , also inhibit GENE"
"CHEMICAL ( ENTITY1 ) , a nonselective irreversible inhibitor of GENE GENE ( GENE ) , also inhibit GENE GENE GENE ( ENTITY2 ) , markedly increase brain"
"GENE ) , also inhibit ENTITY2 ( GENE GENE GENE ) , markedly increase brain ENTITY1 level ."
"a nonselective irreversible inhibitor of ENTITY2 ( GENE ) , also inhibit GENE GENE GENE ( GENE GENE GENE ) , markedly increase brain ENTITY1 level ."
"inhibitor of GENE GENE ( ENTITY2 ) , also inhibit GENE GENE GENE ( GENE GENE GENE ) , markedly increase brain ENTITY1 level ."
"inhibit GENE GENE GENE ( ENTITY2 ) , markedly increase brain ENTITY1 level ."
"GENE be more effective than ENTITY2 , probably because GENE be unable to operate in the reverse mode , which give -PRON- an advantage in maintain the high cytosolic ENTITY1 concentration require for efficient vesicular"
"in maintain the high cytosolic ENTITY1 concentration require for efficient vesicular loading by ENTITY2 ."
"however , ENTITY2 be more effective than GENE , probably because GENE be unable to operate in the reverse mode , which give -PRON- an advantage in maintain the high cytosolic ENTITY1 concentration require for efficient vesicular"
"than GENE , probably because ENTITY2 be unable to operate in the reverse mode , which give -PRON- an advantage in maintain the high cytosolic ENTITY1 concentration require for efficient vesicular"
"gabaergic through mixed event when ENTITY1 be introduce into the secretory cell and compete for uptake by ENTITY2 ."
"GENE length dependent effect of ENTITY1 on ENTITY2 activity in pnt1a , but"
"GENE length dependent effect of ENTITY1 on GENE activity in pnt1a , but not in pc-3 cell , indicate as a cell - specific effect of CHEMICAL on ENTITY2 activity . 
"
"in conclusion , the ENTITY2 length dependent effect of ENTITY1 on GENE activity in pnt1a"
"dependent effect of CHEMICAL on ENTITY2 activity in pnt1a , but not in pc-3 cell , indicate as a cell - specific effect of ENTITY1 on GENE activity . 
"
"cell - specific effect of ENTITY1 on ENTITY2 activity . 
"
"in conclusion , the ENTITY2 length dependent effect of CHEMICAL on GENE activity in pnt1a , but not in pc-3 cell , indicate as a cell - specific effect of ENTITY1 on GENE activity . 
"
"exocytosis in the presence of ENTITY2 , and a point mutation of unc-47 that abolish ENTITY1 transmission in the worm confer"
"interestingly , the ENTITY2 ortholog from caenorhabditis elegan ( unc-47 ) , a specie lack CHEMICAL transmission , also support CHEMICAL exocytosis in the presence of GENE , and a point mutation of unc-47 that abolish ENTITY1 transmission in the worm confer"
") , a specie lack ENTITY1 transmission , also support CHEMICAL exocytosis in the presence of ENTITY2 , and a point mutation"
"interestingly , the ENTITY2 ortholog from caenorhabditis elegan ( unc-47 ) , a specie lack ENTITY1 transmission , also support CHEMICAL"
"CHEMICAL transmission , also support ENTITY1 exocytosis in the presence of ENTITY2 , and a point mutation"
"interestingly , the ENTITY2 ortholog from caenorhabditis elegan ( unc-47 ) , a specie lack CHEMICAL transmission , also support ENTITY1 exocytosis in the presence of"
"escalate single dos of oral ENTITY1 ( 0.0001 - 3   mg ) to 12 healthy participant , stratify accord to ENTITY2 carrier status , to assess"
"an increase cytosolic availability of ENTITY1 in ENTITY2 - contain terminal be crucial"
"ENTITY1 attenuate allergic airway inflammation by regulation of cd4(+)cd25(+ ) regulatory t cell ( tregs)/th17 balance in ENTITY2 - sensitized mouse . 	"
"rat midbrain slice with the ENTITY2 ( GENE ) agonist , ENTITY1 , trigger an increase in"
"( GENE ) agonist , ENTITY1 , trigger an increase in the expression of GENE that be temporally precede by an increase in the level of CHEMICAL GENE GENE GENE GENE ( ENTITY2 ) , a dna -"
"( GENE ) agonist , ENTITY1 , trigger an increase in the expression of ENTITY2 that be temporally precede by"
"the GENE GENE GENE ( ENTITY2 ) agonist , ENTITY1 , trigger an increase in"
"rat midbrain slice with the ENTITY2 ( GENE ) agonist , CHEMICAL , trigger an increase in the expression of GENE that be temporally precede by an increase in the level of ENTITY1 GENE GENE GENE GENE ("
"increase in the level of ENTITY1 GENE GENE GENE GENE ( ENTITY2 ) , a dna -"
"increase in the expression of ENTITY2 that be temporally precede by an increase in the level of ENTITY1 GENE GENE GENE GENE ("
"the GENE GENE GENE ( ENTITY2 ) agonist , CHEMICAL , trigger an increase in the expression of GENE that be temporally precede by an increase in the level of ENTITY1 GENE GENE GENE GENE ("
"namely GENE , GENE , ENTITY2 and ENTITY1 GENE GENE be increase in"
"four protein , namely ENTITY2 , GENE , GENE and ENTITY1 GENE GENE be increase in"
"protein , namely GENE , ENTITY2 , GENE and ENTITY1 GENE GENE be increase in"
"ENTITY2 , which be particularly relevant to gc metabolism in the lung , be also show to efficiently metabolize CHEMICAL CHEMICAL , CHEMICAL , and ENTITY1 ."
"ENTITY2 , which be particularly relevant to gc metabolism in the lung , be also show to efficiently metabolize CHEMICAL CHEMICAL , ENTITY1 , and CHEMICAL CHEMICAL ."
"ENTITY2 , which be particularly relevant to gc metabolism in the lung , be also show to efficiently metabolize ENTITY1 , CHEMICAL , and CHEMICAL"
"cell culture study demonstrate that ENTITY1 be capable of deliver anti - GENE ENTITY2 sirna to lipopolysaccharide ( lps)-stimulat"
"cell culture study demonstrate that ENTITY1 be capable of deliver anti - ENTITY2 GENE GENE GENE GENE sirna"
"of deliver anti - GENE ENTITY2 sirna to lipopolysaccharide ( lps)-stimulat macrophage and significantly inhibit the expression of GENE a mouse model of CHEMICAL ( CHEMICAL acute liver failure be use to evaluate in vivo sirna delivery efficacy of ENTITY1 ."
"capable of deliver anti - ENTITY2 GENE GENE GENE GENE sirna to lipopolysaccharide ( lps)-stimulat macrophage and significantly inhibit the expression of GENE a mouse model of CHEMICAL ( CHEMICAL acute liver failure be use to evaluate in vivo sirna delivery efficacy of ENTITY1 ."
"of deliver anti - GENE ENTITY2 sirna to lipopolysaccharide ( lps)-stimulat macrophage and significantly inhibit the expression of GENE a mouse model of ENTITY1 ( CHEMICAL acute liver failure"
"capable of deliver anti - ENTITY2 GENE GENE GENE GENE sirna to lipopolysaccharide ( lps)-stimulat macrophage and significantly inhibit the expression of GENE a mouse model of ENTITY1 ( CHEMICAL acute liver failure"
"non - CHEMICAL CHEMICAL derive ENTITY1 , where high selectivity against GENE could be obtained.(22 ) the inhibitor present here in some case possess sub - nanomolar inhibition of GENE , nanomolar potency in ppmlc cell base assay , low to fair ENTITY2 inhibition , and good human"
"non - CHEMICAL CHEMICAL derive ENTITY1 , where high selectivity against ENTITY2 could be obtained.(22 ) the"
"this be distinct from ENTITY2 inhibitor base on non - CHEMICAL CHEMICAL derive ENTITY1 , where high selectivity against"
"non - CHEMICAL CHEMICAL derive ENTITY1 , where high selectivity against GENE could be obtained.(22 ) the inhibitor present here in some case possess sub - nanomolar inhibition of ENTITY2 , nanomolar potency in ppmlc"
"inhibitor base on non - ENTITY1 derive CHEMICAL , where high selectivity against GENE could be obtained.(22 ) the inhibitor present here in some case possess sub - nanomolar inhibition of GENE , nanomolar potency in ppmlc cell base assay , low to fair ENTITY2 inhibition , and good human"
"inhibitor base on non - ENTITY1 derive CHEMICAL , where high selectivity against ENTITY2 could be obtained.(22 ) the"
"this be distinct from ENTITY2 inhibitor base on non - ENTITY1 derive CHEMICAL , where high"
"inhibitor base on non - ENTITY1 derive CHEMICAL , where high selectivity against GENE could be obtained.(22 ) the inhibitor present here in some case possess sub - nanomolar inhibition of ENTITY2 , nanomolar potency in ppmlc"
"increase of both GENE and ENTITY2 expression follow CHEMICAL - evoke ENTITY1 release in sh - sy5y"
"block the increase of both ENTITY2 and GENE expression follow CHEMICAL - evoke ENTITY1 release in sh - sy5y"
"moreover , the ENTITY2 inhibitor CHEMICAL block the increase of both GENE and GENE expression follow CHEMICAL - evoke ENTITY1 release in sh - sy5y"
"moreover , the GENE inhibitor ENTITY1 block the increase of both GENE and ENTITY2 expression follow CHEMICAL - evoke"
"moreover , the GENE inhibitor ENTITY1 block the increase of both ENTITY2 and GENE expression follow CHEMICAL"
"moreover , the ENTITY2 inhibitor ENTITY1 block the increase of both"
"increase of both GENE and ENTITY2 expression follow ENTITY1 - evoke CHEMICAL release in"
"block the increase of both ENTITY2 and GENE expression follow ENTITY1 - evoke CHEMICAL release in"
"moreover , the ENTITY2 inhibitor CHEMICAL block the increase of both GENE and GENE expression follow ENTITY1 - evoke CHEMICAL release in"
"show reduced alpha activity and ENTITY2 latency in the ENTITY1 group compare to the control"
"in contrast , ENTITY1 be only metabolize via GENE , with no significant turnover by ENTITY2 or GENE ."
"in contrast , ENTITY1 be only metabolize via ENTITY2 , with no significant turnover"
"in contrast , ENTITY1 be only metabolize via GENE , with no significant turnover by GENE or ENTITY2 ."
"to address the possibility that ENTITY1 ( CHEMICAL ) stimulate ENTITY2 activity in bovine aortic endothelial"
"the possibility that CHEMICAL ( ENTITY1 ) stimulate ENTITY2 activity in bovine aortic endothelial"
"ENTITY1 evoke ENTITY2 activation in bovine aortic endothelial"
"ENTITY2 - base design of a ENTITY1 prodrug . 	"
"this be confirm on add ENTITY1 the ENTITY2 inhibitor which abolish the protection"
"( GENE ) and/or decrease ENTITY2 ( GENE ) . 	 newly synthesize CHEMICAL derivative CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 1 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 2 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 3 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 4 ) CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 5 ) , and ENTITY1 ( 6 ) be investigate"
"and/or decrease GENE GENE ( ENTITY2 ) . 	 newly synthesize CHEMICAL derivative CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 1 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 2 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 3 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 4 ) CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 5 ) , and ENTITY1 ( 6 ) be investigate"
"weight through enhancement of hypothalamic ENTITY2 ( GENE ) and/or decrease GENE GENE ( GENE ) . 	 newly synthesize CHEMICAL derivative CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 1 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 2 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 3 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 4 ) CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 5 ) , and ENTITY1 ( 6 ) be investigate"
"hypothalamic GENE GENE GENE ( ENTITY2 ) and/or decrease GENE GENE ( GENE ) . 	 newly synthesize CHEMICAL derivative CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 1 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 2 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 3 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 4 ) CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 5 ) , and ENTITY1 ( 6 ) be investigate"
"( GENE ) and/or decrease ENTITY2 ( GENE ) . 	 newly synthesize CHEMICAL derivative CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 1 ) , ENTITY1 ( 2 ) , CHEMICAL"
"and/or decrease GENE GENE ( ENTITY2 ) . 	 newly synthesize CHEMICAL derivative CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 1 ) , ENTITY1 ( 2 ) , CHEMICAL"
"weight through enhancement of hypothalamic ENTITY2 ( GENE ) and/or decrease GENE GENE ( GENE ) . 	 newly synthesize CHEMICAL derivative CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 1 ) , ENTITY1 ( 2 ) , CHEMICAL"
"hypothalamic GENE GENE GENE ( ENTITY2 ) and/or decrease GENE GENE ( GENE ) . 	 newly synthesize CHEMICAL derivative CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 1 ) , ENTITY1 ( 2 ) , CHEMICAL"
"( GENE ) and/or decrease ENTITY2 ( GENE ) . 	 newly synthesize CHEMICAL derivative CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 1 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 2 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 3 ) , ENTITY1 ( 4 ) CHEMICAL CHEMICAL"
"and/or decrease GENE GENE ( ENTITY2 ) . 	 newly synthesize CHEMICAL derivative CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 1 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 2 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 3 ) , ENTITY1 ( 4 ) CHEMICAL CHEMICAL"
"weight through enhancement of hypothalamic ENTITY2 ( GENE ) and/or decrease GENE GENE ( GENE ) . 	 newly synthesize CHEMICAL derivative CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 1 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 2 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 3 ) , ENTITY1 ( 4 ) CHEMICAL CHEMICAL"
"hypothalamic GENE GENE GENE ( ENTITY2 ) and/or decrease GENE GENE ( GENE ) . 	 newly synthesize CHEMICAL derivative CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 1 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 2 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 3 ) , ENTITY1 ( 4 ) CHEMICAL CHEMICAL"
"( GENE ) and/or decrease ENTITY2 ( GENE ) . 	 newly synthesize CHEMICAL derivative CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 1 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 2 ) , ENTITY1 ( 3 ) , CHEMICAL"
"and/or decrease GENE GENE ( ENTITY2 ) . 	 newly synthesize CHEMICAL derivative CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 1 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 2 ) , ENTITY1 ( 3 ) , CHEMICAL"
"weight through enhancement of hypothalamic ENTITY2 ( GENE ) and/or decrease GENE GENE ( GENE ) . 	 newly synthesize CHEMICAL derivative CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 1 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 2 ) , ENTITY1 ( 3 ) , CHEMICAL"
"hypothalamic GENE GENE GENE ( ENTITY2 ) and/or decrease GENE GENE ( GENE ) . 	 newly synthesize CHEMICAL derivative CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 1 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 2 ) , ENTITY1 ( 3 ) , CHEMICAL"
"( GENE ) and/or decrease ENTITY2 ( GENE ) . 	 newly synthesize CHEMICAL derivative ENTITY1 ( 1 ) , CHEMICAL"
"and/or decrease GENE GENE ( ENTITY2 ) . 	 newly synthesize CHEMICAL derivative ENTITY1 ( 1 ) , CHEMICAL"
"weight through enhancement of hypothalamic ENTITY2 ( GENE ) and/or decrease GENE GENE ( GENE ) . 	 newly synthesize CHEMICAL derivative ENTITY1 ( 1 ) , CHEMICAL"
"hypothalamic GENE GENE GENE ( ENTITY2 ) and/or decrease GENE GENE ( GENE ) . 	 newly synthesize CHEMICAL derivative ENTITY1 ( 1 ) , CHEMICAL"
"( GENE ) and/or decrease ENTITY2 ( GENE ) . 	 newly synthesize CHEMICAL derivative CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 1 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 2 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 3 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 4 ) ENTITY1 ( 5 ) , and"
"and/or decrease GENE GENE ( ENTITY2 ) . 	 newly synthesize CHEMICAL derivative CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 1 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 2 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 3 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 4 ) ENTITY1 ( 5 ) , and"
"weight through enhancement of hypothalamic ENTITY2 ( GENE ) and/or decrease GENE GENE ( GENE ) . 	 newly synthesize CHEMICAL derivative CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 1 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 2 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 3 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 4 ) ENTITY1 ( 5 ) , and"
"hypothalamic GENE GENE GENE ( ENTITY2 ) and/or decrease GENE GENE ( GENE ) . 	 newly synthesize CHEMICAL derivative CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 1 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 2 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 3 ) , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( 4 ) ENTITY1 ( 5 ) , and"
"novel ENTITY1 derivative that modulate body weight through enhancement of hypothalamic GENE GENE GENE ( GENE ) and/or decrease ENTITY2 ( GENE ) . 	"
"novel ENTITY1 derivative that modulate body weight through enhancement of hypothalamic GENE GENE GENE ( GENE ) and/or decrease GENE GENE ( ENTITY2 ) . 	 newly synthesize"
"novel ENTITY1 derivative that modulate body weight through enhancement of hypothalamic ENTITY2 ( GENE ) and/or decrease"
"novel ENTITY1 derivative that modulate body weight through enhancement of hypothalamic GENE GENE GENE ( ENTITY2 ) and/or decrease GENE GENE"
"( GENE ) and/or decrease ENTITY2 ( GENE ) . 	 newly synthesize ENTITY1 derivative CHEMICAL CHEMICAL CHEMICAL CHEMICAL"
"and/or decrease GENE GENE ( ENTITY2 ) . 	 newly synthesize ENTITY1 derivative CHEMICAL CHEMICAL CHEMICAL CHEMICAL"
"weight through enhancement of hypothalamic ENTITY2 ( GENE ) and/or decrease GENE GENE ( GENE ) . 	 newly synthesize ENTITY1 derivative CHEMICAL CHEMICAL CHEMICAL CHEMICAL"
"hypothalamic GENE GENE GENE ( ENTITY2 ) and/or decrease GENE GENE ( GENE ) . 	 newly synthesize ENTITY1 derivative CHEMICAL CHEMICAL CHEMICAL CHEMICAL"
"the high affinity ENTITY2 receptor agonist , ENTITY1 ( 5-not)-stimulat CHEMICAL CHEMICAL CHEMICAL"
"the high affinity ENTITY2 receptor agonist , CHEMICAL ( 5-not)-stimulat ENTITY1 turnover response be concentration-(0.01 nm"
"in vivo effect at the ENTITY1 GENE GENE ( ENTITY2 ) and CHEMICAL GENE GENE"
"the CHEMICAL GENE GENE ( ENTITY2 ) and ENTITY1 GENE GENE GENE GENE GENE"
"temporal and anatomical determinant of ENTITY1 - induce ENTITY2 activity may indicate functional difference"
"temporal and anatomical determinant of ENTITY1 - induce GENE activity may indicate functional difference among nac shell subregion and suggest the involvement of ENTITY2 in early and late CHEMICAL"
"determinant of CHEMICAL - induce ENTITY2 activity may indicate functional difference among nac shell subregion and suggest the involvement of GENE in early and late ENTITY1 effect . 
"
"and suggest the involvement of ENTITY2 in early and late ENTITY1 effect . 
"
"similarly to that observe with ENTITY1 , a specific ENTITY2 antagonist ."
"and mechanical hypersensitivity induce by ENTITY1 similarly to that observe with CHEMICAL , a specific ENTITY2 antagonist ."
"-PRON- evaluate the role of ENTITY2 in the wound healing process by compare the effect of a nonselective GENE inhibitor , ENTITY1 , with a selective GENE"
"a nonselective GENE inhibitor , ENTITY1 , with a selective ENTITY2 inhibitor , sc-791 ."
"the effect of a nonselective ENTITY2 inhibitor , ENTITY1 , with a selective GENE"
"ENTITY2 / GENE channel be a prime target for the pharmacological management of arrhythmia and be selectively block by class iii antiarrhythmic ENTITY1 drug , such as CHEMICAL"
"GENE / ENTITY2 channel be a prime target for the pharmacological management of arrhythmia and be selectively block by class iii antiarrhythmic ENTITY1 drug , such as CHEMICAL"
"ENTITY2 / GENE channel be a prime target for the pharmacological management of arrhythmia and be selectively block by class iii antiarrhythmic CHEMICAL drug , such as ENTITY1 , CHEMICAL , and CHEMICAL"
"GENE / ENTITY2 channel be a prime target for the pharmacological management of arrhythmia and be selectively block by class iii antiarrhythmic CHEMICAL drug , such as ENTITY1 , CHEMICAL , and CHEMICAL"
"ENTITY2 / GENE channel be a prime target for the pharmacological management of arrhythmia and be selectively block by class iii antiarrhythmic CHEMICAL drug , such as CHEMICAL , CHEMICAL , and ENTITY1 , at submicromolar concentration ."
"GENE / ENTITY2 channel be a prime target for the pharmacological management of arrhythmia and be selectively block by class iii antiarrhythmic CHEMICAL drug , such as CHEMICAL , CHEMICAL , and ENTITY1 , at submicromolar concentration ."
"ENTITY2 / GENE channel be a prime target for the pharmacological management of arrhythmia and be selectively block by class iii antiarrhythmic CHEMICAL drug , such as CHEMICAL , ENTITY1 , and CHEMICAL , at"
"GENE / ENTITY2 channel be a prime target for the pharmacological management of arrhythmia and be selectively block by class iii antiarrhythmic CHEMICAL drug , such as CHEMICAL , ENTITY1 , and CHEMICAL , at"
"of CHEMICAL , but not ENTITY2 , in oocyte inhibit apoptosis , as well as the accumulation of GENE GENE GENE and GENE cause by ENTITY1 ."
"of GENE GENE GENE and ENTITY2 cause by ENTITY1 ."
"well as the accumulation of ENTITY2 and GENE cause by ENTITY1 ."
"ENTITY1 cause g2/m arrest associated with the modulation of GENE and ENTITY2 in human breast cancer mcf-7"
"ENTITY1 cause g2/m arrest associated with the modulation of ENTITY2 and GENE in human breast"
"although ENTITY1 greatly attenuate GENE inactivation by shift -PRON- voltage dependence to more positive potential , -PRON- enhance the rate and extent of ENTITY2 inactivation without alter -PRON- voltage"
"although ENTITY1 greatly attenuate ENTITY2 inactivation by shift -PRON- voltage"
"-PRON- conclude that CHEMICAL and ENTITY1 have additive and synergistic effect on the development of ENTITY2 - positive foci and that"
"finding , -PRON- conclude that ENTITY1 and CHEMICAL have additive and synergistic effect on the development of ENTITY2 - positive foci and that"
"effect on the development of ENTITY2 - positive foci and that high risk be associate with a combination of residual ENTITY1 pesticide in food than with"
"effect on the development of ENTITY2 - positive foci and that high risk be associate with a combination of residual CHEMICAL pesticide in food than with individual residual ENTITY1 pesticide . 
"
"role of ENTITY2 in ENTITY1 metabolism and clearance . 	"
", the involvement of the ENTITY2 - dependent pathway in the process of cell death induce by either ENTITY1 3 g or 3n be"
", the involvement of the ENTITY2 - dependent pathway in the process of cell death induce by either CHEMICAL 3 g or 3n be discard since cell death could not be prevent by pretreatment with the GENE inhibitor ENTITY1 ."
"ENTITY1 CHEMICAL - demethylation in vitro be catalyze by hepatic GENE GENE ( GENE ) and ENTITY2 , but clinical disposition be"
"ENTITY1 CHEMICAL - demethylation in vitro be catalyze by hepatic GENE GENE ( GENE ) and GENE , but clinical disposition be often attribute to ENTITY2 ."
"ENTITY1 CHEMICAL - demethylation in vitro be catalyze by hepatic ENTITY2 ( GENE ) and GENE"
"ENTITY1 CHEMICAL - demethylation in vitro be catalyze by hepatic GENE GENE ( ENTITY2 ) and GENE , but"
"CHEMICAL ENTITY1 - demethylation in vitro be catalyze by hepatic GENE GENE ( GENE ) and ENTITY2 , but clinical disposition be"
"CHEMICAL ENTITY1 - demethylation in vitro be catalyze by hepatic GENE GENE ( GENE ) and GENE , but clinical disposition be often attribute to ENTITY2 ."
"CHEMICAL ENTITY1 - demethylation in vitro be catalyze by hepatic ENTITY2 ( GENE ) and GENE"
"CHEMICAL ENTITY1 - demethylation in vitro be catalyze by hepatic GENE GENE ( ENTITY2 ) and GENE , but"
"result : ENTITY1 be an effective antipsychotic and improve the extrapyramidal symptom and ENTITY2 level elevation note at baseline"
"neither selective ENTITY2 , nor nonselective GENE inhibition have a significant effect on the macroscopic or microscopic morphology of the wound , whereas ENTITY1 treatment result in epidermal and"
"selective GENE , nor nonselective ENTITY2 inhibition have a significant effect on the macroscopic or microscopic morphology of the wound , whereas ENTITY1 treatment result in epidermal and"
"hypothesis that GENE GENE mediate ENTITY2 activation by measure agonist - stimulate ENTITY1 ( CHEMICAL CHEMICAL CHEMICAL CHEMICAL"
"-PRON- test the hypothesis that ENTITY2 mediate GENE activation by measure agonist - stimulate ENTITY1 ( CHEMICAL CHEMICAL CHEMICAL CHEMICAL"
"hypothesis that GENE GENE mediate ENTITY2 activation by measure agonist - stimulate CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) formation in baec culture"
"-PRON- test the hypothesis that ENTITY2 mediate GENE activation by measure agonist - stimulate CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) formation in baec culture"
"ENTITY2 ( GENE ) activator , CHEMICAL and ENTITY1 , increase GENE GENE mrna"
") activator , CHEMICAL and ENTITY1 , increase ENTITY2 mrna level without modify the"
") activator , CHEMICAL and ENTITY1 , increase GENE GENE mrna level without modify the mitochondrial membrane potential in primary culture of rat preadipocyte . 	 GENE GENE ( ENTITY2 ) be inner mitochondrial membrane"
"GENE GENE GENE GENE ( ENTITY2 ) activator , CHEMICAL and ENTITY1 , increase GENE GENE mrna"
") activator , CHEMICAL and ENTITY1 , increase GENE GENE mrna level without modify the mitochondrial membrane potential in primary culture of rat preadipocyte . 	 ENTITY2 ( GENE ) be inner"
"ENTITY2 ( GENE ) activator , ENTITY1 and CHEMICAL , increase GENE"
"( GENE ) activator , ENTITY1 and CHEMICAL , increase ENTITY2 mrna level without modify the"
"( GENE ) activator , ENTITY1 and CHEMICAL , increase GENE GENE mrna level without modify the mitochondrial membrane potential in primary culture of rat preadipocyte . 	 GENE GENE ( ENTITY2 ) be inner mitochondrial membrane"
"GENE GENE GENE GENE ( ENTITY2 ) activator , ENTITY1 and CHEMICAL , increase GENE"
"( GENE ) activator , ENTITY1 and CHEMICAL , increase GENE GENE mrna level without modify the mitochondrial membrane potential in primary culture of rat preadipocyte . 	 ENTITY2 ( GENE ) be inner"
"in addition , neither selective ENTITY2 , nor nonselective GENE inhibition alter keratinocyte proliferation and differentiation , dermal angiogenesis or the recovery of wind tensile strength , whereas ENTITY1 reduce the tensile strength of"
"selective GENE , nor nonselective ENTITY2 inhibition alter keratinocyte proliferation and differentiation , dermal angiogenesis or the recovery of wind tensile strength , whereas ENTITY1 reduce the tensile strength of"
"preliminary clinical investigation with the ENTITY2 substrate probe CHEMICAL establish that ENTITY1 do not inhibit intestinal or"
"substrate probe CHEMICAL establish that ENTITY1 do not inhibit intestinal or hepatic ENTITY2 ."
"preliminary clinical investigation with the ENTITY2 substrate probe ENTITY1 establish that CHEMICAL do not"
"with the GENE substrate probe ENTITY1 establish that CHEMICAL do not inhibit intestinal or hepatic ENTITY2 ."
"two fibrate , CHEMICAL and ENTITY1 , on GENE and ENTITY2 mrna level in primary monolayer"
"two fibrate , CHEMICAL and ENTITY1 , on ENTITY2 and GENE mrna level in"
"effect of two fibrate , ENTITY1 and CHEMICAL , on GENE and ENTITY2 mrna level in primary monolayer"
"effect of two fibrate , ENTITY1 and CHEMICAL , on ENTITY2 and GENE mrna level in"
"base on ENTITY1 GENE inhibition , CHEMICAL - induce ENTITY2 more efficiently than CHEMICAL and"
"inhibition , CHEMICAL - induce ENTITY2 more efficiently than CHEMICAL and ENTITY1 ."
"inhibition , CHEMICAL - induce ENTITY2 more efficiently than ENTITY1 and CHEMICAL ."
"CHEMICAL CHEMICAL GENE inhibition , ENTITY1 - induce ENTITY2 more efficiently than CHEMICAL and"
"the additional subject reveal that ENTITY1 do give rise to transiently high ( 58%-64% ) ENTITY2 occupancy 2 to 3 hour"
"conclusion : ENTITY1 show a transiently high ENTITY2 occupancy , which decrease to"
"thus , ENTITY1 treatment result in an 8-fold induction in ENTITY2 mrna level in preadipocyte compare"
"ENTITY2 inhibition reduce ENTITY1 CHEMICAL - demethylation and clearance"
"GENE inhibition reduce ENTITY1 CHEMICAL - demethylation and clearance , and alter CHEMICAL concentration , demonstrate an important role for ENTITY2 in clinical CHEMICAL disposition ."
"ENTITY2 inhibition reduce CHEMICAL CHEMICAL - demethylation and clearance , and alter ENTITY1 concentration , demonstrate an important"
"and clearance , and alter ENTITY1 concentration , demonstrate an important role for ENTITY2 in clinical CHEMICAL disposition ."
"ENTITY2 inhibition reduce CHEMICAL CHEMICAL - demethylation and clearance , and alter CHEMICAL concentration , demonstrate an important role for GENE in clinical ENTITY1 disposition . 
"
"demonstrate an important role for ENTITY2 in clinical ENTITY1 disposition . 
"
"ENTITY2 inhibition reduce CHEMICAL ENTITY1 - demethylation and clearance ,"
"GENE inhibition reduce CHEMICAL ENTITY1 - demethylation and clearance , and alter CHEMICAL concentration , demonstrate an important role for ENTITY2 in clinical CHEMICAL disposition ."
"of the antitumor activity of ENTITY1 : a novel microtubule inhibitor . 	 CHEMICAL ( sb ) be an GENE GENE GENE ( ENTITY2 ) antagonist that have previously"
"of the antitumor activity of ENTITY1 : a novel microtubule inhibitor . 	 CHEMICAL ( sb ) be an ENTITY2 ( GENE ) antagonist that"
"novel microtubule inhibitor . 	 ENTITY1 ( sb ) be an GENE GENE GENE ( ENTITY2 ) antagonist that have previously"
"novel microtubule inhibitor . 	 ENTITY1 ( sb ) be an ENTITY2 ( GENE ) antagonist that"
"the ENTITY2 - selective agonist ENTITY1 potently and competitively displace ["
"-PRON- result imply that ENTITY2 have the potential to be inhibit by CHEMICAL / ENTITY1 analog , and -PRON- suggest"
"be inhibit by CHEMICAL / ENTITY1 analog , and -PRON- suggest that ENTITY2 act as a target of"
"-PRON- result imply that ENTITY2 have the potential to be inhibit by ENTITY1 / CHEMICAL analog , and"
"potential to be inhibit by ENTITY1 / CHEMICAL analog , and -PRON- suggest that ENTITY2 act as a target of"
"ENTITY2 bind directly to the GENE ENTITY1 terminus and can deubiquitinate and"
"GENE bind directly to the ENTITY2 ENTITY1 terminus and can deubiquitinate and"
"bind directly to the GENE ENTITY1 terminus and can deubiquitinate and stabilize ENTITY2 ."
"excessive ENTITY2 ( GENE production of ENTITY1 ( CHEMICAL ) be involve"
"GENE ( GENE production of ENTITY1 ( CHEMICAL ) be involve in the development and maintenance of chronic pain state , and be mediate by ENTITY2 ( GENE ) ."
"GENE ( GENE production of ENTITY1 ( CHEMICAL ) be involve in the development and maintenance of chronic pain state , and be mediate by GENE GENE GENE ( ENTITY2 ) ."
"excessive ENTITY2 ( GENE production of CHEMICAL CHEMICAL ( ENTITY1 ) be involve in the"
"production of CHEMICAL CHEMICAL ( ENTITY1 ) be involve in the development and maintenance of chronic pain state , and be mediate by ENTITY2 ( GENE ) ."
"production of CHEMICAL CHEMICAL ( ENTITY1 ) be involve in the development and maintenance of chronic pain state , and be mediate by GENE GENE GENE ( ENTITY2 ) ."
"ENTITY1 exhibit full agonism for enhancement of CHEMICAL CHEMICAL bind to human recombinant ENTITY2 receptor ( ec(50 ) 50"
"full agonism for enhancement of ENTITY1 bind to human recombinant ENTITY2 receptor ( ec(50 ) 50"
"GENE ( GENE ) , ENTITY2 mediate a specific coupling between GENE activation and ENTITY1 production ."
"to both the GENE and ENTITY2 ( GENE ) , GENE mediate a specific coupling between GENE activation and ENTITY1 production ."
"and GENE GENE GENE ( ENTITY2 ) , GENE mediate a specific coupling between GENE activation and ENTITY1 production ."
"by bind to both the ENTITY2 and GENE GENE GENE ( GENE ) , GENE mediate a specific coupling between GENE activation and ENTITY1 production ."
"mediate a specific coupling between ENTITY2 activation and ENTITY1 production ."
"ENTITY2 carrier status have no influence on CHEMICAL oral clearance or -PRON- inhibition by ENTITY1 ."
"ENTITY2 carrier status have no influence on ENTITY1 oral clearance or -PRON- inhibition"
"explore the protective effect of ENTITY1 ( non - selective GENE - inhibitor ) or CHEMICAL ( selective ENTITY2 inhibitor ) against chemical kindle"
"explore the protective effect of ENTITY1 ( non - selective ENTITY2 - inhibitor ) or CHEMICAL"
"GENE - inhibitor ) or ENTITY1 ( selective ENTITY2 inhibitor ) against chemical kindle"
"CHEMICAL ( non - selective ENTITY2 - inhibitor ) or ENTITY1 ( selective GENE inhibitor )"
"toxicological profile of select synthetic ENTITY1 show high bind affinity to the ENTITY2 . 	"
"ENTITY1 , popularly know for -PRON- cool effect , activate ENTITY2 - -a cold - activate"
"ENTITY1 , popularly know for -PRON- cool effect , activate GENE - -a cold - activate ENTITY2 ."
"and the underlying mechanism of ENTITY1 on ENTITY2 ( GENE allergic inflammation in"
"the effect of a dimeric ENTITY2 inhibitor , ENTITY1 , and the GENE antagonist"
"a dimeric GENE inhibitor , ENTITY1 , and the ENTITY2 antagonist , CHEMICAL , on"
"the effect of a dimeric ENTITY2 inhibitor , CHEMICAL CHEMICAL CHEMICAL , and the GENE antagonist , ENTITY1 , on mechanical hypersensitivity in"
"CHEMICAL CHEMICAL , and the ENTITY2 antagonist , ENTITY1 , on mechanical hypersensitivity in"
"demonstrate a paradoxical role of ENTITY1 in modulation of warm sensation , and here , -PRON- show that CHEMICAL also activate heat - activate ENTITY2 ."
"here , -PRON- show that ENTITY1 also activate heat - activate ENTITY2 ."
"ENTITY1 suppress GENE gene transcription enhance by GENE GENE GENE ) without affect ENTITY2 expression or smad1 phosphorylation ,"
"ENTITY1 suppress ENTITY2 gene transcription enhance by GENE"
"ENTITY1 suppress GENE gene transcription enhance by GENE GENE GENE ) without affect GENE expression or smad1 phosphorylation , and CHEMICAL - GENE GENE complex be bind to GENE , which form heterodimer with GENE high dos of GENE GENE GENE ) counteract the effect of CHEMICAL on apoptosis of mpobs , which be blunt by neutralize anti - ENTITY2 antibody or GENE small interfere"
"ENTITY1 suppress GENE gene transcription enhance by GENE GENE GENE ) without affect GENE expression or smad1 phosphorylation , and CHEMICAL - GENE GENE complex be bind to GENE , which form heterodimer with GENE high dos of GENE GENE GENE ) counteract the effect of CHEMICAL on apoptosis of mpobs , which be blunt by neutralize anti - GENE antibody or ENTITY2 small interfere rna ."
"ENTITY1 suppress GENE gene transcription enhance by GENE GENE GENE ) without affect GENE expression or smad1 phosphorylation , and CHEMICAL - GENE GENE complex be bind to ENTITY2 , which form heterodimer with"
"ENTITY1 suppress GENE gene transcription enhance by GENE GENE GENE ) without affect GENE expression or smad1 phosphorylation , and CHEMICAL - ENTITY2 complex be bind to GENE"
"GENE GENE ) without affect ENTITY2 expression or smad1 phosphorylation , and ENTITY1 - GENE GENE complex be"
"CHEMICAL suppress ENTITY2 gene transcription enhance by GENE GENE GENE ) without affect GENE expression or smad1 phosphorylation , and ENTITY1 - GENE GENE complex be"
"or smad1 phosphorylation , and ENTITY1 - GENE GENE complex be bind to GENE , which form heterodimer with GENE high dos of GENE GENE GENE ) counteract the effect of CHEMICAL on apoptosis of mpobs , which be blunt by neutralize anti - ENTITY2 antibody or GENE small interfere"
"or smad1 phosphorylation , and ENTITY1 - GENE GENE complex be bind to GENE , which form heterodimer with GENE high dos of GENE GENE GENE ) counteract the effect of CHEMICAL on apoptosis of mpobs , which be blunt by neutralize anti - GENE antibody or ENTITY2 small interfere rna ."
"or smad1 phosphorylation , and ENTITY1 - GENE GENE complex be bind to ENTITY2 , which form heterodimer with"
"or smad1 phosphorylation , and ENTITY1 - ENTITY2 complex be bind to GENE"
"GENE GENE ) without affect ENTITY2 expression or smad1 phosphorylation , and CHEMICAL - GENE GENE complex be bind to GENE , which form heterodimer with GENE high dos of GENE GENE GENE ) counteract the effect of ENTITY1 on apoptosis of mpobs ,"
"CHEMICAL suppress ENTITY2 gene transcription enhance by GENE GENE GENE ) without affect GENE expression or smad1 phosphorylation , and CHEMICAL - GENE GENE complex be bind to GENE , which form heterodimer with GENE high dos of GENE GENE GENE ) counteract the effect of ENTITY1 on apoptosis of mpobs ,"
") counteract the effect of ENTITY1 on apoptosis of mpobs , which be blunt by neutralize anti - ENTITY2 antibody or GENE small interfere"
") counteract the effect of ENTITY1 on apoptosis of mpobs , which be blunt by neutralize anti - GENE antibody or ENTITY2 small interfere rna ."
"GENE complex be bind to ENTITY2 , which form heterodimer with GENE high dos of GENE GENE GENE ) counteract the effect of ENTITY1 on apoptosis of mpobs ,"
"phosphorylation , and CHEMICAL - ENTITY2 complex be bind to GENE , which form heterodimer with GENE high dos of GENE GENE GENE ) counteract the effect of ENTITY1 on apoptosis of mpobs ,"
"-PRON- further show that ENTITY1 inhibit ENTITY2 , potentially explain the use"
"further show that CHEMICAL inhibit ENTITY2 , potentially explain the use of ENTITY1 as an analgesic ."
"similar to ENTITY1 , both CHEMICAL and CHEMICAL ( initially report to be specific activator of ENTITY2 and GENE , respectively )"
"similar to ENTITY1 , both CHEMICAL and CHEMICAL ( initially report to be specific activator of GENE and ENTITY2 , respectively ) also modulate"
"similar to ENTITY1 , both CHEMICAL and CHEMICAL ( initially report to be specific activator of GENE and GENE , respectively ) also modulate other ENTITY2 ."
"similar to CHEMICAL , both ENTITY1 and CHEMICAL ( initially report to be specific activator of ENTITY2 and GENE , respectively )"
"similar to CHEMICAL , both ENTITY1 and CHEMICAL ( initially report to be specific activator of GENE and ENTITY2 , respectively ) also modulate"
"similar to CHEMICAL , both ENTITY1 and CHEMICAL ( initially report to be specific activator of GENE and GENE , respectively ) also modulate other ENTITY2 ."
"CHEMICAL , both CHEMICAL and ENTITY1 ( initially report to be specific activator of ENTITY2 and GENE , respectively )"
"CHEMICAL , both CHEMICAL and ENTITY1 ( initially report to be specific activator of GENE and ENTITY2 , respectively ) also modulate"
"CHEMICAL , both CHEMICAL and ENTITY1 ( initially report to be specific activator of GENE and GENE , respectively ) also modulate other ENTITY2 ."
"suppression of ENTITY2 expression be a common feature of ENTITY1 - resistant and CHEMICAL -"
"suppression of ENTITY2 expression be a common feature of CHEMICAL - resistant and ENTITY1 - resistant rbl-2h3 cell ."
"CHEMICAL - dependent enzyme , ENTITY1 GENE , ENTITY2 , and GENE GENE GENE"
"CHEMICAL - dependent enzyme , ENTITY1 GENE , GENE GENE , and ENTITY2 ."
"ENTITY1 ( CHEMICAL ) be a novel antimetabolite that inhibit at least three CHEMICAL - dependent enzyme , CHEMICAL GENE , ENTITY2 , and GENE GENE GENE"
"ENTITY1 ( CHEMICAL ) be a novel antimetabolite that inhibit at least three CHEMICAL - dependent enzyme , CHEMICAL GENE , GENE GENE , and ENTITY2 ."
"CHEMICAL CHEMICAL ( ENTITY1 ) be a novel antimetabolite that inhibit at least three CHEMICAL - dependent enzyme , CHEMICAL GENE , ENTITY2 , and GENE GENE GENE"
"CHEMICAL CHEMICAL ( ENTITY1 ) be a novel antimetabolite that inhibit at least three CHEMICAL - dependent enzyme , CHEMICAL GENE , GENE GENE , and ENTITY2 ."
"that inhibit at least three ENTITY1 - dependent enzyme , CHEMICAL GENE , ENTITY2 , and GENE GENE GENE"
"that inhibit at least three ENTITY1 - dependent enzyme , CHEMICAL GENE , GENE GENE , and ENTITY2 ."
"the ENTITY1 , CHEMICAL , be the first selective ENTITY2 inhibitor evaluate for the treatment"
"the CHEMICAL CHEMICAL , ENTITY1 , be the first selective ENTITY2 inhibitor evaluate for the treatment"
"as a consequence , ENTITY1 reduce ENTITY2 peptide ( GENE ) formation"
"as a consequence , ENTITY1 reduce GENE GENE GENE peptide ( ENTITY2 ) formation in vitro and"
"central injection of such ENTITY2 antagonist do not affect ENTITY1 - induce bradycardia ."
"that one mechanism by which ENTITY2 agonist act for analgesia be to stimulate spinal ENTITY1 release ."
"do so by action on ENTITY2 , and perhaps other subtype , most likely locate on noradrenergic terminal , rather than by indirectly stimulate CHEMICAL release through CHEMICAL release or ENTITY1 synthesis . 
"
"do so by action on ENTITY2 , and perhaps other subtype , most likely locate on noradrenergic terminal , rather than by indirectly stimulate CHEMICAL release through ENTITY1 release or CHEMICAL CHEMICAL synthesis"
"do so by action on ENTITY2 , and perhaps other subtype , most likely locate on noradrenergic terminal , rather than by indirectly stimulate ENTITY1 release through CHEMICAL release or"
"distinct role of ENTITY1 in modulate spatial memory consolidation , retrieval , reconsolidation and the accompanying change of ENTITY2 and GENE activation in hippocampus"
"distinct role of ENTITY1 in modulate spatial memory consolidation , retrieval , reconsolidation and the accompanying change of GENE and ENTITY2 activation in hippocampus and prefrontal"
"treatment of tissue with the ENTITY2 inhibitor ENTITY1 ."
"compare to that obtain with ENTITY1 ) could be eliminate by prior treatment of tissue with the ENTITY2 inhibitor CHEMICAL ."
"ENTITY1 be a less potent antagonist of tissue response to CHEMICAL , and the underestimation in the pkb ( as compare to that obtain with CHEMICAL ) could be eliminate by prior treatment of tissue with the ENTITY2 inhibitor CHEMICAL ."
"antagonist of tissue response to ENTITY1 , and the underestimation in the pkb ( as compare to that obtain with CHEMICAL ) could be eliminate by prior treatment of tissue with the ENTITY2 inhibitor CHEMICAL ."
"active enantiomer for inhibition of ENTITY2 , whereas CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ' ENTITY1 ' ) have weak activity"
"CHEMICAL CHEMICAL CHEMICAL ( ' ENTITY1 ' ) have weak activity as an ENTITY2 inhibitor and can be dose"
"action of -PRON- enantiomer : ENTITY1 be the active enantiomer for inhibition of ENTITY2 , whereas CHEMICAL CHEMICAL CHEMICAL"
"action of -PRON- enantiomer : ENTITY1 be the active enantiomer for inhibition of GENE , whereas CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ' CHEMICAL ' ) have weak activity as an ENTITY2 inhibitor and can be dose"
"ENTITY1 be also unique because of differ action of -PRON- enantiomer : CHEMICAL CHEMICAL be the active enantiomer for inhibition of ENTITY2 , whereas CHEMICAL CHEMICAL CHEMICAL"
"ENTITY1 be also unique because of differ action of -PRON- enantiomer : CHEMICAL CHEMICAL be the active enantiomer for inhibition of GENE , whereas CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ' CHEMICAL ' ) have weak activity as an ENTITY2 inhibitor and can be dose"
"active enantiomer for inhibition of ENTITY2 , whereas ENTITY1 ( ' CHEMICAL ' )"
"inhibition of GENE , whereas ENTITY1 ( ' CHEMICAL ' ) have weak activity as an ENTITY2 inhibitor and can be dose"
"other mmpis ( e.g. , ENTITY1 ) , these newly report compound be capable of modulate activity of several GENE in the low nanomolar range , include GENE ( ~2 to 50 nm ) , GENE ( ~2 to 50 nm ) , and ENTITY2 ( ~4 to 60 nm"
"other mmpis ( e.g. , ENTITY1 ) , these newly report compound be capable of modulate activity of several GENE in the low nanomolar range , include ENTITY2 ( ~2 to 50 nm"
"other mmpis ( e.g. , ENTITY1 ) , these newly report compound be capable of modulate activity of several ENTITY2 in the low nanomolar range"
"other mmpis ( e.g. , ENTITY1 ) , these newly report compound be capable of modulate activity of several GENE in the low nanomolar range , include GENE ( ~2 to 50 nm ) , ENTITY2 ( ~2 to 50 nm"
"] ) and renal ( ENTITY1 [ CHEMICAL CHEMICAL ] ) CHEMICAL metabolism as in vivo index of the constitutive ENTITY2 pathway ."
"of product of platelet ( ENTITY1 [ CHEMICAL ] ) and renal ( CHEMICAL CHEMICAL CHEMICAL [ CHEMICAL CHEMICAL ] ) CHEMICAL metabolism as in vivo index of the constitutive ENTITY2 pathway ."
"[ CHEMICAL CHEMICAL ] ) ENTITY1 metabolism as in vivo index of the constitutive ENTITY2 pathway ."
"CHEMICAL CHEMICAL CHEMICAL CHEMICAL [ ENTITY1 ] ) and renal ( CHEMICAL CHEMICAL CHEMICAL [ CHEMICAL CHEMICAL ] ) CHEMICAL metabolism as in vivo index of the constitutive ENTITY2 pathway ."
"( CHEMICAL CHEMICAL CHEMICAL [ ENTITY1 ] ) CHEMICAL metabolism as in vivo index of the constitutive ENTITY2 pathway ."
"CHEMICAL GENE ( ENTITY2 ) catalyse the first step in the synthesis of the polyamine ENTITY1 , CHEMICAL and CHEMICAL ."
"ENTITY1 GENE ( ENTITY2 ) catalyse the first step"
"CHEMICAL GENE ( ENTITY2 ) catalyse the first step in the synthesis of the polyamine CHEMICAL , CHEMICAL and ENTITY1 ."
"CHEMICAL GENE ( ENTITY2 ) catalyse the first step in the synthesis of the polyamine CHEMICAL , ENTITY1 and CHEMICAL ."
"produce a low level of ENTITY1 than the wild - type strain , while the GENE ( ENTITY2 ) gene - disrupt mutant"
"produce a low level of ENTITY1 than the wild - type strain , while the ENTITY2 ( GENE GENE ) gene"
"under aerobic condition , the ENTITY2 ( CHEMICAL CHEMICAL CHEMICAL GENE ) gene disrupt mutant produce a low level of ENTITY1 than the wild - type"
", while the GENE ( ENTITY2 ) gene - disrupt mutant produce an increased level of ENTITY1 ."
"type strain , while the ENTITY2 ( GENE GENE ) gene - disrupt mutant produce an increased level of ENTITY1 ."
"under aerobic condition , the ENTITY2 ( CHEMICAL CHEMICAL CHEMICAL GENE ) gene disrupt mutant produce a low level of CHEMICAL than the wild - type strain , while the GENE ( GENE GENE ) gene - disrupt mutant produce an increased level of ENTITY1 ."
"condition , the GENE ( ENTITY1 GENE ) gene disrupt mutant produce a low level of CHEMICAL than the wild - type strain , while the GENE ( ENTITY2 ) gene - disrupt mutant"
"condition , the GENE ( ENTITY1 GENE ) gene disrupt mutant produce a low level of CHEMICAL than the wild - type strain , while the ENTITY2 ( GENE GENE ) gene"
"under aerobic condition , the ENTITY2 ( ENTITY1 GENE ) gene disrupt mutant"
"in ypd medium contain 15% ENTITY1 under aerobic condition , the GENE ( CHEMICAL CHEMICAL CHEMICAL GENE ) gene disrupt mutant produce a low level of CHEMICAL than the wild - type strain , while the GENE ( ENTITY2 ) gene - disrupt mutant"
"in ypd medium contain 15% ENTITY1 under aerobic condition , the GENE ( CHEMICAL CHEMICAL CHEMICAL GENE ) gene disrupt mutant produce a low level of CHEMICAL than the wild - type strain , while the ENTITY2 ( GENE GENE ) gene"
"in ypd medium contain 15% ENTITY1 under aerobic condition , the ENTITY2 ( CHEMICAL CHEMICAL CHEMICAL GENE"
"cell ( pnt1a ) on ENTITY1 - activate ENTITY2 contain GENE GENE within normal"
"cell ( pnt1a ) on ENTITY1 - activate GENE contain ENTITY2 within normal length range ("
"-PRON- investigate the influence of ENTITY1 on prostate cancer cell ( pc-3 ) and non - tumor prostate cell ( pnt1a ) on CHEMICAL - activate ENTITY2 contain GENE GENE within normal"
"-PRON- investigate the influence of ENTITY1 on prostate cancer cell ( pc-3 ) and non - tumor prostate cell ( pnt1a ) on CHEMICAL - activate GENE contain ENTITY2 within normal length range ("
"and lead optimization study for ENTITY2 inhibitor base on CHEMICAL CHEMICAL - derive ENTITY1 be describe ."
"and lead optimization study for ENTITY2 inhibitor base on ENTITY1 - derive CHEMICAL be describe"
", the increased level of ENTITY1 in ENTITY2 disruptant be no longer observe"
", the increased level of ENTITY1 in GENE disruptant be no longer observe , whereas the decreased level of CHEMICAL in the ENTITY2 diruptant be still observe ."
"increased level of CHEMICAL in ENTITY2 disruptant be no longer observe , whereas the decreased level of ENTITY1 in the GENE diruptant be"
"whereas the decreased level of ENTITY1 in the ENTITY2 diruptant be still observe ."
"GENE GENE isozyme gene ( ENTITY2 and GENE ) show a ENTITY1 productivity of 50% as compare"
"isozyme gene ( GENE and ENTITY2 ) show a ENTITY1 productivity of 50% as compare"
"double mutant of the two ENTITY2 isozyme gene ( GENE and GENE ) show a ENTITY1 productivity of 50% as compare"
"GENE GENE isozyme gene ( ENTITY2 and GENE ) show a CHEMICAL productivity of 50% as compare to the parent when cell be incubate in ENTITY1 - buffer solution ."
"isozyme gene ( GENE and ENTITY2 ) show a CHEMICAL productivity of 50% as compare to the parent when cell be incubate in ENTITY1 - buffer solution ."
"double mutant of the two ENTITY2 isozyme gene ( GENE and GENE ) show a CHEMICAL productivity of 50% as compare to the parent when cell be incubate in ENTITY1 - buffer solution ."
"the study be to find ENTITY1 analogue that retain ENTITY2 inhibition but with reduced cytotoxicity"
"ENTITY1 act through the GENE GENE GENE ( GENE ) , which interact with the ENTITY2 ( GENE ) ."
"ENTITY1 act through the GENE GENE GENE ( GENE ) , which interact with the GENE GENE ( ENTITY2 ) ."
"ENTITY1 act through the ENTITY2 ( GENE ) , which"
"ENTITY1 act through the GENE GENE GENE ( ENTITY2 ) , which interact with"
"99% of a dose of ENTITY1 be unavailable for reaction with the target enzyme , because CHEMICAL strongly bind to GENE GENE GENE ( ENTITY2 ) ."
"99% of a dose of ENTITY1 be unavailable for reaction with the target enzyme , because CHEMICAL strongly bind to ENTITY2 ( GENE ) ."
"the target enzyme , because ENTITY1 strongly bind to GENE GENE GENE ( ENTITY2 ) ."
"the target enzyme , because ENTITY1 strongly bind to ENTITY2 ( GENE ) ."
"synthesize CHEMICAL de novo , ENTITY2 ( GENE ) and ENTITY1 GENE ( GENE ) catalyze"
"novo , GENE GENE ( ENTITY2 ) and ENTITY1 GENE ( GENE ) catalyze"
"GENE ( GENE ) and ENTITY1 GENE ( ENTITY2 ) catalyze the attachment of"
"in organism that synthesize ENTITY1 de novo , ENTITY2 ( GENE ) and CHEMICAL"
"in organism that synthesize ENTITY1 de novo , GENE GENE ( ENTITY2 ) and CHEMICAL GENE ("
"in organism that synthesize ENTITY1 de novo , GENE GENE ( GENE ) and CHEMICAL GENE ( ENTITY2 ) catalyze the attachment of"
"synthesize CHEMICAL de novo , ENTITY2 ( GENE ) and CHEMICAL GENE ( GENE ) catalyze the attachment of ENTITY1 residue to the CHEMICAL molecule"
"novo , GENE GENE ( ENTITY2 ) and CHEMICAL GENE ( GENE ) catalyze the attachment of ENTITY1 residue to the CHEMICAL molecule"
") and CHEMICAL GENE ( ENTITY2 ) catalyze the attachment of ENTITY1 residue to the CHEMICAL molecule"
"synthesize CHEMICAL de novo , ENTITY2 ( GENE ) and CHEMICAL GENE ( GENE ) catalyze the attachment of CHEMICAL residue to the ENTITY1 molecule ."
"novo , GENE GENE ( ENTITY2 ) and CHEMICAL GENE ( GENE ) catalyze the attachment of CHEMICAL residue to the ENTITY1 molecule ."
") and CHEMICAL GENE ( ENTITY2 ) catalyze the attachment of CHEMICAL residue to the ENTITY1 molecule ."
"ENTITY1 be a bimodal modulator of ENTITY2 channel . 	"
"and block the effect of ENTITY1 to decrease basal ENTITY2 mrna level ."
"harvest to evaluate GENE GENE ENTITY1 GENE GENE GENE GENE GENE subunit ( GENE , GENE and GENE , ENTITY2 , GENE and GENE ,"
"harvest to evaluate GENE GENE ENTITY1 GENE GENE GENE GENE GENE subunit ( GENE , ENTITY2 and GENE , GENE ,"
"harvest to evaluate GENE GENE ENTITY1 GENE GENE GENE GENE GENE subunit ( GENE , GENE and GENE , GENE , GENE and ENTITY2 , respectively ) ."
"harvest to evaluate GENE GENE ENTITY1 GENE GENE GENE GENE GENE subunit ( GENE , GENE and ENTITY2 , GENE , GENE and"
"harvest to evaluate GENE GENE ENTITY1 GENE GENE GENE GENE GENE subunit ( GENE , GENE and GENE , GENE , ENTITY2 and GENE , respectively )"
"harvest to evaluate GENE GENE ENTITY1 GENE GENE GENE GENE GENE subunit ( ENTITY2 , GENE and GENE ,"
"ENTITY1 and ENTITY2 treatment reverse these alter parameter"
"ENTITY1 GENE ( ENTITY2 ) , a family of"
"ENTITY1 GENE ( GENE ) , a family of ENTITY2 , be widely express in"
"- conopeptide mria partially overlap ENTITY1 GENE GENE GENE GENE on the ENTITY2 . 	"
"of the irreversible inactivation of ENTITY2 by ENTITY1 ."
"of these compound with the ENTITY2 channel reveal that compound carry a basic ENTITY1 in the side chain display"
"CHEMICAL CHEMICAL CHEMICAL CHEMICAL and ENTITY1 reveal a high affinity towards ENTITY2 channel than CHEMICAL ."
"reveal a high affinity towards ENTITY2 channel than ENTITY1 ."
"specifically , ENTITY1 and CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL reveal a high affinity towards ENTITY2 channel than CHEMICAL ."
"GENE CHEMICAL GENE ( ENTITY2 ) be express in escherichia coli and the purified recombinant enzyme use for determination of the bind site for CHEMICAL CHEMICAL and of the residue modify in the inactivation of the enzyme by the enzyme - activate irreversible inhibitor , ENTITY1 ( CHEMICAL ) ."
"GENE CHEMICAL GENE ( ENTITY2 ) be express in escherichia coli and the purified recombinant enzyme use for determination of the bind site for CHEMICAL CHEMICAL and of the residue modify in the inactivation of the enzyme by the enzyme - activate irreversible inhibitor , CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) ."
"GENE ENTITY1 GENE ( ENTITY2 ) be express in escherichia"
"GENE CHEMICAL GENE ( ENTITY2 ) be express in escherichia coli and the purified recombinant enzyme use for determination of the bind site for ENTITY1 and of the residue modify"
", -PRON- provide evidence that ENTITY1 also act on endogenous ENTITY2 in cultured dorsal root ganglion"
", -PRON- provide evidence that ENTITY1 also act on endogenous GENE in cultured dorsal root ganglion neuron from rat and in the enterochromaffin model cell line qgp-1 , from which CHEMICAL be release upon activation of ENTITY2 ."
"CHEMICAL also act on endogenous ENTITY2 in cultured dorsal root ganglion neuron from rat and in the enterochromaffin model cell line qgp-1 , from which ENTITY1 be release upon activation of"
"line qgp-1 , from which ENTITY1 be release upon activation of ENTITY2 ."
") , and the GENE ENTITY1 GENE and ENTITY2 be not inhibit by mria"
"for inhibition of uptake by ENTITY2 of CHEMICAL CHEMICAL ( ki 1.89 microm ) than CHEMICAL CHEMICAL ( ki 4.33 microm ) , and the GENE ENTITY1 GENE and GENE GENE be"
"of uptake by GENE of ENTITY1 ( ki 1.89 microm ) than CHEMICAL CHEMICAL ( ki 4.33 microm ) , and the GENE CHEMICAL GENE and ENTITY2 be not inhibit by mria"
"for inhibition of uptake by ENTITY2 of ENTITY1 ( ki 1.89 microm )"
"ki 1.89 microm ) than ENTITY1 ( ki 4.33 microm ) , and the GENE CHEMICAL GENE and ENTITY2 be not inhibit by mria"
"for inhibition of uptake by ENTITY2 of CHEMICAL CHEMICAL ( ki 1.89 microm ) than ENTITY1 ( ki 4.33 microm )"
"while ENTITY1 be unable to block CHEMICAL - induce dna damage and damage response , such as the upregulation of GENE , CHEMICAL inhibit the CHEMICAL - induce nuclear accumulation of GENE GENE GENE / ENTITY2 and the subsequent downregulation of"
"while ENTITY1 be unable to block CHEMICAL - induce dna damage and damage response , such as the upregulation of GENE , CHEMICAL inhibit the CHEMICAL - induce nuclear accumulation of GENE GENE GENE / GENE and the subsequent downregulation of GENE and upregulation of ENTITY2 , thereby abrogate oocyte cell"
"while ENTITY1 be unable to block CHEMICAL - induce dna damage and damage response , such as the upregulation of GENE , CHEMICAL inhibit the CHEMICAL - induce nuclear accumulation of ENTITY2 / GENE and the subsequent"
"while ENTITY1 be unable to block CHEMICAL - induce dna damage and damage response , such as the upregulation of ENTITY2 , CHEMICAL inhibit the CHEMICAL"
"while ENTITY1 be unable to block CHEMICAL - induce dna damage and damage response , such as the upregulation of GENE , CHEMICAL inhibit the CHEMICAL - induce nuclear accumulation of GENE GENE GENE / GENE and the subsequent downregulation of ENTITY2 and upregulation of GENE ,"
"the upregulation of GENE , ENTITY1 inhibit the CHEMICAL - induce nuclear accumulation of GENE GENE GENE / ENTITY2 and the subsequent downregulation of"
"the upregulation of GENE , ENTITY1 inhibit the CHEMICAL - induce nuclear accumulation of GENE GENE GENE / GENE and the subsequent downregulation of GENE and upregulation of ENTITY2 , thereby abrogate oocyte cell"
"the upregulation of GENE , ENTITY1 inhibit the CHEMICAL - induce nuclear accumulation of ENTITY2 / GENE and the subsequent"
"such as the upregulation of ENTITY2 , ENTITY1 inhibit the CHEMICAL - induce"
"the upregulation of GENE , ENTITY1 inhibit the CHEMICAL - induce nuclear accumulation of GENE GENE GENE / GENE and the subsequent downregulation of ENTITY2 and upregulation of GENE ,"
"CHEMICAL be unable to block ENTITY1 - induce dna damage and damage response , such as the upregulation of GENE , CHEMICAL inhibit the CHEMICAL - induce nuclear accumulation of GENE GENE GENE / ENTITY2 and the subsequent downregulation of"
"CHEMICAL be unable to block ENTITY1 - induce dna damage and damage response , such as the upregulation of GENE , CHEMICAL inhibit the CHEMICAL - induce nuclear accumulation of GENE GENE GENE / GENE and the subsequent downregulation of GENE and upregulation of ENTITY2 , thereby abrogate oocyte cell"
"CHEMICAL be unable to block ENTITY1 - induce dna damage and damage response , such as the upregulation of GENE , CHEMICAL inhibit the CHEMICAL - induce nuclear accumulation of ENTITY2 / GENE and the subsequent"
"CHEMICAL be unable to block ENTITY1 - induce dna damage and damage response , such as the upregulation of ENTITY2 , CHEMICAL inhibit the CHEMICAL"
"CHEMICAL be unable to block ENTITY1 - induce dna damage and damage response , such as the upregulation of GENE , CHEMICAL inhibit the CHEMICAL - induce nuclear accumulation of GENE GENE GENE / GENE and the subsequent downregulation of ENTITY2 and upregulation of GENE ,"
"GENE , CHEMICAL inhibit the ENTITY1 - induce nuclear accumulation of GENE GENE GENE / ENTITY2 and the subsequent downregulation of"
"GENE , CHEMICAL inhibit the ENTITY1 - induce nuclear accumulation of GENE GENE GENE / GENE and the subsequent downregulation of GENE and upregulation of ENTITY2 , thereby abrogate oocyte cell"
"GENE , CHEMICAL inhibit the ENTITY1 - induce nuclear accumulation of ENTITY2 / GENE and the subsequent"
"such as the upregulation of ENTITY2 , CHEMICAL inhibit the ENTITY1 - induce nuclear accumulation of"
"GENE , CHEMICAL inhibit the ENTITY1 - induce nuclear accumulation of GENE GENE GENE / GENE and the subsequent downregulation of ENTITY2 and upregulation of GENE ,"
"upon differentiation , osteoclast expres ENTITY2 ( GENE ) , which be essential for vesicular storage and subsequent exocytosis of ENTITY1 in neuron ."
"GENE GENE GENE GENE ( ENTITY2 ) , which be essential for vesicular storage and subsequent exocytosis of ENTITY1 in neuron ."
"this ENTITY1 be contain in the sequence CHEMICAL , which be find in all know ENTITY2 from eukaryote ."
"be contain in the sequence ENTITY1 , which be find in all know ENTITY2 from eukaryote ."
"ENTITY2 be localize in transcytotic vesicle and accumulate ENTITY1 ."
"pressor and bradycardic effect of ENTITY1 and other ENTITY2 inhibitor in the rat ."
", phα1β do not inhibit ENTITY1 - activate current in patch - clamp recording of hek293 cell that express ENTITY2 receptor ."
"moreover , the production of ENTITY1 during whole blood clotting be assess as an index of the ENTITY2 activity of platelet GENE ex"
"moreover , the production of ENTITY1 during whole blood clotting be assess as an index of the GENE activity of platelet ENTITY2 ex vivo ."
"CHEMICAL uptake by the mutant ENTITY2 reveal that mria bind to GENE occur at a site that be distinct from but overlap with the bind site for ENTITY1 antidepressant and CHEMICAL . 
"
"reveal that mria bind to ENTITY2 occur at a site that be distinct from but overlap with the bind site for ENTITY1 antidepressant and CHEMICAL . 
"
"CHEMICAL uptake by the mutant ENTITY2 reveal that mria bind to GENE occur at a site that be distinct from but overlap with the bind site for CHEMICAL antidepressant and ENTITY1 . 
"
"reveal that mria bind to ENTITY2 occur at a site that be distinct from but overlap with the bind site for CHEMICAL antidepressant and ENTITY1 . 
"
"CHEMICAL and cocaine inhibition of ENTITY1 uptake by the mutant ENTITY2 reveal that mria bind to"
"CHEMICAL and cocaine inhibition of ENTITY1 uptake by the mutant GENE reveal that mria bind to ENTITY2 occur at a site that"
"result with previous datum for ENTITY1 and cocaine inhibition of CHEMICAL uptake by the mutant ENTITY2 reveal that mria bind to"
"result with previous datum for ENTITY1 and cocaine inhibition of CHEMICAL uptake by the mutant GENE reveal that mria bind to ENTITY2 occur at a site that"
"be possible that variation in ENTITY2 enzyme - mediate metabolism of ENTITY1 may contribute to this phenomenon"
"a similar procedure to analyze ENTITY2 label by reaction with CHEMICAL CHEMICAL CHEMICAL CHEMICAL , -PRON- be find that CHEMICAL 69 and ENTITY1 360 form covalent adduct with"
"a similar procedure to analyze ENTITY2 label by reaction with CHEMICAL CHEMICAL CHEMICAL CHEMICAL , -PRON- be find that ENTITY1 69 and CHEMICAL 360 form"
"a similar procedure to analyze ENTITY2 label by reaction with ENTITY1 , -PRON- be find that"
"p<0.05 ) increase in plasma ENTITY1 , ENTITY2 and significant ( p<0.05 )"
"p<0.05 ) increase in plasma ENTITY1 , GENE GENE and significant ( p<0.05 ) decrease in circulate ENTITY2 and GENE ."
"p<0.05 ) increase in plasma ENTITY1 , GENE GENE and significant ( p<0.05 ) decrease in circulate GENE and ENTITY2 ."
"osteoclast expres ENTITY2 , a GENE GENE GENE ENTITY1 GENE ."
"thus , ENTITY1 and other ENTITY2 GENE inhibitor provide an intriguing"
"thus , ENTITY1 and other GENE GENE GENE ENTITY2 inhibitor provide an intriguing new"
"thus , CHEMICAL and other ENTITY2 GENE inhibitor provide an intriguing new way to halt ENTITY1 - induce oocyte death in"
"and other GENE GENE GENE ENTITY2 inhibitor provide an intriguing new way to halt ENTITY1 - induce oocyte death in"
"to clarify the role of ENTITY2 in hyperaccumulation of CHEMICAL and CHEMICAL in rbl-2h3 cell , CHEMICAL - resistant and CHEMICAL - resistant cell be develop from rbl-2h3 cell by continuous exposure to ENTITY1 and CHEMICAL , respectively ."
"to clarify the role of ENTITY2 in hyperaccumulation of CHEMICAL and CHEMICAL in rbl-2h3 cell , CHEMICAL - resistant and CHEMICAL - resistant cell be develop from rbl-2h3 cell by continuous exposure to CHEMICAL and ENTITY1 , respectively ."
"to clarify the role of ENTITY2 in hyperaccumulation of ENTITY1 and CHEMICAL in rbl-2h3 cell"
"to clarify the role of ENTITY2 in hyperaccumulation of CHEMICAL and CHEMICAL in rbl-2h3 cell , ENTITY1 - resistant and CHEMICAL -"
"to clarify the role of ENTITY2 in hyperaccumulation of CHEMICAL and ENTITY1 in rbl-2h3 cell , CHEMICAL"
"to clarify the role of ENTITY2 in hyperaccumulation of CHEMICAL and CHEMICAL in rbl-2h3 cell , CHEMICAL - resistant and ENTITY1 - resistant cell be develop"
"toward GENE isozyme , whereas ENTITY1 , CHEMICAL , CHEMICAL CHEMICAL , CHEMICAL , and CHEMICAL have more than 5 time great preference for inhibit GENE than ENTITY2 ."
"toward GENE isozyme , whereas ENTITY1 , CHEMICAL , CHEMICAL CHEMICAL , CHEMICAL , and CHEMICAL have more than 5 time great preference for inhibit ENTITY2 than GENE ."
"CHEMICAL have little selectivity toward ENTITY2 isozyme , whereas ENTITY1 , CHEMICAL , CHEMICAL CHEMICAL"
"CHEMICAL , CHEMICAL , and ENTITY1 have more than 5 time great preference for inhibit GENE than ENTITY2 ."
"CHEMICAL , CHEMICAL , and ENTITY1 have more than 5 time great preference for inhibit ENTITY2 than GENE ."
"CHEMICAL have little selectivity toward ENTITY2 isozyme , whereas CHEMICAL , CHEMICAL , CHEMICAL CHEMICAL , CHEMICAL , and ENTITY1 have more than 5 time"
", CHEMICAL , CHEMICAL , ENTITY1 , CHEMICAL CHEMICAL , and CHEMICAL have little selectivity toward GENE isozyme , whereas CHEMICAL , CHEMICAL , CHEMICAL CHEMICAL , CHEMICAL , and CHEMICAL have more than 5 time great preference for inhibit GENE than ENTITY2 ."
", CHEMICAL , CHEMICAL , ENTITY1 , CHEMICAL CHEMICAL , and CHEMICAL have little selectivity toward GENE isozyme , whereas CHEMICAL , CHEMICAL , CHEMICAL CHEMICAL , CHEMICAL , and CHEMICAL have more than 5 time great preference for inhibit ENTITY2 than GENE ."
", CHEMICAL , CHEMICAL , ENTITY1 , CHEMICAL CHEMICAL , and CHEMICAL have little selectivity toward ENTITY2 isozyme , whereas CHEMICAL ,"
"CHEMICAL , CHEMICAL CHEMICAL , ENTITY1 , and CHEMICAL have more than 5 time great preference for inhibit GENE than ENTITY2 ."
"CHEMICAL , CHEMICAL CHEMICAL , ENTITY1 , and CHEMICAL have more than 5 time great preference for inhibit ENTITY2 than GENE ."
"CHEMICAL have little selectivity toward ENTITY2 isozyme , whereas CHEMICAL , CHEMICAL , CHEMICAL CHEMICAL , ENTITY1 , and CHEMICAL have more"
": CHEMICAL , CHEMICAL , ENTITY1 , CHEMICAL , CHEMICAL CHEMICAL , and CHEMICAL have little selectivity toward GENE isozyme , whereas CHEMICAL , CHEMICAL , CHEMICAL CHEMICAL , CHEMICAL , and CHEMICAL have more than 5 time great preference for inhibit GENE than ENTITY2 ."
": CHEMICAL , CHEMICAL , ENTITY1 , CHEMICAL , CHEMICAL CHEMICAL , and CHEMICAL have little selectivity toward GENE isozyme , whereas CHEMICAL , CHEMICAL , CHEMICAL CHEMICAL , CHEMICAL , and CHEMICAL have more than 5 time great preference for inhibit ENTITY2 than GENE ."
": CHEMICAL , CHEMICAL , ENTITY1 , CHEMICAL , CHEMICAL CHEMICAL , and CHEMICAL have little selectivity toward ENTITY2 isozyme , whereas CHEMICAL ,"
"result : ENTITY1 , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL CHEMICAL , and CHEMICAL have little selectivity toward GENE isozyme , whereas CHEMICAL , CHEMICAL , CHEMICAL CHEMICAL , CHEMICAL , and CHEMICAL have more than 5 time great preference for inhibit GENE than ENTITY2 ."
"result : ENTITY1 , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL CHEMICAL , and CHEMICAL have little selectivity toward GENE isozyme , whereas CHEMICAL , CHEMICAL , CHEMICAL CHEMICAL , CHEMICAL , and CHEMICAL have more than 5 time great preference for inhibit ENTITY2 than GENE ."
"result : ENTITY1 , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL CHEMICAL , and CHEMICAL have little selectivity toward ENTITY2 isozyme , whereas CHEMICAL ,"
"whereas CHEMICAL , CHEMICAL , ENTITY1 , CHEMICAL , and CHEMICAL have more than 5 time great preference for inhibit GENE than ENTITY2 ."
"whereas CHEMICAL , CHEMICAL , ENTITY1 , CHEMICAL , and CHEMICAL have more than 5 time great preference for inhibit ENTITY2 than GENE ."
"CHEMICAL have little selectivity toward ENTITY2 isozyme , whereas CHEMICAL , CHEMICAL , ENTITY1 , CHEMICAL , and CHEMICAL"
"isozyme , whereas CHEMICAL , ENTITY1 , CHEMICAL CHEMICAL , CHEMICAL , and CHEMICAL have more than 5 time great preference for inhibit GENE than ENTITY2 ."
"isozyme , whereas CHEMICAL , ENTITY1 , CHEMICAL CHEMICAL , CHEMICAL , and CHEMICAL have more than 5 time great preference for inhibit ENTITY2 than GENE ."
"CHEMICAL have little selectivity toward ENTITY2 isozyme , whereas CHEMICAL , ENTITY1 , CHEMICAL CHEMICAL , CHEMICAL"
"result : CHEMICAL , ENTITY1 , CHEMICAL , CHEMICAL , CHEMICAL CHEMICAL , and CHEMICAL have little selectivity toward GENE isozyme , whereas CHEMICAL , CHEMICAL , CHEMICAL CHEMICAL , CHEMICAL , and CHEMICAL have more than 5 time great preference for inhibit GENE than ENTITY2 ."
"result : CHEMICAL , ENTITY1 , CHEMICAL , CHEMICAL , CHEMICAL CHEMICAL , and CHEMICAL have little selectivity toward GENE isozyme , whereas CHEMICAL , CHEMICAL , CHEMICAL CHEMICAL , CHEMICAL , and CHEMICAL have more than 5 time great preference for inhibit ENTITY2 than GENE ."
"result : CHEMICAL , ENTITY1 , CHEMICAL , CHEMICAL , CHEMICAL CHEMICAL , and CHEMICAL have little selectivity toward ENTITY2 isozyme , whereas CHEMICAL ,"
", CHEMICAL CHEMICAL , and ENTITY1 have little selectivity toward GENE isozyme , whereas CHEMICAL , CHEMICAL , CHEMICAL CHEMICAL , CHEMICAL , and CHEMICAL have more than 5 time great preference for inhibit GENE than ENTITY2 ."
", CHEMICAL CHEMICAL , and ENTITY1 have little selectivity toward GENE isozyme , whereas CHEMICAL , CHEMICAL , CHEMICAL CHEMICAL , CHEMICAL , and CHEMICAL have more than 5 time great preference for inhibit ENTITY2 than GENE ."
", CHEMICAL CHEMICAL , and ENTITY1 have little selectivity toward ENTITY2 isozyme , whereas CHEMICAL ,"
", CHEMICAL , CHEMICAL , ENTITY1 , and CHEMICAL have little selectivity toward GENE isozyme , whereas CHEMICAL , CHEMICAL , CHEMICAL CHEMICAL , CHEMICAL , and CHEMICAL have more than 5 time great preference for inhibit GENE than ENTITY2 ."
", CHEMICAL , CHEMICAL , ENTITY1 , and CHEMICAL have little selectivity toward GENE isozyme , whereas CHEMICAL , CHEMICAL , CHEMICAL CHEMICAL , CHEMICAL , and CHEMICAL have more than 5 time great preference for inhibit ENTITY2 than GENE ."
", CHEMICAL , CHEMICAL , ENTITY1 , and CHEMICAL have little selectivity toward ENTITY2 isozyme , whereas CHEMICAL ,"
"result : the density of ENTITY2 in liver tissue in ENTITY1 group be high than that"
", CHEMICAL , CHEMICAL and ENTITY1 ) and of one CHEMICAL ( CHEMICAL ) be study in human cell line and primary cell ; CHEMICAL be include as the classical non - endogenous ENTITY2 ligand ."
"of four CHEMICAL compound ( ENTITY1 , CHEMICAL , CHEMICAL and CHEMICAL ) and of one CHEMICAL ( CHEMICAL ) be study in human cell line and primary cell ; CHEMICAL be include as the classical non - endogenous ENTITY2 ligand ."
"( CHEMICAL , CHEMICAL , ENTITY1 and CHEMICAL ) and of one CHEMICAL ( CHEMICAL ) be study in human cell line and primary cell ; CHEMICAL be include as the classical non - endogenous ENTITY2 ligand ."
"and of one CHEMICAL ( ENTITY1 ) be study in human cell line and primary cell ; CHEMICAL be include as the classical non - endogenous ENTITY2 ligand ."
"line and primary cell ; ENTITY1 be include as the classical non - endogenous ENTITY2 ligand ."
"CHEMICAL ) and of one ENTITY1 ( CHEMICAL ) be study in human cell line and primary cell ; CHEMICAL be include as the classical non - endogenous ENTITY2 ligand ."
"and hormonal activity of four ENTITY1 compound ( CHEMICAL , CHEMICAL , CHEMICAL and CHEMICAL ) and of one CHEMICAL ( CHEMICAL ) be study in human cell line and primary cell ; CHEMICAL be include as the classical non - endogenous ENTITY2 ligand ."
"CHEMICAL compound ( CHEMICAL , ENTITY1 , CHEMICAL and CHEMICAL ) and of one CHEMICAL ( CHEMICAL ) be study in human cell line and primary cell ; CHEMICAL be include as the classical non - endogenous ENTITY2 ligand ."
"ENTITY1 toxicity coincide with reduce GENE level and -PRON- downstream effector : GENE , GENE , GENE and ENTITY2 GENE , GENE suggest repress"
"ENTITY1 toxicity coincide with reduce GENE level and -PRON- downstream effector : GENE , GENE , ENTITY2 and GENE GENE , GENE"
"ENTITY1 toxicity coincide with reduce ENTITY2 level and -PRON- downstream effector"
"ENTITY1 toxicity coincide with reduce GENE level and -PRON- downstream effector : ENTITY2 , GENE , GENE and"
"ENTITY1 toxicity coincide with reduce GENE level and -PRON- downstream effector : GENE , GENE , GENE and GENE ENTITY2 , GENE suggest repress GENE"
"ENTITY1 toxicity coincide with reduce GENE level and -PRON- downstream effector : GENE , ENTITY2 , GENE and GENE GENE"
"ENTITY1 toxicity coincide with reduce GENE level and -PRON- downstream effector : GENE , GENE , GENE and GENE GENE , GENE suggest repress ENTITY2 / GENE signal ."
"ENTITY1 toxicity coincide with reduce GENE level and -PRON- downstream effector : GENE , GENE , GENE and GENE GENE , ENTITY2 suggest repress GENE / GENE"
"ENTITY1 toxicity coincide with reduce GENE level and -PRON- downstream effector : GENE , GENE , GENE and GENE GENE , GENE suggest repress GENE / ENTITY2 signal ."
"however , other ENTITY2 antagonist ( CHEMICAL , CHEMICAL and CHEMICAL ) do not inhibit the bind at a range of concentration that generally exhibit GENE antagonism , and ENTITY1 , CHEMICAL and CHEMICAL be"
"of concentration that generally exhibit ENTITY2 antagonism , and ENTITY1 , CHEMICAL and CHEMICAL be"
"however , other ENTITY2 antagonist ( CHEMICAL , CHEMICAL and ENTITY1 ) do not inhibit the"
"( CHEMICAL , CHEMICAL and ENTITY1 ) do not inhibit the bind at a range of concentration that generally exhibit ENTITY2 antagonism , and CHEMICAL ,"
"however , other ENTITY2 antagonist ( ENTITY1 , CHEMICAL and CHEMICAL )"
", other GENE antagonist ( ENTITY1 , CHEMICAL and CHEMICAL ) do not inhibit the bind at a range of concentration that generally exhibit ENTITY2 antagonism , and CHEMICAL ,"
"however , other ENTITY2 antagonist ( CHEMICAL , CHEMICAL and CHEMICAL ) do not inhibit the bind at a range of concentration that generally exhibit GENE antagonism , and CHEMICAL , CHEMICAL and ENTITY1 be without effect on the"
"of concentration that generally exhibit ENTITY2 antagonism , and CHEMICAL , CHEMICAL and ENTITY1 be without effect on the"
"however , other ENTITY2 antagonist ( CHEMICAL , CHEMICAL and CHEMICAL ) do not inhibit the bind at a range of concentration that generally exhibit GENE antagonism , and CHEMICAL , ENTITY1 and CHEMICAL be without effect"
"of concentration that generally exhibit ENTITY2 antagonism , and CHEMICAL , ENTITY1 and CHEMICAL be without effect"
"however , other ENTITY2 antagonist ( CHEMICAL , CHEMICAL and CHEMICAL ) do not inhibit the bind at a range of concentration that generally exhibit GENE antagonism , and CHEMICAL , CHEMICAL and CHEMICAL be without effect on the ENTITY1 bind ."
"of concentration that generally exhibit ENTITY2 antagonism , and CHEMICAL , CHEMICAL and CHEMICAL be without effect on the ENTITY1 bind ."
"however , other ENTITY2 antagonist ( CHEMICAL , ENTITY1 and CHEMICAL ) do not"
"GENE antagonist ( CHEMICAL , ENTITY1 and CHEMICAL ) do not inhibit the bind at a range of concentration that generally exhibit ENTITY2 antagonism , and CHEMICAL ,"
"be expose to CHEMICAL or ENTITY1 , and immunohistochemical staining be perform to evaluate active ENTITY2 , CHEMICAL CHEMICAL CHEMICAL CHEMICAL"
"be perform to evaluate active ENTITY2 , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) , and CHEMICAL ("
"be perform to evaluate active ENTITY2 , ENTITY1 ( CHEMICAL CHEMICAL CHEMICAL )"
"be perform to evaluate active ENTITY2 , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL CHEMICAL CHEMICAL ) , and ENTITY1 ( CHEMICAL ) ."
"oral mucosa be expose to ENTITY1 or CHEMICAL , and immunohistochemical staining be perform to evaluate active ENTITY2 , CHEMICAL CHEMICAL CHEMICAL CHEMICAL"
"be perform to evaluate active ENTITY2 , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL CHEMICAL CHEMICAL ) , and CHEMICAL ( ENTITY1 ) ."
"ENTITY2 display specie - dependent stereoselectivity for isomer of CHEMICAL , ENTITY1 , and CHEMICAL CHEMICAL CHEMICAL"
"ENTITY2 display specie - dependent stereoselectivity for isomer of ENTITY1 , CHEMICAL , and CHEMICAL"
"ENTITY2 display specie - dependent stereoselectivity for isomer of CHEMICAL , CHEMICAL , and ENTITY1 . 	"
"CHEMICAL and ENTITY1 treatment significantly increase active ENTITY2 level in a time -"
"ENTITY1 and CHEMICAL treatment significantly increase active ENTITY2 level in a time -"
"CHEMICAL ( CHEMICAL ) stimulate ENTITY1 production in human embryonic kidney ( hek)-293 cell express GENE GENE CHEMICAL GENE GENE GENE GENE ( ENTITY2 ) ."
"be report that CHEMICAL , ENTITY1 , CHEMICAL , and the tas CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ) and CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ) stimulate CHEMICAL production in human embryonic kidney ( hek)-293 cell express GENE GENE CHEMICAL GENE GENE GENE GENE ( ENTITY2 ) ."
"that CHEMICAL , CHEMICAL , ENTITY1 , and the tas CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ) and CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ) stimulate CHEMICAL production in human embryonic kidney ( hek)-293 cell express GENE GENE CHEMICAL GENE GENE GENE GENE ( ENTITY2 ) ."
"CHEMICAL , and the tas ENTITY1 ( CHEMICAL ) and CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ) stimulate CHEMICAL production in human embryonic kidney ( hek)-293 cell express GENE GENE CHEMICAL GENE GENE GENE GENE ( ENTITY2 ) ."
"tas CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) and CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ) stimulate CHEMICAL production in human embryonic kidney ( hek)-293 cell express GENE GENE CHEMICAL GENE GENE GENE GENE ( ENTITY2 ) ."
"hek)-293 cell express GENE GENE ENTITY1 GENE GENE GENE GENE ( ENTITY2 ) ."
"CHEMICAL ( CHEMICAL ) and ENTITY1 ( CHEMICAL ) stimulate CHEMICAL production in human embryonic kidney ( hek)-293 cell express GENE GENE CHEMICAL GENE GENE GENE GENE ( ENTITY2 ) ."
"and CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) stimulate CHEMICAL production in human embryonic kidney ( hek)-293 cell express GENE GENE CHEMICAL GENE GENE GENE GENE ( ENTITY2 ) ."
", -PRON- be report that ENTITY1 , CHEMICAL , CHEMICAL , and the tas CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ) and CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ) stimulate CHEMICAL production in human embryonic kidney ( hek)-293 cell express GENE GENE CHEMICAL GENE GENE GENE GENE ( ENTITY2 ) ."
"minimal calcaemic effect , and ENTITY1 , a long - act ENTITY2 agonist , both of which"
"minimal calcaemic effect , and ENTITY1 , a long - act GENE agonist , both of which induce ENTITY2 synthesis in vivo ."
"CHEMICAL CHEMICAL ) analogue ( ENTITY1 ) with minimal calcaemic effect , and CHEMICAL , a long - act ENTITY2 agonist , both of which"
"CHEMICAL CHEMICAL ) analogue ( ENTITY1 ) with minimal calcaemic effect , and CHEMICAL , a long - act GENE agonist , both of which induce ENTITY2 synthesis in vivo ."
"conclusion and clinical relevance : ENTITY2 be selectively inhibit by CHEMICAL , CHEMICAL , and ENTITY1 ; CHEMICAL CHEMICAL and CHEMICAL"
"CHEMICAL , CHEMICAL , and ENTITY1 ; CHEMICAL CHEMICAL and CHEMICAL also appear to be preferential ENTITY2 inhibitor in dog ."
"conclusion and clinical relevance : ENTITY2 be selectively inhibit by ENTITY1 , CHEMICAL , and CHEMICAL"
"GENE be selectively inhibit by ENTITY1 , CHEMICAL , and CHEMICAL ; CHEMICAL CHEMICAL and CHEMICAL also appear to be preferential ENTITY2 inhibitor in dog ."
"conclusion and clinical relevance : ENTITY2 be selectively inhibit by CHEMICAL , ENTITY1 , and CHEMICAL ; CHEMICAL"
"selectively inhibit by CHEMICAL , ENTITY1 , and CHEMICAL ; CHEMICAL CHEMICAL and CHEMICAL also appear to be preferential ENTITY2 inhibitor in dog ."
"conclusion and clinical relevance : ENTITY2 be selectively inhibit by CHEMICAL , CHEMICAL , and CHEMICAL ; ENTITY1 and CHEMICAL also appear to"
"CHEMICAL , and CHEMICAL ; ENTITY1 and CHEMICAL also appear to be preferential ENTITY2 inhibitor in dog ."
"conclusion and clinical relevance : ENTITY2 be selectively inhibit by CHEMICAL , CHEMICAL , and CHEMICAL ; CHEMICAL CHEMICAL and ENTITY1 also appear to be preferential"
"CHEMICAL ; CHEMICAL CHEMICAL and ENTITY1 also appear to be preferential ENTITY2 inhibitor in dog ."
"the discovery that CHEMICAL and ENTITY1 activate the ENTITY2 motivate -PRON- to study the"
"the discovery that CHEMICAL and ENTITY1 activate the GENE motivate -PRON- to study the effect of these drug on the ENTITY2 ( GENE ) and a"
"the discovery that CHEMICAL and ENTITY1 activate the GENE motivate -PRON- to study the effect of these drug on the GENE GENE ( GENE ) and a human - rat chimera ( ENTITY2 ) ."
"the discovery that CHEMICAL and ENTITY1 activate the GENE motivate -PRON- to study the effect of these drug on the GENE GENE ( ENTITY2 ) and a human -"
"the discovery that ENTITY1 and CHEMICAL activate the ENTITY2 motivate -PRON- to study the"
"the discovery that ENTITY1 and CHEMICAL activate the GENE motivate -PRON- to study the effect of these drug on the ENTITY2 ( GENE ) and a"
"the discovery that ENTITY1 and CHEMICAL activate the GENE motivate -PRON- to study the effect of these drug on the GENE GENE ( GENE ) and a human - rat chimera ( ENTITY2 ) ."
"the discovery that ENTITY1 and CHEMICAL activate the GENE motivate -PRON- to study the effect of these drug on the GENE GENE ( ENTITY2 ) and a human -"
"and cortical culture , the ENTITY1 signal cause by activation of native GENE be potentiate by activation of ENTITY2 ."
"and cortical culture , the ENTITY1 signal cause by activation of native ENTITY2 be potentiate by activation of"
"and gc interact to regulate ENTITY2 expression in parallel with osteoblast differentiation and apoptosis and suggest that GENE GENE GENE ) and ENTITY1 may regulate osteoblast differentiation and"
"GENE GENE GENE ) and ENTITY1 may regulate osteoblast differentiation and apoptosis via -PRON- effect on ENTITY2 expression . 
"
"because s-(+)-isomer of CHEMICAL and ENTITY1 be report to be more potent and efficacious in vivo than r-(- ) , -PRON- determine the enantiomeric selectivity of all three specie of ENTITY2 ."
"furthermore , because s-(+)-isomer of ENTITY1 and CHEMICAL be report to be more potent and efficacious in vivo than r-(- ) , -PRON- determine the enantiomeric selectivity of all three specie of ENTITY2 ."
"in response to CHEMICAL , ENTITY1 , or CHEMICAL exposure , the accumulation of CHEMICAL by hek-293 cell stably express different specie of ENTITY2 be concentration- and isomer -"
"in response to ENTITY1 , CHEMICAL , or CHEMICAL exposure , the accumulation of CHEMICAL by hek-293 cell stably express different specie of ENTITY2 be concentration- and isomer -"
"CHEMICAL , CHEMICAL , or ENTITY1 exposure , the accumulation of CHEMICAL by hek-293 cell stably express different specie of ENTITY2 be concentration- and isomer -"
"exposure , the accumulation of ENTITY1 by hek-293 cell stably express different specie of ENTITY2 be concentration- and isomer -"
"ec50 value for ENTITY1 be 0.89 , 0.92 , and 4.44 microm for ENTITY2 , GENE , and GENE"
"ec50 value for ENTITY1 be 0.89 , 0.92 , and 4.44 microm for GENE , GENE , and ENTITY2 , respectively ."
"ec50 value for ENTITY1 be 0.89 , 0.92 , and 4.44 microm for GENE , ENTITY2 , and GENE GENE GENE"
"species of GENE , whereas ENTITY1 be a full agonist for the ENTITY2 but be a partial agonist"
"agonist at each species of ENTITY2 , whereas ENTITY1 be a full agonist for"
"species of GENE , whereas ENTITY1 be a full agonist for the GENE GENE but be a partial agonist at ENTITY2 ."
"ENTITY1 be a potent and full agonist at each species of GENE , whereas CHEMICAL be a full agonist for the ENTITY2 but be a partial agonist"
"ENTITY1 be a potent and full agonist at each species of ENTITY2 , whereas CHEMICAL be a"
"ENTITY1 be a potent and full agonist at each species of GENE , whereas CHEMICAL be a full agonist for the GENE GENE but be a partial agonist at ENTITY2 ."
"interestingly , both isomer of ENTITY1 be full agonist at GENE and GENE GENE GENE , whereas both be partial agonist at ENTITY2 ."
"interestingly , both isomer of ENTITY1 be full agonist at GENE and ENTITY2 , whereas both be partial"
"interestingly , both isomer of ENTITY1 be full agonist at ENTITY2 and GENE GENE GENE ,"
"conversely , ovarian GENE and ENTITY2 be positively regulate by ENTITY1 and CHEMICAL - CHEMICAL combination"
"conversely , ovarian ENTITY2 and GENE be positively regulate by ENTITY1 and CHEMICAL - CHEMICAL combination"
"GENE be positively regulate by ENTITY1 and CHEMICAL - CHEMICAL combination , whereas ENTITY2 be down - regulate in"
"conversely , ovarian GENE and ENTITY2 be positively regulate by CHEMICAL and ENTITY1 - CHEMICAL combination , whereas"
"conversely , ovarian ENTITY2 and GENE be positively regulate by CHEMICAL and ENTITY1 - CHEMICAL combination , whereas"
"positively regulate by CHEMICAL and ENTITY1 - CHEMICAL combination , whereas ENTITY2 be down - regulate in"
"conversely , ovarian GENE and ENTITY2 be positively regulate by CHEMICAL and CHEMICAL - CHEMICAL combination , whereas GENE be down - regulate in the uterus and oviduct after ENTITY1 consumption ."
"conversely , ovarian ENTITY2 and GENE be positively regulate by CHEMICAL and CHEMICAL - CHEMICAL combination , whereas GENE be down - regulate in the uterus and oviduct after ENTITY1 consumption ."
"- CHEMICAL combination , whereas ENTITY2 be down - regulate in the uterus and oviduct after ENTITY1 consumption ."
"conversely , ovarian GENE and ENTITY2 be positively regulate by CHEMICAL and CHEMICAL - ENTITY1 combination , whereas GENE be"
"conversely , ovarian ENTITY2 and GENE be positively regulate by CHEMICAL and CHEMICAL - ENTITY1 combination , whereas GENE be"
"by CHEMICAL and CHEMICAL - ENTITY1 combination , whereas ENTITY2 be down - regulate in"
"site that be insensitive to ENTITY1 and be thus unlikely to be ENTITY2 ."
"kidney , -PRON- find unique ENTITY1 - bind site that be insensitive to CHEMICAL and be thus unlikely to be ENTITY2 ."
"demonstrate that GENE activator suppress ENTITY2 expression , -PRON- examine whether ENTITY1 affect GENE expression in vascular"
"expression , -PRON- examine whether ENTITY1 affect ENTITY2 expression in vascular smooth muscle"
"previous study have demonstrate that ENTITY2 activator suppress GENE expression , -PRON- examine whether ENTITY1 affect GENE expression in vascular"
"of CHEMICAL CHEMICAL CHEMICAL to ENTITY1 - insensitive site be prevent by 100 microm CHEMICAL , the insensitive site be evaluate by subtract CHEMICAL CHEMICAL CHEMICAL bind in the presence of 100 microm CHEMICAL from that in the presence of 10 microm CHEMICAL . CHEMICAL CHEMICAL CHEMICAL bind to the CHEMICAL - insensitive site monophasically with a high affinity ( pk(d ) ; 9.1+/-0.08 , n=8 ) , and the b(max ) value ( 814+/-204 fmol mg(-1 ) protein , n=8 ) be more than ten time that of the CHEMICAL - sensitive ENTITY2 ( pk(d)=9.9+/-0.13 , b(max)=66+/-23 fmol"
"the presence of 10 microm ENTITY1 . CHEMICAL CHEMICAL CHEMICAL bind to the CHEMICAL - insensitive site monophasically with a high affinity ( pk(d ) ; 9.1+/-0.08 , n=8 ) , and the b(max ) value ( 814+/-204 fmol mg(-1 ) protein , n=8 ) be more than ten time that of the CHEMICAL - sensitive ENTITY2 ( pk(d)=9.9+/-0.13 , b(max)=66+/-23 fmol"
"CHEMICAL CHEMICAL bind to the ENTITY1 - insensitive site monophasically with a high affinity ( pk(d ) ; 9.1+/-0.08 , n=8 ) , and the b(max ) value ( 814+/-204 fmol mg(-1 ) protein , n=8 ) be more than ten time that of the CHEMICAL - sensitive ENTITY2 ( pk(d)=9.9+/-0.13 , b(max)=66+/-23 fmol"
"ten time that of the ENTITY1 - sensitive ENTITY2 ( pk(d)=9.9+/-0.13 , b(max)=66+/-23 fmol"
"of 10 microm CHEMICAL . ENTITY1 bind to the CHEMICAL - insensitive site monophasically with a high affinity ( pk(d ) ; 9.1+/-0.08 , n=8 ) , and the b(max ) value ( 814+/-204 fmol mg(-1 ) protein , n=8 ) be more than ten time that of the CHEMICAL - sensitive ENTITY2 ( pk(d)=9.9+/-0.13 , b(max)=66+/-23 fmol"
"be prevent by 100 microm ENTITY1 , the insensitive site be evaluate by subtract CHEMICAL CHEMICAL CHEMICAL bind in the presence of 100 microm CHEMICAL from that in the presence of 10 microm CHEMICAL . CHEMICAL CHEMICAL CHEMICAL bind to the CHEMICAL - insensitive site monophasically with a high affinity ( pk(d ) ; 9.1+/-0.08 , n=8 ) , and the b(max ) value ( 814+/-204 fmol mg(-1 ) protein , n=8 ) be more than ten time that of the CHEMICAL - sensitive ENTITY2 ( pk(d)=9.9+/-0.13 , b(max)=66+/-23 fmol"
"the presence of 100 microm ENTITY1 from that in the presence of 10 microm CHEMICAL . CHEMICAL CHEMICAL CHEMICAL bind to the CHEMICAL - insensitive site monophasically with a high affinity ( pk(d ) ; 9.1+/-0.08 , n=8 ) , and the b(max ) value ( 814+/-204 fmol mg(-1 ) protein , n=8 ) be more than ten time that of the CHEMICAL - sensitive ENTITY2 ( pk(d)=9.9+/-0.13 , b(max)=66+/-23 fmol"
"as the binding of ENTITY1 to CHEMICAL - insensitive site be prevent by 100 microm CHEMICAL , the insensitive site be evaluate by subtract CHEMICAL CHEMICAL CHEMICAL bind in the presence of 100 microm CHEMICAL from that in the presence of 10 microm CHEMICAL . CHEMICAL CHEMICAL CHEMICAL bind to the CHEMICAL - insensitive site monophasically with a high affinity ( pk(d ) ; 9.1+/-0.08 , n=8 ) , and the b(max ) value ( 814+/-204 fmol mg(-1 ) protein , n=8 ) be more than ten time that of the CHEMICAL - sensitive ENTITY2 ( pk(d)=9.9+/-0.13 , b(max)=66+/-23 fmol"
"site be evaluate by subtract ENTITY1 bind in the presence of 100 microm CHEMICAL from that in the presence of 10 microm CHEMICAL . CHEMICAL CHEMICAL CHEMICAL bind to the CHEMICAL - insensitive site monophasically with a high affinity ( pk(d ) ; 9.1+/-0.08 , n=8 ) , and the b(max ) value ( 814+/-204 fmol mg(-1 ) protein , n=8 ) be more than ten time that of the CHEMICAL - sensitive ENTITY2 ( pk(d)=9.9+/-0.13 , b(max)=66+/-23 fmol"
"to determine if ENTITY2 could antagonize androgen effect in normal tissue , -PRON- examine the effect of CHEMICAL on rat ventral prostate organ culture and demonstrate that CHEMICAL can functionally antagonize the action of ENTITY1 on prostate cell proliferation and"
"to determine if ENTITY2 could antagonize androgen effect in normal tissue , -PRON- examine the effect of ENTITY1 on rat ventral prostate organ"
"to determine if ENTITY2 could antagonize androgen effect in normal tissue , -PRON- examine the effect of CHEMICAL on rat ventral prostate organ culture and demonstrate that ENTITY1 can functionally antagonize the action"
"ENTITY2 be increase in ovary and uteri of ENTITY1 - treat rat ."
"cardiovascular effect of three different ENTITY2 inhibitor : CHEMICAL , ENTITY1 and CHEMICAL inject by intravenous"
"cardiovascular effect of three different ENTITY2 inhibitor : CHEMICAL , CHEMICAL and ENTITY1 inject by intravenous ( i.v"
"cardiovascular effect of three different ENTITY2 inhibitor : ENTITY1 , CHEMICAL and CHEMICAL inject"
"of CHEMICAL CHEMICAL ) and ENTITY1 , the expression of ENTITY2 ( GENE GENE GENE GENE"
"of CHEMICAL CHEMICAL ) and ENTITY1 , the expression of GENE ( GENE GENE GENE GENE GENE GENE GENE , encode by ENTITY2 , show a marked suppression"
"- 8-fold increase of the ENTITY1 GENE activity be show in the recombinant strain contain the integrate ENTITY2 gene under the strong constitutive"
"- 8-fold increase of the ENTITY1 GENE activity be show in the recombinant strain contain the integrate GENE GENE GENE gene under the strong constitutive ENTITY2 ."
"a recent study show that ENTITY1 , an ENTITY2 inhibitor , be as effective"
"show that CHEMICAL , an ENTITY2 inhibitor , be as effective or even superior to ENTITY1 when use as a first"
"senescence be not dependent on ENTITY2 or GENE ; however , GENE confer protection against the growth inhibitory effect of ENTITY1 ."
"or GENE ; however , ENTITY2 confer protection against the growth inhibitory effect of ENTITY1 ."
"not dependent on GENE or ENTITY2 ; however , GENE confer protection against the growth inhibitory effect of ENTITY1 ."
"the nonselective GENE GENE antagonist ENTITY1 exhibit pure antagonism at rat brain receptor , but display partial agonism at ENTITY2 receptor ."
"the nonselective ENTITY2 partial agonist CHEMICAL and the nonselective GENE GENE antagonist ENTITY1 exhibit pure antagonism at rat"
"agonist CHEMICAL and the nonselective ENTITY2 antagonist ENTITY1 exhibit pure antagonism at rat"
"nonselective GENE GENE partial agonist ENTITY1 and the nonselective GENE GENE antagonist CHEMICAL CHEMICAL exhibit pure antagonism at rat brain receptor , but display partial agonism at ENTITY2 receptor ."
"the nonselective ENTITY2 partial agonist ENTITY1 and the nonselective GENE GENE"
"nonselective GENE GENE partial agonist ENTITY1 and the nonselective ENTITY2 antagonist CHEMICAL CHEMICAL exhibit pure"
"ENTITY1 also activate dna damage response signaling , result in increase level of CHEMICAL GENE , GENE , and GENE GENE GENE GENE ( ENTITY2 ) , although CHEMICAL do"
"ENTITY1 also activate dna damage response signaling , result in increase level of CHEMICAL GENE , ENTITY2 , and GENE GENE GENE"
"ENTITY1 also activate dna damage response signaling , result in increase level of CHEMICAL GENE , GENE , and ENTITY2 ( GENE ) , although"
"GENE GENE GENE GENE ( ENTITY2 ) , although ENTITY1 do not appear to cause"
"level of CHEMICAL GENE , ENTITY2 , and GENE GENE GENE GENE ( GENE ) , although ENTITY1 do not appear to cause"
"GENE , GENE , and ENTITY2 ( GENE ) , although ENTITY1 do not appear to cause"
"the potentiation of heteromeric ENTITY2 by GENE activation be attenuate by gdpβs , block by an inhibitor of GENE GENE or the CHEMICAL chelator CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) , prolong by the"
"CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) , prolong by the GENE inhibitor CHEMICAL CHEMICAL , but unaffect by the CHEMICAL GENE inhibitor CHEMICAL CHEMICAL GENE GENE GENE ( ENTITY2 ) inhibition reduce the potentiation"
"CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) , prolong by the GENE inhibitor CHEMICAL CHEMICAL , but unaffect by the CHEMICAL GENE inhibitor CHEMICAL CHEMICAL GENE GENE GENE ( GENE ) inhibition reduce the potentiation by GENE of GENE , and conversely , direct activation of ENTITY2 by CHEMICAL CHEMICAL potentiate GENE"
"CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) , prolong by the ENTITY2 inhibitor CHEMICAL CHEMICAL , but"
"block by an inhibitor of ENTITY2 or the CHEMICAL chelator CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) , prolong by the"
"potentiation of heteromeric GENE by ENTITY2 activation be attenuate by gdpβs , block by an inhibitor of GENE GENE or the CHEMICAL chelator CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) , prolong by the"
"CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) , prolong by the GENE inhibitor CHEMICAL CHEMICAL , but unaffect by the CHEMICAL GENE inhibitor CHEMICAL CHEMICAL GENE GENE GENE ( GENE ) inhibition reduce the potentiation by ENTITY2 of GENE , and conversely"
"CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) , prolong by the GENE inhibitor CHEMICAL CHEMICAL , but unaffect by the CHEMICAL GENE inhibitor CHEMICAL CHEMICAL ENTITY2 ( GENE ) inhibition reduce"
"the potentiation of heteromeric ENTITY2 by GENE activation be attenuate by gdpβs , block by an inhibitor of GENE GENE or the CHEMICAL chelator CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ) , prolong by the GENE inhibitor CHEMICAL CHEMICAL , but unaffect by the ENTITY1 GENE inhibitor CHEMICAL CHEMICAL GENE"
", but unaffect by the ENTITY1 GENE inhibitor CHEMICAL CHEMICAL GENE GENE GENE ( ENTITY2 ) inhibition reduce the potentiation"
", but unaffect by the ENTITY1 GENE inhibitor CHEMICAL CHEMICAL GENE GENE GENE ( GENE ) inhibition reduce the potentiation by GENE of GENE , and conversely , direct activation of ENTITY2 by CHEMICAL CHEMICAL potentiate GENE"
") , prolong by the ENTITY2 inhibitor CHEMICAL CHEMICAL , but unaffect by the ENTITY1 GENE inhibitor CHEMICAL CHEMICAL GENE"
"block by an inhibitor of ENTITY2 or the CHEMICAL chelator CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ) , prolong by the GENE inhibitor CHEMICAL CHEMICAL , but unaffect by the ENTITY1 GENE inhibitor CHEMICAL CHEMICAL GENE"
"potentiation of heteromeric GENE by ENTITY2 activation be attenuate by gdpβs , block by an inhibitor of GENE GENE or the CHEMICAL chelator CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ) , prolong by the GENE inhibitor CHEMICAL CHEMICAL , but unaffect by the ENTITY1 GENE inhibitor CHEMICAL CHEMICAL GENE"
", but unaffect by the ENTITY1 GENE inhibitor CHEMICAL CHEMICAL GENE GENE GENE ( GENE ) inhibition reduce the potentiation by ENTITY2 of GENE , and conversely"
", but unaffect by the ENTITY1 GENE inhibitor CHEMICAL CHEMICAL ENTITY2 ( GENE ) inhibition reduce"
"the potentiation of heteromeric ENTITY2 by GENE activation be attenuate by gdpβs , block by an inhibitor of GENE GENE or the ENTITY1 chelator CHEMICAL CHEMICAL CHEMICAL CHEMICAL"
"of GENE GENE or the ENTITY1 chelator CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ) , prolong by the GENE inhibitor CHEMICAL CHEMICAL , but unaffect by the CHEMICAL GENE inhibitor CHEMICAL CHEMICAL GENE GENE GENE ( ENTITY2 ) inhibition reduce the potentiation"
"of GENE GENE or the ENTITY1 chelator CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ) , prolong by the GENE inhibitor CHEMICAL CHEMICAL , but unaffect by the CHEMICAL GENE inhibitor CHEMICAL CHEMICAL GENE GENE GENE ( GENE ) inhibition reduce the potentiation by GENE of GENE , and conversely , direct activation of ENTITY2 by CHEMICAL CHEMICAL potentiate GENE"
"of GENE GENE or the ENTITY1 chelator CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ) , prolong by the ENTITY2 inhibitor CHEMICAL CHEMICAL , but"
"block by an inhibitor of ENTITY2 or the ENTITY1 chelator CHEMICAL CHEMICAL CHEMICAL CHEMICAL"
"potentiation of heteromeric GENE by ENTITY2 activation be attenuate by gdpβs , block by an inhibitor of GENE GENE or the ENTITY1 chelator CHEMICAL CHEMICAL CHEMICAL CHEMICAL"
"of GENE GENE or the ENTITY1 chelator CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ) , prolong by the GENE inhibitor CHEMICAL CHEMICAL , but unaffect by the CHEMICAL GENE inhibitor CHEMICAL CHEMICAL GENE GENE GENE ( GENE ) inhibition reduce the potentiation by ENTITY2 of GENE , and conversely"
"of GENE GENE or the ENTITY1 chelator CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ) , prolong by the GENE inhibitor CHEMICAL CHEMICAL , but unaffect by the CHEMICAL GENE inhibitor CHEMICAL CHEMICAL ENTITY2 ( GENE ) inhibition reduce"
"the potentiation of heteromeric ENTITY2 by GENE activation be attenuate by gdpβs , block by an inhibitor of GENE GENE or the CHEMICAL chelator CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ) , prolong by the GENE inhibitor CHEMICAL CHEMICAL , but unaffect by the CHEMICAL GENE inhibitor CHEMICAL CHEMICAL GENE GENE GENE ( GENE ) inhibition reduce the potentiation by GENE of GENE , and conversely , direct activation of GENE by ENTITY1 potentiate GENE ."
"CHEMICAL GENE GENE GENE ( ENTITY2 ) inhibition reduce the potentiation by GENE of GENE , and conversely , direct activation of GENE by ENTITY1 potentiate GENE ."
"conversely , direct activation of ENTITY2 by ENTITY1 potentiate GENE ."
") , prolong by the ENTITY2 inhibitor CHEMICAL CHEMICAL , but unaffect by the CHEMICAL GENE inhibitor CHEMICAL CHEMICAL GENE GENE GENE ( GENE ) inhibition reduce the potentiation by GENE of GENE , and conversely , direct activation of GENE by ENTITY1 potentiate GENE ."
"block by an inhibitor of ENTITY2 or the CHEMICAL chelator CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ) , prolong by the GENE inhibitor CHEMICAL CHEMICAL , but unaffect by the CHEMICAL GENE inhibitor CHEMICAL CHEMICAL GENE GENE GENE ( GENE ) inhibition reduce the potentiation by GENE of GENE , and conversely , direct activation of GENE by ENTITY1 potentiate GENE ."
"potentiation of heteromeric GENE by ENTITY2 activation be attenuate by gdpβs , block by an inhibitor of GENE GENE or the CHEMICAL chelator CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ) , prolong by the GENE inhibitor CHEMICAL CHEMICAL , but unaffect by the CHEMICAL GENE inhibitor CHEMICAL CHEMICAL GENE GENE GENE ( GENE ) inhibition reduce the potentiation by GENE of GENE , and conversely , direct activation of GENE by ENTITY1 potentiate GENE ."
"inhibition reduce the potentiation by ENTITY2 of GENE , and conversely , direct activation of GENE by ENTITY1 potentiate GENE ."
"CHEMICAL GENE inhibitor CHEMICAL CHEMICAL ENTITY2 ( GENE ) inhibition reduce the potentiation by GENE of GENE , and conversely , direct activation of GENE by ENTITY1 potentiate GENE ."
"the potentiation of heteromeric ENTITY2 by GENE activation be attenuate by gdpβs , block by an inhibitor of GENE GENE or the CHEMICAL chelator CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ) , prolong by the GENE inhibitor ENTITY1 , but unaffect by the"
"prolong by the GENE inhibitor ENTITY1 , but unaffect by the CHEMICAL GENE inhibitor CHEMICAL CHEMICAL GENE GENE GENE ( ENTITY2 ) inhibition reduce the potentiation"
"prolong by the GENE inhibitor ENTITY1 , but unaffect by the CHEMICAL GENE inhibitor CHEMICAL CHEMICAL GENE GENE GENE ( GENE ) inhibition reduce the potentiation by GENE of GENE , and conversely , direct activation of ENTITY2 by CHEMICAL CHEMICAL potentiate GENE"
") , prolong by the ENTITY2 inhibitor ENTITY1 , but unaffect by the"
"block by an inhibitor of ENTITY2 or the CHEMICAL chelator CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ) , prolong by the GENE inhibitor ENTITY1 , but unaffect by the"
"potentiation of heteromeric GENE by ENTITY2 activation be attenuate by gdpβs , block by an inhibitor of GENE GENE or the CHEMICAL chelator CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ) , prolong by the GENE inhibitor ENTITY1 , but unaffect by the"
"prolong by the GENE inhibitor ENTITY1 , but unaffect by the CHEMICAL GENE inhibitor CHEMICAL CHEMICAL GENE GENE GENE ( GENE ) inhibition reduce the potentiation by ENTITY2 of GENE , and conversely"
"prolong by the GENE inhibitor ENTITY1 , but unaffect by the CHEMICAL GENE inhibitor CHEMICAL CHEMICAL ENTITY2 ( GENE ) inhibition reduce"
"the potentiation of heteromeric ENTITY2 by GENE activation be attenuate by gdpβs , block by an inhibitor of GENE GENE or the CHEMICAL chelator ENTITY1 ( CHEMICAL ) , prolong"
"GENE or the CHEMICAL chelator ENTITY1 ( CHEMICAL ) , prolong by the GENE inhibitor CHEMICAL CHEMICAL , but unaffect by the CHEMICAL GENE inhibitor CHEMICAL CHEMICAL GENE GENE GENE ( ENTITY2 ) inhibition reduce the potentiation"
"GENE or the CHEMICAL chelator ENTITY1 ( CHEMICAL ) , prolong by the GENE inhibitor CHEMICAL CHEMICAL , but unaffect by the CHEMICAL GENE inhibitor CHEMICAL CHEMICAL GENE GENE GENE ( GENE ) inhibition reduce the potentiation by GENE of GENE , and conversely , direct activation of ENTITY2 by CHEMICAL CHEMICAL potentiate GENE"
"GENE or the CHEMICAL chelator ENTITY1 ( CHEMICAL ) , prolong by the ENTITY2 inhibitor CHEMICAL CHEMICAL , but"
"block by an inhibitor of ENTITY2 or the CHEMICAL chelator ENTITY1 ( CHEMICAL ) , prolong"
"potentiation of heteromeric GENE by ENTITY2 activation be attenuate by gdpβs , block by an inhibitor of GENE GENE or the CHEMICAL chelator ENTITY1 ( CHEMICAL ) , prolong"
"GENE or the CHEMICAL chelator ENTITY1 ( CHEMICAL ) , prolong by the GENE inhibitor CHEMICAL CHEMICAL , but unaffect by the CHEMICAL GENE inhibitor CHEMICAL CHEMICAL GENE GENE GENE ( GENE ) inhibition reduce the potentiation by ENTITY2 of GENE , and conversely"
"GENE or the CHEMICAL chelator ENTITY1 ( CHEMICAL ) , prolong by the GENE inhibitor CHEMICAL CHEMICAL , but unaffect by the CHEMICAL GENE inhibitor CHEMICAL CHEMICAL ENTITY2 ( GENE ) inhibition reduce"
"that play critical role in ENTITY1 metabolism be GENE GENE GENE GENE GENE ( GENE ) and ENTITY2 ( GENE ) ."
"that play critical role in ENTITY1 metabolism be GENE GENE GENE GENE GENE ( GENE ) and GENE GENE GENE GENE ( ENTITY2 ) ."
"that play critical role in ENTITY1 metabolism be ENTITY2 ( GENE ) and GENE"
"that play critical role in ENTITY1 metabolism be GENE GENE GENE GENE GENE ( ENTITY2 ) and GENE GENE GENE"
"CHEMICAL and ENTITY1 have no effect on the CHEMICAL bind property of the mcf-7 GENE , nor do CHEMICAL interfere with the induction of ENTITY2 by CHEMICAL ."
"CHEMICAL and ENTITY1 have no effect on the CHEMICAL bind property of the mcf-7 ENTITY2 , nor do CHEMICAL interfere"
"ENTITY1 and CHEMICAL have no effect on the CHEMICAL bind property of the mcf-7 GENE , nor do CHEMICAL interfere with the induction of ENTITY2 by CHEMICAL ."
"ENTITY1 and CHEMICAL have no effect on the CHEMICAL bind property of the mcf-7 ENTITY2 , nor do CHEMICAL interfere"
"mcf-7 GENE , nor do ENTITY1 interfere with the induction of ENTITY2 by CHEMICAL ."
"bind property of the mcf-7 ENTITY2 , nor do ENTITY1 interfere with the induction of"
"have no effect on the ENTITY1 bind property of the mcf-7 GENE , nor do CHEMICAL interfere with the induction of ENTITY2 by CHEMICAL ."
"have no effect on the ENTITY1 bind property of the mcf-7 ENTITY2 , nor do CHEMICAL interfere"
"interfere with the induction of ENTITY2 by ENTITY1 ."
"bind property of the mcf-7 ENTITY2 , nor do CHEMICAL interfere with the induction of GENE GENE by ENTITY1 ."
"derivative and the presence of ENTITY1 GENE and ENTITY2 in the cytosol , the"
"the compartmentation of ENTITY2 isoform be in agreement with the predominance of CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL derivative and the presence of ENTITY1 GENE and GENE GENE GENE"
"agreement with the predominance of ENTITY1 derivative and the presence of CHEMICAL GENE and ENTITY2 in the cytosol , the"
"the compartmentation of ENTITY2 isoform be in agreement with the predominance of ENTITY1 derivative and the presence of"
"ENTITY1 ( 1 ) be a non - selective ENTITY2 antagonist that be use clinically"
"significant affinity for GENE , ENTITY2 , and GENE GENE GENE GENE GENE , dose - dependently increase extracellular level of ENTITY1 ( CHEMICAL ) and CHEMICAL"
"which possess significant affinity for ENTITY2 , GENE , and GENE GENE GENE GENE GENE , dose - dependently increase extracellular level of ENTITY1 ( CHEMICAL ) and CHEMICAL"
", and GENE GENE GENE ENTITY2 , dose - dependently increase extracellular level of ENTITY1 ( CHEMICAL ) and CHEMICAL"
"GENE , GENE , and ENTITY2 GENE GENE , dose - dependently increase extracellular level of ENTITY1 ( CHEMICAL ) and CHEMICAL"
"significant affinity for GENE , ENTITY2 , and GENE GENE GENE GENE GENE , dose - dependently increase extracellular level of CHEMICAL ( ENTITY1 ) and CHEMICAL ( CHEMICAL"
"which possess significant affinity for ENTITY2 , GENE , and GENE GENE GENE GENE GENE , dose - dependently increase extracellular level of CHEMICAL ( ENTITY1 ) and CHEMICAL ( CHEMICAL"
", and GENE GENE GENE ENTITY2 , dose - dependently increase extracellular level of CHEMICAL ( ENTITY1 ) and CHEMICAL ( CHEMICAL"
"GENE , GENE , and ENTITY2 GENE GENE , dose - dependently increase extracellular level of CHEMICAL ( ENTITY1 ) and CHEMICAL ( CHEMICAL"
"significant affinity for GENE , ENTITY2 , and GENE GENE GENE GENE GENE , dose - dependently increase extracellular level of CHEMICAL ( CHEMICAL ) and CHEMICAL ( ENTITY1 ) versus CHEMICAL , in"
"which possess significant affinity for ENTITY2 , GENE , and GENE GENE GENE GENE GENE , dose - dependently increase extracellular level of CHEMICAL ( CHEMICAL ) and CHEMICAL ( ENTITY1 ) versus CHEMICAL , in"
", and GENE GENE GENE ENTITY2 , dose - dependently increase extracellular level of CHEMICAL ( CHEMICAL ) and CHEMICAL ( ENTITY1 ) versus CHEMICAL , in"
"GENE , GENE , and ENTITY2 GENE GENE , dose - dependently increase extracellular level of CHEMICAL ( CHEMICAL ) and CHEMICAL ( ENTITY1 ) versus CHEMICAL , in"
"significant affinity for GENE , ENTITY2 , and GENE GENE GENE GENE GENE , dose - dependently increase extracellular level of CHEMICAL ( CHEMICAL ) and CHEMICAL ( CHEMICAL ) versus ENTITY1 , in dialysate of the"
"which possess significant affinity for ENTITY2 , GENE , and GENE GENE GENE GENE GENE , dose - dependently increase extracellular level of CHEMICAL ( CHEMICAL ) and CHEMICAL ( CHEMICAL ) versus ENTITY1 , in dialysate of the"
", and GENE GENE GENE ENTITY2 , dose - dependently increase extracellular level of CHEMICAL ( CHEMICAL ) and CHEMICAL ( CHEMICAL ) versus ENTITY1 , in dialysate of the"
"GENE , GENE , and ENTITY2 GENE GENE , dose - dependently increase extracellular level of CHEMICAL ( CHEMICAL ) and CHEMICAL ( CHEMICAL ) versus ENTITY1 , in dialysate of the"
"significant affinity for GENE , ENTITY2 , and GENE GENE GENE GENE GENE , dose - dependently increase extracellular level of CHEMICAL ( CHEMICAL ) and ENTITY1 ( CHEMICAL ) versus CHEMICAL"
"which possess significant affinity for ENTITY2 , GENE , and GENE GENE GENE GENE GENE , dose - dependently increase extracellular level of CHEMICAL ( CHEMICAL ) and ENTITY1 ( CHEMICAL ) versus CHEMICAL"
", and GENE GENE GENE ENTITY2 , dose - dependently increase extracellular level of CHEMICAL ( CHEMICAL ) and ENTITY1 ( CHEMICAL ) versus CHEMICAL"
"GENE , GENE , and ENTITY2 GENE GENE , dose - dependently increase extracellular level of CHEMICAL ( CHEMICAL ) and ENTITY1 ( CHEMICAL ) versus CHEMICAL"
"ENTITY1 , which possess significant affinity for GENE , ENTITY2 , and GENE GENE GENE"
"ENTITY1 , which possess significant affinity for ENTITY2 , GENE , and GENE"
"ENTITY1 , which possess significant affinity for GENE , GENE , and GENE GENE GENE ENTITY2 , dose - dependently increase"
"ENTITY1 , which possess significant affinity for GENE , GENE , and ENTITY2 GENE GENE , dose -"
"proximal region of the GENE ENTITY1 - terminal domain that , in combination , be require for GENE potentiation of ENTITY2 ."
"membrane proximal region of the ENTITY2 ENTITY1 - terminal domain that ,"
"mutagenesis , -PRON- identify three ENTITY1 ( CHEMICAL , CHEMICAL , and CHEMICAL ) within the membrane proximal region of the GENE CHEMICAL - terminal domain that , in combination , be require for GENE potentiation of ENTITY2 ."
"mutagenesis , -PRON- identify three ENTITY1 ( CHEMICAL , CHEMICAL , and CHEMICAL ) within the membrane proximal region of the ENTITY2 CHEMICAL - terminal domain that"
"evaluate -PRON- ability to displace ENTITY1 ( CHEMICAL CHEMICAL CHEMICAL CHEMICAL ) bind on ENTITY2 ."
"CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) bind on ENTITY2 ."
"ENTITY1 increase urinary CHEMICAL excretion in a dose - dependent manner , and inhibit the increase in plasma CHEMICAL after CHEMICAL loading independently of ENTITY2 secretion in normal rat ."
"increase in plasma CHEMICAL after ENTITY1 loading independently of ENTITY2 secretion in normal rat ."
"CHEMICAL CHEMICAL increase urinary ENTITY1 excretion in a dose - dependent manner , and inhibit the increase in plasma CHEMICAL after CHEMICAL loading independently of ENTITY2 secretion in normal rat ."
"inhibit the increase in plasma ENTITY1 after CHEMICAL loading independently of ENTITY2 secretion in normal rat ."
"1 and 2 potently displace ENTITY1 bind at ENTITY2 , but be less potent"
"1 and 2 potently displace ENTITY1 bind at GENE GENE GENE GENE GENE GENE , but be less potent at the ENTITY2 and GENE subtype ."
"1 and 2 potently displace ENTITY1 bind at GENE GENE GENE GENE GENE GENE , but be less potent at the GENE and ENTITY2 subtype ."
"-PRON- have be propose that ENTITY2 could be involve in the regulation of the use of fatty acid as fuel substrate , the GENE induction achieve after CHEMICAL and CHEMICAL CHEMICAL CHEMICAL treatment may indicate a high oxidation of CHEMICAL CHEMICAL , limit -PRON- availability to be store as ENTITY1 ."
"as fuel substrate , the ENTITY2 induction achieve after CHEMICAL and CHEMICAL CHEMICAL CHEMICAL treatment may indicate a high oxidation of CHEMICAL CHEMICAL , limit -PRON- availability to be store as ENTITY1 ."
"-PRON- have be propose that ENTITY2 could be involve in the regulation of the use of fatty acid as fuel substrate , the GENE induction achieve after ENTITY1 and CHEMICAL CHEMICAL CHEMICAL treatment"
"as fuel substrate , the ENTITY2 induction achieve after ENTITY1 and CHEMICAL CHEMICAL CHEMICAL treatment"
"-PRON- have be propose that ENTITY2 could be involve in the regulation of the use of fatty acid as fuel substrate , the GENE induction achieve after CHEMICAL and ENTITY1 treatment may indicate a high"
"as fuel substrate , the ENTITY2 induction achieve after CHEMICAL and ENTITY1 treatment may indicate a high"
"-PRON- have be propose that ENTITY2 could be involve in the regulation of the use of fatty acid as fuel substrate , the GENE induction achieve after CHEMICAL and CHEMICAL CHEMICAL CHEMICAL treatment may indicate a high oxidation of ENTITY1 , limit -PRON- availability to"
"as fuel substrate , the ENTITY2 induction achieve after CHEMICAL and CHEMICAL CHEMICAL CHEMICAL treatment may indicate a high oxidation of ENTITY1 , limit -PRON- availability to"
"GENE antagonist CHEMICAL or the ENTITY1 GENE GENE antagonist , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ENTITY2 partially but significantly reduce CHEMICAL"
"the ENTITY2 antagonist CHEMICAL or the ENTITY1 GENE GENE antagonist , CHEMICAL"
"the GENE antagonist ENTITY1 or the CHEMICAL GENE GENE antagonist , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ENTITY2 partially but significantly reduce CHEMICAL"
"the ENTITY2 antagonist ENTITY1 or the CHEMICAL GENE GENE"
"CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ENTITY2 partially but significantly reduce ENTITY1 pressor effect and mostly abolish"
"the ENTITY2 antagonist CHEMICAL or the CHEMICAL GENE GENE antagonist , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL GENE partially but significantly reduce ENTITY1 pressor effect and mostly abolish"
"these datum suggest that ENTITY1 facilitate frontocortical dopaminergic ( and adrenergic ) transmission primarily by activation of GENE GENE and , to a less degree , by stimulation of GENE receptor , whereas ENTITY2 receptor be not involve ."
"these datum suggest that ENTITY1 facilitate frontocortical dopaminergic ( and adrenergic ) transmission primarily by activation of GENE GENE and , to a less degree , by stimulation of ENTITY2 receptor , whereas GENE receptor"
"these datum suggest that ENTITY1 facilitate frontocortical dopaminergic ( and adrenergic ) transmission primarily by activation of ENTITY2 and , to a less"
"GENE - CHEMICAL concentration and ENTITY2 activity in rabbit feed high - CHEMICAL diet : comparison with ENTITY1 . 	"
"CHEMICAL CHEMICAL supplementation alter ENTITY2 - CHEMICAL concentration and GENE activity in rabbit feed high - CHEMICAL diet : comparison with ENTITY1 . 	"
"ENTITY1 supplementation alter GENE - CHEMICAL concentration and ENTITY2 activity in rabbit feed high"
"ENTITY1 supplementation alter ENTITY2 - CHEMICAL concentration and GENE"
"CHEMICAL supplementation alter GENE - ENTITY1 concentration and ENTITY2 activity in rabbit feed high"
"CHEMICAL CHEMICAL supplementation alter ENTITY2 - ENTITY1 concentration and GENE activity in"
"GENE - CHEMICAL concentration and ENTITY2 activity in rabbit feed high - ENTITY1 diet : comparison with CHEMICAL"
"CHEMICAL CHEMICAL supplementation alter ENTITY2 - CHEMICAL concentration and GENE activity in rabbit feed high - ENTITY1 diet : comparison with CHEMICAL"
"in vivo method for assess ENTITY2 ( GENE ) activity use therapeutically inert nanogram dos of ENTITY1 ."
"assess GENE GENE GENE ( ENTITY2 ) activity use therapeutically inert nanogram dos of ENTITY1 ."
"in contrast to GENE , ENTITY2 mrna level be only slightly modify by ENTITY1 in adipocyte ."
"in contrast to ENTITY2 , GENE mrna level be only slightly modify by ENTITY1 in adipocyte ."
"whole cell extract show that ENTITY1 increase GENE bind in 3t3 cell prior to increase ENTITY2 synthesis ."
"whole cell extract show that ENTITY1 increase ENTITY2 bind in 3t3 cell prior"
"the induction in ENTITY2 expression be not accompany by change in the mitochondrial membrane potential of rat primary preadipocyte after CHEMICAL or ENTITY1 treatment ."
"the induction in ENTITY2 expression be not accompany by change in the mitochondrial membrane potential of rat primary preadipocyte after ENTITY1 or CHEMICAL treatment ."
"CHEMICAL CHEMICAL and ENTITY1 significantly suppress an increase in plasma total - CHEMICAL ( total - c ) and ENTITY2 CHEMICAL compare to hc -"
"ENTITY1 and CHEMICAL significantly suppress an increase in plasma total - CHEMICAL ( total - c ) and ENTITY2 CHEMICAL compare to hc -"
"increase in plasma total - ENTITY1 ( total - c ) and ENTITY2 CHEMICAL compare to hc -"
"total - c ) and ENTITY2 ENTITY1 compare to hc - control"
"c ratio level and plasma ENTITY2 activity be only significantly high in ENTITY1 group after 8 week ."
"GENE GENE - CHEMICAL ( ENTITY2 - c ) and GENE - c / total - c ratio level and plasma GENE activity be only significantly high in ENTITY1 group after 8 week ."
"GENE - c ) and ENTITY2 - c / total - c ratio level and plasma GENE activity be only significantly high in ENTITY1 group after 8 week ."
"however , plasma ENTITY2 - CHEMICAL ( GENE - c ) and GENE - c / total - c ratio level and plasma GENE activity be only significantly high in ENTITY1 group after 8 week ."
"GENE GENE GENE GENE - ENTITY1 ( GENE - c ) and GENE - c / total - c ratio level and plasma ENTITY2 activity be only significantly high"
"GENE GENE GENE GENE - ENTITY1 ( ENTITY2 - c ) and GENE"
"GENE GENE GENE GENE - ENTITY1 ( GENE - c ) and ENTITY2 - c / total -"
"however , plasma ENTITY2 - ENTITY1 ( GENE - c )"
"CHEMICAL - induce increase in ENTITY1 and CHEMICAL level , while the selective ENTITY2 antagonist , CHEMICAL , be"
"the selective ENTITY2 receptor antagonist , CHEMICAL , slightly attenuate the CHEMICAL CHEMICAL - induce increase in ENTITY1 and CHEMICAL level , while"
"selective GENE receptor antagonist , ENTITY1 , slightly attenuate the CHEMICAL CHEMICAL - induce increase in CHEMICAL and CHEMICAL level , while the selective ENTITY2 antagonist , CHEMICAL , be"
"the selective ENTITY2 receptor antagonist , ENTITY1 , slightly attenuate the CHEMICAL"
"induce increase in CHEMICAL and ENTITY1 level , while the selective ENTITY2 antagonist , CHEMICAL , be"
"the selective ENTITY2 receptor antagonist , CHEMICAL , slightly attenuate the CHEMICAL CHEMICAL - induce increase in CHEMICAL and ENTITY1 level , while the selective"
"level , while the selective ENTITY2 antagonist , ENTITY1 , be ineffective ."
"the selective ENTITY2 receptor antagonist , CHEMICAL , slightly attenuate the CHEMICAL CHEMICAL - induce increase in CHEMICAL and CHEMICAL level , while the selective GENE antagonist , ENTITY1 , be ineffective ."
"CHEMICAL , slightly attenuate the ENTITY1 - induce increase in CHEMICAL and CHEMICAL level , while the selective ENTITY2 antagonist , CHEMICAL , be"
"the selective ENTITY2 receptor antagonist , CHEMICAL , slightly attenuate the ENTITY1 - induce increase in CHEMICAL"
"hepatic ENTITY2 activity be significantly low in both CHEMICAL CHEMICAL and ENTITY1 group than in hc -"
"hepatic ENTITY2 activity be significantly low in both CHEMICAL CHEMICAL and CHEMICAL group than in hc - control group , while CHEMICAL CHEMICAL CHEMICAL GENE activity be the high only in the ENTITY1 group ."
"hepatic ENTITY2 activity be significantly low in both ENTITY1 and CHEMICAL group than in"
"hepatic ENTITY2 activity be significantly low in both CHEMICAL CHEMICAL and CHEMICAL group than in hc - control group , while ENTITY1 GENE activity be the high"
"here -PRON- show that ENTITY1 rapidly increase the level of both GENE and ENTITY2 as well as GENE and"
"here -PRON- show that ENTITY1 rapidly increase the level of both ENTITY2 and GENE as well as"
"- drive structural modification of ENTITY1 be describe , which result in the development of a new series of CHEMICAL CHEMICAL CHEMICAL analogue with high antibacterial activity against gram - positive pathogen , include that against CHEMICAL - resistant strain and low ENTITY2 inhibition ."
"pathogen , include that against ENTITY1 - resistant strain and low ENTITY2 inhibition ."
"of a new series of ENTITY1 analogue with high antibacterial activity against gram - positive pathogen , include that against CHEMICAL - resistant strain and low ENTITY2 inhibition ."
"ENTITY1 be without effect on ENTITY2 mrna level in l929 cell"
"ENTITY1 be without effect on GENE mrna level in l929 cell , whereas CHEMICAL cause significant increase in both ENTITY2 mrna and protein level in"
"CHEMICAL be without effect on ENTITY2 mrna level in l929 cell , whereas ENTITY1 cause significant increase in both"
"in l929 cell , whereas ENTITY1 cause significant increase in both ENTITY2 mrna and protein level in"
", -PRON- utilize a complementary ENTITY1 microarray compose of approximately 6,000 human cancer - relate gene to determine the gene expression pattern alter by re - introduction of ENTITY2 into pc-3 prostate tumor cell"
"the kappa(1)+kappa(3)-opioid receptor agonist / ENTITY2 antagonist ENTITY1 be a pure antagonist at"
"GENE GENE GENE GENE antagonist ENTITY1 be a pure antagonist at both rat brain and human ENTITY2 receptor ."
"ENTITY1 decrease the expression of ENTITY2 at the mrna and protein"
"ENTITY1 / anti - GENE sirna nanocomplex significantly reduce the GENE ( ENTITY2 ) and the hepatic cellular"
"ENTITY1 / anti - ENTITY2 sirna nanocomplex significantly reduce the"
"ENTITY1 / anti - GENE sirna nanocomplex significantly reduce the ENTITY2 ( GENE GENE ) and"
"significantly reduce the GENE ( ENTITY2 ) and the hepatic cellular damage in ENTITY1 - intoxicated mouse ."
"CHEMICAL / anti - ENTITY2 sirna nanocomplex significantly reduce the GENE ( GENE GENE ) and the hepatic cellular damage in ENTITY1 - intoxicated mouse ."
"sirna nanocomplex significantly reduce the ENTITY2 ( GENE GENE ) and the hepatic cellular damage in ENTITY1 - intoxicated mouse ."
"both CHEMICAL and ENTITY1 increase the rate of ENTITY2 mrna degradation ."
"both ENTITY1 and CHEMICAL CHEMICAL increase the rate of ENTITY2 mrna degradation ."
"analysis further confirm increase GENE ENTITY1 GENE GENE GENE GENE ( ENTITY2 ) and GENE protein level"
"analysis further confirm increase GENE ENTITY1 GENE GENE GENE GENE ( GENE ) and GENE protein level and decrease level of ENTITY2 protein with increase GENE protein"
"analysis further confirm increase GENE ENTITY1 GENE GENE GENE GENE ( GENE ) and ENTITY2 protein level and decrease level"
"analysis further confirm increase GENE ENTITY1 GENE GENE GENE GENE ( GENE ) and GENE protein level and decrease level of GENE protein with increase ENTITY2 protein expression ."
"] ) be inhibit by ENTITY1 in vivo and that ENTITY2 GENE activity be directly inhibit"
"] ( also know as ENTITY2 [ 5 ] ) be inhibit by ENTITY1 in vivo and that GENE"
"- induce activation of the ENTITY2 GENE [ 4 ] ( also know as GENE [ 5 ] ) be inhibit by ENTITY1 in vivo and that GENE"
"] ) be inhibit by ENTITY1 in vivo and that GENE ENTITY2 activity be directly inhibit by"
"induce activation of the GENE ENTITY2 [ 4 ] ( also know as GENE [ 5 ] ) be inhibit by ENTITY1 in vivo and that GENE"
"CHEMICAL in vivo and that ENTITY2 GENE activity be directly inhibit by ENTITY1 in vitro ."
"] ( also know as ENTITY2 [ 5 ] ) be inhibit by CHEMICAL in vivo and that GENE GENE activity be directly inhibit by ENTITY1 in vitro ."
"- induce activation of the ENTITY2 GENE [ 4 ] ( also know as GENE [ 5 ] ) be inhibit by CHEMICAL in vivo and that GENE GENE activity be directly inhibit by ENTITY1 in vitro ."
"in vivo and that GENE ENTITY2 activity be directly inhibit by ENTITY1 in vitro ."
"induce activation of the GENE ENTITY2 [ 4 ] ( also know as GENE [ 5 ] ) be inhibit by CHEMICAL in vivo and that GENE GENE activity be directly inhibit by ENTITY1 in vitro ."
"as ENTITY2 be elevate far more than any other gene , -PRON- observe that the CHEMICAL , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL and ENTITY1 , that bind GENE ,"
"CHEMICAL CHEMICAL CHEMICAL CHEMICAL and ENTITY1 , that bind ENTITY2 , promote CHEMICAL CHEMICAL -"
"CHEMICAL CHEMICAL CHEMICAL CHEMICAL and ENTITY1 , that bind GENE , promote CHEMICAL CHEMICAL - associate functional cell differentiation in ENTITY2 pc-3 cell , but not"
"as ENTITY2 be elevate far more than any other gene , -PRON- observe that the CHEMICAL , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL and CHEMICAL CHEMICAL CHEMICAL , that bind GENE , promote ENTITY1 - associate functional cell differentiation"
"CHEMICAL CHEMICAL , that bind ENTITY2 , promote ENTITY1 - associate functional cell differentiation"
"that bind GENE , promote ENTITY1 - associate functional cell differentiation in ENTITY2 pc-3 cell , but not"
"as ENTITY2 be elevate far more than any other gene , -PRON- observe that the ENTITY1 , CHEMICAL CHEMICAL CHEMICAL CHEMICAL"
", -PRON- observe that the ENTITY1 , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL and CHEMICAL CHEMICAL CHEMICAL , that bind ENTITY2 , promote CHEMICAL CHEMICAL -"
", -PRON- observe that the ENTITY1 , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL and CHEMICAL CHEMICAL CHEMICAL , that bind GENE , promote CHEMICAL CHEMICAL - associate functional cell differentiation in ENTITY2 pc-3 cell , but not"
"as ENTITY2 be elevate far more than any other gene , -PRON- observe that the CHEMICAL , ENTITY1 and CHEMICAL CHEMICAL CHEMICAL ,"
"observe that the CHEMICAL , ENTITY1 and CHEMICAL CHEMICAL CHEMICAL , that bind ENTITY2 , promote CHEMICAL CHEMICAL -"
"observe that the CHEMICAL , ENTITY1 and CHEMICAL CHEMICAL CHEMICAL , that bind GENE , promote CHEMICAL CHEMICAL - associate functional cell differentiation in ENTITY2 pc-3 cell , but not"
"ENTITY1 derive CHEMICAL as GENE / ENTITY2 inhibitor . 	"
"ENTITY1 derive CHEMICAL as ENTITY2 / GENE inhibitor . 	"
"CHEMICAL CHEMICAL derive ENTITY1 as GENE / ENTITY2 inhibitor . 	"
"CHEMICAL CHEMICAL derive ENTITY1 as ENTITY2 / GENE inhibitor . 	"
"line therapy for patient with ENTITY2 - positive or ENTITY1 GENE - positive metastatic breast"
"subsequent examination of the ENTITY1 GENE GENE GENE ) expression level demonstrate an absence of ENTITY2 in the neo control cell"
"subsequent examination of the ENTITY1 GENE GENE GENE ) expression level demonstrate an absence of GENE GENE GENE in the neo control cell and re - expression in the GENE express cell , consistent with previous finding where ENTITY2 be believe to play a"
"subsequent examination of the ENTITY1 GENE GENE GENE ) expression level demonstrate an absence of GENE GENE GENE in the neo control cell and re - expression in the ENTITY2 express cell , consistent with"
"subsequent examination of the ENTITY1 GENE ENTITY2 ) expression level demonstrate an"
"new series of ENTITY1 , CHEMICAL CHEMICAL , and CHEMICAL CHEMICAL ENTITY2 inhibitor ( mmpis ) be"
", CHEMICAL CHEMICAL , and ENTITY1 ENTITY2 inhibitor ( mmpis ) be"
"series of CHEMICAL CHEMICAL , ENTITY1 , and CHEMICAL CHEMICAL ENTITY2 inhibitor ( mmpis ) be"
"molecular determinant of ENTITY1 block of ENTITY2 GENE GENE . 	"
"molecular determinant of ENTITY1 block of GENE ENTITY2 . 	"
"commonly use endocrine therapy be ENTITY1 , CHEMICAL CHEMICAL , and ENTITY2 inhibitor ."
"endocrine therapy be CHEMICAL , ENTITY1 , and ENTITY2 inhibitor ."
"the use of ENTITY2 ( GENE ) twice in the conversion of ENTITY1 ( CHEMICAL ; 18:3n-3 )"
"of GENE GENE GENE ( ENTITY2 ) twice in the conversion of ENTITY1 ( CHEMICAL ; 18:3n-3 )"
"the use of ENTITY2 ( GENE ) twice in the conversion of CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ; 18:3n-3 ) to ENTITY1 ( CHEMICAL ; 22:6n-3 )"
"of GENE GENE GENE ( ENTITY2 ) twice in the conversion of CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ; 18:3n-3 ) to ENTITY1 ( CHEMICAL ; 22:6n-3 )"
"the use of ENTITY2 ( GENE ) twice in the conversion of CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ; 18:3n-3 ) to CHEMICAL CHEMICAL ( ENTITY1 ; 22:6n-3 ) suggest that"
"of GENE GENE GENE ( ENTITY2 ) twice in the conversion of CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ; 18:3n-3 ) to CHEMICAL CHEMICAL ( ENTITY1 ; 22:6n-3 ) suggest that"
"the use of ENTITY2 ( GENE ) twice in the conversion of CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ; 18:3n-3 ) to CHEMICAL CHEMICAL ( CHEMICAL ; 22:6n-3 ) suggest that this enzyme may play a key regulatory role in the synthesis and accumulation of ENTITY1 from CHEMICAL ."
"of GENE GENE GENE ( ENTITY2 ) twice in the conversion of CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ; 18:3n-3 ) to CHEMICAL CHEMICAL ( CHEMICAL ; 22:6n-3 ) suggest that this enzyme may play a key regulatory role in the synthesis and accumulation of ENTITY1 from CHEMICAL ."
"the use of ENTITY2 ( GENE ) twice in the conversion of CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ; 18:3n-3 ) to CHEMICAL"
"of GENE GENE GENE ( ENTITY2 ) twice in the conversion of CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ; 18:3n-3 ) to CHEMICAL"
"the use of ENTITY2 ( GENE ) twice in the conversion of CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ; 18:3n-3 ) to CHEMICAL CHEMICAL ( CHEMICAL ; 22:6n-3 ) suggest that this enzyme may play a key regulatory role in the synthesis and accumulation of CHEMICAL from ENTITY1 ."
"of GENE GENE GENE ( ENTITY2 ) twice in the conversion of CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ; 18:3n-3 ) to CHEMICAL CHEMICAL ( CHEMICAL ; 22:6n-3 ) suggest that this enzyme may play a key regulatory role in the synthesis and accumulation of CHEMICAL from ENTITY1 ."
"ENTITY1 be know to be an inhibitor of GENE , and recent datum have show this drug to antagonize ENTITY2 as well ."
"ENTITY1 be know to be an inhibitor of ENTITY2 , and recent datum have"
"ENTITY1 have no effect on ENTITY2 activity in pc-3 cell ,"
"ENTITY1 have no effect on GENE activity in pc-3 cell , whereas the short ENTITY2 variant be induce by CHEMICAL"
"CHEMICAL have no effect on ENTITY2 activity in pc-3 cell , whereas the short GENE variant be induce by ENTITY1 in pnt1a cell ."
"cell , whereas the short ENTITY2 variant be induce by ENTITY1 in pnt1a cell ."
"level of ENTITY1 anion ( CHEMICAL ) , reduce or oxidize CHEMICAL ( CHEMICAL or CHEMICAL ) , CHEMICAL CHEMICAL reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , ENTITY2 ( GENE GENE GENE )"
"level of ENTITY1 anion ( CHEMICAL ) , reduce or oxidize CHEMICAL ( CHEMICAL or CHEMICAL ) , CHEMICAL CHEMICAL reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , GENE GENE GENE GENE ( ENTITY2 ) , GENE GENE GENE"
"level of ENTITY1 anion ( CHEMICAL ) , reduce or oxidize CHEMICAL ( CHEMICAL or CHEMICAL ) , CHEMICAL CHEMICAL reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , GENE GENE GENE GENE ( GENE GENE GENE ) , GENE GENE GENE GENE GENE ( GENE GENE GENE GENE ) , ENTITY2 ( GENE GENE GENE GENE"
"level of ENTITY1 anion ( CHEMICAL ) , reduce or oxidize CHEMICAL ( CHEMICAL or CHEMICAL ) , CHEMICAL CHEMICAL reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , GENE GENE GENE GENE ( GENE GENE GENE ) , GENE GENE GENE GENE GENE ( GENE GENE GENE GENE ) , GENE GENE GENE GENE GENE ( ENTITY2 ) and mitochondrial membrane potential"
"level of ENTITY1 anion ( CHEMICAL ) , reduce or oxidize CHEMICAL ( CHEMICAL or CHEMICAL ) , CHEMICAL CHEMICAL reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , GENE GENE GENE GENE ( GENE GENE GENE ) , ENTITY2 ( GENE GENE GENE GENE"
"level of ENTITY1 anion ( CHEMICAL ) , reduce or oxidize CHEMICAL ( CHEMICAL or CHEMICAL ) , CHEMICAL CHEMICAL reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , GENE GENE GENE GENE ( GENE GENE GENE ) , GENE GENE GENE GENE GENE ( ENTITY2 ) , GENE GENE GENE"
"oxidize CHEMICAL ( CHEMICAL or ENTITY1 ) , CHEMICAL CHEMICAL reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , ENTITY2 ( GENE GENE GENE )"
"oxidize CHEMICAL ( CHEMICAL or ENTITY1 ) , CHEMICAL CHEMICAL reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , GENE GENE GENE GENE ( ENTITY2 ) , GENE GENE GENE"
"oxidize CHEMICAL ( CHEMICAL or ENTITY1 ) , CHEMICAL CHEMICAL reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , GENE GENE GENE GENE ( GENE GENE GENE ) , GENE GENE GENE GENE GENE ( GENE GENE GENE GENE ) , ENTITY2 ( GENE GENE GENE GENE"
"oxidize CHEMICAL ( CHEMICAL or ENTITY1 ) , CHEMICAL CHEMICAL reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , GENE GENE GENE GENE ( GENE GENE GENE ) , GENE GENE GENE GENE GENE ( GENE GENE GENE GENE ) , GENE GENE GENE GENE GENE ( ENTITY2 ) and mitochondrial membrane potential"
"oxidize CHEMICAL ( CHEMICAL or ENTITY1 ) , CHEMICAL CHEMICAL reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , GENE GENE GENE GENE ( GENE GENE GENE ) , ENTITY2 ( GENE GENE GENE GENE"
"oxidize CHEMICAL ( CHEMICAL or ENTITY1 ) , CHEMICAL CHEMICAL reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , GENE GENE GENE GENE ( GENE GENE GENE ) , GENE GENE GENE GENE GENE ( ENTITY2 ) , GENE GENE GENE"
"carbonyl ( pc ) , ENTITY1 , ENTITY2 ( GENE GENE GENE )"
"carbonyl ( pc ) , ENTITY1 , GENE GENE GENE GENE ( ENTITY2 ) , GENE GENE GENE"
"carbonyl ( pc ) , ENTITY1 , GENE GENE GENE GENE ( GENE GENE GENE ) , GENE GENE GENE GENE GENE ( GENE GENE GENE GENE ) , ENTITY2 ( GENE GENE GENE GENE"
"carbonyl ( pc ) , ENTITY1 , GENE GENE GENE GENE ( GENE GENE GENE ) , GENE GENE GENE GENE GENE ( GENE GENE GENE GENE ) , GENE GENE GENE GENE GENE ( ENTITY2 ) and mitochondrial membrane potential"
"carbonyl ( pc ) , ENTITY1 , GENE GENE GENE GENE ( GENE GENE GENE ) , ENTITY2 ( GENE GENE GENE GENE"
"carbonyl ( pc ) , ENTITY1 , GENE GENE GENE GENE ( GENE GENE GENE ) , GENE GENE GENE GENE GENE ( ENTITY2 ) , GENE GENE GENE"
") , reduce or oxidize ENTITY1 ( CHEMICAL or CHEMICAL ) , CHEMICAL CHEMICAL reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , ENTITY2 ( GENE GENE GENE )"
") , reduce or oxidize ENTITY1 ( CHEMICAL or CHEMICAL ) , CHEMICAL CHEMICAL reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , GENE GENE GENE GENE ( ENTITY2 ) , GENE GENE GENE"
") , reduce or oxidize ENTITY1 ( CHEMICAL or CHEMICAL ) , CHEMICAL CHEMICAL reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , GENE GENE GENE GENE ( GENE GENE GENE ) , GENE GENE GENE GENE GENE ( GENE GENE GENE GENE ) , ENTITY2 ( GENE GENE GENE GENE"
") , reduce or oxidize ENTITY1 ( CHEMICAL or CHEMICAL ) , CHEMICAL CHEMICAL reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , GENE GENE GENE GENE ( GENE GENE GENE ) , GENE GENE GENE GENE GENE ( GENE GENE GENE GENE ) , GENE GENE GENE GENE GENE ( ENTITY2 ) and mitochondrial membrane potential"
") , reduce or oxidize ENTITY1 ( CHEMICAL or CHEMICAL ) , CHEMICAL CHEMICAL reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , GENE GENE GENE GENE ( GENE GENE GENE ) , ENTITY2 ( GENE GENE GENE GENE"
") , reduce or oxidize ENTITY1 ( CHEMICAL or CHEMICAL ) , CHEMICAL CHEMICAL reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , GENE GENE GENE GENE ( GENE GENE GENE ) , GENE GENE GENE GENE GENE ( ENTITY2 ) , GENE GENE GENE"
"CHEMICAL or CHEMICAL ) , ENTITY1 reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , ENTITY2 ( GENE GENE GENE )"
"CHEMICAL or CHEMICAL ) , ENTITY1 reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , GENE GENE GENE GENE ( ENTITY2 ) , GENE GENE GENE"
"CHEMICAL or CHEMICAL ) , ENTITY1 reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , GENE GENE GENE GENE ( GENE GENE GENE ) , GENE GENE GENE GENE GENE ( GENE GENE GENE GENE ) , ENTITY2 ( GENE GENE GENE GENE"
"CHEMICAL or CHEMICAL ) , ENTITY1 reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , GENE GENE GENE GENE ( GENE GENE GENE ) , GENE GENE GENE GENE GENE ( GENE GENE GENE GENE ) , GENE GENE GENE GENE GENE ( ENTITY2 ) and mitochondrial membrane potential"
"CHEMICAL or CHEMICAL ) , ENTITY1 reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , GENE GENE GENE GENE ( GENE GENE GENE ) , ENTITY2 ( GENE GENE GENE GENE"
"CHEMICAL or CHEMICAL ) , ENTITY1 reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , GENE GENE GENE GENE ( GENE GENE GENE ) , GENE GENE GENE GENE GENE ( ENTITY2 ) , GENE GENE GENE"
"level of CHEMICAL anion ( ENTITY1 ) , reduce or oxidize CHEMICAL ( CHEMICAL or CHEMICAL ) , CHEMICAL CHEMICAL reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , ENTITY2 ( GENE GENE GENE )"
"level of CHEMICAL anion ( ENTITY1 ) , reduce or oxidize CHEMICAL ( CHEMICAL or CHEMICAL ) , CHEMICAL CHEMICAL reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , GENE GENE GENE GENE ( ENTITY2 ) , GENE GENE GENE"
"level of CHEMICAL anion ( ENTITY1 ) , reduce or oxidize CHEMICAL ( CHEMICAL or CHEMICAL ) , CHEMICAL CHEMICAL reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , GENE GENE GENE GENE ( GENE GENE GENE ) , GENE GENE GENE GENE GENE ( GENE GENE GENE GENE ) , ENTITY2 ( GENE GENE GENE GENE"
"level of CHEMICAL anion ( ENTITY1 ) , reduce or oxidize CHEMICAL ( CHEMICAL or CHEMICAL ) , CHEMICAL CHEMICAL reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , GENE GENE GENE GENE ( GENE GENE GENE ) , GENE GENE GENE GENE GENE ( GENE GENE GENE GENE ) , GENE GENE GENE GENE GENE ( ENTITY2 ) and mitochondrial membrane potential"
"level of CHEMICAL anion ( ENTITY1 ) , reduce or oxidize CHEMICAL ( CHEMICAL or CHEMICAL ) , CHEMICAL CHEMICAL reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , GENE GENE GENE GENE ( GENE GENE GENE ) , ENTITY2 ( GENE GENE GENE GENE"
"level of CHEMICAL anion ( ENTITY1 ) , reduce or oxidize CHEMICAL ( CHEMICAL or CHEMICAL ) , CHEMICAL CHEMICAL reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , GENE GENE GENE GENE ( GENE GENE GENE ) , GENE GENE GENE GENE GENE ( ENTITY2 ) , GENE GENE GENE"
"reduce or oxidize CHEMICAL ( ENTITY1 or CHEMICAL ) , CHEMICAL CHEMICAL reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , ENTITY2 ( GENE GENE GENE )"
"reduce or oxidize CHEMICAL ( ENTITY1 or CHEMICAL ) , CHEMICAL CHEMICAL reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , GENE GENE GENE GENE ( ENTITY2 ) , GENE GENE GENE"
"reduce or oxidize CHEMICAL ( ENTITY1 or CHEMICAL ) , CHEMICAL CHEMICAL reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , GENE GENE GENE GENE ( GENE GENE GENE ) , GENE GENE GENE GENE GENE ( GENE GENE GENE GENE ) , ENTITY2 ( GENE GENE GENE GENE"
"reduce or oxidize CHEMICAL ( ENTITY1 or CHEMICAL ) , CHEMICAL CHEMICAL reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , GENE GENE GENE GENE ( GENE GENE GENE ) , GENE GENE GENE GENE GENE ( GENE GENE GENE GENE ) , GENE GENE GENE GENE GENE ( ENTITY2 ) and mitochondrial membrane potential"
"reduce or oxidize CHEMICAL ( ENTITY1 or CHEMICAL ) , CHEMICAL CHEMICAL reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , GENE GENE GENE GENE ( GENE GENE GENE ) , ENTITY2 ( GENE GENE GENE GENE"
"reduce or oxidize CHEMICAL ( ENTITY1 or CHEMICAL ) , CHEMICAL CHEMICAL reactive substance ( tbars ) , protein carbonyl ( pc ) , CHEMICAL , GENE GENE GENE GENE ( GENE GENE GENE ) , GENE GENE GENE GENE GENE ( ENTITY2 ) , GENE GENE GENE"
"agonist and antagonist for the ENTITY2 and ENTITY1 GENE , GENE , GENE"
"antagonist for the GENE and ENTITY1 GENE , GENE , GENE and ENTITY2 : research tool and potential"
"antagonist for the GENE and ENTITY1 GENE , GENE , ENTITY2 and GENE GENE : research"
"antagonist for the GENE and ENTITY1 GENE , ENTITY2 , GENE and GENE GENE"
"antagonist for the GENE and ENTITY1 ENTITY2 , GENE , GENE and"
"chronic treatment with ENTITY1 reduce the level of ENTITY2 and fast plasma CHEMICAL ,"
"CHEMICAL reduce the level of ENTITY2 and fast plasma ENTITY1 , and improve the glycemic"
"CHEMICAL reduce the level of ENTITY2 and fast plasma CHEMICAL , and improve the glycemic response after ENTITY1 loading in zucker fatty rat"
", various CHEMICAL CHEMICAL ( ENTITY1 ) derivative be further conjugate with CHEMICAL CHEMICAL CHEMICAL and CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL and CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ) to study the structure and activity relationship as both antioxidant and ENTITY2 inhibitor ."
"here , various ENTITY1 ( CHEMICAL ) derivative be further conjugate with CHEMICAL CHEMICAL CHEMICAL and CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL and CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ) to study the structure and activity relationship as both antioxidant and ENTITY2 inhibitor ."
"with CHEMICAL CHEMICAL CHEMICAL and ENTITY1 ( CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL and CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ) to study the structure and activity relationship as both antioxidant and ENTITY2 inhibitor ."
"CHEMICAL CHEMICAL CHEMICAL CHEMICAL and ENTITY1 ) to study the structure and activity relationship as both antioxidant and ENTITY2 inhibitor ."
"and CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 and CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ) to study the structure and activity relationship as both antioxidant and ENTITY2 inhibitor ."
"derivative be further conjugate with ENTITY1 and CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL and CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ) to study the structure and activity relationship as both antioxidant and ENTITY2 inhibitor ."
"that in 5l cell the ENTITY2 gene may have get under the control of a promoter contain ENTITY1 GENE GENE ) lead to"
"control of a promoter contain ENTITY1 GENE GENE ) lead to the induction of ENTITY2 by CHEMICAL ."
"that in 5l cell the ENTITY2 gene may have get under the control of a promoter contain CHEMICAL GENE GENE ) lead to the induction of GENE by ENTITY1 ."
"lead to the induction of ENTITY2 by ENTITY1 ."
"high expression level of ENTITY2 ( GENE ) in cancer have be positively associate with the dna repair capacity and a poor prognosis in nsclc patient treat with ENTITY1 - contain chemotherapy ."
"GENE GENE GENE GENE ( ENTITY2 ) in cancer have be positively associate with the dna repair capacity and a poor prognosis in nsclc patient treat with ENTITY1 - contain chemotherapy ."
"both alone and together with ENTITY1 reuptake inhibitor , dopaminergic , adrenergic , and serotonergic transmission in the fcx via a complex pattern of action at GENE GENE , GENE , and ENTITY2 receptor ."
"both alone and together with ENTITY1 reuptake inhibitor , dopaminergic , adrenergic , and serotonergic transmission in the fcx via a complex pattern of action at GENE GENE , ENTITY2 , and GENE receptor ."
"both alone and together with ENTITY1 reuptake inhibitor , dopaminergic , adrenergic , and serotonergic transmission in the fcx via a complex pattern of action at ENTITY2 , GENE , and GENE"
"in conclusion , ENTITY1 modulate , both alone and together with CHEMICAL reuptake inhibitor , dopaminergic , adrenergic , and serotonergic transmission in the fcx via a complex pattern of action at GENE GENE , GENE , and ENTITY2 receptor ."
"in conclusion , ENTITY1 modulate , both alone and together with CHEMICAL reuptake inhibitor , dopaminergic , adrenergic , and serotonergic transmission in the fcx via a complex pattern of action at GENE GENE , ENTITY2 , and GENE receptor ."
"in conclusion , ENTITY1 modulate , both alone and together with CHEMICAL reuptake inhibitor , dopaminergic , adrenergic , and serotonergic transmission in the fcx via a complex pattern of action at ENTITY2 , GENE , and GENE"
"and western blotting demonstrate that ENTITY1 treatment reduce GENE and ENTITY2 expression in the retinas of"
"and western blotting demonstrate that ENTITY1 treatment reduce ENTITY2 and GENE expression in the"
"ovarian ENTITY2 be not influence by either treatment , and oviduct GENE be reduce after ENTITY1 - CHEMICAL combination ."
"either treatment , and oviduct ENTITY2 be reduce after ENTITY1 - CHEMICAL combination ."
"ovarian ENTITY2 be not influence by either treatment , and oviduct GENE be reduce after CHEMICAL - ENTITY1 combination ."
"either treatment , and oviduct ENTITY2 be reduce after CHEMICAL - ENTITY1 combination ."
"reduce level of GENE and ENTITY2 protein but no change in GENE level could be detect in mcf-7 cell after ENTITY1 3 g or 3n treatment"
", since reduce level of ENTITY2 and GENE protein but no change in GENE level could be detect in mcf-7 cell after ENTITY1 3 g or 3n treatment"
"protein but no change in ENTITY2 level could be detect in mcf-7 cell after ENTITY1 3 g or 3n treatment"
"reduce level of GENE and ENTITY2 protein but no change in GENE level could be detect in mcf-7 cell after CHEMICAL 3 g or 3n treatment -PRON- result suggest that ENTITY1 treat cell die from lethal"
", since reduce level of ENTITY2 and GENE protein but no change in GENE level could be detect in mcf-7 cell after CHEMICAL 3 g or 3n treatment -PRON- result suggest that ENTITY1 treat cell die from lethal"
"protein but no change in ENTITY2 level could be detect in mcf-7 cell after CHEMICAL 3 g or 3n treatment -PRON- result suggest that ENTITY1 treat cell die from lethal"
"of preneoplastic foci positive for ENTITY2 ( GENE GENE GENE ) be consistently high in these group than the sum of individual value in the group treat with CHEMICAL or ENTITY1 alone ."
"GENE GENE GENE GENE ( ENTITY2 ) be consistently high in these group than the sum of individual value in the group treat with CHEMICAL or ENTITY1 alone ."
"of preneoplastic foci positive for ENTITY2 ( GENE GENE GENE ) be consistently high in these group than the sum of individual value in the group treat with ENTITY1 or CHEMICAL alone ."
"GENE GENE GENE GENE ( ENTITY2 ) be consistently high in these group than the sum of individual value in the group treat with ENTITY1 or CHEMICAL alone ."
"the compound identify as ENTITY2 inhibitor can be divide into antioxidant , substrate - analogous , and a large miscellaneous group of inhibitor , where ENTITY1 be potent and more selective"
"group of inhibitor , where ENTITY1 be potent and more selective inhibitor of ENTITY2 ."
", the stereospecificity require at ENTITY2 appear to be retain at the GENE GENE , since ENTITY1 be inactive at both receptor"
"to be retain at the ENTITY2 , since ENTITY1 be inactive at both receptor"
"bind to the ENTITY2 ( GENE ) , which act as a transcription factor -PRON- , be increase as early as 30 min after exposure to of ENTITY1 and maintain up to 24"
"GENE GENE GENE GENE ( ENTITY2 ) , which act as a transcription factor -PRON- , be increase as early as 30 min after exposure to of ENTITY1 and maintain up to 24"
"min after exposure to of ENTITY1 and maintain up to 24 h. increase ENTITY2 binding precede increase GENE mrna"
"min after exposure to of ENTITY1 and maintain up to 24 h. increase GENE binding precede increase ENTITY2 mrna ."
"ENTITY1 be a ENTITY2 secretagogue that also enhance tissue"
"-PRON- explore the toxicity of ENTITY1 toward nscs focus on apoptosis and status of ENTITY2 survival signal ."
"in addition , derivative of ENTITY1 and CHEMICAL CHEMICAL efficiently inhibit ENTITY2 activity and reduced melanin content"
"derivative of CHEMICAL CHEMICAL and ENTITY1 efficiently inhibit ENTITY2 activity and reduced melanin content"
"candidate to be metabolize by ENTITY2 enzyme via in vivo and in vitro oxidation of ENTITY1 and CHEMICAL . 	"
"candidate to be metabolize by ENTITY2 enzyme via in vivo and in vitro oxidation of CHEMICAL and ENTITY1 . 	"
"CHEMICAL - desensitize cell , ENTITY1 and ENTITY2 each cause the expect down"
"CHEMICAL - desensitize cell , ENTITY1 and GENE each cause the expect down - regulation of ENTITY2 mrna ."
"in ENTITY1 - desensitize cell , CHEMICAL CHEMICAL and ENTITY2 each cause the expect down"
"in ENTITY1 - desensitize cell , CHEMICAL CHEMICAL and GENE each cause the expect down - regulation of ENTITY2 mrna ."
"enzyme in the metabolism of ENTITY1 in vitro and relate metabolism to change in ENTITY2 enzyme mrna expression via the"
"enzyme in the metabolism of ENTITY1 in vitro and relate metabolism to change in GENE enzyme mrna expression via the ENTITY2 in lung and liver cell"
"by evaluate the contribution of ENTITY2 , and GENE enzyme in the metabolism of ENTITY1 in vitro and relate metabolism"
"GENE GENE GENE , and ENTITY2 enzyme in the metabolism of ENTITY1 in vitro and relate metabolism"
"ENTITY2 inhibitors base on the ENTITY1 core . 	"
"intake of high CHEMICAL and ENTITY1 appear to increase expression of pbmc ENTITY2 and GENE gene , whilst"
"intake of high CHEMICAL and ENTITY1 appear to increase expression of pbmc GENE and GENE gene , whilst high CHEMICAL intake appear to decrease expression of pbmc ENTITY2 and GENE gene ."
"intake of high CHEMICAL and ENTITY1 appear to increase expression of pbmc GENE and ENTITY2 gene , whilst high CHEMICAL"
"intake of high CHEMICAL and ENTITY1 appear to increase expression of pbmc GENE and GENE gene , whilst high CHEMICAL intake appear to decrease expression of pbmc GENE and ENTITY2 gene ."
"conclusion : intake of high ENTITY1 and CHEMICAL appear to increase expression of pbmc ENTITY2 and GENE gene , whilst"
"conclusion : intake of high ENTITY1 and CHEMICAL appear to increase expression of pbmc GENE and GENE gene , whilst high CHEMICAL intake appear to decrease expression of pbmc ENTITY2 and GENE gene ."
"conclusion : intake of high ENTITY1 and CHEMICAL appear to increase expression of pbmc GENE and ENTITY2 gene , whilst high CHEMICAL"
"conclusion : intake of high ENTITY1 and CHEMICAL appear to increase expression of pbmc GENE and GENE gene , whilst high CHEMICAL intake appear to decrease expression of pbmc GENE and ENTITY2 gene ."
"to increase expression of pbmc ENTITY2 and GENE gene , whilst high ENTITY1 intake appear to decrease expression"
"GENE gene , whilst high ENTITY1 intake appear to decrease expression of pbmc ENTITY2 and GENE gene ."
"expression of pbmc GENE and ENTITY2 gene , whilst high ENTITY1 intake appear to decrease expression"
"GENE gene , whilst high ENTITY1 intake appear to decrease expression of pbmc GENE and ENTITY2 gene ."
"of note , ENTITY1 which be a close structural analogue of CHEMICAL with a potent ENTITY2 antagonistic activity do not exhibit"
"a close structural analogue of ENTITY1 with a potent ENTITY2 antagonistic activity do not exhibit"
"CHEMICAL CHEMICAL ( CHEMICAL , ENTITY1 ) be a novel , multitarget antifolate that inhibit CHEMICAL GENE , ENTITY2 , and GENE GENE GENE"
"CHEMICAL CHEMICAL ( CHEMICAL , ENTITY1 ) be a novel , multitarget antifolate that inhibit CHEMICAL GENE , GENE GENE , and ENTITY2 ."
", multitarget antifolate that inhibit ENTITY1 GENE , ENTITY2 , and GENE GENE GENE"
", multitarget antifolate that inhibit ENTITY1 GENE , GENE GENE , and ENTITY2 ."
"ENTITY1 ( CHEMICAL , CHEMICAL ) be a novel , multitarget antifolate that inhibit CHEMICAL GENE , ENTITY2 , and GENE GENE GENE"
"ENTITY1 ( CHEMICAL , CHEMICAL ) be a novel , multitarget antifolate that inhibit CHEMICAL GENE , GENE GENE , and ENTITY2 ."
"CHEMICAL CHEMICAL ( ENTITY1 , CHEMICAL ) be a novel , multitarget antifolate that inhibit CHEMICAL GENE , ENTITY2 , and GENE GENE GENE"
"CHEMICAL CHEMICAL ( ENTITY1 , CHEMICAL ) be a novel , multitarget antifolate that inhibit CHEMICAL GENE , GENE GENE , and ENTITY2 ."
"ENTITY2 regulation of spinal ENTITY1 release . 	"
"the induction of ENTITY2 protein be dependent on a functional GENE GENE GENE and be precede by a rapid increase in the level of GENE mrna indicate that GENE be a previously unknown transcriptional target of ENTITY1 in 5l cell ."
"increase in the level of ENTITY2 mrna indicate that GENE be a previously unknown transcriptional target of ENTITY1 in 5l cell ."
"of GENE mrna indicate that ENTITY2 be a previously unknown transcriptional target of ENTITY1 in 5l cell ."
"be dependent on a functional ENTITY2 and be precede by a rapid increase in the level of GENE mrna indicate that GENE be a previously unknown transcriptional target of ENTITY1 in 5l cell ."
"these datum suggest that ENTITY1 have a dual effect on tissue response to CHEMICAL - produce potentiation by blockade of GENE and concomitant antagonism by blockade of ENTITY2 ."
"these datum suggest that ENTITY1 have a dual effect on tissue response to CHEMICAL - produce potentiation by blockade of ENTITY2 and concomitant antagonism by blockade"
"effect on tissue response to ENTITY1 - produce potentiation by blockade of GENE and concomitant antagonism by blockade of ENTITY2 ."
"effect on tissue response to ENTITY1 - produce potentiation by blockade of ENTITY2 and concomitant antagonism by blockade"
"positron emission tomography study of ENTITY1 in schizophrenia : a preliminary finding of an antipsychotic effect with only transiently high ENTITY2 occupancy . 	"
"compound be evaluate for -PRON- ENTITY2 ( GENE ) inhibitory activity and ENTITY1 be find to be the"
"evaluate for -PRON- GENE ( ENTITY2 ) inhibitory activity and ENTITY1 be find to be the"
"GENE ) inhibitory activity and ENTITY1 be find to be the most potent against ENTITY2 with ic50 4.16 μmol /"
"this study test whether ENTITY2 agonist stimulate spinal release of the neurotransmitter ENTITY1 either by direct action on"
"this study test whether ENTITY2 agonist stimulate spinal release of the neurotransmitter CHEMICAL either by direct action on noradrenergic terminal or indirectly by stimulate release of other neurotransmitter to induce ENTITY1 release ."
"ENTITY1 in multiple myeloma . 	 CHEMICAL CHEMICAL remove from widespread clinical use by 1962 because of severe teratogenicity -- have anti - angiogenic and immunomodulatory effect , include the inhibition of ENTITY2 ."
"blood neutrophil count , serum ENTITY2 , and other marker of inflammation correspond to ENTITY1 exposure and toxicity and thus"
"ENTITY1 function as a result of -PRON- bind to GENE GENE , with a ki of approximately 9.0 mm , thereby render GENE GENE a less effective substrate for two - chain rec - ENTITY2 ."
"ENTITY1 function as a result of -PRON- bind to ENTITY2 , with a ki of"
"ENTITY1 function as a result of -PRON- bind to GENE GENE , with a ki of approximately 9.0 mm , thereby render ENTITY2 a less effective substrate for"
"optimization of a ENTITY1 series of ENTITY2 assembly inhibitor 2 : structure"
"- CHEMICAL model system and ENTITY2 ENTITY1 ( GENE - c )"
"and GENE GENE GENE GENE ENTITY1 ( ENTITY2 - c ) oxidation assay"
"physiochemical and biological property of ENTITY1 , successfully synthesize chemoenzymatically in -PRON- lab , -PRON- antioxidant activity be evaluate use three different in vitro model system , namely bulk oil model system , CHEMICAL - CHEMICAL model system and ENTITY2 CHEMICAL ( GENE - c"
"physiochemical and biological property of ENTITY1 , successfully synthesize chemoenzymatically in -PRON- lab , -PRON- antioxidant activity be evaluate use three different in vitro model system , namely bulk oil model system , CHEMICAL - CHEMICAL model system and GENE GENE GENE GENE CHEMICAL ( ENTITY2 - c ) oxidation assay"
"bulk oil model system , ENTITY1 - CHEMICAL model system and ENTITY2 CHEMICAL ( GENE - c"
"bulk oil model system , ENTITY1 - CHEMICAL model system and GENE GENE GENE GENE CHEMICAL ( ENTITY2 - c ) oxidation assay"
"model system , CHEMICAL - ENTITY1 model system and ENTITY2 CHEMICAL ( GENE - c"
"model system , CHEMICAL - ENTITY1 model system and GENE GENE GENE GENE CHEMICAL ( ENTITY2 - c ) oxidation assay"
"preferential GENE GENE antagonist , ENTITY1 , and the preferential ENTITY2 antagonist , CHEMICAL , do"
"in distinction , the preferential ENTITY2 antagonist , ENTITY1 , and the preferential GENE"
"CHEMICAL , and the preferential ENTITY2 antagonist , CHEMICAL , do not increase basal level of ENTITY1 , CHEMICAL , or CHEMICAL"
"in distinction , the preferential ENTITY2 antagonist , CHEMICAL , and the preferential GENE GENE antagonist , CHEMICAL , do not increase basal level of ENTITY1 , CHEMICAL , or CHEMICAL"
"CHEMICAL , and the preferential ENTITY2 antagonist , ENTITY1 , do not increase basal"
"in distinction , the preferential ENTITY2 antagonist , CHEMICAL , and the preferential GENE GENE antagonist , ENTITY1 , do not increase basal"
"CHEMICAL , and the preferential ENTITY2 antagonist , CHEMICAL , do not increase basal level of CHEMICAL , CHEMICAL , or ENTITY1 ."
"in distinction , the preferential ENTITY2 antagonist , CHEMICAL , and the preferential GENE GENE antagonist , CHEMICAL , do not increase basal level of CHEMICAL , CHEMICAL , or ENTITY1 ."
"CHEMICAL , and the preferential ENTITY2 antagonist , CHEMICAL , do not increase basal level of CHEMICAL , ENTITY1 , or CHEMICAL ."
"in distinction , the preferential ENTITY2 antagonist , CHEMICAL , and the preferential GENE GENE antagonist , CHEMICAL , do not increase basal level of CHEMICAL , ENTITY1 , or CHEMICAL ."
"the ENTITY2 inhibitor CHEMICAL CHEMICAL prolong the normally transient effect of ENTITY1 for at least 24 h."
"the normally transient effect of ENTITY1 for at least 24 h. -PRON- conclude that GENE GENE GENE exert two oppose effect on ENTITY2 mrna level , 1 )"
"the normally transient effect of ENTITY1 for at least 24 h. -PRON- conclude that GENE GENE GENE exert two oppose effect on GENE GENE GENE mrna level , 1 ) a decrease in the stability of the mrna that require the sustain phosphorylation of a GENE GENE GENE substrate and 2 ) a permissive effect on ENTITY2 gene transcription . 
"
"the normally transient effect of ENTITY1 for at least 24 h. -PRON- conclude that ENTITY2 exert two oppose effect on"
"the normally transient effect of ENTITY1 for at least 24 h. -PRON- conclude that GENE GENE GENE exert two oppose effect on GENE GENE GENE mrna level , 1 ) a decrease in the stability of the mrna that require the sustain phosphorylation of a ENTITY2 substrate and 2 ) a"
"the ENTITY2 inhibitor ENTITY1 prolong the normally transient effect"
"the GENE GENE inhibitor ENTITY1 prolong the normally transient effect of CHEMICAL for at least 24 h. -PRON- conclude that GENE GENE GENE exert two oppose effect on ENTITY2 mrna level , 1 )"
"the GENE GENE inhibitor ENTITY1 prolong the normally transient effect of CHEMICAL for at least 24 h. -PRON- conclude that GENE GENE GENE exert two oppose effect on GENE GENE GENE mrna level , 1 ) a decrease in the stability of the mrna that require the sustain phosphorylation of a GENE GENE GENE substrate and 2 ) a permissive effect on ENTITY2 gene transcription . 
"
"the GENE GENE inhibitor ENTITY1 prolong the normally transient effect of CHEMICAL for at least 24 h. -PRON- conclude that ENTITY2 exert two oppose effect on"
"the GENE GENE inhibitor ENTITY1 prolong the normally transient effect of CHEMICAL for at least 24 h. -PRON- conclude that GENE GENE GENE exert two oppose effect on GENE GENE GENE mrna level , 1 ) a decrease in the stability of the mrna that require the sustain phosphorylation of a ENTITY2 substrate and 2 ) a"
"phα1β toxin prevent ENTITY1 - induce nociceptive behavior and mechanical hypersensitivity without act on ENTITY2 channel . 	"
"GENE agonist CHEMICAL , or ENTITY1 plus ENTITY2 antagonist and CHEMICAL measure in"
"contain nicotine , the specific ENTITY2 agonist CHEMICAL , or ENTITY1 plus GENE antagonist and CHEMICAL"
"GENE GENE GENE GENE agonist ENTITY1 , or CHEMICAL plus ENTITY2 antagonist and CHEMICAL measure in"
"contain nicotine , the specific ENTITY2 agonist ENTITY1 , or CHEMICAL plus GENE"
"CHEMICAL , or CHEMICAL plus ENTITY2 antagonist and ENTITY1 measure in the microdialysate ."
"contain nicotine , the specific ENTITY2 agonist CHEMICAL , or CHEMICAL plus GENE antagonist and ENTITY1 measure in the microdialysate ."
"autophagy , and activation of ENTITY1 GENE GENE GENE GENE ( ENTITY2 ) restore cardiac autophagy and"
"the effect of specific ENTITY1 GENE antagonist and ENTITY2 inhibitor be also examine ."
"GENE on the interaction between ENTITY2 and GENE , a switch between autophagy and apoptosis , in diabetic mouse and high ENTITY1 - treat h9c2 cardiac myoblast"
"the interaction between GENE and ENTITY2 , a switch between autophagy and apoptosis , in diabetic mouse and high ENTITY1 - treat h9c2 cardiac myoblast"
"-PRON- hypothesize that ENTITY2 - induce autophagy ameliorate diabetic cardiomyopathy by inhibit cardiomyocyte apoptosis and examine the effect of GENE on the interaction between GENE and GENE , a switch between autophagy and apoptosis , in diabetic mouse and high ENTITY1 - treat h9c2 cardiac myoblast"
"and examine the effect of ENTITY2 on the interaction between GENE and GENE , a switch between autophagy and apoptosis , in diabetic mouse and high ENTITY1 - treat h9c2 cardiac myoblast"
"by nicotinic antagonist but not ENTITY1 antagonist or ENTITY2 inhibitor ."
"result : both ENTITY1 and CHEMICAL induce CHEMICAL release in spinal microdialsyate , an effect reduce by nicotinic antagonist but not CHEMICAL antagonist or ENTITY2 inhibitor ."
"result : both CHEMICAL and ENTITY1 induce CHEMICAL release in spinal microdialsyate , an effect reduce by nicotinic antagonist but not CHEMICAL antagonist or ENTITY2 inhibitor ."
"both CHEMICAL and CHEMICAL induce ENTITY1 release in spinal microdialsyate , an effect reduce by nicotinic antagonist but not CHEMICAL antagonist or ENTITY2 inhibitor ."
"concentration of these compound block ENTITY1 - induce growth of mcf-7 cell , but ENTITY2 ( GENE ) interaction do"
"concentration of these compound block ENTITY1 - induce growth of mcf-7 cell , but GENE GENE ( ENTITY2 ) interaction do not seem"
", and the effect of ENTITY1 be block at low concentration of GENE than GENE ENTITY2 antagonist ."
"of the nicotinic agonist stimulate ENTITY1 release in synaptosome , and the effect of CHEMICAL be block at low concentration of GENE than GENE ENTITY2 antagonist ."
"ENTITY1 GENE GENE activation lead to an up - regulation of GENE GENE GENE GENE GENE GENE GENE via GENE induction of ENTITY2 . 	"
"ENTITY1 GENE GENE activation lead to an up - regulation of ENTITY2 via GENE induction of GENE"
"ENTITY1 GENE be not an enzyme of the ENTITY2 type , thereby avoid potential"
"inhibition of binding of both ENTITY2 and GENE to GENE by CHEMICAL be similar , although ENTITY1 inhibit the binding of GENE"
"CHEMICAL be similar , although ENTITY1 inhibit the binding of GENE to GENE slightly more than the bind of ENTITY2 to GENE ."
"binding of both GENE and ENTITY2 to GENE by CHEMICAL be similar , although ENTITY1 inhibit the binding of GENE"
"CHEMICAL be similar , although ENTITY1 inhibit the binding of ENTITY2 to GENE slightly more than"
"both GENE and GENE to ENTITY2 by CHEMICAL be similar , although ENTITY1 inhibit the binding of GENE"
"CHEMICAL be similar , although ENTITY1 inhibit the binding of GENE to ENTITY2 slightly more than the bind"
"CHEMICAL be similar , although ENTITY1 inhibit the binding of GENE to GENE slightly more than the bind of GENE to ENTITY2 ."
"inhibition of binding of both ENTITY2 and GENE to GENE by ENTITY1 be similar , although CHEMICAL"
"and GENE to GENE by ENTITY1 be similar , although CHEMICAL inhibit the binding of GENE to GENE slightly more than the bind of ENTITY2 to GENE ."
"binding of both GENE and ENTITY2 to GENE by ENTITY1 be similar , although CHEMICAL"
"and GENE to GENE by ENTITY1 be similar , although CHEMICAL inhibit the binding of ENTITY2 to GENE slightly more than"
"both GENE and GENE to ENTITY2 by ENTITY1 be similar , although CHEMICAL"
"and GENE to GENE by ENTITY1 be similar , although CHEMICAL inhibit the binding of GENE to ENTITY2 slightly more than the bind"
"and GENE to GENE by ENTITY1 be similar , although CHEMICAL inhibit the binding of GENE to GENE slightly more than the bind of GENE to ENTITY2 ."
"suggest that oral consumption of ENTITY1 enhance the efficacy of ENTITY2 ."
"-PRON- identify one compound , ENTITY1 CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL , that activate the isr and dose - dependently increased level of ENTITY2 in transform cell ."
"identify one compound , CHEMICAL ENTITY1 , that activate the isr and dose - dependently increased level of ENTITY2 in transform cell ."
"be also a substrate for ENTITY2 , and study suggest that a metabolite form by the action of this enzyme on CHEMICAL may be responsible for the increase in ENTITY1 observe ."
"ENTITY1 be also a substrate for ENTITY2 , and study suggest that"
"be also a substrate for ENTITY2 , and study suggest that a metabolite form by the action of this enzyme on ENTITY1 may be responsible for the"
"in vascular permeability induce by ENTITY1 in the rat airway be mediate predominantly by ENTITY2 stimulation ."
"evaluate the interaction with the ENTITY2 inhibitor ENTITY1 ( 400   mg q.d"
"evaluate the interaction with the ENTITY2 inhibitor CHEMICAL ( 400   mg q.d . ) after nanogram and regular dos of ENTITY1 ."
"GENE and ENTITY2 metabolize ENTITY1 via hydroxylation ( [ m4"
"ENTITY2 and GENE metabolize ENTITY1 via hydroxylation ( [ m4"
"GENE and GENE metabolize ENTITY1 via hydroxylation ( [ m4 ] and [ m6 ] ) and dehydrogenation ( [ m5 ] ) at similar rate ; ENTITY2 do not metabolize CHEMICAL ."
"GENE and ENTITY2 metabolize CHEMICAL via hydroxylation ( [ m4 ] and [ m6 ] ) and dehydrogenation ( [ m5 ] ) at similar rate ; GENE do not metabolize ENTITY1 ."
"ENTITY2 and GENE metabolize CHEMICAL via hydroxylation ( [ m4 ] and [ m6 ] ) and dehydrogenation ( [ m5 ] ) at similar rate ; GENE do not metabolize ENTITY1 ."
") at similar rate ; ENTITY2 do not metabolize ENTITY1 ."
"ENTITY1 fail to dilate the artery from the ENTITY2 knockout mouse , underscore GENE"
"dilate the artery from the ENTITY2 knockout mouse , underscore GENE GENE GENE role in ENTITY1 action ."
"these finding , CHEMICAL and ENTITY1 have additive or synergistic effect on cell proliferation induction within the preneoplastic foci and ENTITY2 induction , which may lead"
"within the preneoplastic foci and ENTITY2 induction , which may lead to more efficient metabolic activation of CHEMICAL and ENTITY1 ."
"consistent with these finding , ENTITY1 and CHEMICAL have additive or synergistic effect on cell proliferation induction within the preneoplastic foci and ENTITY2 induction , which may lead"
"within the preneoplastic foci and ENTITY2 induction , which may lead to more efficient metabolic activation of ENTITY1 and CHEMICAL ."
"form by the action of ENTITY2 on ENTITY1 may be responsible for the"
"the action of GENE on ENTITY1 may be responsible for the elevation in brain CHEMICAL observe , animal be pretreat with vehicle or the ENTITY2 inhibitor CHEMICAL ( CHEMICAL )"
"form by the action of ENTITY2 on CHEMICAL may be responsible for the elevation in brain CHEMICAL observe , animal be pretreat with vehicle or the GENE inhibitor CHEMICAL ( CHEMICAL ) before vehicle or ENTITY1 ( 15 mg / kg"
"pretreat with vehicle or the ENTITY2 inhibitor CHEMICAL ( CHEMICAL ) before vehicle or ENTITY1 ( 15 mg / kg"
"form by the action of ENTITY2 on CHEMICAL may be responsible for the elevation in brain ENTITY1 observe , animal be pretreat"
"for the elevation in brain ENTITY1 observe , animal be pretreat with vehicle or the ENTITY2 inhibitor CHEMICAL ( CHEMICAL )"
"form by the action of ENTITY2 on CHEMICAL may be responsible for the elevation in brain CHEMICAL observe , animal be pretreat with vehicle or the GENE inhibitor CHEMICAL ( ENTITY1 ) before vehicle or CHEMICAL"
"pretreat with vehicle or the ENTITY2 inhibitor CHEMICAL ( ENTITY1 ) before vehicle or CHEMICAL"
"form by the action of ENTITY2 on CHEMICAL may be responsible for the elevation in brain CHEMICAL observe , animal be pretreat with vehicle or the GENE inhibitor ENTITY1 ( CHEMICAL ) before vehicle"
"pretreat with vehicle or the ENTITY2 inhibitor ENTITY1 ( CHEMICAL ) before vehicle"
", suggest , as with ENTITY1 , that a metabolite of CHEMICAL form by the action of ENTITY2 be responsible for the elevation"
"time - dependently increase in ENTITY1 - treat animal , with level reach approximately 650% of control at 6 and 12 h. pretreatment with CHEMICAL completely abolish the CHEMICAL - induce increase in brain CHEMICAL , suggest , as with CHEMICAL , that a metabolite of CHEMICAL form by the action of ENTITY2 be responsible for the elevation"
"with CHEMICAL completely abolish the ENTITY1 - induce increase in brain CHEMICAL , suggest , as with CHEMICAL , that a metabolite of CHEMICAL form by the action of ENTITY2 be responsible for the elevation"
", that a metabolite of ENTITY1 form by the action of ENTITY2 be responsible for the elevation"
"ENTITY1 level ( measure by an hplc procedure ) be dose- and time - dependently increase in CHEMICAL - treat animal , with level reach approximately 650% of control at 6 and 12 h. pretreatment with CHEMICAL completely abolish the CHEMICAL - induce increase in brain CHEMICAL , suggest , as with CHEMICAL , that a metabolite of CHEMICAL form by the action of ENTITY2 be responsible for the elevation"
"- induce increase in brain ENTITY1 , suggest , as with CHEMICAL , that a metabolite of CHEMICAL form by the action of ENTITY2 be responsible for the elevation"
"form by the action of ENTITY2 be responsible for the elevation of brain ENTITY1 observe ."
"and 12 h. pretreatment with ENTITY1 completely abolish the CHEMICAL - induce increase in brain CHEMICAL , suggest , as with CHEMICAL , that a metabolite of CHEMICAL form by the action of ENTITY2 be responsible for the elevation"
", GENE GENE GENE and ENTITY2 suggest that ENTITY1 activate GENE expression of GENE"
"GENE and GENE suggest that ENTITY1 activate GENE expression of GENE GENE GENE and ENTITY2 and , in turn ,"
"GENE and GENE suggest that ENTITY1 activate GENE expression of GENE GENE GENE and GENE and , in turn , the activation of ENTITY2 by GENE GENE GENE -"
"expression kinetic of GENE , ENTITY2 and GENE suggest that ENTITY1 activate GENE expression of GENE"
"GENE and GENE suggest that ENTITY1 activate GENE expression of ENTITY2 and GENE and , in"
"GENE and GENE suggest that ENTITY1 activate GENE expression of GENE GENE GENE and GENE and , in turn , the activation of GENE by ENTITY2 - induce GENE expression ."
"GENE and GENE suggest that ENTITY1 activate GENE expression of GENE GENE GENE and GENE and , in turn , the activation of GENE by GENE GENE GENE - induce ENTITY2 expression ."
"the expression kinetic of ENTITY2 , GENE GENE GENE and GENE suggest that ENTITY1 activate GENE expression of GENE"
"-PRON- finding indicate that ENTITY1 protect oocyte from CHEMICAL - induce cell death by inhibit ENTITY2 GENE , which would otherwise"
"-PRON- finding indicate that ENTITY1 protect oocyte from CHEMICAL - induce cell death by inhibit GENE GENE GENE ENTITY2 , which would otherwise activate"
"that CHEMICAL protect oocyte from ENTITY1 - induce cell death by inhibit ENTITY2 GENE , which would otherwise"
"that CHEMICAL protect oocyte from ENTITY1 - induce cell death by inhibit GENE GENE GENE ENTITY2 , which would otherwise activate"
"therapeutic implication , a selective ENTITY2 inhibitor , ENTITY1 , be test on three"
"a selective GENE inhibitor , ENTITY1 , be test on three variant of ht-29 colon cancer cell line , ht-29/inv1 , ht-29/inv2 and ht-29/inv3 , with grade increase of in vitro matrigel invasive potential and ENTITY2 expression level ."
"a nanogram dose of the ENTITY2 probe substrate ENTITY1 to evaluate drug interactions ."
"today , -PRON- use ENTITY1 , a hypoxia mimetic that inhibit proteasomal ENTITY2 degradation and generate reactive CHEMICAL"
"hypoxia mimetic that inhibit proteasomal ENTITY2 degradation and generate reactive ENTITY1 specie ( ros ) ."
"potency of a series of ENTITY1 inhibitor of GENE GENE ( ENTITY2 ) assembly be describe ."
"potency of a series of ENTITY1 inhibitor of ENTITY2 ( GENE ) assembly be"
"ENTITY1 interact with a common bind site to elicit opposite effect on inactivation gating of GENE and GENE ENTITY2 . 	"
"ENTITY1 interact with a common bind site to elicit opposite effect on inactivation gating of ENTITY2 and GENE GENE GENE ."
"ENTITY1 interact with a common bind site to elicit opposite effect on inactivation gating of GENE and ENTITY2 GENE GENE . 	"
"administration of the GENE antagonist ENTITY1 ; and ( vi ) may or may not be a direct cardiac effect , inasmuch as datum for in vivo effect on ENTITY2 formation by cardiac fibroblast be"
"plasma or tissue GENE - ENTITY2 system , as fibrosis be largely unaffect by concurrent administration of CHEMICAL or CHEMICAL ; ( iii ) be independent of cardiac hypertrophy , in that -PRON- be equally see in right and leave ventricle , and in rat render hypertensive without cardiac hypertrophy by the administration of CHEMICAL CHEMICAL CHEMICAL CHEMICAL ; ( iv ) be independent of elevated blood pressure , in that -PRON- be find in normotensive animal infuse peripherally with CHEMICAL and intracerebroventricularly with the GENE GENE ( GENE ) antagonist CHEMICAL ; ( v ) be via classical GENE , in that -PRON- be block by concurrent administration of the GENE antagonist ENTITY1 ; and ( vi )"
"CHEMICAL and intracerebroventricularly with the ENTITY2 ( GENE ) antagonist CHEMICAL ; ( v ) be via classical GENE , in that -PRON- be block by concurrent administration of the GENE antagonist ENTITY1 ; and ( vi )"
"with the GENE GENE ( ENTITY2 ) antagonist CHEMICAL ; ( v ) be via classical GENE , in that -PRON- be block by concurrent administration of the GENE antagonist ENTITY1 ; and ( vi )"
"v ) be via classical ENTITY2 , in that -PRON- be block by concurrent administration of the GENE antagonist ENTITY1 ; and ( vi )"
"by concurrent administration of the ENTITY2 antagonist ENTITY1 ; and ( vi )"
"involve the plasma or tissue ENTITY2 - GENE system , as fibrosis be largely unaffect by concurrent administration of CHEMICAL or CHEMICAL ; ( iii ) be independent of cardiac hypertrophy , in that -PRON- be equally see in right and leave ventricle , and in rat render hypertensive without cardiac hypertrophy by the administration of CHEMICAL CHEMICAL CHEMICAL CHEMICAL ; ( iv ) be independent of elevated blood pressure , in that -PRON- be find in normotensive animal infuse peripherally with CHEMICAL and intracerebroventricularly with the GENE GENE ( GENE ) antagonist CHEMICAL ; ( v ) be via classical GENE , in that -PRON- be block by concurrent administration of the GENE antagonist ENTITY1 ; and ( vi )"
"GENE ( GENE ) antagonist ENTITY1 ; ( v ) be via classical GENE , in that -PRON- be block by concurrent administration of the GENE antagonist CHEMICAL CHEMICAL ; and ( vi ) may or may not be a direct cardiac effect , inasmuch as datum for in vivo effect on ENTITY2 formation by cardiac fibroblast be"
"plasma or tissue GENE - ENTITY2 system , as fibrosis be largely unaffect by concurrent administration of CHEMICAL or CHEMICAL ; ( iii ) be independent of cardiac hypertrophy , in that -PRON- be equally see in right and leave ventricle , and in rat render hypertensive without cardiac hypertrophy by the administration of CHEMICAL CHEMICAL CHEMICAL CHEMICAL ; ( iv ) be independent of elevated blood pressure , in that -PRON- be find in normotensive animal infuse peripherally with CHEMICAL and intracerebroventricularly with the GENE GENE ( GENE ) antagonist ENTITY1 ; ( v ) be"
"CHEMICAL and intracerebroventricularly with the ENTITY2 ( GENE ) antagonist ENTITY1 ; ( v ) be"
"with the GENE GENE ( ENTITY2 ) antagonist ENTITY1 ; ( v ) be"
"GENE ( GENE ) antagonist ENTITY1 ; ( v ) be via classical ENTITY2 , in that -PRON- be"
"GENE ( GENE ) antagonist ENTITY1 ; ( v ) be via classical GENE , in that -PRON- be block by concurrent administration of the ENTITY2 antagonist CHEMICAL CHEMICAL ; and"
"involve the plasma or tissue ENTITY2 - GENE system , as fibrosis be largely unaffect by concurrent administration of CHEMICAL or CHEMICAL ; ( iii ) be independent of cardiac hypertrophy , in that -PRON- be equally see in right and leave ventricle , and in rat render hypertensive without cardiac hypertrophy by the administration of CHEMICAL CHEMICAL CHEMICAL CHEMICAL ; ( iv ) be independent of elevated blood pressure , in that -PRON- be find in normotensive animal infuse peripherally with CHEMICAL and intracerebroventricularly with the GENE GENE ( GENE ) antagonist ENTITY1 ; ( v ) be"
"concurrent administration of CHEMICAL or ENTITY1 ; ( iii ) be independent of cardiac hypertrophy , in that -PRON- be equally see in right and leave ventricle , and in rat render hypertensive without cardiac hypertrophy by the administration of CHEMICAL CHEMICAL CHEMICAL CHEMICAL ; ( iv ) be independent of elevated blood pressure , in that -PRON- be find in normotensive animal infuse peripherally with CHEMICAL and intracerebroventricularly with the GENE GENE ( GENE ) antagonist CHEMICAL ; ( v ) be via classical GENE , in that -PRON- be block by concurrent administration of the GENE antagonist CHEMICAL CHEMICAL ; and ( vi ) may or may not be a direct cardiac effect , inasmuch as datum for in vivo effect on ENTITY2 formation by cardiac fibroblast be"
"plasma or tissue GENE - ENTITY2 system , as fibrosis be largely unaffect by concurrent administration of CHEMICAL or ENTITY1 ; ( iii ) be"
"concurrent administration of CHEMICAL or ENTITY1 ; ( iii ) be independent of cardiac hypertrophy , in that -PRON- be equally see in right and leave ventricle , and in rat render hypertensive without cardiac hypertrophy by the administration of CHEMICAL CHEMICAL CHEMICAL CHEMICAL ; ( iv ) be independent of elevated blood pressure , in that -PRON- be find in normotensive animal infuse peripherally with CHEMICAL and intracerebroventricularly with the ENTITY2 ( GENE ) antagonist CHEMICAL"
"concurrent administration of CHEMICAL or ENTITY1 ; ( iii ) be independent of cardiac hypertrophy , in that -PRON- be equally see in right and leave ventricle , and in rat render hypertensive without cardiac hypertrophy by the administration of CHEMICAL CHEMICAL CHEMICAL CHEMICAL ; ( iv ) be independent of elevated blood pressure , in that -PRON- be find in normotensive animal infuse peripherally with CHEMICAL and intracerebroventricularly with the GENE GENE ( ENTITY2 ) antagonist CHEMICAL ; ("
"concurrent administration of CHEMICAL or ENTITY1 ; ( iii ) be independent of cardiac hypertrophy , in that -PRON- be equally see in right and leave ventricle , and in rat render hypertensive without cardiac hypertrophy by the administration of CHEMICAL CHEMICAL CHEMICAL CHEMICAL ; ( iv ) be independent of elevated blood pressure , in that -PRON- be find in normotensive animal infuse peripherally with CHEMICAL and intracerebroventricularly with the GENE GENE ( GENE ) antagonist CHEMICAL ; ( v ) be via classical ENTITY2 , in that -PRON- be"
"concurrent administration of CHEMICAL or ENTITY1 ; ( iii ) be independent of cardiac hypertrophy , in that -PRON- be equally see in right and leave ventricle , and in rat render hypertensive without cardiac hypertrophy by the administration of CHEMICAL CHEMICAL CHEMICAL CHEMICAL ; ( iv ) be independent of elevated blood pressure , in that -PRON- be find in normotensive animal infuse peripherally with CHEMICAL and intracerebroventricularly with the GENE GENE ( GENE ) antagonist CHEMICAL ; ( v ) be via classical GENE , in that -PRON- be block by concurrent administration of the ENTITY2 antagonist CHEMICAL CHEMICAL ; and"
"involve the plasma or tissue ENTITY2 - GENE system , as fibrosis be largely unaffect by concurrent administration of CHEMICAL or ENTITY1 ; ( iii ) be"
"hypertrophy by the administration of ENTITY1 ; ( iv ) be independent of elevated blood pressure , in that -PRON- be find in normotensive animal infuse peripherally with CHEMICAL and intracerebroventricularly with the GENE GENE ( GENE ) antagonist CHEMICAL ; ( v ) be via classical GENE , in that -PRON- be block by concurrent administration of the GENE antagonist CHEMICAL CHEMICAL ; and ( vi ) may or may not be a direct cardiac effect , inasmuch as datum for in vivo effect on ENTITY2 formation by cardiac fibroblast be"
"plasma or tissue GENE - ENTITY2 system , as fibrosis be largely unaffect by concurrent administration of CHEMICAL or CHEMICAL ; ( iii ) be independent of cardiac hypertrophy , in that -PRON- be equally see in right and leave ventricle , and in rat render hypertensive without cardiac hypertrophy by the administration of ENTITY1 ; ( iv ) be"
"hypertrophy by the administration of ENTITY1 ; ( iv ) be independent of elevated blood pressure , in that -PRON- be find in normotensive animal infuse peripherally with CHEMICAL and intracerebroventricularly with the ENTITY2 ( GENE ) antagonist CHEMICAL"
"hypertrophy by the administration of ENTITY1 ; ( iv ) be independent of elevated blood pressure , in that -PRON- be find in normotensive animal infuse peripherally with CHEMICAL and intracerebroventricularly with the GENE GENE ( ENTITY2 ) antagonist CHEMICAL ; ("
"hypertrophy by the administration of ENTITY1 ; ( iv ) be independent of elevated blood pressure , in that -PRON- be find in normotensive animal infuse peripherally with CHEMICAL and intracerebroventricularly with the GENE GENE ( GENE ) antagonist CHEMICAL ; ( v ) be via classical ENTITY2 , in that -PRON- be"
"hypertrophy by the administration of ENTITY1 ; ( iv ) be independent of elevated blood pressure , in that -PRON- be find in normotensive animal infuse peripherally with CHEMICAL and intracerebroventricularly with the GENE GENE ( GENE ) antagonist CHEMICAL ; ( v ) be via classical GENE , in that -PRON- be block by concurrent administration of the ENTITY2 antagonist CHEMICAL CHEMICAL ; and"
"involve the plasma or tissue ENTITY2 - GENE system , as fibrosis be largely unaffect by concurrent administration of CHEMICAL or CHEMICAL ; ( iii ) be independent of cardiac hypertrophy , in that -PRON- be equally see in right and leave ventricle , and in rat render hypertensive without cardiac hypertrophy by the administration of ENTITY1 ; ( iv ) be"
"unaffect by concurrent administration of ENTITY1 or CHEMICAL ; ( iii ) be independent of cardiac hypertrophy , in that -PRON- be equally see in right and leave ventricle , and in rat render hypertensive without cardiac hypertrophy by the administration of CHEMICAL CHEMICAL CHEMICAL CHEMICAL ; ( iv ) be independent of elevated blood pressure , in that -PRON- be find in normotensive animal infuse peripherally with CHEMICAL and intracerebroventricularly with the GENE GENE ( GENE ) antagonist CHEMICAL ; ( v ) be via classical GENE , in that -PRON- be block by concurrent administration of the GENE antagonist CHEMICAL CHEMICAL ; and ( vi ) may or may not be a direct cardiac effect , inasmuch as datum for in vivo effect on ENTITY2 formation by cardiac fibroblast be"
"plasma or tissue GENE - ENTITY2 system , as fibrosis be largely unaffect by concurrent administration of ENTITY1 or CHEMICAL ; ( iii"
"unaffect by concurrent administration of ENTITY1 or CHEMICAL ; ( iii ) be independent of cardiac hypertrophy , in that -PRON- be equally see in right and leave ventricle , and in rat render hypertensive without cardiac hypertrophy by the administration of CHEMICAL CHEMICAL CHEMICAL CHEMICAL ; ( iv ) be independent of elevated blood pressure , in that -PRON- be find in normotensive animal infuse peripherally with CHEMICAL and intracerebroventricularly with the ENTITY2 ( GENE ) antagonist CHEMICAL"
"unaffect by concurrent administration of ENTITY1 or CHEMICAL ; ( iii ) be independent of cardiac hypertrophy , in that -PRON- be equally see in right and leave ventricle , and in rat render hypertensive without cardiac hypertrophy by the administration of CHEMICAL CHEMICAL CHEMICAL CHEMICAL ; ( iv ) be independent of elevated blood pressure , in that -PRON- be find in normotensive animal infuse peripherally with CHEMICAL and intracerebroventricularly with the GENE GENE ( ENTITY2 ) antagonist CHEMICAL ; ("
"unaffect by concurrent administration of ENTITY1 or CHEMICAL ; ( iii ) be independent of cardiac hypertrophy , in that -PRON- be equally see in right and leave ventricle , and in rat render hypertensive without cardiac hypertrophy by the administration of CHEMICAL CHEMICAL CHEMICAL CHEMICAL ; ( iv ) be independent of elevated blood pressure , in that -PRON- be find in normotensive animal infuse peripherally with CHEMICAL and intracerebroventricularly with the GENE GENE ( GENE ) antagonist CHEMICAL ; ( v ) be via classical ENTITY2 , in that -PRON- be"
"unaffect by concurrent administration of ENTITY1 or CHEMICAL ; ( iii ) be independent of cardiac hypertrophy , in that -PRON- be equally see in right and leave ventricle , and in rat render hypertensive without cardiac hypertrophy by the administration of CHEMICAL CHEMICAL CHEMICAL CHEMICAL ; ( iv ) be independent of elevated blood pressure , in that -PRON- be find in normotensive animal infuse peripherally with CHEMICAL and intracerebroventricularly with the GENE GENE ( GENE ) antagonist CHEMICAL ; ( v ) be via classical GENE , in that -PRON- be block by concurrent administration of the ENTITY2 antagonist CHEMICAL CHEMICAL ; and"
"involve the plasma or tissue ENTITY2 - GENE system , as fibrosis be largely unaffect by concurrent administration of ENTITY1 or CHEMICAL ; ( iii"
"normotensive animal infuse peripherally with ENTITY1 and intracerebroventricularly with the GENE GENE ( GENE ) antagonist CHEMICAL ; ( v ) be via classical GENE , in that -PRON- be block by concurrent administration of the GENE antagonist CHEMICAL CHEMICAL ; and ( vi ) may or may not be a direct cardiac effect , inasmuch as datum for in vivo effect on ENTITY2 formation by cardiac fibroblast be"
"plasma or tissue GENE - ENTITY2 system , as fibrosis be largely unaffect by concurrent administration of CHEMICAL or CHEMICAL ; ( iii ) be independent of cardiac hypertrophy , in that -PRON- be equally see in right and leave ventricle , and in rat render hypertensive without cardiac hypertrophy by the administration of CHEMICAL CHEMICAL CHEMICAL CHEMICAL ; ( iv ) be independent of elevated blood pressure , in that -PRON- be find in normotensive animal infuse peripherally with ENTITY1 and intracerebroventricularly with the GENE"
"normotensive animal infuse peripherally with ENTITY1 and intracerebroventricularly with the ENTITY2 ( GENE ) antagonist CHEMICAL"
"normotensive animal infuse peripherally with ENTITY1 and intracerebroventricularly with the GENE GENE ( ENTITY2 ) antagonist CHEMICAL ; ("
"normotensive animal infuse peripherally with ENTITY1 and intracerebroventricularly with the GENE GENE ( GENE ) antagonist CHEMICAL ; ( v ) be via classical ENTITY2 , in that -PRON- be"
"normotensive animal infuse peripherally with ENTITY1 and intracerebroventricularly with the GENE GENE ( GENE ) antagonist CHEMICAL ; ( v ) be via classical GENE , in that -PRON- be block by concurrent administration of the ENTITY2 antagonist CHEMICAL CHEMICAL ; and"
"involve the plasma or tissue ENTITY2 - GENE system , as fibrosis be largely unaffect by concurrent administration of CHEMICAL or CHEMICAL ; ( iii ) be independent of cardiac hypertrophy , in that -PRON- be equally see in right and leave ventricle , and in rat render hypertensive without cardiac hypertrophy by the administration of CHEMICAL CHEMICAL CHEMICAL CHEMICAL ; ( iv ) be independent of elevated blood pressure , in that -PRON- be find in normotensive animal infuse peripherally with ENTITY1 and intracerebroventricularly with the GENE"
"the effect of ENTITY1 - a peripheral opiate agonist - on plasma GENE response to GENE GENE GENE GENE ( ENTITY2 ) have be investigate in"
"the effect of ENTITY1 - a peripheral opiate agonist - on plasma ENTITY2 response to GENE GENE GENE"
"the effect of ENTITY1 - a peripheral opiate agonist - on plasma GENE response to ENTITY2 ( GENE ) have be"
"these datum suggest that ENTITY2 be the master regulator of ENTITY1 - induce oocyte death ."
"to show whether CHEMICAL and ENTITY1 be substrate of ENTITY2 in rat lung ."
"study be to show whether ENTITY1 and CHEMICAL be substrate of ENTITY2 in rat lung ."
"result of this study , ENTITY1 ( 1 ) be find to be a selective cytotoxic agent for colon cancer cell over normal colon cell and to exhibit GENE GENE antagonistic activity for both the ENTITY2 subtype . 
"
"result of this study , ENTITY1 ( 1 ) be find to be a selective cytotoxic agent for colon cancer cell over normal colon cell and to exhibit ENTITY2 antagonistic activity for both the"
"GENE GENE GENE GENE GENE ENTITY1 GENE ( GENE ) , several of these compound be show to be active as ENTITY2 antagonist ."
"GENE GENE GENE GENE GENE ENTITY1 GENE ( ENTITY2 ) , several of these"
"widespread use of the selective ENTITY2 inhibitor , ENTITY1 , -PRON- want to determine"
"the selective GENE inhibitor , ENTITY1 , -PRON- want to determine if inhibition of ENTITY2 would affect incisional skin wound"
"pharmacokinetic and metabolism of ENTITY1 , a novel ENTITY2 inhibitor , in human ."
"orally active , highly selective ENTITY2 inhibitor , be investigate after a single oral dose of 100 mg/1.92 mbq ENTITY1 to six healthy man ."
"the disposition of ENTITY1 , an orally active , highly selective ENTITY2 inhibitor , be investigate after"
"furthermore , ENTITY1 be able to not only decrease the CHEMICAL - induce ENTITY2 GENE - mediate GENE expression"
"furthermore , ENTITY1 be able to not only decrease the CHEMICAL - induce GENE ENTITY2 - mediate GENE expression ,"
"furthermore , ENTITY1 be able to not only decrease the CHEMICAL - induce GENE GENE - mediate ENTITY2 expression , but also augment"
"to not only decrease the ENTITY1 - induce ENTITY2 GENE - mediate GENE expression"
"to not only decrease the ENTITY1 - induce GENE ENTITY2 - mediate GENE expression ,"
"to not only decrease the ENTITY1 - induce GENE GENE - mediate ENTITY2 expression , but also augment"
"decrease the CHEMICAL - induce ENTITY2 GENE - mediate GENE expression , but also augment the cytotoxic effect induce by ENTITY1 ."
"the CHEMICAL - induce GENE ENTITY2 - mediate GENE expression , but also augment the cytotoxic effect induce by ENTITY1 ."
"induce GENE GENE - mediate ENTITY2 expression , but also augment the cytotoxic effect induce by ENTITY1 ."
"activation of GENE ENTITY1 GENE ( ENTITY2 ) result in the production"
"GENE CHEMICAL CHEMICAL GENE ( ENTITY2 ) result in the production of ENTITY1 ( CHEMICAL ) that mediate"
"GENE CHEMICAL CHEMICAL GENE ( ENTITY2 ) result in the production of CHEMICAL CHEMICAL ( ENTITY1 ) that mediate the vasorelax"
"have a good affinity towards ENTITY1 - bind site on ENTITY2 subunit ."
"via selective targeting of the ENTITY1 CHEMICAL - recognition site in the ENTITY2 by a novel nonsteroidal agent"
"selective targeting of the CHEMICAL ENTITY1 - recognition site in the ENTITY2 by a novel nonsteroidal agent"
"autophagy take place in mutate ENTITY2 neuroblastoma cell in response to hypoxia mimetic ENTITY1 . 	"
"endogenous CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) dilate cerebral artery via GENE GENE activation , which require recognition by a ENTITY2 site that include CHEMICAL ."
"endogenous CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) dilate cerebral artery via ENTITY2 activation , which require recognition"
"the endogenous ENTITY1 CHEMICAL CHEMICAL ( CHEMICAL ) dilate cerebral artery via GENE GENE activation , which require recognition by a ENTITY2 site that include CHEMICAL ."
"the endogenous ENTITY1 CHEMICAL CHEMICAL ( CHEMICAL ) dilate cerebral artery via ENTITY2 activation , which require recognition"
"the endogenous CHEMICAL ENTITY1 ( CHEMICAL ) dilate cerebral artery via GENE GENE activation , which require recognition by a ENTITY2 site that include CHEMICAL ."
"the endogenous CHEMICAL ENTITY1 ( CHEMICAL ) dilate cerebral artery via ENTITY2 activation , which require recognition"
"renal clearance of unbound ENTITY1 and unbound m1 far exceed glomerular filtration rate , indicate active renal elimination : that may reflect the fact that CHEMICAL may be a substrate of GENE , GENE , GENE and GENE , and m1 a substrate of GENE , ENTITY2 , GENE and GENE ."
"renal clearance of unbound ENTITY1 and unbound m1 far exceed glomerular filtration rate , indicate active renal elimination : that may reflect the fact that CHEMICAL may be a substrate of GENE , GENE , ENTITY2 and GENE , and m1"
"renal clearance of unbound ENTITY1 and unbound m1 far exceed glomerular filtration rate , indicate active renal elimination : that may reflect the fact that CHEMICAL may be a substrate of ENTITY2 , GENE , GENE and"
"renal clearance of unbound ENTITY1 and unbound m1 far exceed glomerular filtration rate , indicate active renal elimination : that may reflect the fact that CHEMICAL may be a substrate of GENE , GENE , GENE and GENE , and m1 a substrate of GENE , GENE , GENE and ENTITY2 . 
"
"renal clearance of unbound ENTITY1 and unbound m1 far exceed glomerular filtration rate , indicate active renal elimination : that may reflect the fact that CHEMICAL may be a substrate of GENE , GENE , GENE and ENTITY2 , and m1 a substrate"
"renal clearance of unbound ENTITY1 and unbound m1 far exceed glomerular filtration rate , indicate active renal elimination : that may reflect the fact that CHEMICAL may be a substrate of GENE , GENE , GENE and GENE , and m1 a substrate of GENE , GENE , ENTITY2 and GENE . 
"
"renal clearance of unbound ENTITY1 and unbound m1 far exceed glomerular filtration rate , indicate active renal elimination : that may reflect the fact that CHEMICAL may be a substrate of GENE , ENTITY2 , GENE and GENE ,"
"renal clearance of unbound ENTITY1 and unbound m1 far exceed glomerular filtration rate , indicate active renal elimination : that may reflect the fact that CHEMICAL may be a substrate of GENE , GENE , GENE and GENE , and m1 a substrate of ENTITY2 , GENE , GENE and"
"may reflect the fact that ENTITY1 may be a substrate of GENE , GENE , GENE and GENE , and m1 a substrate of GENE , ENTITY2 , GENE and GENE ."
"may reflect the fact that ENTITY1 may be a substrate of GENE , GENE , ENTITY2 and GENE , and m1"
"may reflect the fact that ENTITY1 may be a substrate of ENTITY2 , GENE , GENE and"
"may reflect the fact that ENTITY1 may be a substrate of GENE , GENE , GENE and GENE , and m1 a substrate of GENE , GENE , GENE and ENTITY2 . 
"
"may reflect the fact that ENTITY1 may be a substrate of GENE , GENE , GENE and ENTITY2 , and m1 a substrate"
"may reflect the fact that ENTITY1 may be a substrate of GENE , GENE , GENE and GENE , and m1 a substrate of GENE , GENE , ENTITY2 and GENE . 
"
"may reflect the fact that ENTITY1 may be a substrate of GENE , ENTITY2 , GENE and GENE ,"
"may reflect the fact that ENTITY1 may be a substrate of GENE , GENE , GENE and GENE , and m1 a substrate of ENTITY2 , GENE , GENE and"
"CHEMICAL GENE ( ENTITY2 ) catalyse the formation of CHEMICAL , a bioactive ENTITY1 ."
"CHEMICAL GENE ( ENTITY2 ) catalyse the formation of ENTITY1 , a bioactive CHEMICAL ."
"ENTITY1 GENE ( ENTITY2 ) catalyse the formation of"
"pharmacological activator of ENTITY2 have different effect on ENTITY1 transport process across human lung"
"ENTITY1 GENE GENE agonist and ENTITY2 antagonist effect of the natural"
"CHEMICAL GENE GENE agonist and ENTITY2 antagonist effect of the natural product ENTITY1 : molecular modeling and dynamic"
"of isolated perfused lung with ENTITY1 ( GENE and ENTITY2 ( GENE ) inhibit )"
"of isolated perfused lung with ENTITY1 ( GENE and GENE GENE GENE GENE GENE ( ENTITY2 ) inhibit ) , the"
"of isolated perfused lung with ENTITY1 ( ENTITY2 and GENE GENE GENE GENE"
"CHEMICAL CHEMICAL ( GENE and ENTITY2 ( GENE ) inhibit ) , the efflux of ENTITY1 be measure for 30 min"
"GENE GENE GENE GENE ( ENTITY2 ) inhibit ) , the efflux of ENTITY1 be measure for 30 min"
"with CHEMICAL CHEMICAL CHEMICAL ( ENTITY2 and GENE GENE GENE GENE GENE ( GENE ) inhibit ) , the efflux of ENTITY1 be measure for 30 min"
"effect of the potent antiviral ENTITY1 on ENTITY2 production by murine macrophages stimulate"
"insight into dynamical behavior of ENTITY2 and -PRON- interaction mode with CHEMICAL be crucial in understand the structural and functional characteristic of ENTITY1 GENE ."
"insight into dynamical behavior of ENTITY2 and -PRON- interaction mode with ENTITY1 be crucial in understand the"
"background and purpose : ENTITY2 ( GENE ) be activate by CHEMICAL , CHEMICAL , and the ENTITY1 mimetic , CHEMICAL CHEMICAL CHEMICAL"
"GENE GENE GENE GENE ( ENTITY2 ) be activate by CHEMICAL , CHEMICAL , and the ENTITY1 mimetic , CHEMICAL CHEMICAL CHEMICAL"
"background and purpose : ENTITY2 ( GENE ) be activate by CHEMICAL , CHEMICAL , and the CHEMICAL mimetic , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) ."
"GENE GENE GENE GENE ( ENTITY2 ) be activate by CHEMICAL , CHEMICAL , and the CHEMICAL mimetic , CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) ."
"background and purpose : ENTITY2 ( GENE ) be activate by ENTITY1 , CHEMICAL , and the"
"GENE GENE GENE GENE ( ENTITY2 ) be activate by ENTITY1 , CHEMICAL , and the"
"background and purpose : ENTITY2 ( GENE ) be activate by CHEMICAL , ENTITY1 , and the CHEMICAL mimetic"
"GENE GENE GENE GENE ( ENTITY2 ) be activate by CHEMICAL , ENTITY1 , and the CHEMICAL mimetic"
"background and purpose : ENTITY2 ( GENE ) be activate by CHEMICAL , CHEMICAL , and the CHEMICAL mimetic , ENTITY1 ( CHEMICAL ) ."
"GENE GENE GENE GENE ( ENTITY2 ) be activate by CHEMICAL , CHEMICAL , and the CHEMICAL mimetic , ENTITY1 ( CHEMICAL ) ."
"when ENTITY2 be also inhibit , 10 nmol / l CHEMICAL cause 84% inhibition of the deamination of ENTITY1 by GENE GENE GENE in"
"inhibition of the deamination of ENTITY1 by ENTITY2 in the lung ."
"when ENTITY2 be also inhibit , 10 nmol / l ENTITY1 cause 84% inhibition of the"
", 10 nmol / l ENTITY1 cause 84% inhibition of the deamination of CHEMICAL by ENTITY2 in the lung ."
"the dual action mechanism of ENTITY1 on the ENTITY2 , with the eventual aim"
": identification of residue of ENTITY1 GENE and ENTITY2 responsible for enzyme catalytic and"
"ENTITY2 regulation , an enzyme - enzyme activity control : identification of residue of ENTITY1 GENE and GENE responsible for"
"GENE GENE GENE GENE ( ENTITY2 ) be 100-fold less sensitive to ENTITY1 ."
"contrast , the closely relate ENTITY2 ( GENE ) be 100-fold less sensitive to ENTITY1 ."
"by GENE ( GENE , ENTITY2 and vesicular transport inhibit ) , 10 nmol / l CHEMICAL have no effect and 300 nmol / l CHEMICAL cause only 36% inhibition of deamination of ENTITY1 ."
"the amine be accumulate by ENTITY2 ( GENE , GENE and vesicular transport inhibit ) , 10 nmol / l CHEMICAL have no effect and 300 nmol / l CHEMICAL cause only 36% inhibition of deamination of ENTITY1 ."
"be accumulate by GENE ( ENTITY2 , GENE and vesicular transport inhibit ) , 10 nmol / l CHEMICAL have no effect and 300 nmol / l CHEMICAL cause only 36% inhibition of deamination of ENTITY1 ."
"nmol / l ENTITY1 under condition where the amine be accumulate by GENE ( GENE , ENTITY2 and vesicular transport inhibit )"
"nmol / l ENTITY1 under condition where the amine be accumulate by ENTITY2 ( GENE , GENE and"
"nmol / l ENTITY1 under condition where the amine be accumulate by GENE ( ENTITY2 , GENE and vesicular transport"
"by GENE ( GENE , ENTITY2 and vesicular transport inhibit ) , 10 nmol / l ENTITY1 have no effect and 300"
"the amine be accumulate by ENTITY2 ( GENE , GENE and vesicular transport inhibit ) , 10 nmol / l ENTITY1 have no effect and 300"
"be accumulate by GENE ( ENTITY2 , GENE and vesicular transport inhibit ) , 10 nmol / l ENTITY1 have no effect and 300"
"by GENE ( GENE , ENTITY2 and vesicular transport inhibit ) , 10 nmol / l CHEMICAL have no effect and 300 nmol / l ENTITY1 cause only 36% inhibition of"
"the amine be accumulate by ENTITY2 ( GENE , GENE and vesicular transport inhibit ) , 10 nmol / l CHEMICAL have no effect and 300 nmol / l ENTITY1 cause only 36% inhibition of"
"be accumulate by GENE ( ENTITY2 , GENE and vesicular transport inhibit ) , 10 nmol / l CHEMICAL have no effect and 300 nmol / l ENTITY1 cause only 36% inhibition of"
"1000 time more potent and ENTITY1 be about 20 time more potent for GENE inhibition in rat lung than in tissue homogenate , and the reason for -PRON- high potency in the intact lung be transport and accumulation of the drug in the pulmonary endothelial cell by ENTITY2 ."
"1000 time more potent and ENTITY1 be about 20 time more potent for ENTITY2 inhibition in rat lung than"
"in the literature show that ENTITY1 be about 1000 time more potent and CHEMICAL be about 20 time more potent for GENE inhibition in rat lung than in tissue homogenate , and the reason for -PRON- high potency in the intact lung be transport and accumulation of the drug in the pulmonary endothelial cell by ENTITY2 ."
"in the literature show that ENTITY1 be about 1000 time more potent and CHEMICAL be about 20 time more potent for ENTITY2 inhibition in rat lung than"
"l CHEMICAL CHEMICAL CHEMICAL ( ENTITY2 inhibit ) , 10 , 30 and 300 nmol / l CHEMICAL cause 58% , 76% and 74% inhibition of CHEMICAL deamination , respectively , and 30 , 300 and 3000 nmol / l ENTITY1 cause 56% , 89% and"
"l CHEMICAL CHEMICAL CHEMICAL ( ENTITY2 inhibit ) , 10 , 30 and 300 nmol / l CHEMICAL cause 58% , 76% and 74% inhibition of ENTITY1 deamination , respectively , and"
"l CHEMICAL CHEMICAL CHEMICAL ( ENTITY2 inhibit ) , 10 , 30 and 300 nmol / l CHEMICAL cause 58% , 76% and 74% inhibition of CHEMICAL deamination , respectively , and 30 , 300 and 3000 nmol / l CHEMICAL cause 56% , 89% and 96% inhibition of ENTITY1 deamination , respectively ."
"with 1 nmol / l ENTITY1 ( ENTITY2 inhibit ) , 10 ,"
"l CHEMICAL CHEMICAL CHEMICAL ( ENTITY2 inhibit ) , 10 , 30 and 300 nmol / l ENTITY1 cause 58% , 76% and"
"modulation of dialysate level of ENTITY1 , CHEMICAL , and CHEMICAL ( CHEMICAL ) in the frontal cortex of freely - move rat by CHEMICAL CHEMICAL alone and in association with CHEMICAL reuptake inhibitor : comparative role of beta - adrenergic , GENE , and ENTITY2 receptor . 	"
"CHEMICAL , CHEMICAL , and ENTITY1 ( CHEMICAL ) in the frontal cortex of freely - move rat by CHEMICAL CHEMICAL alone and in association with CHEMICAL reuptake inhibitor : comparative role of beta - adrenergic , GENE , and ENTITY2 receptor . 	"
"CHEMICAL , and CHEMICAL ( ENTITY1 ) in the frontal cortex of freely - move rat by CHEMICAL CHEMICAL alone and in association with CHEMICAL reuptake inhibitor : comparative role of beta - adrenergic , GENE , and ENTITY2 receptor . 	"
"alone and in association with ENTITY1 reuptake inhibitor : comparative role of beta - adrenergic , GENE , and ENTITY2 receptor . 	"
"dialysate level of CHEMICAL , ENTITY1 , and CHEMICAL ( CHEMICAL ) in the frontal cortex of freely - move rat by CHEMICAL CHEMICAL alone and in association with CHEMICAL reuptake inhibitor : comparative role of beta - adrenergic , GENE , and ENTITY2 receptor . 	"
"freely - move rat by ENTITY1 alone and in association with CHEMICAL reuptake inhibitor : comparative role of beta - adrenergic , GENE , and ENTITY2 receptor . 	"
"-PRON- search for inhibitor of ENTITY2 from the ENTITY1 extract of the petal of"
"-PRON- act by reactivation of ENTITY2 inhibit by ENTITY1 ."
"GENE , mutation of putative ENTITY1 bind residue , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , and CHEMICAL greatly reduce the affinity for CHEMICAL and impair the interaction with ENTITY2 ."
"in ENTITY2 , mutation of putative ENTITY1 bind residue , CHEMICAL ,"
"greatly reduce the affinity for ENTITY1 and impair the interaction with ENTITY2 ."
"in ENTITY2 , mutation of putative CHEMICAL bind residue , CHEMICAL , CHEMICAL , CHEMICAL , CHEMICAL , and CHEMICAL greatly reduce the affinity for ENTITY1 and impair the interaction with"
"agent , e.g. CHEMICAL , ENTITY2 reactivator such as one of the recommend CHEMICAL CHEMICAL ( CHEMICAL , CHEMICAL , ENTITY1 and CHEMICAL ) and CHEMICAL"
"an antimuscarinic agent , e.g. ENTITY1 , ENTITY2 reactivator such as one of"
"agent , e.g. CHEMICAL , ENTITY2 reactivator such as one of the recommend CHEMICAL CHEMICAL ( ENTITY1 , CHEMICAL , CHEMICAL and"
"agent , e.g. CHEMICAL , ENTITY2 reactivator such as one of the recommend CHEMICAL CHEMICAL ( CHEMICAL , CHEMICAL , CHEMICAL and ENTITY1 ) and CHEMICAL be use"
"agent , e.g. CHEMICAL , ENTITY2 reactivator such as one of the recommend ENTITY1 ( CHEMICAL , CHEMICAL ,"
"agent , e.g. CHEMICAL , ENTITY2 reactivator such as one of the recommend CHEMICAL CHEMICAL ( CHEMICAL , ENTITY1 , CHEMICAL and CHEMICAL )"
"agent , e.g. CHEMICAL , ENTITY2 reactivator such as one of the recommend CHEMICAL CHEMICAL ( CHEMICAL , CHEMICAL , CHEMICAL and CHEMICAL ) and ENTITY1 be use for the treatment"
"agent , e.g. CHEMICAL , ENTITY2 reactivator such as one of the recommend CHEMICAL CHEMICAL ( CHEMICAL , CHEMICAL , CHEMICAL and CHEMICAL ) and CHEMICAL be use for the treatment of ENTITY1 poisoning in human ."
"use sirna -PRON- find that ENTITY2 , but not GENE , be important for CHEMICAL CHEMICAL ability to increase ENTITY1 level under basal condition whereas"
"CHEMICAL CHEMICAL ability to increase ENTITY1 level under basal condition whereas both ENTITY2 and GENE appear to cooperate"
"that GENE , but not ENTITY2 , be important for CHEMICAL CHEMICAL ability to increase ENTITY1 level under basal condition whereas"
"CHEMICAL CHEMICAL ability to increase ENTITY1 level under basal condition whereas both GENE and ENTITY2 appear to cooperate to increase"
"use sirna -PRON- find that ENTITY2 , but not GENE , be important for CHEMICAL CHEMICAL ability to increase CHEMICAL level under basal condition whereas both GENE and GENE appear to cooperate to increase ENTITY1 level under oxidative stress condition"
"under basal condition whereas both ENTITY2 and GENE appear to cooperate to increase ENTITY1 level under oxidative stress condition"
"that GENE , but not ENTITY2 , be important for CHEMICAL CHEMICAL ability to increase CHEMICAL level under basal condition whereas both GENE and GENE appear to cooperate to increase ENTITY1 level under oxidative stress condition"
"condition whereas both GENE and ENTITY2 appear to cooperate to increase ENTITY1 level under oxidative stress condition"
"line , and knockdown of ENTITY2 significantly increase the antiproliferative effect of ENTITY1 ."
"ENTITY1 be a collective term for compound which bind to and activate GENE GENE GENE ( ENTITY2 and GENE GENE GENE GENE"
"ENTITY1 be a collective term for compound which bind to and activate ENTITY2 ( GENE GENE GENE GENE"
"ENTITY1 be a collective term for compound which bind to and activate GENE GENE GENE ( GENE GENE GENE GENE GENE and ENTITY2 ) , member of GENE"
"ENTITY1 be a collective term for compound which bind to and activate GENE GENE GENE ( GENE GENE GENE GENE GENE and GENE GENE GENE GENE GENE ) , member of ENTITY2 superfamily ."
"that GENE be a prominent ENTITY2 isoform responsible for clinical ENTITY1 CHEMICAL - demethylation and clearance"
"investigation test the hypothesis that ENTITY2 be a prominent GENE isoform responsible for clinical ENTITY1 CHEMICAL - demethylation and clearance"
"GENE isoform responsible for clinical ENTITY1 CHEMICAL - demethylation and clearance , use the in vivo mechanism - base ENTITY2 inhibitor CHEMICAL , give orally"
"that GENE be a prominent ENTITY2 isoform responsible for clinical CHEMICAL CHEMICAL - demethylation and clearance , use the in vivo mechanism - base GENE inhibitor ENTITY1 , give orally for 4"
"investigation test the hypothesis that ENTITY2 be a prominent GENE isoform responsible for clinical CHEMICAL CHEMICAL - demethylation and clearance , use the in vivo mechanism - base GENE inhibitor ENTITY1 , give orally for 4"
"in vivo mechanism - base ENTITY2 inhibitor ENTITY1 , give orally for 4"
"that GENE be a prominent ENTITY2 isoform responsible for clinical CHEMICAL ENTITY1 - demethylation and clearance ,"
"investigation test the hypothesis that ENTITY2 be a prominent GENE isoform responsible for clinical CHEMICAL ENTITY1 - demethylation and clearance ,"
"isoform responsible for clinical CHEMICAL ENTITY1 - demethylation and clearance , use the in vivo mechanism - base ENTITY2 inhibitor CHEMICAL , give orally"
"the most important endogeneous ENTITY1 be CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL ) which be an ENTITY2 ligand ."
"most important endogeneous CHEMICAL be ENTITY1 ( CHEMICAL ) which be an ENTITY2 ligand ."
"CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) which be an ENTITY2 ligand ."
"GENE GENE ( ENTITY2 ) and CHEMICAL GENE ( GENE ) catalyze the two - step oxidation of ENTITY1 to CHEMICAL ."
"ENTITY2 ( GENE ) and CHEMICAL GENE ( GENE ) catalyze the two - step oxidation of ENTITY1 to CHEMICAL ."
") and CHEMICAL GENE ( ENTITY2 ) catalyze the two - step oxidation of ENTITY1 to CHEMICAL ."
"GENE GENE ( ENTITY2 ) and CHEMICAL GENE ( GENE ) catalyze the two - step oxidation of CHEMICAL to ENTITY1 ."
"ENTITY2 ( GENE ) and CHEMICAL GENE ( GENE ) catalyze the two - step oxidation of CHEMICAL to ENTITY1 ."
") and CHEMICAL GENE ( ENTITY2 ) catalyze the two - step oxidation of CHEMICAL to ENTITY1 ."
"GENE GENE ( ENTITY2 ) and ENTITY1 GENE ( GENE ) catalyze"
"ENTITY2 ( GENE ) and ENTITY1 GENE ( GENE ) catalyze"
"GENE ( GENE ) and ENTITY1 GENE ( ENTITY2 ) catalyze the two -"
"ENTITY1 may provide clinical benefit by simultaneously target multiple pathway of importance in mtc , include GENE , GENE , and ENTITY2 ."
"ENTITY1 may provide clinical benefit by simultaneously target multiple pathway of importance in mtc , include GENE , ENTITY2 , and GENE ."
"ENTITY1 may provide clinical benefit by simultaneously target multiple pathway of importance in mtc , include ENTITY2 , GENE , and GENE"
"CHEMICAL induce the expression of ENTITY2 in 5l rat hepatoma cell : a cautionary tale of the use of this cell line in study on ENTITY1 toxicity . 	"
"ENTITY1 induce the expression of ENTITY2 in 5l rat hepatoma cell"
"downregulation of ENTITY2 but not ENTITY1 loss lead to mitochondrial dysfunction"
"acute and/or chronic administration of ENTITY1 or CHEMICAL affect the level of opioid peptide and the ENTITY2 in various region of the"
"chronic administration of CHEMICAL or ENTITY1 affect the level of opioid peptide and the ENTITY2 in various region of the"
"GENE GENE reveal a distorted ENTITY2 and a GENE GENE GENE GENE GENE locate above the ENTITY1 - terminal end of the"
"the 2.0-a resolution structure of ENTITY2 reveal a distorted GENE GENE GENE GENE GENE GENE GENE and a GENE GENE GENE GENE GENE locate above the ENTITY1 - terminal end of the"
"GENE GENE GENE and a ENTITY2 locate above the ENTITY1 - terminal end of the"
"-PRON- study demonstrate that ENTITY1 inhibit ENTITY2 - induce increase in eosinophil"
"-PRON- study demonstrate that ENTITY1 inhibit GENE - induce increase in eosinophil count ; GENE GENE GENE level be recover in bronchoalveolar lavage fluid increase ENTITY2 level in bronchoalveolar lavage fluid"
"-PRON- study demonstrate that ENTITY1 inhibit GENE - induce increase in eosinophil count ; ENTITY2 level be recover in bronchoalveolar"
"histological study demonstrate that ENTITY1 substantially inhibit ENTITY2 - induce eosinophilia in lung"
"in the presence of ENTITY1 and CHEMICAL , CHEMICAL GENE ( GENE ) and ENTITY2 form a one - to"
"in the presence of ENTITY1 and CHEMICAL , CHEMICAL GENE ( GENE ) and GENE form a one - to - one enzyme complex in which the activity of GENE be inhibit whereas ENTITY2 remain catalytically active ."
"in the presence of ENTITY1 and CHEMICAL , CHEMICAL GENE ( ENTITY2 ) and GENE form a"
"in the presence of ENTITY1 and CHEMICAL , CHEMICAL GENE ( GENE ) and GENE form a one - to - one enzyme complex in which the activity of ENTITY2 be inhibit whereas GENE remain"
"of CHEMICAL and CHEMICAL , ENTITY1 GENE ( GENE ) and ENTITY2 form a one - to"
"of CHEMICAL and CHEMICAL , ENTITY1 GENE ( GENE ) and GENE form a one - to - one enzyme complex in which the activity of GENE be inhibit whereas ENTITY2 remain catalytically active ."
"of CHEMICAL and CHEMICAL , ENTITY1 GENE ( ENTITY2 ) and GENE form a"
"of CHEMICAL and CHEMICAL , ENTITY1 GENE ( GENE ) and GENE form a one - to - one enzyme complex in which the activity of ENTITY2 be inhibit whereas GENE remain"
"the presence of CHEMICAL and ENTITY1 , CHEMICAL GENE ( GENE ) and ENTITY2 form a one - to"
"the presence of CHEMICAL and ENTITY1 , CHEMICAL GENE ( GENE ) and GENE form a one - to - one enzyme complex in which the activity of GENE be inhibit whereas ENTITY2 remain catalytically active ."
"the presence of CHEMICAL and ENTITY1 , CHEMICAL GENE ( ENTITY2 ) and GENE form a"
"the presence of CHEMICAL and ENTITY1 , CHEMICAL GENE ( GENE ) and GENE form a one - to - one enzyme complex in which the activity of ENTITY2 be inhibit whereas GENE remain"
"ENTITY2 be inactive in the glucuronidation of CHEMICAL , CHEMICAL , CHEMICAL and ENTITY1 ."
"ENTITY2 be inactive in the glucuronidation of CHEMICAL , CHEMICAL , ENTITY1 and CHEMICAL ."
"ENTITY2 be inactive in the glucuronidation of ENTITY1 , CHEMICAL , CHEMICAL and"
"ENTITY2 be inactive in the glucuronidation of CHEMICAL , ENTITY1 , CHEMICAL and CHEMICAL ."
"a series of novel ENTITY1 be design , synthesize and biologically evaluate for ENTITY2 inhibition ."
"ENTITY2 inhibit ENTITY1 - induce cell death ,"
"GENE inhibit ENTITY1 - induce cell death , which be antagonize by ENTITY2 monoclonal antibody ."
"CHEMICAL activate the ENTITY2 clone from rat cerebral artery myocyte with a potency ( ec50 = 53 μm ) similar to and an efficacy ( ×2.5 potentiation ) significantly great than that of ENTITY1 ."
"ENTITY1 activate the ENTITY2 clone from rat cerebral artery"
"the result in vivo show ENTITY2 - induce significantly break treg / th17 balance ; ENTITY1 treatment markedly attenuate the inflammatory"
"study of the expression of ENTITY2 and GENE gene in chinese who live in european country with high ENTITY1 and CHEMICAL diet would be"
"the expression of GENE and ENTITY2 gene in chinese who live in european country with high ENTITY1 and CHEMICAL diet would be"
"study of the expression of ENTITY2 and GENE gene in chinese who live in european country with high CHEMICAL and ENTITY1 diet would be of interest"
"the expression of GENE and ENTITY2 gene in chinese who live in european country with high CHEMICAL and ENTITY1 diet would be of interest"
"ENTITY1 GENE ( ENTITY2 ) , the pivotal enzyme"
"CHEMICAL GENE ( ENTITY2 ) , the pivotal enzyme for the biosynthesis of ENTITY1 ( ref ."
"finally , -PRON- demonstrate that ENTITY2 react with CHEMICAL ) produce ENTITY1 ."
"recently , the ENTITY2 GENE inhibitor ENTITY1 ( CHEMICAL ) have become"
", the GENE GENE GENE ENTITY2 inhibitor ENTITY1 ( CHEMICAL ) have become"
"recently , the ENTITY2 GENE inhibitor CHEMICAL CHEMICAL ( ENTITY1 ) have become the focus"
", the GENE GENE GENE ENTITY2 inhibitor CHEMICAL CHEMICAL ( ENTITY1 ) have become the focus"
"recently , the ENTITY2 GENE inhibitor CHEMICAL CHEMICAL ( CHEMICAL ) have become the focus of research as a fertoprotective drug against ENTITY1 ."
", the GENE GENE GENE ENTITY2 inhibitor CHEMICAL CHEMICAL ( CHEMICAL ) have become the focus of research as a fertoprotective drug against ENTITY1 ."
"membrane - associate protein in ENTITY1 and CHEMICAL metabolism that include GENE GENE GENE GENE , GENE GENE GENE GENE GENE ( ENTITY2 ) , and GENE GENE"
"membrane - associate protein in ENTITY1 and CHEMICAL metabolism that include ENTITY2 , GENE GENE GENE GENE"
"membrane - associate protein in ENTITY1 and CHEMICAL metabolism that include GENE GENE GENE GENE , ENTITY2 ( GENE ) , and"
"membrane - associate protein in ENTITY1 and CHEMICAL metabolism that include GENE GENE GENE GENE , GENE GENE GENE GENE GENE ( GENE ) , and ENTITY2 ( ref ."
"associate protein in CHEMICAL and ENTITY1 metabolism that include GENE GENE GENE GENE , GENE GENE GENE GENE GENE ( ENTITY2 ) , and GENE GENE"
"associate protein in CHEMICAL and ENTITY1 metabolism that include ENTITY2 , GENE GENE GENE GENE"
"associate protein in CHEMICAL and ENTITY1 metabolism that include GENE GENE GENE GENE , ENTITY2 ( GENE ) , and"
"associate protein in CHEMICAL and ENTITY1 metabolism that include GENE GENE GENE GENE , GENE GENE GENE GENE GENE ( GENE ) , and ENTITY2 ( ref ."
"this be significant because ENTITY1 production underlie the role of GENE GENE in GENE apoptosis , imply commonality between ENTITY2 . 
"
"this be significant because ENTITY1 production underlie the role of ENTITY2 in GENE apoptosis , imply"
"drug , include CHEMICAL , ENTITY1 , CHEMICAL CHEMICAL CHEMICAL , and CHEMICAL , which be also ENTITY2 substrate ."
"furthermore , knockdown of ENTITY2 enhance cell death cause by other drug , include CHEMICAL , ENTITY1 , CHEMICAL CHEMICAL CHEMICAL ,"
"include CHEMICAL , CHEMICAL , ENTITY1 , and CHEMICAL , which be also ENTITY2 substrate ."
"furthermore , knockdown of ENTITY2 enhance cell death cause by other drug , include CHEMICAL , CHEMICAL , ENTITY1 , and CHEMICAL , which"
"CHEMICAL CHEMICAL CHEMICAL , and ENTITY1 , which be also ENTITY2 substrate ."
"furthermore , knockdown of ENTITY2 enhance cell death cause by other drug , include CHEMICAL , CHEMICAL , CHEMICAL CHEMICAL CHEMICAL , and ENTITY1 , which be also GENE"
"by other drug , include ENTITY1 , CHEMICAL , CHEMICAL CHEMICAL CHEMICAL , and CHEMICAL , which be also ENTITY2 substrate ."
"furthermore , knockdown of ENTITY2 enhance cell death cause by other drug , include ENTITY1 , CHEMICAL , CHEMICAL CHEMICAL"
"ENTITY2 inhibition result in the accumulation of ENTITY1 at cholinergic receptor site ,"
"the endogenous substrate derive from ENTITY1 through the ENTITY2 pathway ."
"ENTITY2 conjugate CHEMICAL to CHEMICAL , the endogenous substrate derive from ENTITY1 through the GENE pathway ."
"GENE conjugate ENTITY1 to CHEMICAL , the endogenous substrate derive from CHEMICAL CHEMICAL through the ENTITY2 pathway ."
"ENTITY2 conjugate ENTITY1 to CHEMICAL , the endogenous"
"GENE conjugate CHEMICAL to ENTITY1 , the endogenous substrate derive from CHEMICAL CHEMICAL through the ENTITY2 pathway ."
"ENTITY2 conjugate CHEMICAL to ENTITY1 , the endogenous substrate derive"
"animal study also show that ENTITY2 knockdown enhance the cytotoxic action of ENTITY1 ."
"rescue of ENTITY1 - damage oocyte from program cell death through inactivation of the ENTITY2 family signal network . 	"
"meanwhile , the alteration of ENTITY2 , GENE GENE GENE and GENE GENE GENE level be also observe in response to ENTITY1 treatment ."
", GENE GENE GENE and ENTITY2 level be also observe in response to ENTITY1 treatment ."
"GENE GENE GENE GENE , ENTITY2 and GENE GENE GENE level be also observe in response to ENTITY1 treatment ."
"15 , 16 ) , ENTITY2 do not conjugate ENTITY1 to xenobiotic ."
"in contrast with GENE and ENTITY2 ( refs 15 , 16 ) , GENE do not conjugate ENTITY1 to xenobiotic ."
"in contrast with ENTITY2 and GENE ( refs 15 , 16 ) , GENE do not conjugate ENTITY1 to xenobiotic ."
"GENE in a complex with ENTITY1 at 3.3 a resolution by x - ray crystallography and provide insight into the high substrate specificity for CHEMICAL and CHEMICAL that distinguish GENE from other ENTITY2 ."
"show the atomic structure of ENTITY2 in a complex with ENTITY1 at 3.3 a resolution by"
"GENE in a complex with ENTITY1 at 3.3 a resolution by x - ray crystallography and provide insight into the high substrate specificity for CHEMICAL and CHEMICAL that distinguish ENTITY2 from other GENE ."
"the high substrate specificity for ENTITY1 and CHEMICAL that distinguish GENE from other ENTITY2 ."
"show the atomic structure of ENTITY2 in a complex with CHEMICAL at 3.3 a resolution by x - ray crystallography and provide insight into the high substrate specificity for ENTITY1 and CHEMICAL that distinguish GENE"
"the high substrate specificity for ENTITY1 and CHEMICAL that distinguish ENTITY2 from other GENE ."
"substrate specificity for CHEMICAL and ENTITY1 that distinguish GENE from other ENTITY2 ."
"show the atomic structure of ENTITY2 in a complex with CHEMICAL at 3.3 a resolution by x - ray crystallography and provide insight into the high substrate specificity for CHEMICAL and ENTITY1 that distinguish GENE from other"
"substrate specificity for CHEMICAL and ENTITY1 that distinguish ENTITY2 from other GENE ."
"ENTITY1 be much less potent as a GENE inhibitor in cell with the ENTITY2 , such as the myocardial"
"ENTITY1 be much less potent as a ENTITY2 inhibitor in cell with the"
"ENTITY1 modifie but do not block the GENE GENE GENE GENE - induce ENTITY2 response in patient with addison"
"ENTITY1 modifie but do not block the ENTITY2 - induce GENE response in"
"dna fragment consist of the ENTITY2 gene ( encode the GENE GENE , enzyme that convert ENTITY1 to CHEMICAL ) drive by"
"GENE gene ( encode the ENTITY2 , enzyme that convert ENTITY1 to CHEMICAL ) drive by"
"GENE , enzyme that convert ENTITY1 to CHEMICAL ) drive by the strong promoter ( the regulate ENTITY2 or constitutive GENE GENE )"
"GENE , enzyme that convert ENTITY1 to CHEMICAL ) drive by the strong promoter ( the regulate GENE or constitutive ENTITY2 ) be isolate ."
"dna fragment consist of the ENTITY2 gene ( encode the GENE GENE , enzyme that convert CHEMICAL to ENTITY1 ) drive by the strong"
"GENE gene ( encode the ENTITY2 , enzyme that convert CHEMICAL to ENTITY1 ) drive by the strong"
"enzyme that convert CHEMICAL to ENTITY1 ) drive by the strong promoter ( the regulate ENTITY2 or constitutive GENE GENE )"
"enzyme that convert CHEMICAL to ENTITY1 ) drive by the strong promoter ( the regulate GENE or constitutive ENTITY2 ) be isolate ."
"acidification produce by the relevant ENTITY1 hydrase activity of enamel ENTITY2 , which lead to the"
"CHEMICAL hydrase activity of enamel ENTITY2 , which lead to the formation of proton and ENTITY1 and may have a role"
"although ENTITY1 greatly increase the stability of both GENE and ENTITY2 , only the effect on"
"although ENTITY1 greatly increase the stability of both GENE and GENE , only the effect on ENTITY2 be dependent on GENE GENE"
"although ENTITY1 greatly increase the stability of both GENE and GENE , only the effect on GENE be dependent on ENTITY2 activity ."
"although ENTITY1 greatly increase the stability of both ENTITY2 and GENE , only the"
"potential secondary effect on apical ENTITY1 conductance , ENTITY2 activity and monolayer resistance ,"
"potential secondary effect on apical ENTITY1 conductance , GENE activity and monolayer resistance , have important consequence for -PRON- use as pharmacological activator of ENTITY2 in cell system where CHEMICAL"
"additional pharmacological effect evoke by ENTITY1 and CHEMICAL on CHEMICAL ) , with potential secondary effect on apical CHEMICAL conductance , ENTITY2 activity and monolayer resistance ,"
"additional pharmacological effect evoke by ENTITY1 and CHEMICAL on CHEMICAL ) , with potential secondary effect on apical CHEMICAL conductance , GENE activity and monolayer resistance , have important consequence for -PRON- use as pharmacological activator of ENTITY2 in cell system where CHEMICAL"
"effect evoke by CHEMICAL and ENTITY1 on CHEMICAL ) , with potential secondary effect on apical CHEMICAL conductance , ENTITY2 activity and monolayer resistance ,"
"effect evoke by CHEMICAL and ENTITY1 on CHEMICAL ) , with potential secondary effect on apical CHEMICAL conductance , GENE activity and monolayer resistance , have important consequence for -PRON- use as pharmacological activator of ENTITY2 in cell system where CHEMICAL"
"drug ( CHEMICAL CHEMICAL , ENTITY1 , CHEMICAL , CHEMICAL CHEMICAL CHEMICAL GENE inhibitor ) reduce GENE GENE GENE GENE GENE GENE GENE ( GENE ) and/or ENTITY2 ( GENE ) by a"
"drug ( CHEMICAL CHEMICAL , ENTITY1 , CHEMICAL , CHEMICAL CHEMICAL CHEMICAL GENE inhibitor ) reduce GENE GENE GENE GENE GENE GENE GENE ( ENTITY2 ) and/or GENE GENE GENE"
"drug ( CHEMICAL CHEMICAL , ENTITY1 , CHEMICAL , CHEMICAL CHEMICAL CHEMICAL GENE inhibitor ) reduce GENE GENE GENE GENE GENE GENE GENE ( GENE ) and/or GENE GENE GENE GENE ( ENTITY2 ) by a variety of"
"drug ( CHEMICAL CHEMICAL , ENTITY1 , CHEMICAL , CHEMICAL CHEMICAL CHEMICAL GENE inhibitor ) reduce ENTITY2 ( GENE ) and/or GENE"
"CHEMICAL , CHEMICAL CHEMICAL , ENTITY1 , CHEMICAL CHEMICAL CHEMICAL GENE inhibitor ) reduce GENE GENE GENE GENE GENE GENE GENE ( GENE ) and/or ENTITY2 ( GENE ) by a"
"CHEMICAL , CHEMICAL CHEMICAL , ENTITY1 , CHEMICAL CHEMICAL CHEMICAL GENE inhibitor ) reduce GENE GENE GENE GENE GENE GENE GENE ( ENTITY2 ) and/or GENE GENE GENE"
"CHEMICAL , CHEMICAL CHEMICAL , ENTITY1 , CHEMICAL CHEMICAL CHEMICAL GENE inhibitor ) reduce GENE GENE GENE GENE GENE GENE GENE ( GENE ) and/or GENE GENE GENE GENE ( ENTITY2 ) by a variety of"
"CHEMICAL , CHEMICAL CHEMICAL , ENTITY1 , CHEMICAL CHEMICAL CHEMICAL GENE inhibitor ) reduce ENTITY2 ( GENE ) and/or GENE"
"absorbable drug ( ENTITY1 , CHEMICAL CHEMICAL , CHEMICAL , CHEMICAL CHEMICAL CHEMICAL GENE inhibitor ) reduce GENE GENE GENE GENE GENE GENE GENE ( GENE ) and/or ENTITY2 ( GENE ) by a"
"absorbable drug ( ENTITY1 , CHEMICAL CHEMICAL , CHEMICAL , CHEMICAL CHEMICAL CHEMICAL GENE inhibitor ) reduce GENE GENE GENE GENE GENE GENE GENE ( ENTITY2 ) and/or GENE GENE GENE"
"absorbable drug ( ENTITY1 , CHEMICAL CHEMICAL , CHEMICAL , CHEMICAL CHEMICAL CHEMICAL GENE inhibitor ) reduce GENE GENE GENE GENE GENE GENE GENE ( GENE ) and/or GENE GENE GENE GENE ( ENTITY2 ) by a variety of"
"absorbable drug ( ENTITY1 , CHEMICAL CHEMICAL , CHEMICAL , CHEMICAL CHEMICAL CHEMICAL GENE inhibitor ) reduce ENTITY2 ( GENE ) and/or GENE"
"CHEMICAL CHEMICAL , CHEMICAL , ENTITY1 GENE inhibitor ) reduce GENE GENE GENE GENE GENE GENE GENE ( GENE ) and/or ENTITY2 ( GENE ) by a"
"CHEMICAL CHEMICAL , CHEMICAL , ENTITY1 GENE inhibitor ) reduce GENE GENE GENE GENE GENE GENE GENE ( ENTITY2 ) and/or GENE GENE GENE"
"CHEMICAL CHEMICAL , CHEMICAL , ENTITY1 GENE inhibitor ) reduce GENE GENE GENE GENE GENE GENE GENE ( GENE ) and/or GENE GENE GENE GENE ( ENTITY2 ) by a variety of"
"CHEMICAL CHEMICAL , CHEMICAL , ENTITY1 GENE inhibitor ) reduce ENTITY2 ( GENE ) and/or GENE"
"ENTITY1 , in particular , act by stimulate the catabolism of ENTITY2 and also , as a"
"ENTITY1 , in particular , act by stimulate the catabolism of GENE and also , as a consequence , improve ENTITY2 delipidation , thus favor receptor"
"the protein level of GENE ENTITY1 GENE ( ENTITY2 ) and GENE ( GENE"
"the protein level of GENE ENTITY1 GENE ( GENE ) and GENE ( ENTITY2 ) and concomitant reduction in"
"the protein level of GENE ENTITY1 GENE ( GENE ) and ENTITY2 ( GENE ) and concomitant"
"GENE CHEMICAL CHEMICAL GENE ( ENTITY2 ) and GENE ( GENE ) and concomitant reduction in the production of ENTITY1 and CHEMICAL CHEMICAL ) ("
"GENE ) and GENE ( ENTITY2 ) and concomitant reduction in the production of ENTITY1 and CHEMICAL CHEMICAL ) ("
"GENE ( GENE ) and ENTITY2 ( GENE ) and concomitant reduction in the production of ENTITY1 and CHEMICAL CHEMICAL ) ("
"GENE CHEMICAL CHEMICAL GENE ( ENTITY2 ) and GENE ( GENE ) and concomitant reduction in the production of CHEMICAL and CHEMICAL CHEMICAL ) ( ENTITY1 ) ."
"GENE ) and GENE ( ENTITY2 ) and concomitant reduction in the production of CHEMICAL and CHEMICAL CHEMICAL ) ( ENTITY1 ) ."
"GENE ( GENE ) and ENTITY2 ( GENE ) and concomitant reduction in the production of CHEMICAL and CHEMICAL CHEMICAL ) ( ENTITY1 ) ."
"ENTITY1 induce dose - dependent reduction of the protein level of GENE CHEMICAL CHEMICAL GENE ( ENTITY2 ) and GENE ( GENE"
"ENTITY1 induce dose - dependent reduction of the protein level of GENE CHEMICAL CHEMICAL GENE ( GENE ) and GENE ( ENTITY2 ) and concomitant reduction in"
"ENTITY1 induce dose - dependent reduction of the protein level of GENE CHEMICAL CHEMICAL GENE ( GENE ) and ENTITY2 ( GENE ) and concomitant"
"ENTITY1 and acipimox interfere with the biosynthesis of GENE and can also improve the clearance of ENTITY2 / GENE ."
"ENTITY1 and acipimox interfere with the biosynthesis of ENTITY2 and can also improve the"
"ENTITY1 and acipimox interfere with the biosynthesis of GENE and can also improve the clearance of GENE / ENTITY2 ."
"inhibition of ENTITY2 provide a molecular explanation of the attenuation of dna - damage checkpoint response and for the increase radiosensitivity of ENTITY1 - treat cell [ 6"
"CHEMICAL stimulate the conversion of ENTITY1 ( CHEMICAL CHEMICAL CHEMICAL CHEMICAL ) to CHEMICAL CHEMICAL CHEMICAL CHEMICAL , indicate ENTITY2 activation ."
"CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( ENTITY1 ) to CHEMICAL CHEMICAL CHEMICAL CHEMICAL , indicate ENTITY2 activation ."
"-PRON- find that ENTITY1 stimulate the conversion of CHEMICAL CHEMICAL CHEMICAL CHEMICAL ( CHEMICAL CHEMICAL CHEMICAL CHEMICAL ) to CHEMICAL CHEMICAL CHEMICAL CHEMICAL , indicate ENTITY2 activation ."
"CHEMICAL CHEMICAL CHEMICAL ) to ENTITY1 , indicate ENTITY2 activation ."
"i.e. accelerate reverse transport of ENTITY1 from ENTITY2 to GENE GENE GENE GENE"
"i.e. accelerate reverse transport of ENTITY1 from GENE GENE GENE GENE to ENTITY2 ."
"ENTITY1 act by a newly describe mechanism , i.e. accelerate reverse transport of CHEMICAL CHEMICAL from ENTITY2 to GENE GENE GENE GENE"
"ENTITY1 act by a newly describe mechanism , i.e. accelerate reverse transport of CHEMICAL CHEMICAL from GENE GENE GENE GENE to ENTITY2 ."
"phorbol ester and ENTITY1 destabilize ENTITY2 mrna in vascular smooth muscle"
"finally , ENTITY2 inhibitor , interfere with the biosynthesis of ENTITY1 , can induce an increase"
"interfere with the biosynthesis of ENTITY1 , can induce an increase expression of liver high - affinity ENTITY2 ."
"purpose : ENTITY1 ( CHEMICAL ) be a potent inhibitor of GENE , GENE GENE GENE GENE GENE GENE ( GENE ) , and ENTITY2 , with robust antiangiogenic ,"
"purpose : ENTITY1 ( CHEMICAL ) be a potent inhibitor of GENE , ENTITY2 ( GENE ) , and"
"purpose : ENTITY1 ( CHEMICAL ) be a potent inhibitor of ENTITY2 , GENE GENE GENE GENE"
"purpose : ENTITY1 ( CHEMICAL ) be a potent inhibitor of GENE , GENE GENE GENE GENE GENE GENE ( ENTITY2 ) , and GENE ,"
"purpose : CHEMICAL ( ENTITY1 ) be a potent inhibitor of GENE , GENE GENE GENE GENE GENE GENE ( GENE ) , and ENTITY2 , with robust antiangiogenic ,"
"purpose : CHEMICAL ( ENTITY1 ) be a potent inhibitor of GENE , ENTITY2 ( GENE ) , and"
"purpose : CHEMICAL ( ENTITY1 ) be a potent inhibitor of ENTITY2 , GENE GENE GENE GENE"
"purpose : CHEMICAL ( ENTITY1 ) be a potent inhibitor of GENE , GENE GENE GENE GENE GENE GENE ( ENTITY2 ) , and GENE ,"
"GENE for localized sequestration of ENTITY1 that be available to newly up - regulate ENTITY2 , GENE GENE GENE ,"
"- regulate the expression of ENTITY2 for localized sequestration of ENTITY1 that be available to newly"
"GENE for localized sequestration of ENTITY1 that be available to newly up - regulate GENE GENE GENE , ENTITY2 , and GENE GENE GENE"
"re - expression of the ENTITY2 appear to partially reverse de - differentiation of prostate cancer cell by up - regulate the expression of GENE for localized sequestration of ENTITY1 that be available to newly"
"GENE for localized sequestration of ENTITY1 that be available to newly up - regulate GENE GENE GENE , GENE GENE GENE , and ENTITY2 . 
"
"ENTITY1 biosynthesis in plant : molecular and functional characterization of ENTITY2 and three isoform of GENE"
"ENTITY1 biosynthesis in plant : molecular and functional characterization of GENE GENE and three isoform of ENTITY2 in arabidopsis thaliana . 	"
"in ENTITY2 , two CHEMICAL at the ENTITY1 terminus of the protein be"
", two CHEMICAL at the ENTITY1 terminus of the protein be crucial for -PRON- ENTITY2 function but not for -PRON-"
"in ENTITY2 , two ENTITY1 at the CHEMICAL terminus of"
"in GENE , two ENTITY1 at the CHEMICAL terminus of the protein be crucial for -PRON- ENTITY2 function but not for -PRON-"
"when ENTITY2 be coexpress with GENE GENE GENE GENE ( GENE ) , ENTITY1 be find to act as"
"when GENE be coexpress with ENTITY2 ( GENE ) , ENTITY1 be find to act as"
"GENE GENE GENE GENE ( ENTITY2 ) , ENTITY1 be find to act as"
"GENE ( GENE ) , ENTITY1 be find to act as a ENTITY2 antagonist to inhibit CHEMICAL -"
"GENE ( GENE ) , ENTITY1 be find to act as a GENE antagonist to inhibit CHEMICAL - evoke current , but none of the other compound inhibit ENTITY2 current ."
"when ENTITY2 be coexpress with GENE GENE GENE GENE ( GENE ) , CHEMICAL be find to act as a GENE antagonist to inhibit ENTITY1 - evoke current , but"
"when GENE be coexpress with ENTITY2 ( GENE ) , CHEMICAL be find to act as a GENE antagonist to inhibit ENTITY1 - evoke current , but"
"GENE GENE GENE GENE ( ENTITY2 ) , CHEMICAL be find to act as a GENE antagonist to inhibit ENTITY1 - evoke current , but"
"find to act as a ENTITY2 antagonist to inhibit ENTITY1 - evoke current , but"
"a GENE antagonist to inhibit ENTITY1 - evoke current , but none of the other compound inhibit ENTITY2 current ."
"of GENE GENE GENE ( ENTITY2 ) , a subfamily of ENTITY1 GENE GENE GENE GENE in"
"ENTITY2 increase the mrna and protein expression of GENE GENE GENE ( GENE GENE GENE ) , a subfamily of ENTITY1 GENE GENE GENE GENE in"
"mrna and protein expression of ENTITY2 ( GENE GENE GENE ) , a subfamily of ENTITY1 GENE GENE GENE GENE in"
"both ENTITY1 also decrease cse - induce ros production , CHEMICAL formation and reduce the increase in ENTITY2 and GENE expression cause by"
"both ENTITY1 also decrease cse - induce ros production , CHEMICAL formation and reduce the increase in GENE and ENTITY2 expression cause by cse ."
"- induce ros production , ENTITY1 formation and reduce the increase in ENTITY2 and GENE expression cause by"
"- induce ros production , ENTITY1 formation and reduce the increase in GENE and ENTITY2 expression cause by cse ."
"by 4 kb of the ENTITY2 5'-flank region , contain six putative GENE GENE GENE GENE GENE GENE GENE GENE GENE GENE and two potential GENE GENE GENE GENE GENE GENE GENE , be highly activate in embryonic pituitary cell and up - regulate by ENTITY1 ."
"GENE GENE and two potential ENTITY2 , be highly activate in embryonic pituitary cell and up - regulate by ENTITY1 ."
"region , contain six putative ENTITY2 and two potential GENE GENE GENE GENE GENE GENE GENE , be highly activate in embryonic pituitary cell and up - regulate by ENTITY1 ."
"assess the relative contribution of ENTITY2 uptake in human hepatocyte for CHEMICAL ( 42%-62% ) , ENTITY1 ( 28%-81% ) , CHEMICAL"
"assess the relative contribution of ENTITY2 uptake in human hepatocyte for CHEMICAL ( 42%-62% ) , CHEMICAL ( 28%-81% ) , CHEMICAL ( 64%-72% ) , ENTITY1 ( 84%-98% ) and CHEMICAL"
